Crypt-top and crypt-bottom colonic epithelial cell population microRNA expression demonstrates cell type-specificity and correlation with endoscopic activity in ulcerative colitis

Journal:	*Journal of Crohn's and Colitis*
Manuscript ID	Draft
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Inciuraite, Ruta; Lithuanian University of Health Sciences, Institute for Digestive Research Ramonaite, Rima; Lithuanian University of Health Sciences, Institute for Digestive Research Kupcinskas, Juozas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Dalgediene, Indre; Vilnius University, Life Sciences Center, Institute of Biotechnology Kulokiene, Ugne; Lithuanian University of Health Sciences, Institute for Digestive Research Kiudelis, Vytautas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Varkalaite, Greta; Lithuanian University of Health Sciences, Institute for Digestive Research Zvirbliene, Aurelija; Vilnius University, Institute of Biotechnology Jonaitis, Laimas Virginijus; Lithuanian University of Health Sciences, Institute of Biotechnology; Lithuanian University of Health Sciences, Department of Gastroenterology Kiudelis, Gediminas; Lithuanian University of Health Sciences, Institute for Digestive Research; Lithuanian University of Health Sciences, Department of Gastroenterology Franke, Andre; Christian-Albrechts-Universitat zu Kiel, Institute of Clinical Molecular Biology Schreiber, Stefan; Universitatsklinikum Schleswig-Holstein, Dept. of Internal Medicine I Juzenas, Simonas; Lithuanian University of Health Sciences, Institute for Digestive Research; Vilnius University, Institute of Biotechnology Skieceviciene, Jurgita; Lithuanian University of Health Sciences, Institute for Digestive Research

Subject:	Basic science, experimental models and pathophysiology, Biomarkers
Classifications:	Genetics and molecular epidemiology, Biomarkers

SCHOLARONE™
Manuscripts

Title: *Crypt-top and crypt-bottom colonic epithelial cell population microRNA*

expression demonstrates cell type-specificity and correlation with endoscopic activity

in ulcerative colitis

Short title: Colonic epithelial cell miRNome in aUC and qUC

Authors: Ruta Inciuraite[1]*, Rima Ramonaite[1]*, Juozas Kupcinskas[1,2]*, Indre Dalgediene[3],

Ugne Kulokiene[1], Vytautas Kiudelis[1,2], Greta Varkalaite[1], Aurelija Zvirbliene[3], Laimas Virginijus

Jonaitis[1,2], Gediminas Kiudelis[1,2], Andre Franke[4], Stefan Schreiber[4], Simonas Juzenas[1,3]*,

Jurgita Skieceviciene[1]*

[1] Institute for Digestive Research, Academy of Medicine, Lithuanian University of Health

Sciences, Kaunas, Lithuania

[2] Department of Gastroenterology, Academy of Medicine, Lithuanian University of Health

Sciences, Kaunas, Lithuania

[3] Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania

[4] Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, Kiel, Germany

* These authors contributed equally to this work

Contact details (Email) and ORCiD IDs: Ruta Inciuraite: Email: ruta.inciuraite@lsmuni.lt,

ORCiD ID: 000-0002-5806-6155; Rima Ramonaite: Email: rima.ramonaite@lsmuni.lt, ORCiD

ID: 0000-0001-5093-9305, Juozas Kupcinskas: Email: juozas.kupcinskas@lsmuni.lt, ORCiD

ID: 0000-0002-8760-7416; Indre Dalgediene: indre.dalgediene@bti.vu.lt, ORCiD ID: 0000-

0003-4113-4761; Ugne Kulokiene: ugne.kulokiene@lsmuni.lt, ORCiD ID: 0000-0002-1130-

2472; Vytautas Kiudelis: vytautas.kiudelis@lsmuni.lt, ORCiD ID: 0000-0003-3680-1320;

Greta Varkalaite: greta.varkalaite@lsmuni.lt, ORCiD: 0000-0003-3488-2171; Aurelija

Zvirbliene: aurelija.zvirbliene@bti.vu.lt, ORCiD ID: 0000-0003-3122-8895; Laimas Virginijus

Jonaitis: laimas.jonaitis@lsmuni.lt, ORCiD OD: 0000-0001-9086-3675; Gediminas Kiudelis:

gediminas.kiudelis@lsmuni.lt, ORCiD ID: 0000-0001-5945-8284; Andre Franke:

a.franke@ikmb.uni-kiel.de, ORCiD ID: 0000-0003-1530-5811; Stefan Schreiber:

s.schreiber@mucosa.de; Simonas Juzenas: simonas.juzenas@gmc.vu.lt, ORCiD ID: 0000-

0001-9293-0691; Jurgita Skieceviciene: jurgita.skieceviciene@lsmuni.lt, ORCiD ID: 0000-

0002-4893-6612.

Address for correspondence: Jurgita Skieceviciene, PhD, Institute for Digestive Research,

Academy of Medicine, Lithuanian University of Health Sciences, Eiveniu st. 4, LT-50161,

Kaunas, Lithuania. Email: jurgita.skieceviciene@lsmuni.lt.

Abstract

Background and Aims. Colonic epithelial barrier loss and dysfunction are one of the early events in ulcerative colitis (UC) and microRNAs (miRNAs) participate in its regulation. However, cell type-specific profile of miRNAs during inflammation in UC is still unknown. Thus, we aimed to perform miRNA profiling on colon tissue and epithelial cell levels in active and quiescent UC.

Methods. Small RNA-sequencing in colon tissue, crypt-bottom (CD44+), and crypt-top (CD66a+) colonic epithelial cell populations from two independent cohorts of UC patients (active and quiescent, n=74), and healthy individuals (n=50) was performed. Data analysis encompassed differential expression, weighted gene co-expression network (WGCNA), correlation, gene-set enrichment analyses (GSEA).

Results. In colon tissue of active and quiescent UC, differentially expressed miRNAs were shown to be potentially involved in intestinal barrier integrity regulation. Consecutive analysis of crypt-bottom and crypt-top colonic epithelial cells revealed distinct miRNA expression patterns in response to UC-caused inflammation. GSEA indicated that differentially expressed epithelial miRNAs are commonly involved in inflammation- and intestinal barrier integrity-related processes (such as signalling of interleukin-4 and interleukin-13), while miRNA differences between cell populations might reflect their function, i.e., crypt-bottom cell miRNA target genes involved in regulation of cell differentiation. Finally, pro-inflammatory miRNA co-expression module correlating with endoscopic UC activity was defined not only in both epithelial cell populations, but also in the colon tissue.

Conclusions. miRNA expression patterns are colon epithelial cell population- and UC state-specific and correlate with endoscopic UC activity. Irrespective of the UC stage deregulated epithelial miRNAs are potentially involved in regulation of intestinal barrier integrity.

Keywords

Colon crypt-bottom epithelial cells; colon crypt-top epithelial cells; microRNA; Ulcerative coliti

Introduction

Colonic epithelial cells and their secreted products primarily form and maintain frontline

intestinal barrier function which deteriorates early in ulcerative colitis (UC)[1]. Colonic crypt

epithelial cells such as colonocytes, Goblet and epithelial stem cells have been shown to play

an important role in UC pathogenesis via reduced epithelial mucus secretion and/or increased

barrier permeability[2]. Since one of the aims in UC management is to induce and then to

maintain remission, disentangling molecular mechanisms regulating epithelial barrier may

help to modulate its permeability and retain long-lasting remission in UC.

Recent studies provide evidence for microRNAs (miRNAs) to be involved in regulation of

intestinal epithelial integrity and barrier permeability via interference with protein-coding genes

responsible for tight and adherent junctions[3], also in UC[4]. However, most of the studies have

been either based on immortalized cell cultures or bulk tissue experiments, thus the exact

cellular context of miRNA deregulation during colonic inflammation remains elusive.

Therefore, the search for cell type specific deregulation of miRNAs in UC might uncover novel

aspects of underlying regulatory pathways and molecular targets for therapeutic development.

Here, we report the comprehensive miRNA expression profiling on colon tissue and colonic

crypt-bottom (CD44[+]) and crypt-top (CD66a[+]) cell population levels in active and quiescent

UC. By employing small RNA-seq we determine UC activity-specific, as well as epithelial cell

population-specific, miRNA expression signatures during colonic inflammation. Additionally,

we describe miRNA co-expression network and evaluate its relations to clinical characteristic

of UC. Finally, we explore putative biological pathways in which the deregulated miRNAs are

involved and provide potential miRNA candidates for further development of UC management.

Materials and Methods

Ethics and consent

The approval to perform the study was received from Kaunas Regional Biomedical Research Ethics Committee (No. BE-2-31, 22-03-2018). All subjects have signed a written informed consent form to participate in the study.

Study samples

Study subject recruitment was conducted at the Department of Gastroenterology, Lithuanian University of Health Sciences (Kaunas, Lithuania) during the period of 2011-2014 (Study group I and III) and 2017-2019 (Study group II). For miRNA sequencing, colon biopsies were collected in two independent groups: the first study group contained 23 patients with active UC, 20 patients with quiescent UC and 33 healthy control individuals (HC), while the second study group was composed of 16 patients with active UC, 15 patients with quiescent UC and 17 HC individuals. Additionally, colon biopsies for qPCR-based gene expression analysis were collected in the third independent group which contained 75 patients with active UC, 50 patients with quiescent UC and 75 HC individuals. Demographic and clinical characteristics of subjects of Study groups I and II are presented in **Table 1**, Study group III – in **Supplementary Table S1**. Tissue samples of patients with active UC and quiescent UC were collected from sigmoid colon. Endoscopic activity was determined using the Mayo endoscopic subscore[5]. Quiescent UC was defined as mucosal healing (endoscopic Mayo subscore ≤ 1) with no clinical symptoms. The variables collected for the individuals of both study groups were such as age, sex, body mass index (BMI), smoking status, disease activity, localization, rectal bleeding, stool frequency, endoscopic Mayo subscore, global assessment score, full Mayo score.

138   **Table 1.** Demographic and clinical characteristics of subjects

	Study group I, n=76			Study group II, n=48		
	Active UC, n=23	Quiescent UC, n=20	HC, n=33	Active UC, n=16	Quiescent UC, n=15	HC, n=17
Age						
Mean ± SD	43.9± 16.1 *	47.2 ± 13.5 *	58.5 ± 12.7 *	41.6 ± 16.3 **	57.3 ± 12.1 **	50.5 ± 16.1
Sex, n (%)						
Female	10 (43.5)	9 (45.0)	21 (73.6)	4 (25.0) ***	10 (66.7) ***	10 (58.8) ***
Full Mayo score, n (%)						
Remission	0 (0.0)	20 (100.0)	-	0 (0.0)	15 (100.0)	-
Mild	1 (4.4)	0 (0.0)	-	4 (25.0)	0 (0.0)	-
Moderate	21 (91.3)	0 (0.0)	-	11 (68.8)	0 (0.0)	-
Severe	1 (4.4)	0 (0.0)	-	1 (6.3)	0 (0.0)	-
Endoscopic Mayo subscore, n (%)						
Normal to mild	0 (0.00)	20 (100.0)	33 (100.0)	0 (0.0)	15 (100.0)	17 (100.0)
Moderate to severe	23 (100.0)	0 (0.0)	-	16 (100.0)	0 (0.0)	-
Smoking status, n (%)						
Never	8 (34.8)	11 (55.0)	23 (69.7)	9 (56.3)	10 (66.7)	12 (70.6)
Smoking	8 (34.8)	6 (30.0)	5 (15.2)	3 (18.8)	1 (6.7)	3 (17.7)
Ex-smoker	3 (13.1)	2 (10.0)	1 (5.0)	4 (25.0)	4 (26.7)	2 (11.8)
Unknown	4 (17.4)	1 (5.0)	1 (3.0)	-	-	-
BMI, kg/m^2						
Median, (range)	26.8 (18.1–56.2)	26.2 (19.7–31.5)	27.7 (19.6–39.5)	25.5 (18.0–37.2)	28.4 (19.8–32.7)	25.9 (18.9–31.9)
Unknown, n (%)	1 (4.4)	1 (5.0)	2 (6.1)	-	1 (6.7)	-

* Age differed between both active and quiescent UC groups, and HC, estimated P value < 0.05 (t-test)

**Age differed between both active and quiescent UC groups, and HC, estimated P value < 0.05 (t-test)

***Sex distribution differed between three groups, estimated *P* value < 0.05 (Pearson's chi-squared

test)

SD - Standard deviation

All subjects with active and quiescent UC had a routine colonoscopy performed as a part of

their planned examination programme. The diagnosis of UC was based on standard clinical,

endoscopic, radiological, and histological criteria[6]. The control individuals included in both

study groups consisted of healthy subjects who either underwent colonoscopy due to positive

faecal occult blood test or were consulted on functional complaints, but had a normal

colonoscopy, uninflamed mucosa during histopathological examination and no previous

history of intestinal inflammation. All patients enrolled in the study were of European descent.

Colon tissue disaggregation

Colon biopsies were mechanically and enzymatically separated into single-cell suspensions.

Briefly, four to six biopsies (5–10 mg wet weight each) were washed with PBS solution

containing 50 IU/mL penicillin, 50 µg/mL streptomycin, and 0.5 mg/mL gentamicin. Biopsies

were minced into small pieces (approx. 1-2 mm^3) and incubated in 1X trypsin-EDTA solution

for 40-45 min at room temperature on an agitator to dissociate single epithelial cells from the

lamina propria. After incubation, tissue fragments were gently transferred into PBS and

shaken. The isolated cell suspension was filtered and suspended in DMEM:Ham's F-12

medium (1:1) with 15 mM HEPES (Gibco, USA) buffer for flow cytometry procedures.

Flow cytometry and fluorescence activated cell sorting

In order to minimize the loss of cell viability, fresh cell suspensions prepared shortly before

flow cytometry were used in all cell sorting experiments. Antibody staining was performed in

PBS supplemented with 1% heat-inactivated fetal bovine serum. To minimize nonspecific

binding of antibodies, cells were first incubated with Human TruStain FcX™ (Fc Receptor

Blocking Solution) (BioLegend Inc., USA) for 10 min at a concentration of 3-10 × 10^5 cells/100

μl. Cells were subsequently stained without washing with antibodies at dilutions recommended

by manufacturers. Antibodies used in this study were selected based on previous study[7] and

included: mouse anti-human CD326/EpCAM-FITC (clone VU-1D9, RRID: AB_2534535m Life

Technologies, USA), mouse anti-human CD44-APC (clone G44-26, RRID: AB_395868, BD

Biosciences, USA), mouse anti-human CD66a-PE (clone 283340, R&D Systems, USA). Cells

positive for expression of non-epithelial lineage markers were excluded by staining with mouse

anti-human CD45-APC-Cy7 (clone 2D1, RRID: AB_2566375, Biolegend Inc., USA) (see

gating strategy in **Supplementary Figure S1a**). After 20 min, stained cells were washed of

excess unbound antibodies and resuspended in PBS supplemented with 1% heat-inactivated

fetal bovine serum. Flow-cytometry analysis was performed using a CyFlow® Space cell sorter

(Sysmex Partec, Germany) (see representative plots of flow cytometry data in

Supplementary Figure S1b-d). In cell sorting experiments, each population of interest was

sorted individually, using a protocol already built-in within the CyFlow® Space flow cytometer

software package (FloMax® 2.8), with appropriate adjustments. Data was analysed and

visualised using FlowJo™ v10.7 (BD FlowJo, USA). Two cell populations (CD45$^-$

/EpCAM$^+$/CD44$^+$/CD66a$^+$ and CD45$^-$/EpCAM$^+$/CD44$^-$/CD66a$^+$) were further described based

on the literature and single-cell RNA-seq dataset of the human colon, available in GEO

database with accession number GSE116222 (see the single-cell RNA-seq data-derived

expression plot of three main cell surface markers in **Supplementary Figure S2**). CD45$^-$

/EpCAM$^+$/CD44$^+$/CD66a$^-$ population was entitled as crypt-bottom cells (consisting of

undifferentiated colonic epithelial cells as well as secretory Goblet and enteroendocrine cells),

while CD45$^-$/EpCAM$^+$/CD44$^-$/CD66a$^+$ population was entitled as crypt-top cells (consisting of

absorptive colonocytes and BEST4$^+$/OTOP2$^+$ cells). Sorted cell samples were frozen and

stored at -70 °C prior to total RNA extraction.

Total RNA extraction

Total RNA extraction from colon biopsies and sorted cells was performed using standard

protocols of commercial miRNeasy Mini Kit (Qiagen, Germany) and Single Cell RNA

Purification Kit (Norgen, Canada), respectively. Total RNA concentration was evaluated by

NanoDrop2000 spectrophotometer (Thermo Scientific, USA) and Qubit 4 fluorometer

(Invitrogen, USA). Total RNA quality was assessed using Agilent 2100 Bioanalyzer (Agilent

Biotechnologies, USA).

Quantitative Reverse Transcription PCR and data analysis

To estimate the expression of *IL-4* and *IL-13* genes in colon tissue of UC patients, total RNA

from colon tissue samples was reverse transcribed using a High-Capacity cDNA Reverse

Transcription Kit (Applied Biosystems™, USA). Further, expression levels were measured

using TaqMan™ Gene Expression Assays (Assay IDs: *IL-4* Hs00174122_m1; *IL-13*

Hs00174379_m1) on the 7500 Fast Real-Time PCR System (Applied Biosystems™, USA).

The cycle threshold (C_T) values of *IL-4* and *IL-13* were normalized to the value of *GAPDH*

(Assay ID: Hs99999905_m1) reference gene. All the procedures were performed in

accordance with the manufacturer's protocol. Statistical analysis was performed using R

studio software (version 4.0.3). Data distribution was determined using the Shapiro-Wilk test,

gene expression differences were analysed the two-sided Mann-Whitney U test. The

difference between the values was considered significant when $P < 0.05$.

Preparation of small RNA libraries and next-generation sequencing

Small RNA libraries from tissue samples were prepared using TruSeq Small RNA Sample

Preparation Kit (Illumina, USA) with 1 µg of total RNA input per sample. Small RNA libraries

from sorted cells were prepared using NEXTFLEX Small RNA-seq Kit v3 (Bioo Scientific, USA)

with up to 50 ng of total RNA input per sample. Procedures were conducted according to the

manufacturers' protocols. The yield of sequencing libraries was assessed using the Agilent

2200 TapeStation system (Agilent Biotechnologies, USA). Subsequently, the TruSeq libraries

were pooled with around 24 samples per lane, while the NEXTFLEX libraries were pooled with

around 16 samples per lane and then sequenced on HiSeq 4000 (Illumina, USA) next-

generation sequencing platform.

Bioinformatics and statistical analysis of small RNA-seq data

The demultiplexed raw reads (.fastq) were processed with nf-core/smrnaseq v1.0.0 best-

practise analysis pipeline using default parameters (Nextflow version v20.01.0)[8]. The pipeline

was executed within a Docker container. Briefly, depending on the small RNA-seq library

preparation kits, "illumina" or "nextflex" protocol was selected for processing of the libraries

generated from tissue and sorted cell samples, respectively. First, Trim Galore (v0.6.3) was

used to remove 3' adapter (5' - TGGAATTCTCGGGTGCCAAGG - 3' for both "illumina" and

"nextflex" protocols) sequences from the reads and additional 4 nucleotides from both 5' and

3' ends of reads (only for "nextflex" protocol). Second, to reduce computational time, the reads

with identical sequences were collapsed using seqcluster[9] while saving the information about

the read counts. Third, Bowtie1 v1.2.2[10] was used to perform the alignment of collapsed reads

against mature and hairpin miRNA sequences in miRbase database v22.1[11]. Finally, miRNA

annotation was performed using the mirTOP v0.4.23[12]. Further, sample and miRNA QC was

performed: samples with initial read count < 1.5 IQR and number of detected miRNAs < 1.5

IQR on $\log_2$ scale as well as non-expressed (mean raw < 1) and non-variable miRNAs were

excluded from further analysis. Subsequently, to perform differential expression analyses of

the size factor normalized counts of mature miRNAs between samples, negative binomial

generalized linear models implemented in the R package DESeq2[13] were used including age

(scaled and centred) and sex as covariates in the model. The *P*-values resulting from Wald

tests were corrected for false discovery rate (FDR) according to Benjamini and Hochberg. The

miRNAs with FDR < 0.05 and absolute value of $\log_2$FC > 1 were considered to be significantly

differentially expressed. A multidimensional scaling (MDS) analysis using Euclidean distance

was performed on variance stabilizing transformation (VST) normalized miRNA count data.

Additionally, Spearman's rank correlation analysis was performed between sex- and age-

adjusted normalized miRNA read counts and endoscopic Mayo subscore. FDR < 0.05 was

considered statistically significant. Removal of sex and age effects from normalized data was

performed using removeBatchEffect function from the limma R package[14]. Statistical analyses

and data processing were performed using R version 4.0.3[15]. Visualization of graphs was

performed using the ggplot2 package[16].

Gene set enrichment analysis

In order to obtain putative biological functions of differentially expressed miRNAs, gene set

enrichment analysis (GSEA) was performed using Reactome pathways[17] and GO

categories[18]. More specifically, luciferase assay-validated miRNA-target interactions (MTIs)

were obtained from miRecords[19], miRTarBase[20] and TarBase[21] using the multiMiR package[22].

The retrieved MTIs were then submitted to a hypergeometric test implemented in the

enrichPathway (from the ReactomePA package[23]) and enrichGO (from the clusterProfiler

package[24]) functions using genes that are expressed in colon crypt-bottom (CD44[+]) and crypt-

top (CD66a[+]) cells as a background reference (defined as universe). The universe genes were

obtained from single-cell RNA-seq data of the human colon, available in GEO database with

accession number GSE116222[25]. The pathways with FDR < 0.05 were considered to be

significantly deregulated.

miRNA co-expression analysis

Samples of study group II were used for weighted gene co-expression network analysis

(WGCNA) aiming to identify modules of co-expressed miRNAs using CEMiTool package[26]

(version 1.22.0) for R. Normalized (variance stabilizing transformation) miRNA count table was

used to generate the co-expression modules. Filtering based on variance was applied on gene

expression table prior to identification of miRNA co-expression modules. Minimal number of

miRNAs per submodule as well as minimum size of gene sets for GSEA analysis was set to

five, while *P*-value threshold for filtering was set to 0.1. Further, the eigengene value of the

co-expression module identified in colonic epithelial cells was also calculated in colon tissue

data using the expression table of co-expressed miRNAs and WGCNA package[27] (version

1.72-1) for R. Next, Spearman's rank correlation coefficients were calculated between module

eigengene values and endoscopic Mayo subscore in both colonic epithelial cell populations

281 as well as in colon tissue. FDR < 0.05 was considered statistically significant. Finally, to assess

282 the performance of the identified module eigengene value for distinguishing between the

283 active and quiescent UC in both colon tissue and distinct colonic epithelial cell populations,

284 analysis of Area Under the Receiver Operating Characteristic curve (AUC-ROC) was applied

285 using pROC package[28] (version 1.18.4) for R.

1
2
3   **Results**
4
5   *Differentially expressed miRNAs in active and quiescent UC tissues are involved in*
6
7   *regulation of inflammation-related pathways*
8
9   To identify differentially expressed miRNAs and their putative regulatory processes during
10
11   chronic colon inflammation, small RNA-seq was performed on inflamed (active) and non-
12
13   inflamed (quiescent) colonic mucosal biopsies of UC patients and healthy controls (HC)
14
15   (**Figure 1a**).
16
17

Results

Differentially expressed miRNAs in active and quiescent UC tissues are involved in

regulation of inflammation-related pathways

To identify differentially expressed miRNAs and their putative regulatory processes during

chronic colon inflammation, small RNA-seq was performed on inflamed (active) and non-

inflamed (quiescent) colonic mucosal biopsies of UC patients and healthy controls (HC)

(**Figure 1a**).

Figure 1: Small RNA-seq defines differentially expressed miRNAs involved in inflammation-

associated pathways in active and quiescent UC tissues. (a) Design of the initial study phase. **(b)**

MDS plot showing the similarity structure of the miRNA transcriptomes in active (aUC) (n=23), quiescent

UC (qUC) (n=20) and HC (n=30) tissue samples based on normalized expression values. The dots

represent samples coloured by group. The centroid of ellipses corresponds to the group mean; the

shapes are defined by covariance within a given group. **(c)** Differentially expressed miRNAs in active

(aUC) (n=23) and quiescent UC (qUC) (n=20). The red colour represents significantly (FDR < 0.05)

differentially expressed miRNAs with an absolute value of $\log_2FC > 1$, while the blue colour represents

non-differentially expressed miRNAs. **(d)** Top 10 overrepresented pathways in active (aUC) (n=23) and

quiescent UC (qUC) (n=20) tissues identified by miRNA set enrichment analysis. Dot size represents

the number of miRNA-target gene count in the significantly enriched (FDR < 0.05) Reactome pathways.

After count data normalization and quality control, 573 unique miRNAs were found to be

expressed in colon tissue samples. The overall similarity structure (based on MDS analysis;

see **Methods**) of colon miRNA transcriptomes revealed two clearly resolved clusters

corresponding to active UC and HC tissues, while the third cluster corresponding to quiescent

UC overlapped with both active UC and HC clusters, suggesting a shift of miRNA expression

from healthy to inflammatory state (**Figure 1b**). To evaluate expression of specific miRNAs in

active UC and quiescent UC, differential gene expression analysis was performed. As

expected, the most profound miRNA deregulation was observed comparing active UC to HC

or to quiescent UC (93 and 59 differentially expressed miRNAs [FDR < 0.05 and $|\log_2FC| > 1$],

respectively). Interestingly, although substantially lower than in active UC, a differential

expression of miRNAs (n=32) was also observed in quiescent UC compared to HC (**Figure

1c**; **Supplementary Table S2**). Among the differentially expressed miRNAs, a considerable

number (n=13) of molecules, including miR-106-5p, miR-125b-1-3p, miR-205-5p and miR-

3182 were deregulated in both active and quiescent UC compared to HC. Contrarily, majority

of miRNAs (n=80) including, miR-190a-5p, miR-3168, miR-378i, and miR-223-3p were

deregulated only in active UC, while miRNAs (n=19) such as miR-331-3p, miR-409-5p, miR-

4497 and miR-629-5p - only in the quiescent UC. In addition, the gradual decrease in miR-1-

3p expression was found in all pairwise comparisons (active UC vs quiescent UC, active UC

vs HC and quiescent UC vs HC; **Supplementary Table S2**). Thus, besides shared miRNA

deregulation patterns, the data also suggests unique and perhaps non-overlapping functions

of some miRNAs in active and quiescent UC.

To further determine the biological function of differentially expressed miRNAs in UC

pathogenesis, GSEA was performed for each pairwise comparison (active UC vs HC;

quiescent UC vs HC; active vs quiescent UC) using validated target genes of significantly

deregulated miRNAs and Reactome pathways (**Supplementary Table S3**). Intriguingly, both

active UC and quiescent UC compared to HC had over-represented interleukin signalling-

related pathways among the top significant ones, such as "*Signaling by Interleukins*" [R-HSA-

449147] and "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807] (**Figure 1d**). To

further evaluate this finding, the expression patterns of two main cytokines IL-4 and IL-13 in

colon tissue was analysed. The gradual increase in *IL-13* expression was observed between

UC patients and HC individuals (2.19-fold [P = 0.031] increase in quiescent UC vs. HC, 2.91-

fold [P = 0.0007] increase in active UC vs. quiescent UC, 6.38-fold [P = 2 × 10^{-10}] increase in

active UC vs. HC), whereas the expression of *IL-4* did not differ between the groups

(**Supplementary Figure S3**). *In silico* (enrichment in the interleukin signalling-related target

genes), as well as *in vivo* (interleukin expression in colon tissue) analysis confirmed that these

pathways remain dysregulated in the colonic mucosa during the disease course of UC.

Taken together, differential miRNA expression and GSEA analyses in UC tissues suggest that

dysregulated miRNAs are likely involved in regulation of inflammation-related pathways and

that some of the pathways, i.e., interleukin-4 and interleukin-13 signalling, remarkably, remain

dysregulated in the colonic mucosa of quiescent UC.

Sequencing of FACS-sorted colonic epithelial cells shows cell type-specific miRNA

expression during colonic inflammation in UC

The role of interleukin-4 and interleukin-13 in mediating permeability of epithelial barrier as

well as its relation to the pathogenesis of UC has been previously described[29]. Given that this

pathway is deregulated in active UC tissues and remains deregulated in quiescent UC (based

on miRNA and mRNA expression levels in our study) and the fact that it affects epithelial

barrier function, we further decided to focus on miRNA expression in crypt-bottom (CD44+)

and crypt-top (CD66a+) colonic epithelial cells.

FACS was applied to select and enrich for crypt-bottom and crypt-top colonic epithelial cells

from active and quiescent UC patients and healthy controls using CD44+ and CD66a+ surface

markers (**Supplementary Figure S1**). Analysis of FACS enriched cell populations over single-

cell analysis was chosen due to limitations of single-cell transcriptome sequencing technology,

which is not yet compatible with small RNA-seq. Interestingly, analysis of flow cytometry

showed significant (FDR < 0.05) increase in crypt-bottom (CD44+) cells in active UC compared

to HC (**Figure 2a**), suggesting a potential inflammation-stimulated cell proliferation[30,31].

Figure 2: Sequencing data reveals differentially expressed miRNAs in colonic epithelial cells of

patients with active and quiescent UC. (a) FACS of colonic epithelial cells and distribution of crypt-

top CD44-CD66+ and crypt-bottom CD44+CD66- epithelial cell types in inflammatory (aUC) (n=16) and

non-inflammatory (qUC and HC) (n=15 and 17) colon tissues. Each dot represents a sample from the

patients of the second study group. Mean ±SD of each group is represented by vertical lines. To

compare the groups a nonparametric Mann–Whitney U test was performed, p* < 0.05. **(b)** MDS plot

showing the similarity structure of the miRNA transcriptomes in crypt-top (CD66a⁺) and crypt-bottom

(CD44⁺) colonic epithelial cell populations in active (aUC) (n=16), quiescent UC (qUC) (n=15), and in

HC (n=17) based on normalized expression values. The dots represent samples shaped by cell

population. Dot colours represent condition. The centroid of ellipses corresponds to the condition group

mean; the shapes are defined by covariance within the group. **(c, d)** Volcano plots of differentially

expressed miRNAs in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cell populations

in active (aUC) (n=16), quiescent UC (qUC) (n=15), and HC (n=17). Colours indicate significantly (FDR

< 0.05) differentially expressed miRNAs with an absolute value of $\log_2FC > 1$ between compared

groups. **(e-g)** Venn diagrams representing the numbers of commonly and uniquely differentially

expressed miRNAs in **(e)** crypt-bottom (CD44⁺) and **(f)** crypt-top (CD66a⁺) epithelial cell populations in

different UC activity, and **(g)** between crypt-bottom and crypt-top cells in the same condition.

Using sequencing, a total number of 436 unique miRNAs were found to be expressed in crypt-

bottom (CD44⁺) and crypt-top (CD66a⁺) epithelial cells. Although miRNA transcriptomes of

these colonic epithelial cell populations were strongly overlapping (**Figure 2b**), significant

changes in expression profiles were observed within and between cell populations in different

stages of the disease (**Figure 2c and 2d**; **Supplementary Table S4**). Initially, pairwise

comparisons were performed in the same epithelial cell population to identify UC inflammation-

associated miRNAs. As in the tissue data, the number of differentially expressed miRNAs

(FDR < 0.05 and $|\log_2FC| > 1$) in both colonic epithelial cell populations were gradually

increased depending on the disease activity, i.e., the highest number of differentially

expressed miRNAs were observed in active UC compared to HC and to quiescent UC (**Figure**

2c). Among deregulated molecules, none of miRNAs were commonly differentially expressed

across all three comparisons (active UC vs HC; quiescent UC vs HC; active UC vs quiescent

UC) in both crypt-bottom (CD44⁺) and crypt-top (CD66a⁺) colonic epithelial cells. However, six

miRNAs (miR-15b-5p, miR-222-3p, miR-223-3p, miR-194-3p, miR-3195 and miR-574-3p)

were identified as commonly differentially expressed in crypt-bottom (CD44⁺) cells and eight

miRNAs (let-7c-5p, miR-106b-3p, miR-125b-5p, miR-1-3p, miR-1290, miR-194-3p, miR-335-

5p, miR-552-3p) - in crypt-top (CD66a⁺) cells in the active and quiescent UC when compared

to HC (**Figure 2e and 2f**). Further, the response of distinct epithelial cell populations to

inflammation was determined by performing pairwise comparisons with the separate

populations of colonic epithelial cells. Twenty-four miRNAs (such as miR-501-3p, miR-1-3p,

miR-296-5p, and miR-122-5p) were identified to be differentially expressed in active UC, nine

miRNAs (such as miR-1290, miR-3168, and miR-660-5p) in quiescent UC, and twenty-two

miRNAs (such as miR-598-3p, miR-340-3p, and miR-223-3p) - HC when compared crypt-

bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells (**Figure 2d, Supplementary**

Table S4). Notably, the vast majority of identified differentially expressed miRNAs between

distinct epithelial cell types in different stages of inflammation were found to be uniquely

dysregulated. Only two commonly differentially expressed miRNAs were observed between

two comparison groups (miR-106b-3p and miR-1290 in active UC CD44$^+$ vs CD66a$^+$ and

quiescent UC CD44$^+$ vs CD66a$^+$; miR-296-5p and miR-432-5p active UC CD44$^+$ vs CD66a$^+$

and HC CD44$^+$ vs CD66a$^+$) (**Figure 2g**). This suggests that even at different disease activity

stages there are cell population-specific responses, in terms of miRNA expression.

Aberrantly expressed miRNAs in crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) colonic

epithelial cells are involved in regulation of inflammation and intestinal epithelial barrier

function-related processes

To further evaluate the potential functional role of differentially expressed miRNAs in crypt-

bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic epithelial cells in UC pathogenesis, GSEA was

performed on validated target genes of differentially expressed miRNAs (**Supplementary**

Table S5). Similarly, to the colonic tissue data (**Figure 1b**), majority of the overrepresented

pathways in both colonic epithelial cell populations in both stages of disease activity

overlapped and included signalling pathways such as "*Signaling by Interleukins*" (R-HSA-

449147), "*Interleukin-4 and Interleukin-13 signaling*" [R-HSA-6785807], "*Signaling by*

Receptor Tyrosine Kinases" [R-HSA-9006934] (**Figure 3a**). This supports that observations in

the colon biopsy samples were mainly driven by colonic epithelial cells. Notably, not all

comparison groups in crypt-bottom (CD44$^+$) cells showed uniform results. The most

overrepresented Reactome pathways in crypt-bottom (CD44$^+$) cells of quiescent UC patient

group differed from those in active UC groups and exclusively included *"Signaling by Nuclear*

Receptors" (R-HSA-9006931), *"Extra-nuclear estrogen signaling"* [R-HSA-9009391] pathways

which were shown to regulate the permeability of intestinal epithelium and thus be associated

with pathogenesis of inflammatory bowel disease[32] (**Figure 3a**). Finally, to assess which

biological processes (from Gene Ontology terms) are overrepresented in crypt-bottom

(CD44$^+$) compared to crypt-top (CD66a$^+$) cells, GSEA of deregulated miRNAs in active UC,

quiescent UC, and HC groups was performed. The results revealed that overrepresented

processes between the cell populations were mainly related to cell differentiation and motility

in both active UC and HC (**Figure 3b**), suggesting that in inflamed and healthy colon mucosa

these pathways are differentially regulated between the cell types. In addition, significant

enrichment between crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells in "*epithelium*

migration" [GO:0090132] and *"epithelial cell migration"* [GO:0010631] were uniquely identified

only in active UC among the most overrepresented biological processes (**Figure 3b**). Target

genes of differentially expressed miRNAs between cell populations in the UC remission group

were mainly related to cell migration and were least different between those populations

(**Figure 3b**).

Figure 3: Aberrantly expressed miRNAs of crypt-top (CD66a+) and crypt-bottom (CD44+) colonic epithelial cells are involved in UC-related processes. Top 10 overrepresented pathways within **(a)** and between **(b)** crypt-top (CD66a+) and crypt-bottom (CD44+) colonic epithelial cell populations during active (aUC) (n=16), quiescent UC (qUC) (n=15) and in controls (HC) (n=17) identified by miRNA-target gene set enrichment analysis. Dot size represents the number of miRNA gene-target count in the significantly enriched (FDR < 0.05) Reactome pathways **(a)** and GO categories **(b)**.

To summarize, despite the significant overlap of aberrantly expressed miRNAs of both colonic epithelial cell populations in regulatory signalling pathways, GSEA results reveal unique

involvement of miRNAs in UC-, inflammation- and intestinal barrier integrity-related processes

in different stages of disease activity and/or cell population.

miRNAs in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cells exhibit

co-expression pattern which is related to UC activity

First, to unveil the relation between individual miRNA expression levels and endoscopic Mayo

subscore in crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) colonic epithelial cells, Spearman

correlation analysis was applied. In crypt-bottom (CD44⁺) and crypt-top (CD66a⁺) colonic

epithelial cells, a number (n=34 and n=23, respectively) moderate positive ($0.4 <$ rho < 0.7;

FDR < 0.05) and a few (n=6 and n=7, respectively) moderate negative (-0.7 $<$ rho < -0.4; FDR

< 0.05) correlations were observed among the normalized miRNA expression levels and

endoscopic Mayo subscore (**Supplementary Figure S5; Supplementary Table S6;**

Supplementary Table S7). Noteworthy, analysis resulted not only in a substantial overlapping

in disease activity-associated miRNAs between both colonic epithelial cell populations (29

common moderately correlating miRNAs), but also revealed few cell population-unique

correlations.

Subsequently, we decided to perform more complex analysis and evaluate if certain colonic

epithelial cell miRNAs of both populations are co-expressed together. First, WGCNA

performed on all miRNAs of colonic epithelial cell populations uncovered the miRNA co-

expression network (**Figure 4a**) and identified two co-expression modules (M1 and M2).

Module M1 was comprised of 13 miRNAs (miR-10b-5p, miR-182-5p, miR-146a-5p, miR-196b-

5p, miR-222-3p, miR-27a-3p, miR-221-3p, miR-194-3p, miR-183-5p, miR-223-3p, miR-574-

5p, miR-135b-5p, miR-31-5p); while module M2 consisted of 11 miRNAs such as let-7b-5p,

miR-143-3p, miR-125a-5p, miR-15b-5p, let-7e-5p, miR-5100, miR-181b-5p, miR-1-3p, miR-

125b-5p, miR-100-5p, miR-195-5p. Module enrichment analysis based on the evaluation of

normalized enrichment score (NES) (**Figure 4b**) further revealed that module M1 was

significantly enriched in both crypt-top (CD66a⁺) and crypt-bottom (CD44⁺) epithelial cells of

patients with active UC (NES = 1.71 [$P_{adj.}$ = 9.7×10^{-3}] and 1.67 [$P_{adj.}$ = 2.9×10^{-2}], respectively),

while in both cell populations of control group individuals it was decreased (NES = -1.79 [$P_{adj.}$

= 7.7 × 10^{-3}] and -1.74 [$P_{adj.}$ = 5.0 × 10^{-2}], respectively). Interestingly, the enrichment values for

the module M2 were opposite to what was observed for M1, meaning the normalized

expression of module M2 in both crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) epithelial cell

populations of patients with active UC was significantly decreased (NES = -1.84 [$P_{adj.}$ = 9.7 ×

10^{-3}] and -1.80 [$P_{adj.}$ = 2.9 × 10^{-2}], respectively), while it was significantly enriched exclusively

in crypt-bottom (CD44$^+$) cells of patients with quiescent UC (NES = 2.08 [$P_{adj.}$ = 3.3 × 10^{-4}]).

Further, we focused on potentially pro-inflammatory module M1 and explored whether the

expression of this module in each of the studied epithelial cell populations is associated with

clinical characteristics of UC. Therefore, Spearman correlation analysis was applied to check

for the association between endoscopic Mayo subscore and module M1 eigengene value

(summarized module expression value). Analysis resulted in the significant moderate positive

correlation in both crypt-top (CD66a$^+$) and crypt-bottom (CD44$^+$) cells (rho = 0.68 [P = 1.08 ×

10^{-7}] and 0.60 [P = 1.07 × 10^{-5}], respectively) (**Figure 4c**). Next, AUC-ROC analysis was

employed to assess the performance of the module M1 eigengene value at distinguishing

between the active and quiescent UC in each of the studied colonic epithelial cell populations.

In the crypt-bottom (CD44$^+$) cells, analysis resulted in the AUC value of 80.0% (confidence

interval (CI): 63.6% - 96.4%), while in the crypt-top (CD66a$^+$) cells M1 eigengene expression

value demonstrated even better performance and showed the AUC value of 87.9% (CI: 74.0%

- 100.0%) when separating quiescent *vs.* active UC (**Figure 4d**). To evaluate the concordance

of the epithelial cell population-derived data with the situation in the colon tissue, we calculated

module M1 eigengene values in the tissue and performed analogous analysis as in the crypt-

top and crypt-bottom cell populations. Briefly, analysis provided almost identical results to

those observed in colonic epithelial cell populations with higher similarity to crypt-top cells.

More precisely, in colon tissue, module M1 eigenvalue showed strong positive correlation with

endoscopic Mayo subscore (rho = 0.703 [P = 1.22 × 10^{-11}]) and produced AUC value of 85.0%

(CI: 72.2% - 97.1%).

Generally, the results uncovered potential UC endoscopic activity-related miRNA co-

expression patterns that are not only characteristic for both crypt-top and crypt-bottom colonic

epithelial cell populations, but also reflect the overall situation in the more heterogenous colon

tissue.

Figure 4: WGCNA in colonic epithelial cell populations reveals miRNA co-expression module

which reflects endoscopic activity of UC. (a) Network displaying identified co-expression modules

(M1 and M2) in crypt-top (CD66a) and crypt-bottom (CD44) colonic epithelial cells of patients with active

(aUC) (n=16), quiescent UC (qUC) (n=15) and control individuals (n=17). The color and size of the node

represents distinct modules and strength of connectivity, respectively. **(b)** The dot plot showing

normalized enrichment score (NES) of the modules M1 and M2 in crypt-top (CD66a) and crypt-bottom

(CD44) colonic epithelial cells of patients with active, quiescent UC and control individuals. The color

and size of the dot represents the value and absolute value of NES, respectively. The box marks

significant value ($p_{adj,} < 0.05$). Plots **(c)** and **(e)** show the correlation between module M1 eigengene

value and Mayo endoscopic activity in crypt-bottom (CD44) and crypt-top (CD66a) colonic epithelial

cells as well as colon tissue, respectively. rho – Spearman correlation coefficient. Each dot represents

different sample. Plots **(d)** and **(f)** show the AUC-ROC curves reflecting the performance of M1 module

eigengene value at distinguishing between active (aUC) and quiescent UC (qUC) in crypt-bottom

(CD44) and crypt-top (CD66a) colonic epithelial cells as well as in colon tissue, respectively.

Discussion

Although UC is a well-studied complex disease and huge efforts have been made to explore

its molecular mechanisms, the disease pathogenesis still remains largely unclear[33].

Especially, there is a substantial knowledge gap about expression patterns of regulatory non-

coding miRNA in UC in a cell type-specific context. Thus, here we provide an overview of the

miRNA expression in the unsorted whole colonic mucosa samples of UC patients and present

detailed colonic epithelial cell population-specific miRNA expression profiles from active and

quiescent UC patients and describe differences in miRNA expression patterns between two

distinct - crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) - cell populations. Furthermore, we

describe putative biological pathways in which deregulated miRNAs of UC colonic epithelial

cell populations might be involved, identify potential inflammatory miRNA co-expression

module, determine its associations with endoscopic disease activity and evaluate the

performance in distinguishing between active and quiescent stages of UC.

Most importantly, we determined distinct responses in miRNA expression of different colonic

epithelial cell populations during UC. Our findings showed that in colon crypt-bottom (CD44$^+$)

cells (compared to crypt-top [CD66a$^+$] cells) inflammation promoted/suppressed the

expression of several miRNAs possibly involved in cell proliferation, differentiation and/or

permeability of intestinal barrier. For example, let-7c-5p showed considerable down-regulation

and miR-501-3p up-regulation in crypt-bottom (CD44$^+$) cells during active UC. It has previously

been shown that overexpression of let-7c-5p as well as inhibition of miR-501-3p can reduce

the proliferation of colorectal cancer cells[34,35]. Thus, deregulation of these miRNAs might be

related to the relative increase of the crypt-bottom (CD44$^+$) cells in active UC when compared

to controls, as it has been shown in our flow cytometry experiment. On the other hand, we

observed increased expression of miR-1-3p and decreased expression of miR-125b-5p in

crypt-bottom compared to crypt-top cells only during active UC. Both miRNAs were shown to

be involved in barrier function dysregulation, where decrease of miR-125b-5p[36] and increase

of miR-1-3p[37] contribute to disruption of epithelial barrier in colon tissue. This would suggest

that epithelial barrier is already impaired in crypt-bottom epithelial cells during active UC;

however, it remains unclear if this is a UC specific event or rather a normal cell response to

inflammation in the gut.

Furthermore, our analysis showed that not only certain individual miRNAs are associated with

the endoscopic Mayo subscore, but they also form an inflammation-related co-expression

network, which directly correlates with clinical disease activity. Of two identified miRNA co-

expression modules in both crypt-bottom (CD44[+]) and/or crypt-top (CD66a[+]) cells, module M1

was significantly enriched in both epithelial cell populations of active UC patients and was

comprised of such miRNAs as miR-31-5p, miR-135b-5p, miR-27a-3p, miR-222-3p, miR-223-

3p, etc. In the literature, these small non-coding RNAs are also reported to be upregulated in

inflamed, non-inflamed and/or pre-cancerous colon tissues as well as in faeces (specifically,

miR-223-3p) of UC patients[38–43] and are involved in the regulation of inflammatory response

(e.g. miR-222-3p targets *SOCS1* and activates STAT3 signalling)[44–46]. Additionally, we

observed that all miRNAs belonging to module M1 were involved in Reactome pathways

related to interleukin signalling by targeting various validated genes (such as *FOXO3, IGF1R,*

ICAM1, STAT6, STAT1, STAT5A, CCND1, etc.). Interestingly, when comparing crypt-top and

crypt-bottom cell populations-derived module M1 performance and association results to colon

tissue, both the correlation coefficient and AUC values in tissue were more like those observed

in crypt-top (CD66a[+]) cells. This may be at least partially explained by the cellular composition

of the colon mucosa, the most abundant cell type in mucosal layer being absorptive

colonocytes[47]. Of note, even though the second identified miRNA co-expression module M2

did not show meaningful associations with clinical characteristics of UC, its exclusive

enrichment in crypt-bottom (CD44[+]) colonic epithelial cells of patients with quiescent disease

provides novel insights in regulatory mechanisms during UC. For example, among module M2

miRNAs we identified let-7e-5p, the individual expression of which also negatively correlated

with the endoscopic Mayo subscore exclusively in crypt-bottom (CD44[+]) colonic epithelial

cells. Additionally, in the intestinal epithelium let-7 family member let-7b appears to be among

the highest-expressed miRNAs in let-7 group/family (**Supplementary Figure S4**). It has

previously been shown that expression of let-7 miRNAs (especially let-7e) is increased and

affects maintenance of cell differentiation[48]. Altogether, these observations suggest the

relevance of let-7 miRNAs during intestinal inflammation via maintenance of stemness of

crypt-bottom (CD44[+]) cells and thereby explain their expression correlation with disease

activity, exclusively in undifferentiated colonic epithelial cells.

Finally, we described potential involvement of differentially expressed miRNAs in regulatory

biological pathways. Our initial small RNA-seq of colonic mucosa biopsies from active and

quiescent UC compared to healthy controls, at first, revealed multiple deregulated miRNAs,

which were significantly enriched in inflammation- and intestinal epithelial barrier function-

related biological pathways. Interestingly, miRNAs enriched in interleukin biological pathways,

such as interleukin-4 and interleukin-13 signalling, were deregulated not only in active, but

also in quiescent UC, suggesting lasting derangement of this pathway in mucosa of UC. The

interleukin-4 and interleukin-13 pathway is known to differentially regulate epithelial chloride

secretion and cause epithelial barrier dysfunction[49]. It has been shown that large amounts of

interleukin-13 are produced in colon mucosa of UC patients and thereby impair epithelial

barrier function by affecting epithelial apoptosis, tight junctions, and restitution velocity[29,50]. We

also confirmed the increased expression of interleukin-13 gene during the course of UC when

analysing active and quiescent UC patient colon tissue samples. Contrarily, some studies

report decreased mucosal amounts of interleukin-13 in active UC[51]. Nevertheless, the

attempts are still being made to adapt the inhibition of interleukin-13-based treatment to induce

UC remission (e.g., clinical trials of anti-interleukin-13 monoclonal antibodies (tralokinumab

and anrukinzumab)[52] and preclinical studies of anti-interleukin-Rα2[53]). Our findings on

differentially expressed miRNA involvement in interleukin-4 and interleukin-13 regulation even

in quiescent UC as well as controversial data in the literature led us to further focus on miRNA

expression analysis in less differentiated crypt-bottom (CD44[+]) and fully differentiated

absorptive crypt-top (CD66a[+]) colonic epithelial cells, which are responsible for intestinal

barrier integrity and permeability[2]. Similarly to the results in colonic biopsies, both crypt-bottom

(CD44[+]) and crypt-top (CD66a[+]) epithelial cell populations showed deregulation in miRNAs

during UC, the targets of which were significantly enriched in the interleukin-4 and interleukin-

13 signalling pathway. Since interleukin-4 and interleukin-13 cytokines are predominantly

produced by immune cells[54], the expected regulatory action of deregulated miRNAs in the

colonic epithelial cells would be downstream targets of the pathway, such as *STAT3*, *FOXO3*,

SOCS1, etc. During active UC in both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells, we

found miR-221-3p, miR-182-6p, miR-222-3p and miR-31-5p to be up-regulated, which are

known to target *FOXO3* gene[22]. The up-regulation of the aforementioned miRNAs,

theoretically, would lead to decreased expression of the *FOXO3* gene, which was already

observed in colonic mucosa of UC patients[55]. This in turn, may lead to more severe colonic

inflammation during UC[56]. Additionally, both crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$)

cells of patients with active UC had increased expression of hsa-miR-221-3p and hsa-miR-21-

5p, that target *SOCS1* gene[22]. SOCS1 is an important regulator of interleukin-4 signalling, and

its forced expression was shown to inhibit interleukin-13 signalling in epithelial cells[57]. In

addition to involvement in interleukin signalling pathways, we also detected unique intestinal

epithelial barrier function-related processes regulated by disease stage and/or cell population-

specific miRNAs. For example, differentially expressed miRNAs, such as miR-222-3p, miR-

223-3p, miR-15b-5p, in crypt-bottom (CD44$^+$) colonic epithelial cells of quiescent UC could

potentially regulate nuclear receptors and extra-nuclear estrogen signalling pathways. These

findings fall in accordance with other studies demonstrating the importance of impairment of

signal transduction via nuclear receptors in inflammatory bowel disease, as nuclear receptors

regulate essential aspects of intestinal barrier functions such as mucus secretion, expression

of tight junction proteins and others[32]. Moreover, we observed a few aberrantly expressed

miRNAs between crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) cells in active UC, that

possibly exert their biological function through regulation of epithelial cell migration, which is

known to happen along the crypt-villus axis[58] and is increased during IBD[59]. Noteworthy, the

GSEA results should be treated with caution, since the selection of miRNA targets significantly

affects the results[60]. However, currently, there are no methods to solve this issue, since miRNA

target prediction as well as its dosage to affect target expression are still rather unsolved

problems in the field.

In summary, our study determined crypt-bottom (CD44$^+$) and crypt-top (CD66a$^+$) colonic

epithelial cell-specific miRNA deregulation in UC in cell type- and disease stage-dependent

manner. We also revealed cell population-specific miRNA expression patterns and networks

as well as their associations with clinical disease activity. Furthermore, we unveiled the

potential functional role of differentially expressed miRNAs and observed their possible

involvement in biological pathways associated with maintenance of intestinal barrier function

in active as well as quiescent UC, in both epithelial cell populations. Together, these

observations not only highlight regulatory importance of miRNAs in distinct colonic epithelial

cell populations during pathogenesis of UC, but also provide potential miRNA candidates for

the development of new treatment strategies to maintain the remission of mucosal

inflammation.

Funding

This work was supported by the Research Council of Lithuania and European Crohn's and

Colitis Organisation (grant numbers S-MIP-20-56 and ECCO Grant 2016, respectively).

Conflict of Interest

The authors declare no conflict of interest.

Data Availability

The small RNA-seq data underlying this article are available in Gene Expression Omnibus

(GEO) Database and can be accessed with accession numbers GSE185101 (reviewer token:

gxytcgywnvejvit) and GSE185102 (reviewer token: **ijydywoajxyvxmr**).

Author contributions

JS, SJ, and JK participated in the concept and design of the study. JK, LVJ, VK, UK, GV and

GK participated in patient recruitment and material collection and sample processing. RR, ID,

and AZ were responsible for fluorescence-activated cell sorting. AF and SS provided

infrastructure for small RNA library preparation and sequencing. RI and SJ were responsible

for bioinformatics, statistical analysis, data interpretation and writing the first draft of the

manuscript. All authors were members of the writing group and participated in the drafting

revision of the manuscript.

References

1. Antoni L., Nuding S., Wehkamp J., Stange EF. Intestinal barrier in inflammatory bowel disease. *World J Gastroenterol* 2014;**20**(5):1165–79.

2. Nyström EEL., Martinez-Abad B., Arike L., Birchenough GMH., Nonnecke EB., Castillo PA., et al. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. *Science* 2021;**372**(6539).

3. Cichon C., Sabharwal H., Rüter C., Schmidt MA. MicroRNAs regulate tight junction proteins and modulate epithelial/endothelial barrier functions. *Tissue Barriers* 2014;**2**(4).

4. Ye D., Guo S., Alsadi R., Ma TY. MicroRNA regulation of intestinal epithelial tight junction permeability. *Gastroenterology* 2011;**141**(4):1323–33.

5. Schroeder KW., Tremaine WJ., Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;**317**(26):1625–9.

6. Magro F., Gionchetti P., Eliakim R., Ardizzone S., Armuzzi A., Barreiro-de Acosta M., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *J Crohns Colitis* 2017;**11**(6):649–70.

7. Dalerba P., Kalisky T., Sahoo D., Rajendran PS., Rothenberg ME., Leyrat AA., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. *Nat Biotechnol* 2011;**29**(12):1120–7.

8. Ewels PA., Peltzer A., Fillinger S., Patel H., Alneberg J., Wilm A., et al. The nf-core framework for community-curated bioinformatics pipelines. *Nat Biotechnol* 2020:276–8.

9.   Pantano L., Estivill X., Martí E. A non-biased framework for the annotation and

classification of the non-miRNA small   RNA transcriptome. *Bioinformatics*

2011;**27**(22):3202–3.

10.   Langmead B., Trapnell C., Pop M., Salzberg SL. Ultrafast and memory-efficient

alignment of short DNA sequences to the human genome. *Genome Biol*

2009;**10**(3):1–10.

11.   Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: from microRNA

sequences to function. *Nucleic Acids Res* 2019;**47**(D1):D155–62.

12.   Desvignes T., Loher P., Eilbeck K., Ma J., Urgese G., Fromm B., et al. Unification

of miRNA and isomiR research: the mirGFF3 format and the mirtop API.

Bioinformatics 2020;**36**(3):698–703.

13.   Love MI., Huber W., Anders S. Moderated estimation of fold change and

dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;**15**(12):1–21.

14.   Ritchie ME., Phipson B., Wu D., Hu Y., Law CW., Shi W., et al. limma powers

differential expression analyses for RNA-sequencing and microarray studies.

Nucleic Acids Res 2015;**43**(7):e47.

15.   R Foundation for Statistical Computing. R Core Team. R: A language and

environment for statistical computing 2021:https://www.r-project.org/.

16.   Wickham H. ggplot2: Elegant Graphics for Data Analysis 2016.

17.   Jassal B., Matthews L., Viteri G., Gong C., Lorente P., Fabregat A., et al. The

reactome pathway knowledgebase. *Nucleic Acids Res* 2020;**48**(D1):D498–503.

18.   Thomas PD., Ebert D., Muruganujan A., Mushayahama T., Albou LP., Mi H.

PANTHER: Making genome-scale phylogenetics accessible to all. *Protein Sci*

2022;**31**(1):8–22.

19.   Xiao F., Zuo Z., Cai G., Kang S., Gao X., Li T. miRecords: an integrated resource

for microRNA-target interactions. *Nucleic Acids Res* 2009;**37**(Database

issue):D105–10.

20.   Hsu S-D., Lin F-M., Wu W-Y., Liang C., Huang W-C., Chan W-L., et al.

miRTarBase: a database curates experimentally validated microRNA-target

interactions. *Nucleic Acids Res* 2011;**39**(Database issue):D163–9.

21.   Karagkouni D., Paraskevopoulou MD., Chatzopoulos S., Vlachos IS.,

Tastsoglou S., Kanellos I., et al. DIANA-TarBase v8: a decade-long collection of

experimentally supported miRNA-gene interactions. *Nucleic Acids Res*

2018;**46**(D1):D239–45.

22.   Ru Y., Kechris KJ., Tabakoff B., Hoffman P., Radcliffe RA., Bowler R., et al. The

multiMiR R package and database: integration of microRNA-target interactions

along with their disease and drug associations. *Nucleic Acids Res*

2014;**42**(17):e133.

23.   Yu G., He Q-Y. ReactomePA: an R/Bioconductor package for reactome pathway

analysis and visualization. *Mol Biosyst* 2016;**12**(2):477–9.

24.   Wu T., Hu E., Xu S., Chen M., Guo P., Dai Z., et al. clusterProfiler 4.0: A

universal enrichment tool for interpreting omics data. *Innov* 2021;**2**(3).

25.   Parikh K., Antanaviciute A., Fawkner-Corbett D., Jagielowicz M., Aulicino A.,

Lagerholm C., et al. Colonic epithelial cell diversity in health and inflammatory

bowel disease. *Nature* 2019;**567**(7746):49–55.

26.   Russo PST., Ferreira GR., Cardozo LE., Bürger MC., Arias-Carrasco R.,

Maruyama SR., et al. CEMiTool: a Bioconductor package for performing

comprehensive modular co-expression analyses. *BMC Bioinformatics*

2018;**19**(1):56.

27.   Langfelder P., Horvath S. WGCNA: an R package for weighted correlation

network analysis. *BMC Bioinformatics* 2008;**9**(1):559.

28.   Robin X., Turck N., Hainard A., Tiberti N., Lisacek F., Sanchez J-C., et al. pROC:

an open-source package for R and S+ to analyze and compare ROC curves.

BMC Bioinformatics 2011;**12**(1):77.

29.   Heller F., Florian P., Bojarski C., Richter J., Christ M., Hillenbrand B., et al.

Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects

epithelial tight junctions, apoptosis, and cell restitution. *Gastroenterology*

2005;**129**(2):550–64.

30.   Yao D., Dong M., Dai C., Wu S. Inflammation and Inflammatory Cytokine

Contribute to the Initiation and Development of Ulcerative Colitis and Its

Associated Cancer. *Inflamm Bowel Dis* 2019;**25**(10):1595–602.

31.   MacDonald TT. Epithelial proliferation in response to gastrointestinal

inflammation. *Ann N Y Acad Sci* 1992;**664**:202–9.

32.   Jacenik D., Zielińska M., Mokrowiecka A., Michlewska S., Małecka-Panas E.,

Kordek R., et al. G protein-coupled estrogen receptor mediates anti-

inflammatory action in Crohn's disease. *Sci Rep* 2019;**9**(1):6749.

33.   Ungaro R., Mehandru S., Allen PB., Peyrin-Biroulet L., Colombel J-F. Ulcerative

colitis. *Lancet (London, England)* 2017;**389**(10080):1756–70.

34.   Wu F., Xing T., Gao X., Liu F. miR-501-3p promotes colorectal cancer

progression via activation of Wnt/β-catenin signaling. *Int J Oncol*

2019;**55**(3):671–83.

35.   Akao Y., Nakagawa Y., Naoe T. let-7 microRNA functions as a potential growth

suppressor in human colon cancer cells. *Biol Pharm Bull* 2006;**29**(5):903–6.

36.   Martínez C., Rodiño-Janeiro BK., Lobo B., Stanifer ML., Klaus B., Granzow M.,

et al. miR-16 and miR-125b are involved in barrier function dysregulation

through the modulation of claudin-2 and cingulin expression in the jejunum in

IBS with diarrhoea. *Gut* 2017;**66**(9):1537–8.

37. Sun T-Y., Li Y-Q., Zhao F-Q., Sun H-M., Gao Y., Wu B., et al. MiR-1-3p and

MiR-124-3p Synergistically Damage the Intestinal Barrier in the Ageing Colon.

J Crohns Colitis 2022;**16**(4):656–67.

38. Tian Y., Xu J., Li Y., Zhao R., Du S., Lv C., et al. MicroRNA-31 Reduces

Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and

Delivery of Mimics in Microspheres Reduces Colitis in Mice. *Gastroenterology*

2019;**156**(8):2281-2296.e6.

39. Masi L., Capobianco I., Magrì C., Marafini I., Petito V., Scaldaferri F. MicroRNAs

as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of

Colorectal Cancer. *Int J Mol Sci* 2022.

40. Su C., Huang D-P., Liu J-W., Liu W-Y., Cao Y-O. miR-27a-3p regulates

proliferation and apoptosis of colon cancer cells by potentially targeting BTG1.

Oncol Lett 2019;**18**(3):2825–34.

41. Zhou J., Liu J., Gao Y., Shen L., Li S., Chen S. miRNA-Based Potential

Biomarkers and New Molecular Insights in Ulcerative Colitis. *Front Pharmacol*

2021;**12**:707776.

42. Béres NJ., Szabó D., Kocsis D., Szűcs D., Kiss Z., Müller KE., et al. Role of

Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients

with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2016;**22**(2):327–35.

43. Neudecker V., Haneklaus M., Jensen O., Khailova L., Masterson JC., Tye H., et

al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of

the NLRP3 inflammasome. *J Exp Med* 2017;**214**(6):1737–52.

44. Gwiggner M., Martinez-Nunez RT., Whiteoak SR., Bondanese VP., Claridge A.,

Collins JE., et al. MicroRNA-31 and MicroRNA-155 Are Overexpressed in

Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13

Receptor α-1. *Genes (Basel)* 2018.

45.   Xia F., Bo W., Ding J., Yu Y., Wang J. MiR-222-3p Aggravates the Inflammatory

Response by Targeting SOCS1 to Activate STAT3 Signaling in Ulcerative

Colitis. *Turkish J Gastroenterol Off J Turkish Soc Gastroenterol*

2022;**33**(11):934–44.

46.   Wang H., Chao K., Ng SC., Bai AH., Yu Q., Yu J., et al. Pro-inflammatory miR-

223 mediates the cross-talk between the IL23 pathway and the intestinal barrier

in inflammatory bowel disease. *Genome Biol* 2016;**17**:58.

47.   Allaire JM., Crowley SM., Law HT., Chang S-Y., Ko H-J., Vallance BA. The

Intestinal Epithelium: Central Coordinator of Mucosal Immunity. *Trends Immunol*

2018;**39**(9):677–96.

48.   Chirshev E., Oberg KC., Ioffe YJ., Unternaehrer JJ. Let-7 as biomarker,

prognostic indicator, and therapy for precision medicine in cancer. *Clin Transl*

Med 2019;**8**(1):24.

49.   Saatian B., Rezaee F., Desando S., Emo J., Chapman T., Knowlden S., et al.

Interleukin-4 and interleukin-13 cause barrier dysfunction in human airway

epithelial cells. *Tissue Barriers* 2013;**1**(2):e24333.

50.   Rosen MJ., Frey MR., Washington MK., Chaturvedi R., Kuhnhein LA., Matta P.,

et al. STAT6 activation in ulcerative colitis: a new target for prevention of IL-13-

induced colon epithelial cell dysfunction. *Inflamm Bowel Dis* 2011;**17**(11):2224–

34.

51.   Kadivar K., Ruchelli ED., Markowitz JE., Defelice ML., Strogatz ML., Kanzaria

MM., et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease

patients. *Inflamm Bowel Dis* 2004;**10**(5):593–8.

52.   Giuffrida P., Caprioli F., Facciotti F., Di Sabatino A. The role of interleukin-13 in

chronic inflammatory intestinal disorders. *Autoimmun Rev* 2019;**18**(5):549–55.

53.   Karmele EP., Pasricha TS., Ramalingam TR., Thompson RW., Gieseck RL 3rd.,

Knilans KJ., et al. Anti-IL-13Rα2 therapy promotes recovery in a murine model

of inflammatory bowel disease. *Mucosal Immunol* 2019;**12**(5):1174–86.

54.   Junttila IS. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and

IL-13 Receptor Complexes. *Front Immunol* 2018;**9**:888.

55.   Min M., Yang J., Yang Y-S., Liu Y., Liu L-M., Xu Y. Expression of Transcription

Factor FOXO3a is Decreased in Patients with Ulcerative Colitis. *Chin Med J*

(Engl) 2015;**128**(20):2759–63.

56.   Snoeks L., Weber CR., Wasland K., Turner JR., Vainder C., Qi W., et al. Tumor

suppressor FOXO3 participates in the regulation of intestinal inflammation. *Lab*

Invest 2009;**89**(9):1053–62.

57.   Doran E., Choy DF., Shikotra A., Butler CA., O'Rourke DM., Johnston JA., et al.

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic

asthma. *Eur Respir J* 2016;**48**(3):715–25.

58.   Krndija D., El Marjou F., Guirao B., Richon S., Leroy O., Bellaiche Y., et al. Active

cell migration is critical for steady-state epithelial turnover in the gut. *Science*

2019;**365**(6454):705–10.

59.   Martini E., Krug SM., Siegmund B., Neurath MF., Becker C. Mend Your Fences:

The Epithelial Barrier and its Relationship With Mucosal Immunity in

Inflammatory Bowel Disease. *Cell Mol Gastroenterol Hepatol* 2017;**4**(1):33–46.

60.   Godard P., van Eyll J. Pathway analysis from lists of microRNAs: common

pitfalls and alternative strategy. *Nucleic Acids Res* 2015;**43**(7):3490–7.

Supplementary Figure S1: Fluorescence-activated cell sorting (FACS) of crypt-bottom (CD44+) and crypt-top (CD66a+) colonic epithelial cells from patients with active and quiescent UC and healthy controls (HC). (a) Gating strategy for FACS isolation of crypt-top CD44+/CD66a- and crypt-bottom CD44-/CD66a+ epithelial cell populations: selection of epithelial cells by CD45 exclusion, EpCAM inclusion and further isolation of populations by CD44 and CD66a expression. **(b-d)** Representative plots of flow cytometry data showing distribution of CD44+/CD66a- and CD44-/CD66a+ colonic epithelial cell populations during **(b)** active UC (aUC), **(c)** quiescent UC (qUC), and **(d)** in healthy controls (HC).

Supplementary Figure S2: The expression levels of *IL-4* and *IL-13* genes measured by RT-qPCR in colon tissue samples of an independent cohort of HC, active UC, and quiescent UC individuals. Dots represent outliers in each group. Gene expression is represented in logarithmic scale, ΔCt values are inversed in order to show true direction of the expression. Significance levels: * p <= 0.05, *** p <= 0.001, **** p <= 0.0001, ns – not significant.

Supplementary Figure S3. Most abundant (top 20) miRNA expression in colonic epithelial cell CD44+ and CD66a+ populations from UC patients (active and remission) and healthy controls. In each cell population and condition, the median normalized expression levels are represented by color, and rank by dot size. Most abundant miRNAs are ranked in descending order, to be precise, the highest expression value is ranked as 1.

Supplementary Table S1. Demographic and clinical characteristics of Study group III subjects recruited for *IL-4* and *IL-13* gene expression analysis in colon tissues

	Study group III, n=200		
	Active UC, n=75	Quiescent UC, n=50	HC, n=75
Age			
Mean ± SD	46.1 ± 13.7	47.3 ± 16.1	46.3 ± 11.9
Sex, n (%)			
Female	37 (49.3)	24 (48.0)	38 (50.7)
Full Mayo score, n (%)			
Remission	0 (0.0)	50 (100.0)	-
Mild	3 (4.0)	0 (0.0)	-
Moderate	70 (93.3)	0 (0.0)	-
Severe	2 (2.7)	0 (0.0)	-
Endoscopic Mayo subscore, n (%)			
Normal to mild	0 (0.0)	50 (100.0)	75 (100.0)
Moderate to severe	75 (100.0)	0 (0.0)	-
Smoking status, n (%)			
Never	43 (57.3)	24 (48.0)	43 (57.3)
Smoking	8 (10.7)	8 (16.0)	17 (22.7)
Ex-smoker	22 (29.3)	16 (32.0)	12 (16.0)
Unknown	2 (2.7)	2 (4.0)	3 (4.0)
BMI, kg/m^2			
Median,	24.9	25.8	24.9
(range)	(16.2–41.5)	(19.5–34.6)	(16.9–49.3)
Unknown, n (%)		2 (4.0)	5 (6.7)

SD - Standard deviation

Supplementary Table S2. The list of differentially expressed colon tissue miRNAs in active (aUC) and quiescent (qUC) UC

mir	baseMean	log2FoldChange	lfcSE	stat	pvalue	padj	comparison
hsa-let-7i-3p	86,84697092	1,032192316	0,162608863	6,347700233	2,18557E-10	2,85686E-09	aUC_vs_HC
hsa-miR-1-3p	45,63524901	-2,177255122	0,308443343	-7,058849456	1,67887E-12	3,84041E-11	aUC_vs_HC
hsa-miR-101-3p	5009,576619	-1,021882072	0,113592099	-8,996066427	2,3395E-19	3,21096E-17	aUC_vs_HC
hsa-miR-106a-5p	7,864580879	-2,173205539	0,455936996	-4,766460185	1,87491E-06	1,06116E-05	aUC_vs_HC
hsa-miR-10b-5p	122360,1491	-1,569178268	0,20857132	-7,523461367	5,33448E-14	1,83039E-12	aUC_vs_HC
hsa-miR-1180-3p	21,60809363	1,225578767	0,245182637	4,998636046	5,77373E-07	3,60202E-06	aUC_vs_HC
hsa-miR-1185-1-3p	3,125659317	1,507760439	0,282196711	5,342941224	9,14504E-08	6,87757E-07	aUC_vs_HC
hsa-miR-124-3p	1,968730778	-1,502208785	0,435183154	-3,451900126	0,000556654	0,001898155	aUC_vs_HC
hsa-miR-1247-3p	4,964618308	-1,052171052	0,339634825	-3,097948077	0,001948656	0,005486215	aUC_vs_HC
hsa-miR-125b-1-3p	26,59922677	1,951882024	0,258606278	7,547697745	4,4302E-14	1,62145E-12	aUC_vs_HC
hsa-miR-1261	6,828010694	1,107609554	0,264311253	4,190550117	2,78279E-05	0,00012125	aUC_vs_HC
hsa-miR-1271-5p	5,030666509	-1,556292302	0,558285461	-2,787628213	0,005309544	0,012955287	aUC_vs_HC
hsa-miR-130b-3p	320,174747	1,179371908	0,133733179	8,818842995	1,15648E-18	1,26982E-16	aUC_vs_HC
hsa-miR-132-5p	21,32720117	1,353139976	0,195751344	6,912544992	4,76035E-12	9,67938E-11	aUC_vs_HC
hsa-miR-135a-5p	1,478716928	-1,357836125	0,597622986	-2,272061412	0,023082801	0,047285291	aUC_vs_HC
hsa-miR-137-3p	1,561737961	-1,411311512	0,437967787	-3,222409393	0,001271174	0,003792795	aUC_vs_HC
hsa-miR-138-1-3p	2,017574347	1,891697916	0,421088218	4,492402866	7,0424E-06	3,45204E-05	aUC_vs_HC
hsa-miR-138-5p	58,32514755	1,185434796	0,210999646	5,618183817	1,92975E-08	1,59918E-07	aUC_vs_HC
hsa-miR-146a-5p	2578,691154	1,438063623	0,239982974	5,992356877	2,06821E-09	2,18356E-08	aUC_vs_HC
hsa-miR-146b-3p	131,694782	1,091530489	0,170292315	6,409746039	1,45762E-10	2,05188E-09	aUC_vs_HC
hsa-miR-150-3p	10,85123407	1,665312473	0,324159634	5,137322158	2,78681E-07	1,82138E-06	aUC_vs_HC
hsa-miR-150-5p	2111,72082	1,000240405	0,234036173	4,273870975	1,92108E-05	8,78895E-05	aUC_vs_HC
hsa-miR-155-5p	990,5539321	1,427450703	0,186793564	7,641862342	2,14102E-14	8,39586E-13	aUC_vs_HC
hsa-miR-181b-3p	1,83619171	1,133378149	0,349597803	3,241948719	0,001187154	0,003561461	aUC_vs_HC
hsa-miR-185-3p	3,736284581	1,12778486	0,274959224	4,101644038	4,10225E-05	0,000171919	aUC_vs_HC
hsa-miR-190a-3p	9,619305454	-1,037177475	0,252801228	-4,102739066	4,08288E-05	0,000171919	aUC_vs_HC
hsa-miR-190a-5p	464,0866948	-2,371130192	0,226927531	-10,4488432	1,48323E-25	8,14295E-23	aUC_vs_HC
hsa-miR-191-3p	6,696832516	1,227723929	0,265322231	4,627293862	3,70475E-06	1,93705E-05	aUC_vs_HC
hsa-miR-192-5p	406326,2139	-1,3899334	0,174124233	-7,9824237	1,43488E-15	8,75274E-14	aUC_vs_HC
hsa-miR-194-3p	150,6914997	-1,272355981	0,162716803	-7,81945048	5,30544E-15	2,42724E-13	aUC_vs_HC
hsa-miR-200c-3p	4008,129423	-1,024502993	0,152360528	-6,72420215	1,76557E-11	2,78785E-10	aUC_vs_HC
hsa-miR-204-5p	62,05433726	-1,204955314	0,264681881	-4,552466197	5,30207E-06	2,64621E-05	aUC_vs_HC
hsa-miR-205-5p	17,95505274	-9,943858929	2,289954432	-4,342382883	1,40946E-05	6,55755E-05	aUC_vs_HC
hsa-miR-20a-5p	811,7990547	-1,396745706	0,173751808	-8,038740564	9,07665E-16	6,22885E-14	aUC_vs_HC
hsa-miR-212-3p	30,48085194	1,577523626	0,193123203	8,168483122	3,12291E-16	2,44925E-14	aUC_vs_HC
hsa-miR-218-5p	77,94441265	-1,064708207	0,163008098	-6,531627672	6,50587E-11	9,39927E-10	aUC_vs_HC
hsa-miR-222-5p	1,053424073	1,653489648	0,545302847	3,032240993	0,002427453	0,006597385	aUC_vs_HC
hsa-miR-223-3p	651,8784999	2,392458551	0,255755992	9,354457462	8,40299E-21	2,30662E-18	aUC_vs_HC
hsa-miR-223-5p	9,333993505	1,642102616	0,329461765	4,984197841	6,22194E-07	3,83803E-06	aUC_vs_HC
hsa-miR-25-5p	11,60936066	1,323947131	0,223766747	5,916639311	3,28586E-09	3,22132E-08	aUC_vs_HC
hsa-miR-27a-5p	27,7926062	1,153381048	0,226109365	5,100987523	3,37886E-07	2,15697E-06	aUC_vs_HC
hsa-miR-31-5p	165,9807895	2,190879573	0,63845352	3,431541223	0,000600162	0,001996902	aUC_vs_HC
hsa-miR-3117-3p	1,989608279	1,285027211	0,4054146	3,1696619	0,001526164	0,004480557	aUC_vs_HC
hsa-miR-3131	1,15081761	-1,182126445	0,479479484	-2,465436966	0,013684625	0,030051437	aUC_vs_HC
hsa-miR-3150b-3p	1,703386787	-1,005305904	0,38058088	-2,641503964	0,008253884	0,019364882	aUC_vs_HC
hsa-miR-3168	4,064948507	4,463050883	0,815284531	5,474224906	4,39431E-08	3,35066E-07	aUC_vs_HC
hsa-miR-3176	5,988027981	1,265612221	0,339932062	3,723132829	0,000196766	0,000744997	aUC_vs_HC
hsa-miR-3182	6,296971943	2,499271721	0,547890208	4,561628744	5,07583E-06	2,55654E-05	aUC_vs_HC
hsa-miR-342-5p	8,253483302	2,014707864	0,315663253	6,382459297	1,74266E-10	2,33347E-09	aUC_vs_HC
hsa-miR-34a-3p	1,245512505	1,159761855	0,434338232	2,670181369	0,007581029	0,017939589	aUC_vs_HC
hsa-miR-3605-3p	5,610256945	1,54692813	0,299422539	5,166371689	2,38682E-07	1,59984E-06	aUC_vs_HC
hsa-miR-3609	1,222421126	1,868048216	0,47017792	3,973066654	7,09532E-05	0,000286421	aUC_vs_HC
hsa-miR-3614-5p	10,11772198	1,049562412	0,224786747	4,669147208	3,02453E-06	1,6121E-05	aUC_vs_HC
hsa-miR-3615	37,87345141	1,422727385	0,228825106	6,217531857	5,05036E-10	5,77635E-09	aUC_vs_HC
hsa-miR-362-5p	44,73684131	-1,661882245	0,247184865	-6,723236256	1,77732E-11	2,78785E-10	aUC_vs_HC
hsa-miR-378a-3p	20556,27074	-1,176076514	0,148448231	-7,922469018	2,3284E-15	1,24589E-13	aUC_vs_HC
hsa-miR-378a-5p	134,3466478	-1,495187584	0,214151454	-6,981916556	2,9118E-12	6,39431E-11	aUC_vs_HC
hsa-miR-378i	8,278677288	-3,080178358	0,579172494	-5,318240055	1,04776E-07	7,77323E-07	aUC_vs_HC
hsa-miR-423-5p	842,8864905	1,513286332	0,22711965	6,662947633	2,68389E-11	4,09294E-10	aUC_vs_HC
hsa-miR-424-3p	21,42277155	1,420632599	0,222459834	6,386018427	1,7026E-10	2,33347E-09	aUC_vs_HC
hsa-miR-431-3p	2,39402778	1,158190324	0,378233373	3,062105057	0,002197863	0,006033134	aUC_vs_HC

hsa-miR-431-5p	10,71876204	1,829237631	0,268459786	6,813823615	9,50382E-12	1,6831E-10	aUC_vs_HC
hsa-miR-4326	4,597156676	1,106142242	0,282106077	3,921015291	8,81767E-05	0,00035079	aUC_vs_HC
hsa-miR-4448	5,359009229	2,612686845	0,507761522	5,14549987	2,66809E-07	1,7648E-06	aUC_vs_HC
hsa-miR-4454	32,35078856	1,05156346	0,247938123	4,241233444	2,22295E-05	0,000100859	aUC_vs_HC
hsa-miR-4455	1,825290976	1,383568973	0,438537318	3,154962912	0,001605185	0,00466268	aUC_vs_HC
hsa-miR-449c-5p	1,553470785	1,413938598	0,58906155	2,400324039	0,016380564	0,035545177	aUC_vs_HC
hsa-miR-4516	25,0311553	1,848471166	0,50832383	3,6364047	0,00027647	0,001018671	aUC_vs_HC
hsa-miR-451a	3390,36826	-1,056383964	0,291925832	-3,618672448	0,000296118	0,001077432	aUC_vs_HC
hsa-miR-4636	1,622644125	-1,583538451	0,442206344	-3,580994423	0,000342289	0,001212365	aUC_vs_HC
hsa-miR-486-5p	6784,687476	-1,100433516	0,271604255	-4,051606325	5,08672E-05	0,000209971	aUC_vs_HC
hsa-miR-493-3p	18,42199711	1,031030186	0,197013565	5,233295402	1,66514E-07	1,20285E-06	aUC_vs_HC
hsa-miR-511-5p	9,780917612	1,527305649	0,275784363	5,538042964	3,0587E-08	2,43366E-07	aUC_vs_HC
hsa-miR-548au-5p	1,45074882	1,431312293	0,395556653	3,618476096	0,000296343	0,001077432	aUC_vs_HC
hsa-miR-548az-5p	1,378670418	-1,649262186	0,534920327	-3,083192213	0,002047928	0,005707171	aUC_vs_HC
hsa-miR-549a-5p	2,928751124	2,771494101	0,60229855	4,601528765	4,19401E-06	2,15188E-05	aUC_vs_HC
hsa-miR-550a-5p	2,193287616	1,709816147	0,410506507	4,165137744	3,11165E-05	0,000134511	aUC_vs_HC
hsa-miR-551b-3p	4,182970423	-1,002532044	0,386211821	-2,595808804	0,009436856	0,021952686	aUC_vs_HC
hsa-miR-552-3p	17,46052299	-1,625010798	0,245018121	-6,632206593	3,30705E-11	4,90695E-10	aUC_vs_HC
hsa-miR-552-5p	11,81078551	-1,606097138	0,268580888	-5,979938305	2,23222E-09	2,31224E-08	aUC_vs_HC
hsa-miR-5571-3p	14,88030368	1,846041382	0,315286278	5,855127583	4,76644E-09	4,43521E-08	aUC_vs_HC
hsa-miR-5571-5p	6,465962202	2,645368813	0,36622185	7,223405191	5,07017E-13	1,46501E-11	aUC_vs_HC
hsa-miR-584-5p	29,79418754	1,438767611	0,212231354	6,779241532	1,20808E-11	2,07262E-10	aUC_vs_HC
hsa-miR-618	1,854002716	1,272536742	0,407762644	3,120778131	0,001803739	0,005130842	aUC_vs_HC
hsa-miR-625-3p	21,77849347	1,11155585	0,236537817	4,6992733	2,61089E-06	1,44786E-05	aUC_vs_HC
hsa-miR-625-5p	34,05882263	1,249226796	0,136573291	9,146933408	5,85726E-20	1,07188E-17	aUC_vs_HC
hsa-miR-628-5p	14,9630011	1,02350918	0,167631953	6,10569263	1,02356E-09	1,12387E-08	aUC_vs_HC
hsa-miR-651-5p	15,83452534	-1,032889311	0,176142301	-5,863948095	4,51989E-09	4,27831E-08	aUC_vs_HC
hsa-miR-668-3p	1,181534903	1,377406478	0,529978525	2,598985454	0,009349974	0,02184313	aUC_vs_HC
hsa-miR-708-5p	33,37604443	1,179952575	0,286299066	4,121398624	3,76579E-05	0,000160265	aUC_vs_HC
hsa-miR-766-3p	6,389347077	1,413112638	0,253895989	5,56571471	2,6108E-08	2,10784E-07	aUC_vs_HC
hsa-miR-7974	13,65651025	1,50645337	0,342528561	4,398037245	1,09234E-05	5,26049E-05	aUC_vs_HC
hsa-miR-9-5p	131,5546171	-1,285655064	0,162457183	-7,913808676	2,49632E-15	1,24589E-13	aUC_vs_HC
hsa-let-7i-5p	7433,139774	1,020338489	0,190482182	5,356608579	8,47985E-08	1,43901E-06	aUC_vs_qUC
hsa-miR-1-3p	45,63524901	-1,118583549	0,32843045	-3,405846039	0,000659594	0,002777236	aUC_vs_qUC
hsa-miR-1180-3p	21,60809363	1,42086927	0,269663409	5,269047341	1,37134E-07	1,9691E-06	aUC_vs_qUC
hsa-miR-1249-3p	2,635178737	-1,267964412	0,343241513	-3,694088169	0,000220677	0,001123448	aUC_vs_qUC
hsa-miR-1261	6,828010694	1,125706136	0,303460486	3,709564134	0,000207616	0,001066653	aUC_vs_qUC
hsa-miR-130b-3p	320,174747	1,064506299	0,144266943	7,378726391	1,59811E-13	2,00831E-11	aUC_vs_qUC
hsa-miR-132-5p	21,32720117	1,175089726	0,214143544	5,487392725	4,0791E-08	7,36869E-07	aUC_vs_qUC
hsa-miR-137-3p	1,561737961	-1,492382145	0,468351732	-3,186455912	0,001440274	0,005449687	aUC_vs_qUC
hsa-miR-138-1-3p	2,017574347	1,377890506	0,463012627	2,975924251	0,00292107	0,0097369	aUC_vs_qUC
hsa-miR-145-5p	1857,847135	-1,297235809	0,255432445	-5,078586665	3,80253E-07	4,34575E-06	aUC_vs_qUC
hsa-miR-146a-5p	2578,691154	1,452360548	0,258678444	5,614540291	1,97086E-08	4,0877E-07	aUC_vs_qUC
hsa-miR-150-3p	10,85123407	1,56892364	0,355995555	4,407143909	1,04743E-05	8,26139E-05	aUC_vs_qUC
hsa-miR-155-5p	990,5539321	1,192023232	0,201296912	5,921716442	3,18599E-09	8,10978E-08	aUC_vs_qUC
hsa-miR-16-2-3p	179,5440595	1,062484547	0,176939342	6,004795401	1,91573E-09	5,64637E-08	aUC_vs_qUC
hsa-miR-183-3p	3,053337942	1,242735461	0,394527906	3,149930443	0,001633093	0,00601666	aUC_vs_qUC
hsa-miR-190a-5p	464,0866948	-1,575056325	0,243686017	-6,46346617	1,02331E-10	4,09326E-09	aUC_vs_qUC
hsa-miR-191-3p	6,696832516	1,488382123	0,315385635	4,719245136	2,36721E-06	2,32568E-05	aUC_vs_qUC
hsa-miR-204-5p	62,05433726	-1,210955602	0,281455256	-4,302479975	1,68897E-05	0,000127814	aUC_vs_qUC
hsa-miR-205-5p	17,95505274	7,94850066	2,499092458	3,180554859	0,001469933	0,005524581	aUC_vs_qUC
hsa-miR-212-3p	30,48085194	1,286936457	0,209019706	6,157010187	7,41311E-10	2,44197E-08	aUC_vs_qUC
hsa-miR-223-3p	651,8784999	1,407810163	0,275343743	5,112918656	3,17219E-07	3,91563E-06	aUC_vs_qUC
hsa-miR-23a-5p	5,650538118	1,153718646	0,314739359	3,665631934	0,000246729	0,001222726	aUC_vs_qUC
hsa-miR-25-5p	11,60936066	1,301270978	0,252876278	5,145879989	2,6627E-07	3,42434E-06	aUC_vs_qUC
hsa-miR-3168	4,064948507	3,329171651	0,89060354	3,738107366	0,000185411	0,000970374	aUC_vs_qUC
hsa-miR-331-3p	72,3342511	-1,702956249	0,253483773	-6,718206172	1,83975E-11	9,36601E-10	aUC_vs_qUC
hsa-miR-342-5p	8,253483302	1,826371265	0,349511534	5,225496405	1,73688E-07	2,37233E-06	aUC_vs_qUC
hsa-miR-3605-3p	5,610256945	1,582894539	0,348727124	4,539063444	5,65046E-06	4,86809E-05	aUC_vs_qUC
hsa-miR-3609	1,222421126	2,752158095	0,646294343	4,25836637	2,05926E-05	0,000151735	aUC_vs_qUC
hsa-miR-3614-5p	10,11772198	1,271515613	0,259245737	4,904673186	9,3583E-07	9,88802E-06	aUC_vs_qUC
hsa-miR-362-5p	44,73684131	-1,235684662	0,262172958	-4,71324224	2,43806E-06	2,35399E-05	aUC_vs_qUC
hsa-miR-378a-5p	134,3466478	-1,270871535	0,229182838	-5,545229952	2,93568E-08	5,87136E-07	aUC_vs_qUC

hsa-miR-378i	8,278677288	-2,086653578	0,622182333	-3,353765395	0,000797199	0,003282585	aUC_vs_qUC
hsa-miR-381-3p	544,4493226	-1,024188654	0,159532866	-6,419922618	1,36344E-10	5,09016E-09	aUC_vs_qUC
hsa-miR-423-5p	842,8864905	1,879580063	0,244999954	7,671756795	1,69656E-14	3,16692E-12	aUC_vs_qUC
hsa-miR-431-5p	10,71876204	1,035720321	0,282105069	3,671399189	0,000241226	0,001206131	aUC_vs_qUC
hsa-miR-4326	4,597156676	1,18460341	0,325354265	3,640964745	0,000271618	0,001334265	aUC_vs_qUC
hsa-miR-4448	5,359009229	1,364867864	0,537145828	2,540963351	0,011054751	0,03207596	aUC_vs_qUC
hsa-miR-4492	19,8462304	-2,159800637	0,459393303	-4,701419505	2,58359E-06	2,41135E-05	aUC_vs_qUC
hsa-miR-4497	6,888801966	-6,285829022	0,803188276	-7,826096579	5,03251E-15	1,4091E-12	aUC_vs_qUC
hsa-miR-4508	7,739863441	-3,958074545	0,567154719	-6,978826789	2,97655E-12	1,85208E-10	aUC_vs_qUC
hsa-miR-4516	25,0311553	-1,715580754	0,531055205	-3,230513018	0,001235683	0,004707363	aUC_vs_qUC
hsa-miR-4636	1,622644125	-1,658358209	0,465230523	-3,564594597	0,000364419	0,001677164	aUC_vs_qUC
hsa-miR-504-5p	1,981209572	-1,673709625	0,414017013	-4,042610749	5,28593E-05	0,000340244	aUC_vs_qUC
hsa-miR-511-5p	9,780917612	1,58678953	0,308478282	5,143926245	2,69055E-07	3,42434E-06	aUC_vs_qUC
hsa-miR-548au-5p	1,45074882	1,170855248	0,464063165	2,523051463	0,011634137	0,033583077	aUC_vs_qUC
hsa-miR-548f-3p	1,978397462	-1,268703006	0,379704811	-3,341287677	0,000833908	0,003408674	aUC_vs_qUC
hsa-miR-549a-5p	2,928751124	2,755832669	0,695924434	3,959959636	7,49624E-05	0,000441884	aUC_vs_qUC
hsa-miR-5571-3p	14,88030368	1,183245521	0,336347185	3,51792902	0,000434929	0,001964194	aUC_vs_qUC
hsa-miR-5571-5p	6,465962202	1,758760029	0,389645136	4,513748193	6,36918E-06	5,40416E-05	aUC_vs_qUC
hsa-miR-5701	65,08592096	-1,1363678	0,280365815	-4,053161053	5,05302E-05	0,000332905	aUC_vs_qUC
hsa-miR-584-5p	29,79418754	1,335067879	0,23166853	5,762836592	8,27119E-09	1,92994E-07	aUC_vs_qUC
hsa-miR-6126	1,448649919	-4,553327338	0,897327063	-5,074322982	3,88878E-07	4,35543E-06	aUC_vs_qUC
hsa-miR-625-5p	34,05882263	1,113132941	0,151171501	7,363378255	1,79313E-13	2,00831E-11	aUC_vs_qUC
hsa-miR-664a-3p	33,73200555	-1,314729348	0,217786666	-6,036776143	1,57224E-09	4,8914E-08	aUC_vs_qUC
hsa-miR-744-5p	150,5376248	1,143721244	0,173680843	6,585189402	4,54306E-11	1,95701E-09	aUC_vs_qUC
hsa-miR-7704	33,46400331	-2,176009889	0,365493131	-5,95362731	2,62264E-09	7,26746E-08	aUC_vs_qUC
hsa-miR-7974	13,65651025	1,096117188	0,369498492	2,966499758	0,003012106	0,009980943	aUC_vs_qUC
hsa-miR-873-5p	2,38577459	-1,000145635	0,37974992	-2,633695447	0,008446121	0,024980831	aUC_vs_qUC
hsa-miR-942-5p	7,341665876	1,835028413	0,343278281	5,345600095	9,0118E-08	1,4843E-06	aUC_vs_qUC
hsa-miR-1-3p	45,63524901	-1,058671574	0,327880779	-3,228830844	0,001242974	0,011048657	qUC_vs_HC
hsa-miR-106a-5p	7,864580879	-2,327070819	0,502042393	-4,635207805	3,56579E-06	0,000117461	qUC_vs_HC
hsa-miR-1185-1-3p	3,125659317	1,198969427	0,309074489	3,879224812	0,00010479	0,001892978	qUC_vs_HC
hsa-miR-1249-3p	2,635178737	1,159333073	0,323413991	3,58467199	0,000337502	0,004108721	qUC_vs_HC
hsa-miR-125b-1-3p	26,59922677	1,117442697	0,284176821	3,932209151	8,41688E-05	0,001571151	qUC_vs_HC
hsa-miR-1271-5p	5,030666509	-1,83818757	0,612650828	-3,000383718	0,002696397	0,019868187	qUC_vs_HC
hsa-miR-205-5p	17,95505274	-17,89235959	2,528753253	-7,075565623	1,4884E-12	8,33506E-10	qUC_vs_HC
hsa-miR-3150b-3p	1,703386787	-1,270996447	0,457448061	-2,778449741	0,005461896	0,032196441	qUC_vs_HC
hsa-miR-3182	6,296971943	1,601455594	0,60406854	2,651115706	0,008022635	0,043922256	qUC_vs_HC
hsa-miR-3195	6,477130497	1,170273018	0,407422682	2,872380628	0,00407392	0,026341669	qUC_vs_HC
hsa-miR-331-3p	72,3342511	1,174028046	0,256487658	4,577327634	4,70954E-06	0,000146519	qUC_vs_HC
hsa-miR-409-5p	2,593071508	-1,934984291	0,647826962	-2,986884466	0,002818362	0,020497179	qUC_vs_HC
hsa-miR-424-5p	118,0502618	1,108730662	0,27587833	4,018911753	5,84676E-05	0,001212661	qUC_vs_HC
hsa-miR-4286	26,85650667	1,000016514	0,17513754	5,709892415	1,13048E-08	6,33067E-07	qUC_vs_HC
hsa-miR-431-3p	2,39402778	1,28212261	0,39635033	3,234821605	0,001217188	0,010993952	qUC_vs_HC
hsa-miR-4454	32,35078856	1,032187639	0,269389475	3,831581167	0,000127322	0,002160622	qUC_vs_HC
hsa-miR-4492	19,8462304	2,459136743	0,468984804	5,243531816	1,57532E-07	7,35148E-06	qUC_vs_HC
hsa-miR-4497	6,888801966	4,842669712	0,765598795	6,325336118	2,52682E-10	2,83004E-08	qUC_vs_HC
hsa-miR-4508	7,739863441	3,660547664	0,560463122	6,531290854	6,52052E-11	1,21716E-08	qUC_vs_HC
hsa-miR-4516	25,0311553	3,56405192	0,549516664	6,485794065	8,82657E-11	1,23572E-08	qUC_vs_HC
hsa-miR-485-3p	5,547149404	1,16588218	0,233354671	4,996181024	5,84768E-07	2,18313E-05	qUC_vs_HC
hsa-miR-501-3p	61,37291486	-1,031649877	0,280432546	-3,678780842	0,000234352	0,003525806	qUC_vs_HC
hsa-miR-504-5p	1,981209572	1,028898675	0,36975191	2,782673054	0,00539131	0,032196441	qUC_vs_HC
hsa-miR-5100	6,950990718	1,415941659	0,272979896	5,186981452	2,1373E-07	9,20683E-06	qUC_vs_HC
hsa-miR-6126	1,448649919	4,024984824	0,903125629	4,456727495	8,32203E-06	0,000233017	qUC_vs_HC
hsa-miR-629-5p	23,74957856	-1,044094731	0,208875649	-4,998642654	5,77353E-07	2,18313E-05	qUC_vs_HC
hsa-miR-665	5,880670429	1,025254911	0,324606292	3,158456681	0,001586069	0,013664593	qUC_vs_HC
hsa-miR-708-3p	17,66362198	1,05339501	0,302606236	3,481075024	0,000499406	0,005593343	qUC_vs_HC
hsa-miR-708-5p	33,37604443	1,126245844	0,311895979	3,610966222	0,000305058	0,003882561	qUC_vs_HC
hsa-miR-766-3p	6,389347077	1,118059539	0,275575308	4,057183308	4,96681E-05	0,001069774	qUC_vs_HC
hsa-miR-7704	33,46400331	2,249926451	0,371696766	6,053123558	1,42064E-09	1,32593E-07	qUC_vs_HC
hsa-miR-873-5p	2,38577459	1,07876081	0,369268202	2,92134769	0,003485206	0,024705261	qUC_vs_HC

Supplementary Table S3. The list of Reactome pathways significantly enriched with differentially expressed colon tissue miRNAs in active (aUC) and quiescent (qUC)

comparison	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue
aUC_vs_qUC	R-HSA-449147	Signaling by Interleukins	72/422	461/10704	9.77431E-25	1.10254E-21	7.09924E-22
aUC_vs_qUC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	34/422	108/10704	4.56679E-22	2.46706E-19	1.58853E-19
aUC_vs_qUC	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	62/422	387/10704	6.56134E-22	2.46706E-19	1.58853E-19
aUC_vs_qUC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	25/422	101/10704	7.88546E-14	2.2237E-11	1.43183E-11
aUC_vs_qUC	R-HSA-1257604	PIP3 activates AKT signaling	39/422	264/10704	6.59585E-13	1.48802E-10	9.58134E-11
aUC_vs_qUC	R-HSA-9006925	Intracellular signaling by second messengers	42/422	306/10704	1.02743E-12	1.93157E-10	1.24373E-10
aUC_vs_qUC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	11/422	17/10704	3.14586E-12	4.43566E-10	2.85611E-10
aUC_vs_qUC	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	11/422	17/10704	3.14586E-12	4.43566E-10	2.85611E-10
aUC_vs_qUC	R-HSA-8848021	Signaling by PTK6	17/422	54/10704	1.20202E-11	1.35588E-09	8.73047E-10
aUC_vs_qUC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	17/422	54/10704	1.20202E-11	1.35588E-09	8.73047E-10
aUC_vs_qUC	R-HSA-199418	Negative regulation of the PI3K/AKT network	23/422	110/10704	3.41806E-11	3.50507E-09	2.2569E-09
aUC_vs_qUC	R-HSA-8878166	Transcriptional regulation by RUNX2	23/422	121/10704	2.60669E-10	2.45029E-08	1.57773E-08
aUC_vs_qUC	R-HSA-1433557	Signaling by SCF-KIT	14/422	43/10704	4.87164E-10	4.22709E-08	2.72181E-08
aUC_vs_qUC	R-HSA-8939211	ESR-mediated signaling	31/422	223/10704	7.98434E-10	6.4331E-08	4.14225E-08
aUC_vs_qUC	R-HSA-9669938	Signaling by KIT in disease	10/422	20/10704	1.05864E-09	7.46342E-08	4.80567E-08
aUC_vs_qUC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	10/422	20/10704	1.05864E-09	7.46342E-08	4.80567E-08
aUC_vs_qUC	R-HSA-166520	Signaling by NTRKs	23/422	134/10704	2.13508E-09	1.39847E-07	9.0047E-08
aUC_vs_qUC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	8/422	12/10704	2.35558E-09	1.39847E-07	9.0047E-08
aUC_vs_qUC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	8/422	12/10704	2.35558E-09	1.39847E-07	9.0047E-08
aUC_vs_qUC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	20/422	103/10704	2.64693E-09	1.49287E-07	9.61254E-08
aUC_vs_qUC	R-HSA-1236394	Signaling by ERBB4	15/422	58/10704	4.23752E-09	2.27615E-07	1.46561E-07
aUC_vs_qUC	R-HSA-194138	Signaling by VEGF	20/422	108/10704	6.27625E-09	3.0054E-07	1.93517E-07
aUC_vs_qUC	R-HSA-9675126	Diseases of mitotic cell cycle	12/422	36/10704	6.39447E-09	3.0054E-07	1.93517E-07
aUC_vs_qUC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	12/422	36/10704	6.39447E-09	3.0054E-07	1.93517E-07
aUC_vs_qUC	R-HSA-9006931	Signaling by Nuclear Receptors	35/422	299/10704	8.81092E-09	3.07309E-07	1.97875E-07
aUC_vs_qUC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	19/422	99/10704	8.1477E-09	3.53485E-07	2.27608E-07
aUC_vs_qUC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	10/422	24/10704	9.74798E-09	4.07249E-07	2.62226E-07
aUC_vs_qUC	R-HSA-8986944	Transcriptional Regulation by MECP2	15/422	62/10704	1.1465E-08	4.61877E-07	2.97401E-07
aUC_vs_qUC	R-HSA-2559583	Cellular Senescence	27/422	197/10704	1.39146E-08	5.41232E-07	3.48497E-07
aUC_vs_qUC	R-HSA-187037	Signaling by NTRK1 (TRKA)	20/422	115/10704	1.92802E-08	7.24936E-07	4.66784E-07
aUC_vs_qUC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	16/422	75/10704	2.5859E-08	9.40934E-07	6.05865E-07
aUC_vs_qUC	R-HSA-2559585	Oncogene Induced Senescence	11/422	33/10704	2.77518E-08	9.78252E-07	6.29894E-07
aUC_vs_qUC	R-HSA-9009391	Extra-nuclear estrogen signaling	16/422	77/10704	3.84523E-08	1.31437E-06	8.46319E-07
aUC_vs_qUC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	8/422	17/10704	9.71455E-08	3.22294E-06	2.07524E-06
aUC_vs_qUC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	20/422	129/10704	1.40832E-07	4.3702E-06	2.81396E-06
aUC_vs_qUC	R-HSA-5655302	Signaling by FGFR1 in disease	11/422	38/10704	1.44336E-07	4.3702E-06	2.81396E-06
aUC_vs_qUC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	17/422	95/10704	1.47223E-07	4.3702E-06	2.81396E-06
aUC_vs_qUC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	17/422	95/10704	1.47223E-07	4.3702E-06	2.81396E-06
aUC_vs_qUC	R-HSA-9614085	FOXO-mediated transcription	14/422	65/10704	1.71194E-07	4.90452E-06	3.158E-06
aUC_vs_qUC	R-HSA-69231	Cyclin D associated events in G1	12/422	47/10704	1.79886E-07	4.90452E-06	3.158E-06
aUC_vs_qUC	R-HSA-69236	G1 Phase	12/422	47/10704	1.79886E-07	4.90452E-06	3.158E-06
aUC_vs_qUC	R-HSA-5683057	MAPK family signaling cascades	34/422	325/10704	1.82615E-07	4.90452E-06	3.158E-06
aUC_vs_qUC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	17/422	98/10704	2.3536E-07	5.90588E-06	3.80273E-06
aUC_vs_qUC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	17/422	98/10704	2.3536E-07	5.90588E-06	3.80273E-06
aUC_vs_qUC	R-HSA-8941326	RUNX2 regulates bone development	10/422	32/10704	2.4136E-07	5.90588E-06	3.80273E-06
aUC_vs_qUC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	9/422	25/10704	2.46075E-07	5.90588E-06	3.80273E-06
aUC_vs_qUC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	9/422	25/10704	2.46075E-07	5.90588E-06	3.80273E-06
aUC_vs_qUC	R-HSA-166166	MyD88-independent TLR4 cascade	17/422	99/10704	2.74023E-07	6.30812E-06	4.06178E-06
aUC_vs_qUC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	17/422	99/10704	2.74023E-07	6.30812E-06	4.06178E-06
aUC_vs_qUC	R-HSA-1227990	Signaling by ERBB2 in Cancer	9/422	26/10704	3.6333E-07	8.19677E-06	5.27787E-06
aUC_vs_qUC	R-HSA-1227986	Signaling by ERBB2	12/422	50/10704	3.7534E-07	8.30164E-06	5.3454E-06
aUC_vs_qUC	R-HSA-9671555	Signaling by PDGFR in disease	8/422	20/10704	4.53381E-07	9.83487E-06	6.33264E-06
aUC_vs_qUC	R-HSA-75153	Apoptotic execution phase	12/422	52/10704	5.93963E-07	1.26413E-05	8.13971E-06
aUC_vs_qUC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	6/422	10/10704	6.65412E-07	1.38997E-05	8.94999E-06
aUC_vs_qUC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	17/422	94/10704	6.96998E-07	1.42268E-05	9.1606E-06
aUC_vs_qUC	R-HSA-168898	Toll-like Receptor Cascades	21/422	155/10704	7.06295E-07	1.42268E-05	9.1606E-06
aUC_vs_qUC	R-HSA-186763	Downstream signal transduction	9/422	29/10704	1.04793E-06	2.0738E-05	1.33531E-05
aUC_vs_qUC	R-HSA-1250196	SHC1 events in ERBB2 signaling	8/422	22/10704	1.07342E-06	2.08761E-05	1.34421E-05
aUC_vs_qUC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	7/422	16/10704	1.18357E-06	2.26283E-05	1.45703E-05
aUC_vs_qUC	R-HSA-2990846	SUMOylation	23/422	188/10704	1.30781E-06	2.45869E-05	1.58314E-05
aUC_vs_qUC	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	12/422	56/10704	1.39262E-06	2.5201E-05	1.62269E-05
aUC_vs_qUC	R-HSA-5655291	Signaling by FGFR4 in disease	6/422	11/10704	1.41524E-06	2.5201E-05	1.62269E-05
aUC_vs_qUC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	6/422	11/10704	1.41524E-06	2.5201E-05	1.62269E-05
aUC_vs_qUC	R-HSA-111465	Apoptotic cleavage of cellular proteins	10/422	38/10704	1.42985E-06	2.5201E-05	1.62269E-05
aUC_vs_qUC	R-HSA-6783783	Interleukin-10 signaling	11/422	47/10704	1.5157E-06	2.63032E-05	1.69365E-05
aUC_vs_qUC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	7/422	17/10704	1.94407E-06	3.3226E-05	2.13941E-05
aUC_vs_qUC	R-HSA-982772	Growth hormone receptor signaling	8/422	24/10704	2.30281E-06	3.87696E-05	2.49637E-05
aUC_vs_qUC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	15/422	91/10704	2.36659E-06	3.92576E-05	2.52778E-05
aUC_vs_qUC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	22/422	182/10704	2.72418E-06	4.39489E-05	2.82985E-05
aUC_vs_qUC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	15/422	92/10704	2.72732E-06	4.39489E-05	2.82985E-05
aUC_vs_qUC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	15/422	93/10704	3.13648E-06	4.98303E-05	3.20856E-05
aUC_vs_qUC	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	8/422	25/10704	3.27068E-06	5.05387E-05	3.25417E-05
aUC_vs_qUC	R-HSA-9006335	Signaling by Erythropoietin	8/422	25/10704	3.27068E-06	5.05387E-05	3.25417E-05
aUC_vs_qUC	R-HSA-2428928	IRS-related events triggered by IGF1R	11/422	52/10704	4.39947E-06	6.70622E-05	4.31812E-05
aUC_vs_qUC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	15/422	96/10704	4.71333E-06	6.99558E-05	4.50443E-05
aUC_vs_qUC	R-HSA-8878159	Transcriptional regulation by RUNX3	15/422	96/10704	4.71333E-06	6.99558E-05	4.50443E-05
aUC_vs_qUC	R-HSA-1226099	Signaling by FGFR in disease	12/422	63/10704	5.18117E-06	7.31289E-05	4.70875E-05
aUC_vs_qUC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	14/422	85/10704	5.18644E-06	7.31289E-05	4.70875E-05
aUC_vs_qUC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	14/422	85/10704	5.18644E-06	7.31289E-05	4.70875E-05
aUC_vs_qUC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	14/422	85/10704	5.18644E-06	7.31289E-05	4.70875E-05
aUC_vs_qUC	R-HSA-2428924	IGF1R signaling cascade	11/422	53/10704	5.3577E-06	7.46109E-05	4.80417E-05
aUC_vs_qUC	R-HSA-451927	Interleukin-2 family signaling	10/422	44/10704	6.06938E-06	8.3491E-05	5.37596E-05
aUC_vs_qUC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	11/422	54/10704	6.49319E-06	8.82448E-05	5.68206E-05
aUC_vs_qUC	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	6/422	14/10704	8.3129E-06	0.00011163	7.18784E-05
aUC_vs_qUC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	14/422	90/10704	1.03064E-05	0.000135284	8.7109E-05
aUC_vs_qUC	R-HSA-73887	Death Receptor Signalling	18/422	141/10704	1.03142E-05	0.000135284	8.7109E-05
aUC_vs_qUC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/422	29/10704	1.12948E-05	0.000145814	9.38893E-05
aUC_vs_qUC	R-HSA-6806834	Signaling by MET	13/422	79/10704	1.13756E-05	0.000145814	9.38893E-05
aUC_vs_qUC	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/422	15/10704	1.33955E-05	0.00016789	0.000108104
aUC_vs_qUC	R-HSA-5637812	Signaling by EGFRvIII in Cancer	6/422	15/10704	1.33955E-05	0.00016789	0.000108104
aUC_vs_qUC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	7/422	22/10704	1.43593E-05	0.000177993	0.000114609
aUC_vs_qUC	R-HSA-525793	Myogenesis	8/422	30/10704	1.45716E-05	0.000182397	0.000117445
aUC_vs_qUC	R-HSA-157118	Signaling by NOTCH	24/422	236/10704	1.95897E-05	0.000237604	0.000152993
aUC_vs_qUC	R-HSA-1963640	GRB2 events in ERBB2 signaling	6/422	16/10704	2.07226E-05	0.000246053	0.000158433
aUC_vs_qUC	R-HSA-1963642	PI3K events in ERBB2 signaling	6/422	16/10704	2.07226E-05	0.000246053	0.000158433
aUC_vs_qUC	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	13/422	84/10704	2.25489E-05	0.000264949	0.0001706
aUC_vs_qUC	R-HSA-170834	Signaling by TGF-beta Receptor Complex	12/422	73/10704	2.498E-05	0.000290489	0.000187045
aUC_vs_qUC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	7/422	24/10704	2.7211E-05	0.000313204	0.000201671
aUC_vs_qUC	R-HSA-2586552	Signaling by Leptin	5/422	11/10704	3.52944E-05	0.00039888	0.000256837
aUC_vs_qUC	R-HSA-450294	MAP kinase activation	11/422	64/10704	3.53617E-05	0.00039888	0.000256837
aUC_vs_qUC	R-HSA-400685	Sema4D in semaphorin signaling	7/422	25/10704	3.65211E-05	0.000407879	0.000262632
aUC_vs_qUC	R-HSA-9006936	Signaling by TGFB family members	14/422	102/10704	4.40495E-05	0.000483156	0.000311103
aUC_vs_qUC	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	6/422	18/10704	4.49112E-05	0.000483156	0.000311103
aUC_vs_qUC	R-HSA-210993	Tie2 Signaling	6/422	18/10704	4.49112E-05	0.000483156	0.000311103
aUC_vs_qUC	R-HSA-5688426	Deubiquitination	27/422	297/10704	4.49746E-05	0.000483156	0.000311103
aUC_vs_qUC	R-HSA-3700989	Transcriptional Regulation by TP53	31/422	365/10704	4.62076E-05	0.000491718	0.000316616
aUC_vs_qUC	R-HSA-5357801	Programmed Cell Death	20/422	190/10704	5.92496E-05	0.000624613	0.000402186
aUC_vs_qUC	R-HSA-5684996	MAPK1/MAPK3 signaling	26/422	286/10704	6.21867E-05	0.000644983	0.000415303
aUC_vs_qUC	R-HSA-912526	Interleukin receptor SHC signaling	7/422	27/10704	6.30066E-05	0.000644983	0.000415303
aUC_vs_qUC	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/422	19/10704	6.34691E-05	0.000644983	0.000415303
aUC_vs_qUC	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/422	19/10704	6.34691E-05	0.000644983	0.000415303
aUC_vs_qUC	R-HSA-109581	Apoptosis	19/422	178/10704	7.47871E-05	0.000753213	0.00048499
aUC_vs_qUC	R-HSA-168638	NOD1/2 Signaling Pathway	8/422	37/10704	7.69907E-05	0.000768544	0.000494863
aUC_vs_qUC	R-HSA-453279	Mitotic G1 phase and G1/S transition	17/422	149/10704	7.76953E-05	0.000768774	0.000495011
aUC_vs_qUC	R-HSA-9018519	Estrogen-dependent gene expression	17/422	150/10704	8.45162E-05	0.000828994	0.000533787
aUC_vs_qUC	R-HSA-12399	IRS-mediated signalling	9/422	48/10704	9.01656E-05	0.000869289	0.000559733
aUC_vs_qUC	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	9/422	48/10704	9.01656E-05	0.000869289	0.000559733
aUC_vs_qUC	R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	5/422	13/10704	9.20732E-05	0.000880158	0.000566731
aUC_vs_qUC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	8/422	38/10704	9.42054E-05	0.000892972	0.000574982
aUC_vs_qUC	R-HSA-202733	Cell surface interactions at the vascular wall	16/422	137/10704	9.50191E-05	0.000893179	0.000575115
aUC_vs_qUC	R-HSA-9067240	FLT3 Signaling	26/422	294/10704	9.83365E-05	0.000916724	0.000590276
aUC_vs_qUC	R-HSA-448424	Interleukin-17 signaling	11/422	72/10704	0.000108248	0.00100846	0.00064442
aUC_vs_qUC	R-HSA-8853884	Transcriptional Regulation by VENTX	8/422	39/10704	0.000114848	0.00104386	0.000672162
aUC_vs_qUC	R-HSA-5673001	RAF/MAP kinase cascade	25/422	280/10704	0.000114705	0.00104386	0.000672162
aUC_vs_qUC	R-HSA-177929	Signaling by EGFR	9/422	50/10704	0.000125614	0.00113539	0.000729882
aUC_vs_qUC	R-HSA-4090294	SUMOylation of intracellular receptors	7/422	30/10704	0.000130374	0.00157965	0.00074561
aUC_vs_qUC	R-HSA-5654696	Downstream signaling of activated FGFR2	7/422	30/10704	0.000130374	0.00157965	0.00074561
aUC_vs_qUC	R-HSA-198323	AKT phosphorylates targets in the cytosol	5/422	14/10704	0.000138607	0.001200995	0.000773317
aUC_vs_qUC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	5/422	14/10704	0.000138607	0.001200995	0.000773317
aUC_vs_qUC	R-HSA-9027284	Erythropoietin activates RAS	5/422	14/10704	0.000138607	0.001200995	0.000773317
aUC_vs_qUC	R-HSA-1980143	Signaling by NOTCH1	11/422	74/10704	0.000139477	0.001200995	0.000773317
aUC_vs_qUC	R-HSA-5655253	Signaling by FGFR3 in disease	6/422	22/10704	0.000157816	0.001338466	0.000861834
aUC_vs_qUC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	6/422	22/10704	0.000157816	0.001338466	0.000861834
aUC_vs_qUC	R-HSA-1839124	FGFR1 mutant receptor activation	7/422	31/10704	0.000162751	0.001359872	0.000875618
aUC_vs_qUC	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	7/422	31/10704	0.000162751	0.001359872	0.000875618
aUC_vs_qUC	R-HSA-383280	Nuclear Receptor transcription pathway	9/422	52/10704	0.000172025	0.00142692	0.000918707
aUC_vs_qUC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	8/422	42/10704	0.000198015	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5339716	Misspliced GSK3beta mutants stabilize beta-catenin	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5358508	Mismatch Repair	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-6785631	ERBB2 Regulates Cell Motility	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	5/422	15/10704	0.000201212	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-1251985	Nuclear signaling by ERBB4	7/422	32/10704	0.000201337	0.001544954	0.000994791
aUC_vs_qUC	R-HSA-74751	Insulin receptor signalling cascade	9/422	54/10704	0.000231908	0.001767517	0.00113809
aUC_vs_qUC	R-HSA-389356	CD28 co-stimulation	7/422	33/10704	0.000246981	0.001857299	0.001195909
aUC_vs_qUC	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	7/422	33/10704	0.000246981	0.001857299	0.001195909
aUC_vs_qUC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	15/422	134/10704	0.00025079	0.001873448	0.001206308
aUC_vs_qUC	R-HSA-5260271	Diseases of Immune System	6/422	24/10704	0.00026623	0.001937469	0.001247531
aUC_vs_qUC	R-HSA-5602358	Diseases associated with the TLR signaling cascade	6/422	24/10704	0.00026623	0.001937469	0.001247531
aUC_vs_qUC	R-HSA-6783589	Interleukin-6 family signaling	6/422	24/10704	0.00026623	0.001937469	0.001247531
aUC_vs_qUC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	6/422	24/10704	0.00026623	0.001937469	0.001247531
aUC_vs_qUC	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/422	44/10704	0.000277509	0.002006605	0.001292047

aUC_vs_qUC	R-HSA-187687	Signalling to ERKs	7/422	34/10704	0,000300599	0,002146049	0,001381834
aUC_vs_qUC	R-HSA-4791275	Signaling by WNT in cancer	7/422	34/10704	0,000300599	0,002146049	0,001381834
aUC_vs_qUC	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	9/422	56/10704	0,000308146	0,002186092	0,001407618
aUC_vs_qUC	R-HSA-1643713	Signaling by EGFR in Cancer	6/422	25/10704	0,00033877	0,002373494	0,001528286
aUC_vs_qUC	R-HSA-5654708	Downstream signaling of activated FGFR3	6/422	25/10704	0,00033877	0,002373494	0,001528286
aUC_vs_qUC	R-HSA-196299	Beta-catenin phosphorylation cascade	5/422	17/10704	0,000388373	0,00267124	0,001720009
aUC_vs_qUC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	5/422	17/10704	0,000388373	0,00267124	0,001720009
aUC_vs_qUC	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	5/422	17/10704	0,000388373	0,00267124	0,001720009
aUC_vs_qUC	R-HSA-186797	Signaling by PDGF	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644603	Signaling by NOTCH1 in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	9/422	58/10704	0,00040401	0,002680723	0,001726109
aUC_vs_qUC	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	4/422	10/10704	0,000413875	0,00271425	0,001747697
aUC_vs_qUC	R-HSA-9675135	Diseases of DNA repair	4/422	10/10704	0,000413875	0,00271425	0,001747697
aUC_vs_qUC	R-HSA-1912420	Pre-NOTCH Processing in Golgi	5/422	18/10704	0,000520474	0,003341006	0,002172577
aUC_vs_qUC	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	5/422	18/10704	0,000520474	0,003341006	0,002172577
aUC_vs_qUC	R-HSA-5654716	Downstream signaling of activated FGFR4	6/422	27/10704	0,0005296	0,003413649	0,002198039
aUC_vs_qUC	R-HSA-1059683	Interleukin-6 signaling	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-8851805	MET activates RAS signaling	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/422	11/10704	0,000630207	0,003971359	0,002557146
aUC_vs_qUC	R-HSA-350054	Notch-HLH transcription pathway	6/422	28/10704	0,000651895	0,004085206	0,002630452
aUC_vs_qUC	R-HSA-5654736	Signaling by FGFR1	8/422	50/10704	0,000683704	0,004260875	0,002743564
aUC_vs_qUC	R-HSA-5654741	Signaling by FGFR3	7/422	40/10704	0,000849576	0,005265504	0,003390442
aUC_vs_qUC	R-HSA-1181150	Signaling by NODAL	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-167044	Signalling to RAS	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-5625900	RHO GTPases activate CIT	5/422	20/10704	0,000882362	0,005380022	0,00346418
aUC_vs_qUC	R-HSA-389359	CD28 dependent Vav1 pathway	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9664420	Killing mechanisms	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-9673324	WNT5:FZD7-mediated leishmania damping	4/422	12/10704	0,000916035	0,00546713	0,003520268
aUC_vs_qUC	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	10/422	78/10704	0,000931065	0,005498647	0,003540562
aUC_vs_qUC	R-HSA-74752	Signaling by Insulin receptor	10/422	78/10704	0,000931065	0,005498647	0,003540562
aUC_vs_qUC	R-HSA-373755	Semaphorin interactions	9/422	65/10704	0,000950994	0,00558709	0,003597511
aUC_vs_qUC	R-HSA-2424491	DAP12 signaling	6/422	30/10704	0,000961124	0,005617345	0,003616991
aUC_vs_qUC	R-HSA-5654743	Signaling by FGFR4	7/422	41/10704	0,000990327	0,005758188	0,00370768
aUC_vs_qUC	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	5/422	21/10704	0,001121009	0,00645152	0,004154114
aUC_vs_qUC	R-HSA-445144	Signal transduction by L1	5/422	21/10704	0,001121009	0,00645152	0,004154114
aUC_vs_qUC	R-HSA-5654687	Downstream signaling of activated FGFR1	6/422	31/10704	0,001152733	0,006600422	0,004249992
aUC_vs_qUC	R-HSA-171007	p38MAPK events	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-179812	GRB2 events in EGFR signaling	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-209560	NF-kB is activated and signals survival	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	4/422	13/10704	0,00128224	0,007195856	0,00463339
aUC_vs_qUC	R-HSA-5655253	Signaling by FGFR2 in disease	7/422	43/10704	0,001326466	0,007407194	0,00476947
aUC_vs_qUC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	6/422	32/10704	0,001372286	0,007587935	0,004885849
aUC_vs_qUC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	6/422	32/10704	0,001372286	0,007587935	0,004885849
aUC_vs_qUC	R-HSA-195721	Signaling by WNT	33/422	332/10704	0,001458574	0,008025715	0,005167734
aUC_vs_qUC	R-HSA-193704	p75 NTR receptor-mediated signalling	11/422	97/10704	0,001475171	0,008077634	0,005201164
aUC_vs_qUC	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	12/422	112/10704	0,001502881	0,008189613	0,005273267
aUC_vs_qUC	R-HSA-69202	Cyclin E associated events during G1/S transition	10/422	83/10704	0,00151132	0,008196004	0,005277382
aUC_vs_qUC	R-HSA-75893	TNF signaling	7/422	44/10704	0,001524917	0,008230173	0,005299384
aUC_vs_qUC	R-HSA-9022692	Regulation of MECP2 expression and activity	6/422	33/10704	0,001622354	0,008714358	0,005611149
aUC_vs_qUC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	5/422	23/10704	0,00173703	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-1250347	SHC1 events in ERBB4 signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-180336	SHC1 events in EGFR signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5358565	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5358606	Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-877312	Regulation of IFNG signaling	4/422	14/10704	0,001739694	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-1566948	Elastic fibre formation	7/422	45/10704	0,001745757	0,008830555	0,005685967
aUC_vs_qUC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	10/422	85/10704	0,001813255	0,009131035	0,005879446
aUC_vs_qUC	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	10/422	86/10704	0,001981533	0,009934083	0,006396526
aUC_vs_qUC	R-HSA-5627123	RHO GTPases activate PAKs	5/422	24/10704	0,002124083	0,010554913	0,006796277
aUC_vs_qUC	R-HSA-933542	TRAF6 mediated NF-kB activation	5/422	24/10704	0,002124083	0,010554913	0,006796277
aUC_vs_qUC	R-HSA-190236	Signaling by FGFR	10/422	87/10704	0,002162186	0,010697131	0,00688785
aUC_vs_qUC	R-HSA-5654738	Signaling by FGFR2	9/422	73/10704	0,002189343	0,010737299	0,006913715
aUC_vs_qUC	R-HSA-8939902	Regulation of RUNX2 expression and activity	9/422	73/10704	0,002189343	0,010737299	0,006913715
aUC_vs_qUC	R-HSA-114604	GPVI-mediated activation cascade	6/422	35/10704	0,00224707	0,010863505	0,006994978
aUC_vs_qUC	R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-71336	Pentose phosphate pathway	4/422	15/10704	0,002299141	0,011083041	0,007136337
aUC_vs_qUC	R-HSA-9658195	Leishmania infection	20/422	252/10704	0,002312373	0,01100939	0,007146864
aUC_vs_qUC	R-HSA-195258	RHO GTPase Effectors	24/422	327/10704	0,002528486	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	7/422	48/10704	0,002559503	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-6793312	TP53 Regulates Transcription of Cell Cycle Genes	7/422	48/10704	0,002559503	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5654700	FRS-mediated FGFR2 signaling	5/422	25/10704	0,002570411	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-8854691	Interleukin-20 family signaling	5/422	25/10704	0,002570411	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-1266695	Interleukin-7 signaling	6/422	36/10704	0,002582497	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5673000	RAF activation	6/422	36/10704	0,002582497	0,012037423	0,007750861
aUC_vs_qUC	R-HSA-5689880	Ub-specific processing proteases	18/422	220/10704	0,0027111	0,012584859	0,008103352
aUC_vs_qUC	R-HSA-1433559	Regulation of KIT signaling	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-193639	p75NTR signals via NF-kB	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	4/422	16/10704	0,002971104	0,0136236	0,008772195
aUC_vs_qUC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	5/422	26/10704	0,003081006	0,01407042	0,009059851
aUC_vs_qUC	R-HSA-373752	Netrin-1 signaling	7/422	50/10704	0,003245697	0,01476687	0,009509649
aUC_vs_qUC	R-HSA-2682334	EPH-Ephrin signaling	10/422	92/10704	0,003274411	0,014774144	0,009513027
aUC_vs_qUC	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	10/422	92/10704	0,003274411	0,014774144	0,009513027
aUC_vs_qUC	R-HSA-2129379	Molecules associated with elastic fibres	6/422	38/10704	0,003425473	0,015333068	0,009872916
aUC_vs_qUC	R-HSA-5689896	Ovarian tumor domain proteases	6/422	38/10704	0,003425473	0,015333068	0,009872916
aUC_vs_qUC	R-HSA-180292	GAB1 signalosome	4/422	17/10704	0,003765791	0,01678977	0,010810882
aUC_vs_qUC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	9/422	80/10704	0,004107433	0,018240886	0,01174525
aUC_vs_qUC	R-HSA-1592230	Mitochondrial biogenesis	10/422	95/10704	0,004134362	0,018288473	0,011775892
aUC_vs_qUC	R-HSA-8853659	RET signaling	6/422	40/10704	0,004451664	0,019641581	0,012647154
aUC_vs_qUC	R-HSA-6802952	Signaling by BRAF and RAF fusions	8/422	67/10704	0,004641358	0,020371406	0,013117087
aUC_vs_qUC	R-HSA-69242	S Phase	14/422	162/10704	0,004801298	0,020991721	0,013516506
aUC_vs_qUC	R-HSA-1500931	Cell-Cell communication	12/422	129/10704	0,004890108	0,021297457	0,013713368
aUC_vs_qUC	R-HSA-5218920	VEGFR2 mediated vascular permeability	5/422	29/10704	0,005048334	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-9645723	Diseases of programmed cell death	5/422	29/10704	0,005048334	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-8875878	MET promotes cell motility	6/422	41/10704	0,005052064	0,021750872	0,014005321
aUC_vs_qUC	R-HSA-9705956	SARS-CoV Infections	13/422	147/10704	0,005332736	0,022811962	0,014727187
aUC_vs_qUC	R-HSA-69206	G1/S Transition	12/422	131/10704	0,005528314	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	8/422	69/10704	0,005558309	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-388841	Costimulation by the CD28 family	8/422	69/10704	0,005558309	0,023570575	0,015177022
aUC_vs_qUC	R-HSA-6802957	Oncogenic MAPK signaling	9/422	84/10704	0,005681856	0,024002031	0,015454835
aUC_vs_qUC	R-HSA-3928662	EPHB-mediated forward signaling	6/422	42/10704	0,00570261	0,024002031	0,015454835
aUC_vs_qUC	R-HSA-8874081	MET activates PTK2 signaling	5/422	30/10704	0,005865776	0,024597009	0,01583794
aUC_vs_qUC	R-HSA-1250342	PI3K events in ERBB4 signaling	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-74749	Signal attenuation	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-9020958	Interleukin-21 signaling	3/422	10/10704	0,005935239	0,024613787	0,015848743
aUC_vs_qUC	R-HSA-400253	Circadian Clock	8/422	70/10704	0,006065581	0,024907011	0,016078566
aUC_vs_qUC	R-HSA-909733	Interferon alpha/beta signaling	8/422	70/10704	0,006065581	0,024907011	0,016078566
aUC_vs_qUC	R-HSA-9656223	Signaling by RAF1 mutants	6/422	43/10704	0,006412255	0,026301905	0,016935717
aUC_vs_qUC	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	5/422	31/10704	0,00677213	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	5/422	31/10704	0,00677213	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-447115	Interleukin-12 family signaling	7/422	57/10704	0,006789335	0,027548092	0,017738133
aUC_vs_qUC	R-HSA-5627117	RHO GTPases Activate ROCKs	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-622312	Inflammasomes	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-8876384	Listeria monocytogenes entry into host cells	4/422	20/10704	0,006982134	0,027928538	0,017983101
aUC_vs_qUC	R-HSA-109704	PI3K Cascade	6/422	44/10704	0,00718394	0,028634221	0,018437488
aUC_vs_qUC	R-HSA-373760	L1CAM interactions	11/422	119/10704	0,007239603	0,028754478	0,018514922
aUC_vs_qUC	R-HSA-2871796	FCERI mediated MAPK activation	5/422	32/10704	0,007772102	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5626467	RHO GTPases activate IQGAPs	5/422	32/10704	0,007772102	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-193692	Regulated proteolysis of p75NTR	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-2025928	Calcineurin activates NFAT	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-376172	DSCAM interactions	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5603041	IRAK4 deficiency (TLR2/4)	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-5625970	RHO GTPases activate KTN1	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-68689	CDC6 association with the ORC:origin complex	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-9020956	Interleukin-27 signaling	3/422	11/10704	0,007924627	0,03050846	0,019644305
aUC_vs_qUC	R-HSA-2172127	DAP12 interactions	6/422	45/10704	0,008020584	0,030772852	0,019814547
aUC_vs_qUC	R-HSA-9664407	Parasite infection	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-9664417	Leishmania phagocytosis	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-9664422	FCGR3A-mediated phagocytosis	7/422	59/10704	0,008192564	0,031115193	0,020034979
aUC_vs_qUC	R-HSA-3371556	Cellular response to heat stress	9/422	89/10704	0,008262581	0,031275812	0,020138401
aUC_vs_qUC	R-HSA-5218921	VEGFR2 mediated cell proliferation	4/422	21/10704	0,008361223	0,031543342	0,020310663
aUC_vs_qUC	R-HSA-446652	Interleukin-1 family signaling	12/422	140/10704	0,009262775	0,034828036	0,022425667
aUC_vs_qUC	R-HSA-446728	Cell junction organization	9/422	91/10704	0,009513211	0,035650838	0,022955467
aUC_vs_qUC	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	7/422	61/10704	0,009798498	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802906	Signaling by moderate kinase activity BRAF mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802949	Signaling by RAS mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-9649948	Signaling downstream of RAS mutants	6/422	47/10704	0,009900258	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-5654712	FRS-mediated FGFR4 signaling	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-8863678	Neurodegenerative Diseases	4/422	22/10704	0,009907205	0,036049444	0,023212128
aUC_vs_qUC	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/422	12/10704	0,010260824	0,037096825	0,023886533
aUC_vs_qUC	R-HSA-8984772	Interleukin-35 Signalling	3/422	12/10704	0,010260824	0,037096825	0,023886533
aUC_vs_qUC	R-HSA-381426	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	11/422	125/10704	0,010383215	0,037236669	0,023976579
aUC_vs_qUC	R-HSA-5633007	Regulation of TP53 Activity	13/422	160/10704	0,01062468	0,038167642	0,024576029

aUC_vs_qUC	R-HSA-1912422	Pre-NOTCH Expression and Processing	10/422	109/10704	0,010741839	0,038466013	0,02476815
aUC_vs_qUC	R-HSA-201681	TCF dependent signaling in response to WNT	17/422	233/10704	0,010787535	0,038507403	0,0247948
aUC_vs_qUC	R-HSA-400508	Incretin synthesis, secretion, and inactivation	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654695	PI-3K cascade:FGFR2	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-5654699	SHC-mediated cascade:FGFR2	4/422	23/10704	0,011627242	0,040986029	0,02639078
aUC_vs_qUC	R-HSA-9012852	Signaling by NOTCH3	6/422	49/10704	0,012067857	0,042427758	0,02731910
aUC_vs_qUC	R-HSA-983705	Signaling by the B Cell Receptor (BCR)	10/422	112/10704	0,012857115	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-194315	Signaling by Rho GTPases	28/422	455/10704	0,012940983	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-111461	Cytochrome c-mediated apoptotic response	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-140342	Apoptosis induced DNA fragmentation	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-1502540	Signaling by Activin	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-5607763	CLEC7A (Dectin-1) induces NFAT activation	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-75205	Dissolution of Fibrin Clot	3/422	13/10704	0,012954399	0,044550494	0,028685928
aUC_vs_qUC	R-HSA-449836	Other interleukin signaling	4/422	24/10704	0,013527874	0,046240734	0,029774269
aUC_vs_qUC	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	4/422	24/10704	0,013527874	0,046240734	0,029774269
aUC_vs_qUC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	5/422	37/10704	0,014331281	0,048838928	0,031447238
aUC_vs_qUC	R-HSA-9678108	SARS-CoV-1 Infection	6/422	51/10704	0,014563068	0,04947934	0,031859597
aUC_vs_HC	R-HSA-449147	Signaling by Interleukins	107/709	461/10704	3,12022E-32	3,87843E-29	2,39764E-29
aUC_vs_HC	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	94/709	387/10704	6,25139E-30	3,88524E-27	2,40185E-27
aUC_vs_HC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	46/709	108/10704	2,25773E-26	9,35453E-24	5,78296E-24
aUC_vs_HC	R-HSA-194138	Signaling by VEGF	40/709	108/10704	2,1697E-20	6,74233E-18	4,1681E-18
aUC_vs_HC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	36/709	99/10704	3,62701E-18	9,0167E-16	5,57415E-16
aUC_vs_HC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	36/709	101/10704	7,7557E-18	1,4696E-15	9,08506E-16
aUC_vs_HC	R-HSA-1257604	PIP3 activates AKT signaling	60/709	264/10704	8,2761E-18	1,4696E-15	9,08506E-16
aUC_vs_HC	R-HSA-9006925	Intracellular signaling by second messengers	64/709	306/10704	5,37394E-17	8,34975E-15	5,16181E-15
aUC_vs_HC	R-HSA-166520	Signaling by NTRKs	39/709	134/10704	8,97066E-16	1,23895E-13	7,65916E-14
aUC_vs_HC	R-HSA-199418	Negative regulation of the PI3K/AKT network	35/709	110/10704	1,30857E-15	1,62655E-13	1,00553E-13
aUC_vs_HC	R-HSA-8878166	Transcriptional regulation by RUNX2	36/709	121/10704	5,47338E-15	6,18492E-13	3,82351E-13
aUC_vs_HC	R-HSA-9009391	Extra-nuclear estrogen signaling	28/709	77/10704	2,05254E-14	2,12608E-12	1,31434E-12
aUC_vs_HC	R-HSA-8939211	ESR-mediated signaling	49/709	223/10704	3,9049E-14	3,73368E-12	2,30816E-12
aUC_vs_HC	R-HSA-9006931	Signaling by Nuclear Receptors	58/709	299/10704	5,63133E-14	4,9998E-12	3,09088E-12
aUC_vs_HC	R-HSA-8848021	Signaling by PTK6	23/709	54/10704	8,31543E-14	6,46005E-12	3,9936E-12
aUC_vs_HC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	23/709	54/10704	8,31543E-14	6,46005E-12	3,9936E-12
aUC_vs_HC	R-HSA-2559583	Cellular Senescence	45/709	197/10704	1,01447E-13	7,41756E-12	4,58553E-12
aUC_vs_HC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	13/709	17/10704	7,90134E-13	5,16914E-11	3,19556E-11
aUC_vs_HC	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	13/709	17/10704	7,90134E-13	5,16914E-11	3,19556E-11
aUC_vs_HC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	29/709	95/10704	1,21809E-12	7,20993E-11	4,45717E-11
aUC_vs_HC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	29/709	95/10704	1,21809E-12	7,20993E-11	4,45717E-11
aUC_vs_HC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	30/709	103/10704	1,93542E-12	1,09351E-10	6,76008E-11
aUC_vs_HC	R-HSA-5683057	MAPK family signaling cascades	58/709	325/10704	2,2806E-12	1,23251E-10	7,61939E-11
aUC_vs_HC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	29/709	98/10704	2,922E-12	1,45282E-10	8,98129E-11
aUC_vs_HC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	29/709	98/10704	2,922E-12	1,45282E-10	8,98129E-11
aUC_vs_HC	R-HSA-186763	Downstream signal transduction	16/709	29/10704	3,50658E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-69231	Cyclin D associated events in G1	20/709	47/10704	3,62435E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-69236	G1 Phase	20/709	47/10704	3,62435E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-166166	MyD88-independent TLR4 cascade	29/709	99/10704	3,87798E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	29/709	99/10704	3,87798E-12	1,60677E-10	9,93306E-11
aUC_vs_HC	R-HSA-1433557	Signaling by SCF-KIT	19/709	43/10704	5,57549E-12	2,23559E-10	1,38204E-10
aUC_vs_HC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	28/709	94/10704	5,82955E-12	2,26442E-10	1,39986E-10
aUC_vs_HC	R-HSA-187037	Signaling by NTRK1 (TRKA)	31/709	115/10704	7,86699E-12	2,91633E-10	1,80287E-10
aUC_vs_HC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	33/709	129/10704	7,97709E-12	2,91633E-10	1,80287E-10
aUC_vs_HC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	27/709	91/10704	1,54859E-11	5,49969E-10	3,3999E-10
aUC_vs_HC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	26/709	85/10704	1,71371E-11	5,60564E-10	3,4654E-10
aUC_vs_HC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	27/709	92/10704	2,0569E-11	6,4772E-10	4,00143E-10
aUC_vs_HC	R-HSA-9669938	Signaling by KIT in disease	13/709	20/10704	2,13501E-11	6,4772E-10	4,00143E-10
aUC_vs_HC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	13/709	20/10704	2,13501E-11	6,4772E-10	4,00143E-10
aUC_vs_HC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	27/709	93/10704	2,71993E-11	8,0497E-10	4,97631E-10
aUC_vs_HC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	14/709	24/10704	2,91024E-11	8,41263E-10	5,20068E-10
aUC_vs_HC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	24/709	75/10704	3,55822E-11	1,0052E-09	6,21412E-10
aUC_vs_HC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	27/709	96/10704	6,13008E-11	1,69327E-09	1,04677E-09
aUC_vs_HC	R-HSA-168898	Toll-like Receptor Cascades	35/709	155/10704	8,37313E-11	2,26257E-09	1,39872E-09
aUC_vs_HC	R-HSA-9006936	Signaling by TGFB family members	27/709	102/10704	2,80011E-10	7,40539E-09	4,578E-09
aUC_vs_HC	R-HSA-1236394	Signaling by ERBB4	20/709	58/10704	3,42086E-10	8,85859E-09	5,47637E-09
aUC_vs_HC	R-HSA-9607240	FLT3 Signaling	50/709	294/10704	4,67941E-10	1,18704E-08	7,33828E-09
aUC_vs_HC	R-HSA-9614085	FOXO-mediated transcription	21/709	65/10704	4,94671E-10	1,22975E-08	7,60231E-09
aUC_vs_HC	R-HSA-5684996	MAPK1/MAPK3 signaling	49/709	286/10704	5,41186E-10	1,31901E-08	8,1541E-09
aUC_vs_HC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	11/709	17/10704	8,55909E-10	2,01912E-08	1,24822E-08
aUC_vs_HC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	13/709	25/10704	1,04937E-09	2,4155E-08	1,49326E-08
aUC_vs_HC	R-HSA-1227986	Signaling by ERBB2	18/709	50/10704	1,17758E-09	2,66132E-08	1,64523E-08
aUC_vs_HC	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	19/709	56/10704	1,30179E-09	2,88951E-08	1,78629E-08
aUC_vs_HC	R-HSA-383280	Nuclear Receptor transcription pathway	18/709	52/10704	2,45395E-09	5,32992E-08	3,29495E-08
aUC_vs_HC	R-HSA-450294	MAP kinase activation	20/709	64/10704	2,48701E-09	5,32992E-08	3,29495E-08
aUC_vs_HC	R-HSA-9675126	Diseases of mitotic cell cycle	15/709	36/10704	2,69156E-09	5,57601E-08	3,44708E-08
aUC_vs_HC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	15/709	36/10704	2,69156E-09	5,57601E-08	3,44708E-08
aUC_vs_HC	R-HSA-448424	Interleukin-17 signaling	21/709	72/10704	4,04276E-09	8,23796E-08	5,0927E-08
aUC_vs_HC	R-HSA-8941326	RUNX2 regulates bone development	14/709	32/10704	4,246E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	9/709	12/10704	4,2913E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	9/709	12/10704	4,2913E-09	8,3345E-08	5,15238E-08
aUC_vs_HC	R-HSA-5673001	RAF/MAP kinase cascade	46/709	280/10704	7,37672E-09	1,41066E-07	8,72065E-08
aUC_vs_HC	R-HSA-453279	Mitotic G1 phase and G1/S transition	31/709	149/10704	8,34265E-09	1,5712E-07	9,71313E-08
aUC_vs_HC	R-HSA-177929	Signaling by EGFR	17/709	50/10704	9,3563E-09	1,7358E-07	1,07307E-07
aUC_vs_HC	R-HSA-6802957	Oncogenic MAPK signaling	22/709	84/10704	1,56837E-08	2,86689E-07	1,77231E-07
aUC_vs_HC	R-HSA-2428928	IRS-related events triggered by IGF1R	17/709	52/10704	1,83899E-08	3,31284E-07	2,048E-07
aUC_vs_HC	R-HSA-2990846	SUMOylation	35/709	188/10704	1,9264E-08	3,39822E-07	2,10077E-07
aUC_vs_HC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	10/709	17/10704	1,94106E-08	3,39822E-07	2,10077E-07
aUC_vs_HC	R-HSA-6806834	Signaling by MET	21/709	79/10704	2,50417E-08	4,32318E-07	2,67258E-07
aUC_vs_HC	R-HSA-2428924	IGF1R signaling cascade	17/709	53/10704	2,54263E-08	4,32944E-07	2,67645E-07
aUC_vs_HC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	34/709	182/10704	2,815E-08	4,72843E-07	2,92311E-07
aUC_vs_HC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	17/709	54/10704	3,48506E-08	5,77591E-07	3,57066E-07
aUC_vs_HC	R-HSA-1250196	SHC1 events in ERBB2 signaling	11/709	22/10704	3,587E-08	5,86664E-07	3,62675E-07
aUC_vs_HC	R-HSA-8878159	Transcriptional regulation by RUNX3	23/709	96/10704	4,58703E-08	7,40478E-07	4,57762E-07
aUC_vs_HC	R-HSA-2559585	Oncogene Induced Senescence	13/709	33/10704	7,03798E-08	1,10737E-06	6,84574E-07
aUC_vs_HC	R-HSA-389356	CD28 co-stimulation	13/709	33/10704	7,03798E-08	1,10737E-06	6,84574E-07
aUC_vs_HC	R-HSA-933542	TRAF6 mediated NF-kB activation	11/709	24/10704	1,12252E-07	1,74321E-06	1,07765E-06
aUC_vs_HC	R-HSA-186797	Signaling by PDGF	17/709	58/10704	1,13596E-07	1,74321E-06	1,07765E-06
aUC_vs_HC	R-HSA-9671555	Signaling by PDGFR in disease	10/709	20/10704	1,535E-07	2,32759E-06	1,43891E-06
aUC_vs_HC	R-HSA-1963642	PI3K events in ERBB2 signaling	9/709	16/10704	1,75145E-07	2,62295E-06	1,62151E-06
aUC_vs_HC	R-HSA-400685	Sema4D in semaphorin signaling	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	11/709	25/10704	1,88516E-07	2,72471E-06	1,68441E-06
aUC_vs_HC	R-HSA-6802952	Signaling by BRAF and RAF fusions	18/709	67/10704	2,09637E-07	2,9909E-06	1,84897E-06
aUC_vs_HC	R-HSA-195721	Signaling by WNT	48/709	332/10704	2,11745E-07	2,9909E-06	1,84897E-06
aUC_vs_HC	R-HSA-445144	Signal transduction by L1	10/709	21/10704	2,70734E-07	3,85193E-06	2,38126E-06
aUC_vs_HC	R-HSA-1227990	Signaling by ERBB2 in Cancer	11/709	26/10704	3,07314E-07	4,24435E-06	2,62385E-06
aUC_vs_HC	R-HSA-8986944	Transcriptional Regulation by MECP2	17/709	62/10704	3,3096E-07	4,5207E-06	2,79469E-06
aUC_vs_HC	R-HSA-195258	RHO GTPase Effectors	47/709	327/10704	3,38933E-07	4,57928E-06	2,8309E-06
aUC_vs_HC	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	20/709	84/10704	8,53881E-07	5,15084E-06	3,18424E-06
aUC_vs_HC	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	14/709	44/10704	4,90517E-07	6,4863E-06	4,00982E-06
aUC_vs_HC	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	19/709	78/10704	5,14655E-07	6,73385E-06	4,16286E-06
aUC_vs_HC	R-HSA-8853884	Transcriptional Regulation by VENTX	13/709	39/10704	6,87699E-07	8,90427E-06	5,50461E-06
aUC_vs_HC	R-HSA-5357801	Programmed Cell Death	32/709	190/10704	8,37528E-07	1,07324E-05	6,63474E-06
aUC_vs_HC	R-HSA-194315	Signaling by Rho GTPases	58/709	455/10704	9,11708E-07	1,15638E-05	7,14873E-06
aUC_vs_HC	R-HSA-109606	Intrinsic Pathway for Apoptosis	15/709	53/10704	1,04537E-06	1,31252E-05	8,114E-06
aUC_vs_HC	R-HSA-5218920	VEGFR2 mediated vascular permeability	11/709	29/10704	1,14495E-06	1,42318E-05	8,79806E-06
aUC_vs_HC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	10/709	24/10704	1,27748E-06	1,55677E-05	9,62396E-06
aUC_vs_HC	R-HSA-982772	Growth hormone receptor signaling	10/709	24/10704	1,27748E-06	1,55677E-05	9,62396E-06
aUC_vs_HC	R-HSA-8875878	MET promotes cell motility	13/709	41/10704	1,31817E-06	1,59076E-05	9,83409E-06
aUC_vs_HC	R-HSA-74751	Insulin receptor signalling cascade	15/709	54/10704	1,36002E-06	1,62548E-05	1,00487E-05
aUC_vs_HC	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	16/709	61/10704	1,41077E-06	1,66241E-05	1,0277E-05
aUC_vs_HC	R-HSA-2586552	Signaling by Leptin	7/709	11/10704	1,41767E-06	1,66241E-05	1,0277E-05
aUC_vs_HC	R-HSA-3700989	Transcriptional Regulation by TP53	49/709	365/10704	1,49234E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-5637810	Constitutive Signaling by EGFRvIII	8/709	15/10704	1,51077E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-5637812	Signaling by EGFRvIII in Cancer	8/709	15/10704	1,51077E-06	1,72283E-05	1,06505E-05
aUC_vs_HC	R-HSA-73887	Death Receptor Signalling	26/709	141/10704	1,56837E-06	1,77226E-05	1,09561E-05
aUC_vs_HC	R-HSA-112399	IRS-mediated signalling	14/709	48/10704	1,60529E-06	1,78158E-05	1,10137E-05
aUC_vs_HC	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	14/709	48/10704	1,60529E-06	1,78158E-05	1,10137E-05
aUC_vs_HC	R-HSA-4090294	SUMOylation of intracellular receptors	11/709	30/10704	1,70041E-06	1,87045E-05	1,15631E-05
aUC_vs_HC	R-HSA-3928662	EPHB-mediated forward signaling	13/709	42/10704	1,79458E-06	1,9567E-05	1,20964E-05
aUC_vs_HC	R-HSA-109581	Apoptosis	30/709	178/10704	1,81418E-06	1,9609E-05	1,21223E-05
aUC_vs_HC	R-HSA-2559580	Oxidative Stress Induced Senescence	24/709	125/10704	1,87097E-06	2,00484E-05	1,23939E-05
aUC_vs_HC	R-HSA-9006335	Signaling by Erythropoietin	10/709	25/10704	2,00346E-06	2,12846E-05	1,31581E-05
aUC_vs_HC	R-HSA-168638	NOD1/2 Signaling Pathway	12/709	37/10704	2,5813E-06	2,69627E-05	1,66683E-05
aUC_vs_HC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	12/709	37/10704	2,5813E-06	2,69627E-05	1,66683E-05
aUC_vs_HC	R-HSA-373760	L1CAM interactions	23/709	119/10704	2,71524E-06	2,81254E-05	1,73871E-05
aUC_vs_HC	R-HSA-1433559	Regulation of KIT signaling	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-1963640	GRB2 events in ERBB2 signaling	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	8/709	16/10704	2,8464E-06	2,87648E-05	1,77824E-05
aUC_vs_HC	R-HSA-202733	Cell surface interactions at the vascular wall	25/709	137/10704	3,0262E-06	3,03352E-05	1,87532E-05
aUC_vs_HC	R-HSA-1474244	Extracellular matrix organization	42/709	301/10704	3,15047E-06	3,13282E-05	1,93671E-05
aUC_vs_HC	R-HSA-5218921	VEGFR2 mediated cell proliferation	9/709	21/10704	3,32722E-06	3,27516E-05	2,0247E-05
aUC_vs_HC	R-HSA-1500931	Cell-Cell communication	24/709	129/10704	3,3463E-06	3,27516E-05	2,0247E-05
aUC_vs_HC	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	22/709	112/10704	3,37562E-06	3,27804E-05	2,02648E-05
aUC_vs_HC	R-HSA-5655302	Signaling by FGFR1 in disease	12/709	38/10704	3,54756E-06	3,39766E-05	2,10043E-05
aUC_vs_HC	R-HSA-1251985	Nuclear signaling by ERBB4	11/709	32/10704	3,55346E-06	3,39766E-05	2,10043E-05
aUC_vs_HC	R-HSA-201681	TCF dependent signaling in response to WNT	37/709	233/10704	4,00824E-06	3,8019E-05	2,35033E-05
aUC_vs_HC	R-HSA-76002	Platelet activation, signaling and aggregation	38/709	243/10704	4,03741E-06	3,8019E-05	2,35033E-05
aUC_vs_HC	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	11/709	33/10704	5,01393E-06	4,68595E-05	2,89685E-05
aUC_vs_HC	R-HSA-180292	GAB1 signalosome	8/709	17/10704	5,06511E-06	4,69846E-05	2,90458E-05
aUC_vs_HC	R-HSA-389357	CD28 dependent PI3K/Akt signaling	9/709	22/10704	5,30132E-06	4,84525E-05	2,99533E-05
aUC_vs_HC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	9/709	22/10704	5,30132E-06	4,84525E-05	2,99533E-05
aUC_vs_HC	R-HSA-157118	Signaling by NOTCH	35/709	236/10704	5,3735E-06	4,87537E-05	3,01395E-05
aUC_vs_HC	R-HSA-8853659	RET signaling	12/709	40/10704	6,47329E-06	5,83065E-05	3,6045E-05
aUC_vs_HC	R-HSA-8943724	Regulation of PTEN gene transcription	15/709	61/10704	7,17066E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6783783	Interleukin-10 signaling	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05

aUC_vs_HC	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6802949	Signaling by RAS mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-9649948	Signaling downstream of RAS mutants	13/709	47/10704	7,26374E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-2682334	EPH-Ephrin signaling	19/709	92/10704	7,27765E-06	6,2387E-05	3,85676E-05
aUC_vs_HC	R-HSA-1839911	Signaling by cytosolic FGFR1 fusion mutants	8/709	18/10704	8,58952E-06	7,26311E-05	4,49005E-05
aUC_vs_HC	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	8/709	18/10704	8,58952E-06	7,26311E-05	4,49005E-05
aUC_vs_HC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	12/709	42/10704	1,13312E-05	9,51667E-05	5,88319E-05
aUC_vs_HC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	9/709	24/10704	1,23538E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6783589	Interleukin-6 family signaling	9/709	24/10704	1,23538E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	7/709	13/10704	1,23571E-05	0,000101721	6,2884E-05
aUC_vs_HC	R-HSA-6804757	Regulation of TP53 Degradation	11/709	36/10704	1,29578E-05	0,000105964	6,55069E-05
aUC_vs_HC	R-HSA-525793	Myogenesis	10/709	30/10704	1,35916E-05	0,00011042	6,82617E-05
aUC_vs_HC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	6/709	10/10704	1,37939E-05	0,000111337	6,88282E-05
aUC_vs_HC	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	8/709	19/10704	1,39784E-05	0,000111379	6,88545E-05
aUC_vs_HC	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	8/709	19/10704	1,39784E-05	0,000111379	6,88545E-05
aUC_vs_HC	R-HSA-1643713	Signaling by EGFR in Cancer	9/709	25/10704	1,81759E-05	0,000143902	8,89601E-05
aUC_vs_HC	R-HSA-109704	PI3K Cascade	12/709	44/10704	1,91146E-05	0,000149431	9,23779E-05
aUC_vs_HC	R-HSA-451927	Interleukin-2 family signaling	12/709	44/10704	1,91146E-05	0,000149431	9,23779E-05
aUC_vs_HC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	18/709	90/10704	2,00588E-05	0,000155832	9,63349E-05
aUC_vs_HC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	23/709	134/10704	2,11933E-05	0,000163623	0,000101152
aUC_vs_HC	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-6785631	ERBB2 Regulates Cell Motility	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	7/709	15/10704	2,18477E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-8876384	Listeria monocytogenes entry into host cells	8/709	20/10704	2,1951E-05	0,000165364	0,000102228
aUC_vs_HC	R-HSA-111465	Apoptotic cleavage of cellular proteins	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-5689896	Ovarian tumor domain proteases	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	11/709	38/10704	2,29702E-05	0,000169952	0,000105064
aUC_vs_HC	R-HSA-75153	Apoptotic execution phase	13/709	52/10704	2,40877E-05	0,000177166	0,000109524
aUC_vs_HC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-2871796	FCERI mediated MAPK activation	10/709	32/10704	2,58513E-05	0,00018682	0,000115492
aUC_vs_HC	R-HSA-1059683	Interleukin-6 signaling	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-5655291	Signaling by FGFR4 in disease	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	6/709	11/10704	2,86454E-05	0,000203464	0,000125781
aUC_vs_HC	R-HSA-5688426	Deubiquitination	39/709	297/10704	2,95375E-05	0,000208608	0,000128961
aUC_vs_HC	R-HSA-9031628	NGF-stimulated transcription	11/709	39/10704	3,01012E-05	0,000211388	0,00013068
aUC_vs_HC	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	8/709	21/10704	3,34118E-05	0,00023332	0,000144238
aUC_vs_HC	R-HSA-388841	Costimulation by the CD28 family	15/709	69/10704	3,50631E-05	0,000243483	0,000150521
aUC_vs_HC	R-HSA-74752	Signaling by Insulin receptor	16/709	78/10704	4,14673E-05	0,000286353	0,000177023
aUC_vs_HC	R-HSA-400253	Circadian Clock	15/709	70/10704	4,19423E-05	0,000288034	0,000178062
aUC_vs_HC	R-HSA-9018519	Estrogen-dependent gene expression	24/709	150/10704	4,65365E-05	0,000316198	0,000195473
aUC_vs_HC	R-HSA-4791275	Signaling by WNT in cancer	10/709	34/10704	4,65521E-05	0,000316198	0,000195473
aUC_vs_HC	R-HSA-1834949	Cytosolic sensors of pathogen-associated DNA	14/709	63/10704	4,9144E-05	0,000331979	0,000205229
aUC_vs_HC	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	12/709	48/10704	4,94096E-05	0,000331979	0,000205229
aUC_vs_HC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	7/709	17/10704	5,87194E-05	0,00039241	0,000242587
aUC_vs_HC	R-HSA-8863795	Downregulation of ERBB2 signaling	9/709	29/10704	7,00745E-05	0,000463312	0,000286419
aUC_vs_HC	R-HSA-9645723	Diseases of programmed cell death	9/709	29/10704	7,00745E-05	0,000463312	0,000286419
aUC_vs_HC	R-HSA-373755	Semaphorin interactions	14/709	65/10704	7,08564E-05	0,000466003	0,000288082
aUC_vs_HC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	8/709	23/10704	7,14882E-05	0,000467683	0,000289121
aUC_vs_HC	R-HSA-5654736	Signaling by FGFR1	12/709	50/10704	7,61749E-05	0,000495735	0,000306463
aUC_vs_HC	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	10/709	36/10704	7,9958E-05	0,000517644	0,000320007
aUC_vs_HC	R-HSA-9656223	Signaling by RAF1 mutants	11/709	43/10704	8,09649E-05	0,000521447	0,000322358
aUC_vs_HC	R-HSA-1980143	Signaling by NOTCH1	15/709	74/10704	8,27561E-05	0,000530236	0,000327791
aUC_vs_HC	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	7/709	18/10704	9,06203E-05	0,000577646	0,0003571
aUC_vs_HC	R-HSA-8874081	MET activates PTK2 signaling	9/709	30/10704	9,42815E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-179812	GRB2 events in EGFR signaling	6/709	13/10704	9,48234E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	6/709	13/10704	9,48234E-05	0,00059528	0,000368002
aUC_vs_HC	R-HSA-3000171	Non-integrin membrane-ECM interactions	13/709	59/10704	9,97967E-05	0,000623353	0,000385356
aUC_vs_HC	R-HSA-5260271	Diseases of Immune System	8/709	24/10704	0,000101055	0,000624935	0,000386334
aUC_vs_HC	R-HSA-5602358	Diseases associated with the TLR signaling cascade	8/709	24/10704	0,000101055	0,000624935	0,000386334
aUC_vs_HC	R-HSA-182971	EGFR downregulation	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-1839124	FGFR1 mutant receptor activation	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	9/709	31/10704	0,000125126	0,000758692	0,000469023
aUC_vs_HC	R-HSA-1566948	Elastic fibre formation	11/709	45/10704	0,000126515	0,00076339	0,00047192 7
aUC_vs_HC	R-HSA-2129379	Molecules associated with elastic fibres	10/709	38/10704	0,000131781	0,000791325	0,000489196
aUC_vs_HC	R-HSA-69206	G1/S Transition	21/709	131/10704	0,000132811	0,000793673	0,000490648
aUC_vs_HC	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	16/709	86/10704	0,000141791	0,000843284	0,000521317
aUC_vs_HC	R-HSA-180336	SHC1 events in EGFR signaling	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-198323	AKT phosphorylates targets in the cytosol	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-9027284	Erythropoietin activates RAS	6/709	14/10704	0,000156673	0,000914294	0,000565216
aUC_vs_HC	R-HSA-76009	Platelet Aggregation (Plug Formation)	10/709	39/10704	0,000166844	0,000969096	0,000599094
aUC_vs_HC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/709	26/10704	0,000196971	0,00110223 46	0,000681469
aUC_vs_HC	R-HSA-5625900	RHO GTPases activate CIT	7/709	20/10704	0,000196377	0,00111 9711	0,000692204
aUC_vs_HC	R-HSA-5627117	RHO GTPases Activate ROCKs	7/709	20/10704	0,000196377	0,00111 9711	0,000692204
aUC_vs_HC	R-HSA-622312	Inflammasomes	7/709	20/10704	0,000196377	0,00111 9711	0,000692204
aUC_vs_HC	R-HSA-1226099	Signaling by FGFR in disease	13/709	63/10704	0,000201913	0,00114601 7	0,000708466
aUC_vs_HC	R-HSA-5674135	MAP2K and MAPK activation	10/709	40/10704	0,000209437	0,00118331 9	0,000731526
aUC_vs_HC	R-HSA-450341	Activation of the AP-1 family of transcription factors	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-74749	Signal attenuation	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	5/709	10/10704	0,000239393	0,001329758	0,000822055
aUC_vs_HC	R-HSA-9679191	Potential therapeutics for SARS	15/709	81/10704	0,000239635	0,001329758	0,000822055
aUC_vs_HC	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	12/709	56/10704	0,000242818	0,001341434	0,000829273
aUC_vs_HC	R-HSA-3772470	Negative regulation of TCF-dependent signaling by WNT ligand antagonists	6/709	15/10704	0,000246557	0,001350088	0,000834623
aUC_vs_HC	R-HSA-844456	The NLRP3 inflammasome	6/709	15/10704	0,000246557	0,001350088	0,000834623
aUC_vs_HC	R-HSA-1538133	G0 and Early G1	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-3000170	Syndecan interactions	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-354192	Integrin signaling	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-912526	Interleukin receptor SHC signaling	8/709	27/10704	0,000255385	0,001374216	0,000849539
aUC_vs_HC	R-HSA-186712	Regulation of beta-cell development	10/709	41/10704	0,000260794	0,001397269	0,00086379
aUC_vs_HC	R-HSA-187687	Signalling to ERKs	9/709	34/10704	0,000272066	0,001451408	0,000897259
aUC_vs_HC	R-HSA-1606322	ZBP1(DAI) mediated induction of type I IFNs	7/709	21/10704	0,00027786	0,001475983	0,000912451
aUC_vs_HC	R-HSA-201451	Signaling by BMP	8/709	28/10704	0,000337013	0,001764791	0,001090991
aUC_vs_HC	R-HSA-6807070	PTEN Regulation	21/709	140/10704	0,000342107	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644603	Signaling by NOTCH1 in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	12/709	58/10704	0,000343267	0,001764791	0,001090991
aUC_vs_HC	R-HSA-373752	Netrin-1 signaling	11/709	50/10704	0,000343691	0,001764791	0,001090991
aUC_vs_HC	R-HSA-114604	GPVI-mediated activation cascade	9/709	35/10704	0,000345007	0,001764791	0,001090991
aUC_vs_HC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	7/709	22/10704	0,00038444	0,00195044 3	0,001205761
aUC_vs_HC	R-HSA-8863678	Neurodegenerative Diseases	7/709	22/10704	0,00038444	0,00195044 3	0,001205761
aUC_vs_HC	R-HSA-8875555	MET activates RAP1 and RAC1	5/709	11/10704	0,000415017	0,00208852 5	0,001291124
aUC_vs_HC	R-HSA-9613399	Regulation of localization of FOXO transcription factors	5/709	11/10704	0,000415017	0,00208852 5	0,001291124
aUC_vs_HC	R-HSA-1266695	Interleukin-7 signaling	9/709	36/10704	0,000433357	0,00217202 8	0,001342745
aUC_vs_HC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/709	29/10704	0,000438704	0,00218999 8	0,001353854
aUC_vs_HC	R-HSA-75893	TNF signaling	10/709	44/10704	0,000481826	0,00239564	0,001480982
aUC_vs_HC	R-HSA-112409	RAF-independent MAPK1/3 activation	7/709	23/10704	0,000521356	0,002581854	0,001596099
aUC_vs_HC	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-196299	Beta-catenin phosphorylation cascade	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	6/709	17/10704	0,000543676	0,002660588	0,001644772
aUC_vs_HC	R-HSA-114452	Activation of BH3-only proteins	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-3000157	Laminin interactions	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	8/709	30/10704	0,000563949	0,002727582	0,001686188
aUC_vs_HC	R-HSA-193704	p75 NTR receptor-mediated signalling	16/709	97/10704	0,000588511	0,002835348	0,001752808
aUC_vs_HC	R-HSA-9679506	SARS-CoV Infections	21/709	147/10704	0,000665707	0,003194878	0,001975069
aUC_vs_HC	R-HSA-933543	NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	5/709	12/10704	0,000672826	0,003216627	0,001988515
aUC_vs_HC	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	18/709	120/10704	0,000693811	0,003281997	0,002028926
aUC_vs_HC	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	7/709	24/10704	0,000694421	0,003281997	0,002028926
aUC_vs_HC	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	7/709	24/10704	0,000694421	0,003281997	0,002028926
aUC_vs_HC	R-HSA-111471	Apoptotic factor-mediated response	6/709	18/10704	0,00070204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-1912420	Pre-NOTCH Processing in Golgi	6/709	18/10704	0,00070204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-210993	Tie2 Signaling	6/709	18/10704	0,00070204	0,003599111	0,002224966
aUC_vs_HC	R-HSA-5633007	Regulation of TP53 Activity	22/709	160/10704	0,000847721	0,003946507	0,002439726
aUC_vs_HC	R-HSA-446728	Cell junction organization	15/709	91/10704	0,00087075	0,004038589	0,002496651
aUC_vs_HC	R-HSA-5654741	Signaling by FGFR3	9/709	40/10704	0,00099182	0,00458302	0,002833217
aUC_vs_HC	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	10/709	48/10704	0,000998868	0,004598491	0,002842782
aUC_vs_HC	R-HSA-69202	Cyclin E associated events during G1/S transition	14/709	83/10704	0,001015063	0,004655805	0,002878213
aUC_vs_HC	R-HSA-209560	NF-kB is activated and signals survival	5/709	13/10704	0,001034078	0,004725585	0,002921351
aUC_vs_HC	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	15/709	93/10704	0,001096791	0,004993812	0,003087168
aUC_vs_HC	R-HSA-447115	Interleukin-12 family signaling	11/709	57/10704	0,001111568	0,005042623	0,003117343
aUC_vs_HC	R-HSA-9012852	Signaling by NOTCH3	10/709	49/10704	0,001181453	0,005342426	0,003302681
aUC_vs_HC	R-HSA-165159	MTOR signalling	9/709	41/10704	0,001197421	0,005373266	0,003321746
aUC_vs_HC	R-HSA-5654743	Signaling by FGFR4	9/709	41/10704	0,001197421	0,005373266	0,003321746
aUC_vs_HC	R-HSA-216083	Integrin cell surface interactions	14/709	85/10704	0,001290049	0,005747422	0,003553049
aUC_vs_HC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	14/709	85/10704	0,001290049	0,005747422	0,003553049
aUC_vs_HC	R-HSA-1592230	Mitochondrial biogenesis	15/709	95/10704	0,001370391	0,006083557	0,003760847
aUC_vs_HC	R-HSA-1181150	Signaling by NODAL	6/709	20/10704	0,001434729	0,006324001	0,00390949
aUC_vs_HC	R-HSA-167044	Signaling to RAS	6/709	20/10704	0,001434729	0,006324001	0,00390949
aUC_vs_HC	R-HSA-9664407	Parasite infection	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-9664417	Leishmania phagocytosis	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-9664422	FCGR3A-mediated phagocytosis	11/709	59/10704	0,001494413	0,006499161	0,004017773
aUC_vs_HC	R-HSA-1250347	SHC1 events in ERBB4 signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-162594	Early Phase of HIV Life Cycle	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-418885	DCC mediated attractive signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-8941856	RUNX3 regulates NOTCH signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-8983432	Interleukin-15 signaling	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-918233	TRAF3-dependent IRF activation pathway	5/709	14/10704	0,001521525	0,006499161	0,004017773
aUC_vs_HC	R-HSA-1632852	Macroautophagy	19/709	136/10704	0,001543597	0,006570859	0,004062097
aUC_vs_HC	R-HSA-190236	Signaling by FGFR	14/709	87/10704	0,001624749	0,006892708	0,004261063
aUC_vs_HC	R-HSA-5357905	Regulation of TNFR1 signaling	8/709	35/10704	0,001689664	0,007119498	0,004401265
aUC_vs_HC	R-HSA-8953750	Transcriptional Regulation by E2F6	8/709	35/10704	0,001689664	0,007119498	0,004401265
aUC_vs_HC	R-HSA-210745	Regulation of gene expression in beta cells	6/709	21/10704	0,001897477	0,00796812	0,004925882
aUC_vs_HC	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	11/709	63/10704	0,001978996	0,008282465	0,00512021
aUC_vs_HC	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	9/709	44/10704	0,002027793	0,008458209	0,005228854

Group	ID	Name	Ratio1	Ratio2	p	FDR	q
aUC_vs_HC	R-HSA-5663213	RHO GTPases Activate WASPs and WAVEs	8/709	36/10704	0,002048608	0,008516456	0,005264862
aUC_vs_HC	R-HSA-1912422	Pre-NOTCH Expression and Processing	16/709	109/10704	0,002111109	0,008629096	0,005334496
aUC_vs_HC	R-HSA-438064	Post NMDA receptor activation events	13/709	80/10704	0,002150718	0,008629096	0,005334496
aUC_vs_HC	R-HSA-372708	p130Cas linkage to MAPK signaling for integrins	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-4839716	Misspliced GSK3beta mutants stabilize beta-catenin	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-8875360	InlB-mediated entry of Listeria monocytogenes into host cell	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-937039	IRAK1 recruits IKK complex	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-975144	IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	5/709	15/10704	0,002159009	0,008629096	0,005334496
aUC_vs_HC	R-HSA-1474228	Degradation of the extracellular matrix	19/709	140/10704	0,002172761	0,008656224	0,005351267
aUC_vs_HC	R-HSA-1604999	Synthesis of PIPs at the plasma membrane	10/709	53/10704	0,002207416	0,008766193	0,00541925
aUC_vs_HC	R-HSA-4086398	Ca2+ pathway	11/709	62/10704	0,002265275	0,008967315	0,005543583
aUC_vs_HC	R-HSA-565332	Signaling by FGFR3 in disease	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-912631	Regulation of signaling by CBL	6/709	22/10704	0,002464866	0,009665073	0,005974936
aUC_vs_HC	R-HSA-375165	NCAM signaling for neurite out-growth	11/709	63/10704	0,00258422	0,010101212	0,006244557
aUC_vs_HC	R-HSA-5689880	Ub-specific processing proteases	26/709	220/10704	0,002847216	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2424491	DAP12 signaling	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-5654696	Downstream signaling of activated FGFR2	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	7/709	30/10704	0,002884768	0,011090145	0,006855914
aUC_vs_HC	R-HSA-110056	MAPK3 (ERK1) activation	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-1250342	PI3K events in ERBB4 signaling	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-9020958	Interleukin-21 signaling	4/709	10/10704	0,002903387	0,011090145	0,006855914
aUC_vs_HC	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	8/709	38/10704	0,002944618	0,011090145	0,006855914
aUC_vs_HC	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-193639	p75NTR signals via NF-kB	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-391160	Signal regulatory protein family interactions	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-5684264	MAP3K8 (TPL2)-dependent MAPK1/3 activation	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-9614657	FOXO-mediated transcription of cell death genes	5/709	16/10704	0,002971052	0,011090145	0,006855914
aUC_vs_HC	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	6/709	23/10704	0,00315081	0,01172592	0,007248949
aUC_vs_HC	R-HSA-437239	Recycling pathway of L1	9/709	47/10704	0,003263365	0,01207208	0,007463209
aUC_vs_HC	R-HSA-9020591	Interleukin-12 signaling	9/709	47/10704	0,003263365	0,012072508	0,007463209
aUC_vs_HC	R-HSA-5654687	Downstream signaling of activated FGFR1	7/709	31/10704	0,003517155	0,012972772	0,008019752
aUC_vs_HC	R-HSA-449836	Other interleukin signaling	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-5627123	RHO GTPases activate PAKs	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-9660826	Purinergic signaling in leishmaniasis infection	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-9664424	Cell recruitment (pro-inflammatory response)	6/709	24/10704	0,003969607	0,014469857	0,008945248
aUC_vs_HC	R-HSA-8856825	Cargo recognition for clathrin-mediated endocytosis	15/709	106/10704	0,004100067	0,014901705	0,009212216
aUC_vs_HC	R-HSA-5626467	RHO GTPases activate IQGAPs	7/709	32/10704	0,004249739	0,01540067	0,009520667
aUC_vs_HC	R-HSA-1234158	Regulation of gene expression by Hypoxia-inducible Factor	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-5625970	RHO GTPases activate KTN1	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-8851805	MET activates RAS signaling	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/709	11/10704	0,004325312	0,01544932	0,00955075
aUC_vs_HC	R-HSA-1989781	PPARA activates gene expression	16/709	117/10704	0,004356048	0,015514519	0,009591056
aUC_vs_HC	R-HSA-5628897	TP53 Regulates Metabolic Genes	13/709	87/10704	0,004564358	0,016209992	0,010020997
aUC_vs_HC	R-HSA-210991	Basigin interactions	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-5654708	Downstream signaling of activated FGFR3	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-8854691	Interleukin-20 family signaling	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-937041	IKK complex recruitment mediated by RIP1	6/709	25/10704	0,004935796	0,017233693	0,010653848
aUC_vs_HC	R-HSA-446652	Interleukin-1 family signaling	18/709	140/10704	0,005036222	0,017486101	0,010809886
aUC_vs_HC	R-HSA-5663220	RHO GTPases Activate Formins	18/709	140/10704	0,005036222	0,017486101	0,010809886
aUC_vs_HC	R-HSA-1592389	Activation of Matrix Metalloproteinases	7/709	33/10704	0,00509207	0,017554997	0,010852477
aUC_vs_HC	R-HSA-1980145	Signaling by NOTCH2	7/709	33/10704	0,00509207	0,017554997	0,010852477
aUC_vs_HC	R-HSA-9612973	Autophagy	19/709	151/10704	0,005098434	0,017554997	0,010852477
aUC_vs_HC	R-HSA-400206	Regulation of lipid metabolism by PPARalpha	16/709	119/10704	0,005149806	0,017682899	0,010931546
aUC_vs_HC	R-HSA-446353	Cell-extracellular matrix interactions	5/709	18/10704	0,005217942	0,017867499	0,011045666
aUC_vs_HC	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	9/709	51/10704	0,005753713	0,019647982	0,012146358
aUC_vs_HC	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	16/709	121/10704	0,006057396	0,020390356	0,012605293
aUC_vs_HC	R-HSA-5619507	Activation of HOX genes during differentiation	16/709	121/10704	0,006057396	0,020390356	0,012605293
aUC_vs_HC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	12/709	80/10704	0,00611264	0,020390356	0,012605293
aUC_vs_HC	R-HSA-416482	G alpha (12/13) signalling events	12/709	80/10704	0,00611264	0,020390356	0,012605293
aUC_vs_HC	R-HSA-1474151	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-210990	PECAM1 interactions	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-2197563	NOTCH2 intracellular domain regulates transcription	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-389359	CD28 dependent Vav1 pathway	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9664420	Killing mechanisms	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-9673324	WNT5:FZD7-mediated leishmania damping	4/709	12/10704	0,006151555	0,020390356	0,012605293
aUC_vs_HC	R-HSA-3928664	Ephrin signaling	5/709	19/10704	0,00670177	0,022155054	0,013696227
aUC_vs_HC	R-HSA-6798695	Neutrophil degranulation	46/709	480/10704	0,006991877	0,023052793	0,014251208
aUC_vs_HC	R-HSA-5654716	Downstream signaling of activated FGFR4	6/709	27/10704	0,007368922	0,024231666	0,014979986
aUC_vs_HC	R-HSA-9020702	Interleukin-1 signaling	14/709	103/10704	0,00779261	0,025557295	0,015799488
aUC_vs_HC	R-HSA-1912408	Pre-NOTCH Transcription and Translation	13/709	93/10704	0,008051554	0,026337057	0,016281536
aUC_vs_HC	R-HSA-5654738	Signaling by FGFR2	11/709	73/10704	0,008200529	0,026612881	0,01645205
aUC_vs_HC	R-HSA-8939902	Regulation of RUNX2 expression and activity	11/709	73/10704	0,008200529	0,026612881	0,01645205
aUC_vs_HC	R-HSA-5673000	RAF activation	7/709	36/10704	0,008375049	0,026612881	0,01645205
aUC_vs_HC	R-HSA-111461	Cytochrome c-mediated apoptotic response	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-1502540	Signaling by Activin	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-171007	p38MAPK events	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-203615	eNOS activation	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-2892247	POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-5210891	Uptake and function of anthrax toxins	4/709	13/10704	0,00842599	0,026612881	0,01645205
aUC_vs_HC	R-HSA-168927	TICAM1, RIP1-mediated IKK complex recruitment	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-2028269	Signaling by Hippo	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-3232118	SUMOylation of transcription factors	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-9013695	NOTCH4 Intracellular Domain Regulates Transcription	5/709	20/10704	0,008457451	0,026612881	0,01645205
aUC_vs_HC	R-HSA-8878171	Transcriptional regulation by RUNX1	26/709	239/10704	0,00847844	0,026612881	0,01645205
aUC_vs_HC	R-HSA-350054	Notch-HLH transcription pathway	6/709	28/10704	0,008684939	0,027686228	0,017115592
aUC_vs_HC	R-HSA-69205	G1/S-Specific Transcription	6/709	28/10704	0,008864919	0,027686228	0,017115592
aUC_vs_HC	R-HSA-9658195	Leishmania infection	27/709	252/10704	0,008997666	0,028030324	0,017328311
aUC_vs_HC	R-HSA-194840	Rho GTPase cycle	17/709	138/10704	0,009601439	0,02983647	0,018444869
aUC_vs_HC	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	7/709	37/10704	0,00975408	0,030235216	0,018691373
aUC_vs_HC	R-HSA-389513	CTLA4 inhibitory signaling	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5654689	PI-3K cascade:FGFR1	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-6807004	Negative regulation of MET activity	5/709	21/10704	0,010507442	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5213460	RIPK1-mediated regulated necrosis	6/709	29/10704	0,010556625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5218859	Regulated Necrosis	6/709	29/10704	0,010556625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-5675482	Regulation of necroptotic cell death	6/709	29/10704	0,010556625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-933541	TRAF6 mediated IRF7 activation	6/709	29/10704	0,010556625	0,032190807	0,019900317
aUC_vs_HC	R-HSA-69242	S Phase	19/709	162/10704	0,0069126	0,03249202	0,020086526
aUC_vs_HC	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	11/709	76/10704	0,011035126	0,032702764	0,020216808
aUC_vs_HC	R-HSA-3000178	ECM proteoglycans	11/709	76/10704	0,011035126	0,032702764	0,020216808
aUC_vs_HC	R-HSA-189483	Heme degradation	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5358565	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467348	AXIN missense mutants destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-877312	Regulation of IFNG signaling	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9005891	Loss of function of MECP2 in Rett syndrome	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9005895	Pervasive developmental disorders	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9675151	Disorders of Developmental Biology	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9697154	Disorders of Nervous System Development	4/709	14/10704	0,011187776	0,032702764	0,020216808
aUC_vs_HC	R-HSA-9024446	NR1H2 and NR1H3-mediated signaling	8/709	47/10704	0,011207866	0,032702764	0,020216808
aUC_vs_HC	R-HSA-202424	Downstream TCR signaling	13/709	98/10704	0,012327811	0,035886345	0,022184894
aUC_vs_HC	R-HSA-3928663	EPHA-mediated growth cone collapse	6/709	30/10704	0,012486621	0,036263714	0,022418183
aUC_vs_HC	R-HSA-198753	ERK/MAPK targets	5/709	22/10704	0,012872906	0,037298421	0,023057837
aUC_vs_HC	R-HSA-3371556	Cellular response to heat stress	12/709	89/10704	0,014029477	0,040554977	0,025071036
aUC_vs_HC	R-HSA-111447	Activation of BAD and translocation to mitochondria	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2691232	Signaling by NOTCH1 HD Domain Mutants in Cancer	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-5358508	Mismatch Repair	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-71336	Pentose phosphate pathway	4/709	15/10704	0,014470964	0,041255522	0,025504112
aUC_vs_HC	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	6/709	31/10704	0,014639293	0,04163991	0,025741741
aUC_vs_HC	R-HSA-373753	Nephrin family interactions	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-5654693	FRS-mediated FGFR1 signaling	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-5654695	PI-3K cascade:FGFR2	5/709	23/10704	0,015573488	0,043995105	0,027197719
aUC_vs_HC	R-HSA-983705	Signaling by the B Cell Receptor (BCR)	14/709	112/10704	0,015773056	0,044457843	0,027483783
aUC_vs_HC	R-HSA-3858494	Beta-catenin independent WNT signaling	17/709	146/10704	0,016261756	0,045628358	0,028207394
aUC_vs_HC	R-HSA-8856828	Clathrin-mediated endocytosis	17/709	146/10704	0,016261756	0,045628358	0,028207394
qUC_vs_HC	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	18/190	108/10704	4,70976E-13	3,9562E-10	2,64242E-10
qUC_vs_HC	R-HSA-8878166	Transcriptional regulation by RUNX2	18/190	121/10704	3,53299E-12	1,48386E-09	9,91098E-10
qUC_vs_HC	R-HSA-449147	Signaling by Interleukins	32/190	461/10704	2,47598E-11	6,93275E-09	4,63052E-09
qUC_vs_HC	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	8/190	17/10704	1,80375E-10	3,0303E-08	2,024E-08
qUC_vs_HC	R-HSA-9659949	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	8/190	17/10704	1,80375E-10	3,0303E-08	2,024E-08
qUC_vs_HC	R-HSA-9661202	Diseases of signal transduction by growth factor receptors and second messengers	27/190	387/10704	9,56396E-10	1,33895E-07	8,94314E-08
qUC_vs_HC	R-HSA-9006925	Intracellular signaling by second messengers	22/190	306/10704	2,27692E-08	2,73231E-06	1,82496E-06
qUC_vs_HC	R-HSA-2559583	Cellular Senescence	17/190	197/10704	7,24214E-08	7,53779E-06	5,03464E-06
qUC_vs_HC	R-HSA-2559586	Oncogene Induced Senescence	8/190	33/10704	8,0762E-08	7,53779E-06	5,03464E-06
qUC_vs_HC	R-HSA-69231	Cyclin D associated events in G1	9/190	47/10704	1,10212E-07	8,41622E-06	5,62136E-06
qUC_vs_HC	R-HSA-69236	G1 Phase	9/190	47/10704	1,10212E-07	8,41622E-06	5,62136E-06
qUC_vs_HC	R-HSA-9675126	Diseases of mitotic cell cycle	8/190	36/10704	1,68176E-07	1,08668E-05	7,25813E-06
qUC_vs_HC	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	8/190	36/10704	1,68176E-07	1,08668E-05	7,25813E-06

qUC_vs_HC	R-HSA-1257604	PIP3 activates AKT signaling	19/190	264/10704	2,1667E-07	1,30002E-05	8,68308E-06
qUC_vs_HC	R-HSA-8848021	Signaling by PTK6	9/190	54/10704	3,86441E-07	2,02881E-05	1,35509E-05
qUC_vs_HC	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	9/190	54/10704	3,86441E-07	2,02881E-05	1,35509E-05
qUC_vs_HC	R-HSA-199418	Negative regulation of the PI3K/AKT network	12/190	110/10704	5,32948E-07	2,63339E-05	1,75889E-05
qUC_vs_HC	R-HSA-8941326	RUNX2 regulates bone development	7/190	32/10704	1,14925E-06	5,36314E-05	3,58215E-05
qUC_vs_HC	R-HSA-9006931	Signaling by Nuclear Receptors	19/190	299/10704	1,45254E-06	6,42174E-05	4,28921E-05
qUC_vs_HC	R-HSA-69202	Cyclin E associated events during G1/S transition	10/190	83/10704	1,93804E-06	7,85376E-05	5,24568E-05
qUC_vs_HC	R-HSA-9614085	FOXO-mediated transcription	9/190	65/10704	1,96344E-06	7,85376E-05	5,24568E-05
qUC_vs_HC	R-HSA-8939211	ESR-mediated signaling	16/190	223/10704	2,14333E-06	8,18361E-05	5,46599E-05
qUC_vs_HC	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	10/190	85/10704	2,41785E-06	8,83042E-05	5,89801E-05
qUC_vs_HC	R-HSA-5655302	Signaling by FGFR1 in disease	7/190	38/10704	3,93793E-06	0,000137827	9,20576E-05
qUC_vs_HC	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	5/190	17/10704	8,69872E-06	0,000281036	0,000187709
qUC_vs_HC	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	5/190	17/10704	8,69872E-06	0,000281036	0,000187709
qUC_vs_HC	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	7/190	44/10704	1,09284E-05	0,000339994	0,000227089
qUC_vs_HC	R-HSA-2219528	PI3K/AKT Signaling in Cancer	10/190	101/10704	1,16134E-05	0,000348401	0,000232704
qUC_vs_HC	R-HSA-453279	Mitotic G1 phase and G1/S transition	12/190	149/10704	1,3157E-05	0,000381099	0,000254544
qUC_vs_HC	R-HSA-9018519	Estrogen-dependent gene expression	12/190	150/10704	1,4082E-05	0,000394296	0,000263358
qUC_vs_HC	R-HSA-3700989	Transcriptional Regulation by TP53	19/190	365/10704	2,57114E-05	0,000696696	0,000465337
qUC_vs_HC	R-HSA-2428928	IRS-related events triggered by IGF1R	7/190	52/10704	3,38454E-05	0,000888441	0,000593408
qUC_vs_HC	R-HSA-109606	Intrinsic Pathway for Apoptosis	7/190	53/10704	3,84166E-05	0,000949117	0,000633934
qUC_vs_HC	R-HSA-2428924	IGF1R signaling cascade	7/190	53/10704	3,84166E-05	0,000949117	0,000633934
qUC_vs_HC	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	7/190	54/10704	4,34829E-05	0,001043589	0,000697034
qUC_vs_HC	R-HSA-8878159	Transcriptional regulation by RUNX3	9/190	96/10704	4,96315E-05	0,001128997	0,00075408
qUC_vs_HC	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	6/190	38/10704	4,97296E-05	0,001128997	0,00075408
qUC_vs_HC	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	5/190	24/10704	5,4006E-05	0,001193818	0,000797375
qUC_vs_HC	R-HSA-5688426	Deubiquitination	16/190	297/10704	7,66288E-05	0,001650466	0,001102379
qUC_vs_HC	R-HSA-9006936	Signaling by TGFB family members	9/190	102/10704	8,00239E-05	0,001680502	0,001122441
qUC_vs_HC	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/190	14/10704	8,37589E-05	0,001716035	0,001146174
qUC_vs_HC	R-HSA-69206	G1/S Transition	10/190	131/10704	0,000110112	0,002200341	0,001469652
qUC_vs_HC	R-HSA-71336	Pentose phosphate pathway	4/190	15/10704	0,000112637	0,002200341	0,001469652
qUC_vs_HC	R-HSA-2173791	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	6/190	44/10704	0,000116406	0,002216605	0,001480515
qUC_vs_HC	R-HSA-1226099	Signaling by FGFR in disease	7/190	63/10704	0,000118747	0,002216605	0,001480515
qUC_vs_HC	R-HSA-69242	S Phase	11/190	162/10704	0,00014 3528	0,002620939	0,001750577
qUC_vs_HC	R-HSA-5689880	Ub-specific processing proteases	13/190	220/10704	0,000147532	0,002636733	0,001761126
qUC_vs_HC	R-HSA-9616222	Transcriptional regulation of granulopoiesis	8/190	90/10704	0,000190242	0,003093557	0,002066248
qUC_vs_HC	R-HSA-112399	IRS-mediated signalling	6/190	48/10704	0,000190803	0,003093557	0,002066248
qUC_vs_HC	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	6/190	48/10704	0,000190803	0,003093557	0,002066248
qUC_vs_HC	R-HSA-9034015	Signaling by NTRK3 (TRKC)	4/190	17/10704	0,000191	0,003093557	0,002066248
qUC_vs_HC	R-HSA-1839124	FGFR1 mutant receptor activation	5/190	31/10704	0,000195189	0,003093557	0,002066248
qUC_vs_HC	R-HSA-5654687	Downstream signaling of activated FGFR1	5/190	31/10704	0,000195189	0,003093557	0,002066248
qUC_vs_HC	R-HSA-5683057	MAPK family signaling cascades	16/190	325/10704	0,000217479	0,00338301	0,00225 9579
qUC_vs_HC	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	5/190	32/10704	0,000228032	0,003420483	0,002284608
qUC_vs_HC	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	5/190	32/10704	0,000228032	0,003420483	0,002284608
qUC_vs_HC	R-HSA-1227986	Signaling by ERBB2	6/190	50/10704	0,000239921	0,003474712	0,002320829
qUC_vs_HC	R-HSA-5654736	Signaling by FGFR1	6/190	50/10704	0,000239921	0,003474712	0,002320829
qUC_vs_HC	R-HSA-170834	Signaling by TGF-beta Receptor Complex	7/190	73/10704	0,000301245	0,004288911	0,002864648
qUC_vs_HC	R-HSA-109581	Apoptosis	11/190	178/10704	0,000326636	0,004572909	0,003054336
qUC_vs_HC	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	7/190	75/10704	0,000356197	0,004905003	0,003276148
qUC_vs_HC	R-HSA-74751	Insulin receptor signalling cascade	6/190	54/10704	0,000367705	0,004981301	0,00332745
qUC_vs_HC	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	11/190	182/10704	0,000395054	0,005267385	0,003518191
qUC_vs_HC	R-HSA-74752	Signaling by Insulin receptor	7/190	78/10704	0,000453404	0,005782477	0,003862231
qUC_vs_HC	R-HSA-5218921	VEGFR2 mediated cell proliferation	4/190	21/10704	0,000454337	0,005782477	0,003862231
qUC_vs_HC	R-HSA-5654689	PI-3K cascade:FGFR1	4/190	21/10704	0,000454337	0,005782477	0,003862231
qUC_vs_HC	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	8/190	103/10704	0,000479773	0,006015059	0,004017577
qUC_vs_HC	R-HSA-2990846	SUMOylation	11/190	188/10704	0,000520013	0,006348246	0,004240119
qUC_vs_HC	R-HSA-5689896	Ovarian tumor domain proteases	5/190	38/10704	0,000521463	0,006348246	0,004240119
qUC_vs_HC	R-HSA-12501 96	SHC1 events in ERBB2 signaling	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-5655332	Signaling by FGFR3 in disease	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/190	22/10704	0,000547648	0,006389228	0,004267492
qUC_vs_HC	R-HSA-5357801	Programmed Cell Death	11/190	190/10704	0,000568388	0,006540354	0,004368432
qUC_vs_HC	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	3/190	10/10704	0,000602601	0,00684033	0,004568792
qUC_vs_HC	R-HSA-166520	Signaling by NTRKs	9/190	134/10704	0,000626916	0,007021455	0,004689769
qUC_vs_HC	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	4/190	23/10704	0,000653811	0,00713248	0,004763925
qUC_vs_HC	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/190	23/10704	0,000653811	0,00713248	0,004763925
qUC_vs_HC	R-HSA-6802957	Oncogenic MAPK signaling	7/190	84/10704	0,000710964	0,007656532	0,00511395
qUC_vs_HC	R-HSA-9607240	FLT3 Signaling	14/190	294/10704	0,000751146	0,007783996	0,005199085
qUC_vs_HC	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-975871	MyD88 cascade initiated on plasma membrane	7/190	85/10704	0,000763338	0,007783996	0,005199085
qUC_vs_HC	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	4/190	24/10704	0,000773772	0,007783996	0,005199085
qUC_vs_HC	R-HSA-8986944	Transcriptional Regulation by MECP2	6/190	62/10704	0,0007784	0,007783996	0,005199085
qUC_vs_HC	R-HSA-5655291	Signaling by FGFR4 in disease	3/190	11/10704	0,000817779	0,00798 7604	0,005335079
qUC_vs_HC	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/190	11/10704	0,000817779	0,007987604	0,005335079
qUC_vs_HC	R-HSA-190236	Signaling by FGFR	7/190	87/10704	0,000877229	0,008469794	0,005657143
qUC_vs_HC	R-HSA-5654708	Downstream signaling of activated FGFR3	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-9006115	Signaling by NTRK2 (TRKB)	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-9664565	Signaling by ERBB2 KD Mutants	4/190	25/10704	0,000908482	0,008479166	0,005663403
qUC_vs_HC	R-HSA-1433557	Signaling by SCF-KIT	5/190	43/10704	0,000930893	0,008592861	0,005739342
qUC_vs_HC	R-HSA-109704	PI3K Cascade	5/190	44/10704	0,001035315	0,00931945	0,006224645
qUC_vs_HC	R-HSA-1227990	Signaling by ERBB2 in Cancer	4/190	26/10704	0,001058896	0,00931945	0,006224645
qUC_vs_HC	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	4/190	26/10704	0,001058896	0,00931945	0,006224645
qUC_vs_HC	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	3/190	12/10704	0,001076175	0,00931945	0,006224645
qUC_vs_HC	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	7/190	91/10704	0,001145041	0,009814636	0,0065539
qUC_vs_HC	R-HSA-6802952	Signaling by BRAF and RAF fusions	6/190	67/10704	0,001174513	0,009965566	0,006656199
qUC_vs_HC	R-HSA-975155	MyD88 dependent cascade initiated on endosome	7/190	92/10704	0,001221084	0,00999818	0,006677982
qUC_vs_HC	R-HSA-1538133	G0 and Early G1	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-380994	ATF4 activates genes in response to endoplasmic reticulum stress	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-5654716	Downstream signaling of activated FGFR4	4/190	27/10704	0,001225967	0,00999818	0,006677982
qUC_vs_HC	R-HSA-69615	G1/S DNA Damage Checkpoints	6/190	68/10704	0,001269488	0,010253555	0,006848553
qUC_vs_HC	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	7/190	93/10704	0,00130103	0,010408239	0,006951869
qUC_vs_HC	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-1502540	Signaling by Activin	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-5210891	Uptake and function of anthrax toxins	3/190	13/10704	0,001380827	0,010673512	0,00712905
qUC_vs_HC	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	7/190	94/10704	0,001385015	0,010673512	0,00712905
qUC_vs_HC	R-HSA-201451	Signaling by BMP	4/190	28/10704	0,001410648	0,010772223	0,007194981
qUC_vs_HC	R-HSA-5673001	RAF/MAP kinase cascade	14/190	280/10704	0,00145426	0,010951069	0,007314436
qUC_vs_HC	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	7/190	95/10704	0,00147318	0,010951069	0,007314436
qUC_vs_HC	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	7/190	95/10704	0,00147318	0,010951069	0,007314436
qUC_vs_HC	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	7/190	96/10704	0,001565664	0,011536473	0,007705439
qUC_vs_HC	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/190	29/10704	0,001613887	0,011788393	0,007873701
qUC_vs_HC	R-HSA-2559580	Oxidative Stress Induced Senescence	8/190	125/10704	0,001705735	0,01234919 3	0,00824827
qUC_vs_HC	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/190	14/10704	0,001734572	0,012349193	0,00824827
qUC_vs_HC	R-HSA-5684996	MAPK1/MAPK3 signaling	13/190	286/10704	0,001757267	0,012349193	0,00824827
qUC_vs_HC	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	7/190	98/10704	0,00176417	0,012349193	0,00824827
qUC_vs_HC	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	7/190	98/10704	0,00176417	0,012349193	0,00824827
qUC_vs_HC	R-HSA-114452	Activation of BH3-only proteins	4/190	30/10704	0,001836627	0,012645628	0,008446265
qUC_vs_HC	R-HSA-5654696	Downstream signaling of activated FGFR2	4/190	30/10704	0,001836627	0,012645628	0,008446265
qUC_vs_HC	R-HSA-166166	MyD88-independent TLR4 cascade	7/190	99/10704	0,001870485	0,012671027	0,008463 23
qUC_vs_HC	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	7/190	99/10704	0,001870485	0,012671027	0,008463 23
qUC_vs_HC	R-HSA-8866910	TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	3/190	15/10704	0,002140056	0,014381179	0,009605474
qUC_vs_HC	R-HSA-383280	Nuclear Receptor transcription pathway	5/190	52/10704	0,002210064	0,01473376	0,00984097
qUC_vs_HC	R-HSA-381042	PERK regulates gene expression	4/190	32/10704	0,002344342	0,015505882	0,010356686
qUC_vs_HC	R-HSA-9009391	Extra-nuclear estrogen signaling	6/190	77/10704	0,002415504	0,015825496	0,010570162
qUC_vs_HC	R-HSA-156711	Polo-like kinase mediated events	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-1963642	PI3K events in ERBB2 signaling	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/190	16/10704	0,002599737	0,016543784	0,011049921
qUC_vs_HC	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	8/190	134/10704	0,002640889	0,016679298	0,011140433
qUC_vs_HC	R-HSA-6806834	Signaling by MET	6/190	79/10704	0,002746011	0,017213803	0,011497944
qUC_vs_HC	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	6/190	80/10704	0,002925753	0,018204684	0,012159269
qUC_vs_HC	R-HSA-194138	Signaling by VEGF	7/190	108/10704	0,003066592	0,018940714	0,012650878
qUC_vs_HC	R-HSA-6807070	PTEN Regulation	8/190	140/10704	0,00345954	0,02121178	0,01416776 8
qUC_vs_HC	R-HSA-5673000	RAF activation	4/190	36/10704	0,003634253	0,021962393	0,014669117
qUC_vs_HC	R-HSA-6804757	Regulation of TP53 Degradation	4/190	36/10704	0,003634253	0,021962393	0,014669117
qUC_vs_HC	R-HSA-5654710	PI-3K cascade:FGFR3	3/190	18/10704	0,003690639	0,021986784	0,014685408
qUC_vs_HC	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	3/190	18/10704	0,003690639	0,021986784	0,014685408
qUC_vs_HC	R-HSA-6806003	Regulation of TP53 Expression and Degradation	4/190	37/10704	0,004019085	0,023774867	0,015879705
qUC_vs_HC	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	3/190	19/10704	0,00432591	0,025410939	0,016972469
qUC_vs_HC	R-HSA-5628897	TP53 Regulates Metabolic Genes	6/190	87/10704	0,0044408	0,025904843	0,017302358
qUC_vs_HC	R-HSA-9679506	SARS-CoV Infections	8/190	147/10704	0,004649764	0,026936563	0,017991464
qUC_vs_HC	R-HSA-1181150	Signaling by NODAL	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654706	FRS-mediated FGFR3 signaling	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654720	PI-3K cascade:FGFR4	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9669938	Signaling by KIT in disease	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-9671555	Signaling by PDGFR in disease	3/190	20/10704	0,005023493	0,027761408	0,018542394
qUC_vs_HC	R-HSA-5654743	Signaling by FGFR3	4/190	40/10704	0,005336785	0,029299996	0,019570047
qUC_vs_HC	R-HSA-450294	MAP kinase activation	5/190	64/10704	0,005466087	0,029815021	0,019914043
qUC_vs_HC	R-HSA-445144	Signal transduction by L1	3/190	21/10704	0,005785019	0,031150101	0,020805769
qUC_vs_HC	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/190	21/10704	0,005785019	0,031150101	0,020805769
qUC_vs_HC	R-HSA-5654743	Signaling by FGFR4	4/190	41/10704	0,005833811	0,031208999	0,020845109
qUC_vs_HC	R-HSA-1912408	Pre-NOTCH Transcription and Translation	6/190	93/10704	0,006144339	0,032666104	0,021818337
qUC_vs_HC	R-HSA-2426168	Activation of gene expression by SREBF (SREBP)	4/190	42/10704	0,006359279	0,033386214	0,022299313
qUC_vs_HC	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	4/190	42/10704	0,006359279	0,033386214	0,022299313
qUC_vs_HC	R-HSA-381119	Unfolded Protein Response (UPR)	6/190	94/10704	0,006468838	0,033660948	0,022482814
qUC_vs_HC	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-8863678	Neurodegenerative Diseases	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	3/190	22/10704	0,006611972	0,033660948	0,022482814
qUC_vs_HC	R-HSA-5655253	Signaling by FGFR2 in disease	4/190	43/10704	0,006916036	0,034787248	0,023235092
qUC_vs_HC	R-HSA-9656223	Signaling by RAF1 mutants	4/190	43/10704	0,006916036	0,034787248	0,023235092
qUC_vs_HC	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	3/190	23/10704	0,007505696	0,037087298	0,024771341
qUC_vs_HC	R-HSA-5654695	PI-3K cascade:FGFR2	3/190	23/10704	0,007505696	0,037087298	0,024771341
qUC_vs_HC	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	5/190	69/10704	0,007505763	0,037087298	0,024771341
qUC_vs_HC	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	7/190	129/10704	0,008066067	0,039392419	0,026310977

qUC_vs_HC	R-HSA-5576891	Cardiac conduction	7/190	129/10704	0,008066067	0,039392419	0,026310977
qUC_vs_HC	R-HSA-3899300	SUMOylation of transcription cofactors	4/190	45/10704	0,008124199	0,039446975	0,026347416
qUC_vs_HC	R-HSA-4420097	VEGFA-VEGFR2 Pathway	6/190	99/10704	0,00828078	0,039976178	0,026700881
qUC_vs_HC	R-HSA-933542	TRAF6 mediated NF-kB activation	3/190	24/10704	0,0084674	0,04041259	0,026992369
qUC_vs_HC	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	3/190	24/10704	0,0084674	0,04041259	0,026992369
qUC_vs_HC	R-HSA-448424	Interleukin-17 signaling	5/190	72/10704	0,008956068	0,042503372	0,028388843
qUC_vs_HC	R-HSA-6783783	Interleukin-10 signaling	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802949	Signaling by RAS mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-9024446	NR1H2 and NR1H3-mediated signaling	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-9649948	Signaling downstream of RAS mutants	4/190	47/10704	0,009463132	0,042665537	0,028497157
qUC_vs_HC	R-HSA-5654738	Signaling by FGFR2	5/190	73/10704	0,009479645	0,042665537	0,028497157
qUC_vs_HC	R-HSA-2029485	Role of phospholipids in phagocytosis	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-400685	Sema4D in semaphorin signaling	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/190	25/10704	0,009498161	0,042665537	0,028497157
qUC_vs_HC	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	8/190	168/10704	0,01014579	0,045332252	0,0302 78309
qUC_vs_HC	R-HSA-8878171	Transcriptional regulation by RUNX1	10/190	239/10704	0,010232347	0,0454771	0,030375055

Supplementary Table S4. The list of differentially expressed miRNAs in colonic epithelial cell populations of active (aUC) and quiescent (qUC) UC patients, and Healthy controls (HC)

mir	baseMean	log2FoldChange	lfcSE	stat	pvalue	padj	comparison
hsa-let-7b-5p	4102,037314	-1,290433431	0,398984507	-3,234294584	0,001219436	0,00924739	aUC_CD44+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	-4,092102762	0,985228677	-4,153454784	3,27493E-05	0,000596037	aUC_CD44+_vs_HC_CD44+
hsa-let-7d-3p	49,35015724	-1,756703232	0,49719175	-3,533250966	0,000410483	0,003735392	aUC_CD44+_vs_HC_CD44+
hsa-let-7e-5p	114,8820552	-3,295229762	0,595852276	-5,530279725	3,19721E-08	5,81891E-06	aUC_CD44+_vs_HC_CD44+
hsa-miR-100-5p	46,30336212	-3,379219905	1,179436696	-2,86511342	0,004168599	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-10b-5p	600,0771585	-1,535362017	0,364255825	-4,2150651	2,49706E-05	0,000504961	aUC_CD44+_vs_HC_CD44+
hsa-miR-125a-5p	236,4881554	-1,975118993	0,550954338	-3,584905059	0,000337201	0,003230029	aUC_CD44+_vs_HC_CD44+
hsa-miR-1261	44,62962729	11,91305391	3,031064083	3,930320699	8,48326E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-1275	51,24049769	4,656421378	1,022340043	4,554669859	5,24679E-06	0,000201465	aUC_CD44+_vs_HC_CD44+
hsa-miR-141-3p	120,4713798	1,879837192	0,518174044	3,62781041	0,000285835	0,00289011	aUC_CD44+_vs_HC_CD44+
hsa-miR-142-3p	20,78100957	6,391480659	1,45730493	4,385822436	1,15548E-05	0,000262873	aUC_CD44+_vs_HC_CD44+
hsa-miR-143-3p	1460,473479	-2,95966206	0,660347053	-4,481979659	7,39538E-06	0,000224327	aUC_CD44+_vs_HC_CD44+
hsa-miR-145-5p	9,949487301	-4,278512073	1,489313115	-2,872808969	0,0040684	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-148a-3p	731,928219	1,076156929	0,349654887	3,07776888	0,002085566	0,013088724	aUC_CD44+_vs_HC_CD44+
hsa-miR-15b-5p	92,85579037	2,103257915	0,524031418	4,013610338	5,9797E-05	0,000906922	aUC_CD44+_vs_HC_CD44+
hsa-miR-182-5p	229,8722431	1,805111225	0,472003574	3,824359231	0,000131411	0,001403676	aUC_CD44+_vs_HC_CD44+
hsa-miR-183-5p	155,9953185	1,963155342	0,59292594	3,310962144	0,000929758	0,007691633	aUC_CD44+_vs_HC_CD44+
hsa-miR-194-3p	154,7450325	-1,580928517	0,551239153	-2,86795397	0,004131356	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-196a-1-3p	21,30476447	-5,027549535	1,593693456	-3,154652807	0,001606892	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-miR-197-3p	55,13123525	2,108127721	0,736141103	2,863754944	0,004186518	0,020593141	aUC_CD44+_vs_HC_CD44+
hsa-miR-2110	20,2879364	3,339366961	1,018136338	3,279881915	0,001038505	0,008217739	aUC_CD44+_vs_HC_CD44+
hsa-miR-215-3p	29,8228318	2,257015704	0,678111809	3,328382833	0,000873517	0,007570484	aUC_CD44+_vs_HC_CD44+
hsa-miR-221-3p	160,4347215	2,981531062	0,55723317	5,35059868	8,76637E-08	7,9774E-06	aUC_CD44+_vs_HC_CD44+
hsa-miR-222-3p	143,1615888	1,393298445	0,457825769	3,043294066	0,002340035	0,014196215	aUC_CD44+_vs_HC_CD44+
hsa-miR-223-3p	171,3111872	4,112402164	1,050159785	3,915977572	9,00386E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-25-3p	135,0667348	1,372412004	0,429062264	3,198631335	0,001380816	0,010052342	aUC_CD44+_vs_HC_CD44+
hsa-miR-30e-5p	266,9515329	-1,072522932	0,418929028	-2,560154248	0,010462571	0,04644361	aUC_CD44+_vs_HC_CD44+
hsa-miR-31-5p	83,18260453	5,774119892	1,298414388	4,447054765	8,70556E-06	0,000226345	aUC_CD44+_vs_HC_CD44+
hsa-miR-3195	75,3779283	-6,165100854	1,231510323	-5,006130067	5,55352E-07	3,36914E-05	aUC_CD44+_vs_HC_CD44+
hsa-miR-340-3p	16,00909324	-4,467159217	1,143513153	-3,906521936	9,36341E-05	0,001136094	aUC_CD44+_vs_HC_CD44+
hsa-miR-34a-5p	39,55171268	6,374871999	1,40309841	4,543424717	5,53476E-06	0,000201465	aUC_CD44+_vs_HC_CD44+
hsa-miR-3960	68,24363582	2,166601973	0,72902931	2,971899678	0,002959634	0,016832917	aUC_CD44+_vs_HC_CD44+
hsa-miR-484	22,9909067	2,712927483	0,708117237	3,831184075	0,000127528	0,001403676	aUC_CD44+_vs_HC_CD44+
hsa-miR-501-3p	22,36904062	3,936285866	0,961493653	4,093928083	4,24126E-05	0,000701736	aUC_CD44+_vs_HC_CD44+
hsa-miR-574-5p	67,27365892	-1,583835852	0,528425759	-2,997272226	0,002724039	0,015992947	aUC_CD44+_vs_HC_CD44+
hsa-miR-598-3p	24,10946306	-5,131274573	1,756858998	-2,92070939	0,003492354	0,019260863	aUC_CD44+_vs_HC_CD44+
hsa-miR-6869-5p	34,23920369	-9,926679987	3,137693664	-3,163686788	0,001557843	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-miR-7-5p	230,0862854	1,324097316	0,418761477	3,161936779	0,001567236	0,010444798	aUC_CD44+_vs_HC_CD44+
hsa-let-7e-5p	114,8820552	-2,731813942	0,614717742	-4,444013494	8,82961E-06	0,000342883	aUC_CD44+_vs_qUC_CD44+
hsa-miR-100-5p	46,30336212	-4,775206021	1,19799593	-3,985995194	6,71979E-05	0,001423373	aUC_CD44+_vs_qUC_CD44+
hsa-miR-1261	44,62962729	13,34717383	3,131636492	4,26204442	2,02565E-05	0,000589971	aUC_CD44+_vs_qUC_CD44+
hsa-miR-1275	51,24049769	2,926187108	1,009531358	2,898559895	0,003748807	0,034938881	aUC_CD44+_vs_qUC_CD44+
hsa-miR-141-3p	120,4713798	1,948930314	0,53073652	3,672124757	0,000240542	0,003736244	aUC_CD44+_vs_qUC_CD44+
hsa-miR-142-3p	20,78100957	5,918799437	1,496730622	3,95448543	7,66995E-05	0,00148925	aUC_CD44+_vs_qUC_CD44+
hsa-miR-143-3p	1460,473479	-1,952038848	0,6830912	-2,857654802	0,004267844	0,036829913	aUC_CD44+_vs_qUC_CD44+
hsa-miR-148a-3p	731,928219	1,151009639	0,360756036	3,190548532	0,00142017	0,016543348	aUC_CD44+_vs_qUC_CD44+
hsa-miR-181b-5p	36,39010465	-2,512517597	0,808330642	-3,108279541	0,0018818	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-182-5p	229,8722431	1,399828415	0,482090707	2,903661892	0,003688262	0,034938881	aUC_CD44+_vs_qUC_CD44+
hsa-miR-184	56,85736686	22,25189642	4,207940023	5,288073571	1,23611E-07	7,20036E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-197-3p	55,13123525	2,576427542	0,759541198	3,392083994	0,000693632	0,00897867	aUC_CD44+_vs_qUC_CD44+
hsa-miR-2110	20,2879364	4,597472192	1,053898585	4,362347819	1,28674E-05	0,000428301	aUC_CD44+_vs_qUC_CD44+
hsa-miR-215-3p	29,8228318	2,921581912	0,697804109	4,186822455	2,82887E-05	0,000714417	aUC_CD44+_vs_qUC_CD44+
hsa-miR-221-3p	160,4347215	2,165600932	0,567132637	3,818508744	0,000134261	0,002234484	aUC_CD44+_vs_qUC_CD44+
hsa-miR-224-5p	55,54461285	1,211456182	0,435595437	2,781149841	0,005416673	0,045074457	aUC_CD44+_vs_qUC_CD44+
hsa-miR-23a-5p	8,463931083	-2,908743185	0,939800438	-3,095064726	0,0019677	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-296-5p	27,44112461	30	5,426307953	5,528620982	3,22758E-08	2,50675E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-31-5p	83,18260453	3,792294458	1,31944405	2,874160869	0,004051026	0,036303422	aUC_CD44+_vs_qUC_CD44+
hsa-miR-3168	59,22086756	27,43309881	3,869986564	7,088680634	1,35307E-12	3,15474E-10	aUC_CD44+_vs_qUC_CD44+
hsa-miR-34a-5p	39,55171268	4,729871518	1,417432517	3,336928891	0,000847096	0,010388074	aUC_CD44+_vs_qUC_CD44+
hsa-miR-3960	68,24363582	2,901232147	0,753321358	3,851254336	0,000117514	0,002106219	aUC_CD44+_vs_qUC_CD44+
hsa-miR-432-5p	34,80484808	30	5,425243348	5,529705872	3,20768E-08	2,50675E-06	aUC_CD44+_vs_qUC_CD44+
hsa-miR-4443	15,28178398	3,560256993	1,150561219	3,094365545	0,001972343	0,019980693	aUC_CD44+_vs_qUC_CD44+
hsa-miR-4488	143,0698439	2,577837646	0,709044564	3,635469683	0,000277281	0,004037904	aUC_CD44+_vs_qUC_CD44+
hsa-miR-484	22,9909067	3,498543617	0,725793587	4,820301091	1,43342E-06	6,67972E-05	aUC_CD44+_vs_qUC_CD44+
hsa-miR-501-3p	22,36904062	4,064012539	0,97493506	4,168495631	3,06617E-05	0,000714417	aUC_CD44+_vs_qUC_CD44+
hsa-miR-99a-5p	59,5387003	5,173941954	1,880806515	2,750916648	0,005942876	0,047747937	aUC_CD44+_vs_qUC_CD44+
hsa-miR-140-5p	5,715811254	4,58486284	1,392480479	3,292586796	0,000992703	0,018479539	qUC_CD44+_vs_HC_CD44+
hsa-miR-15b-5p	92,85579037	1,932393875	0,520292627	3,714052004	0,000203967	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-184	56,85736686	-28,25850514	4,022653439	-7,024842079	2,14309E-12	2,59313E-10	qUC_CD44+_vs_HC_CD44+
hsa-miR-194-3p	154,7450325	-2,44157383	0,549537205	-4,442963656	8,87282E-06	0,000429444	qUC_CD44+_vs_HC_CD44+
hsa-miR-222-3p	143,1615888	1,904566277	0,457598762	4,162087918	3,15351E-05	0,001271915	qUC_CD44+_vs_HC_CD44+
hsa-miR-223-3p	171,3111872	3,423456106	1,04821034	3,266001083	0,001090778	0,018854882	qUC_CD44+_vs_HC_CD44+
hsa-miR-296-5p	27,44112461	-18,61962506	5,208170267	-3,575079944	0,000350121	0,008472926	qUC_CD44+_vs_HC_CD44+
hsa-miR-3168	59,22086756	-33,79087539	3,703944654	-9,122964848	7,31115E-20	1,7693E-17	qUC_CD44+_vs_HC_CD44+
hsa-miR-3195	75,3779283	-6,722822124	1,229414128	-5,468313704	4,54337E-08	3,66499E-06	qUC_CD44+_vs_HC_CD44+
hsa-miR-374a-5p	11,0930107	2,221796128	0,710938212	3,125160655	0,00177708	0,02867022	qUC_CD44+_vs_HC_CD44+
hsa-miR-432-5p	34,80484808	-18,30623639	5,208152081	-3,514919709	0,000439887	0,009677513	qUC_CD44+_vs_HC_CD44+
hsa-miR-4488	143,0698439	-2,550117423	0,680195978	-3,749092183	0,00017749	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-5100	92,15853454	3,308809485	0,885198375	3,737929912	0,000185542	0,005484442	qUC_CD44+_vs_HC_CD44+
hsa-miR-574-3p	67,27365892	-1,773167804	0,522290342	-3,394984859	0,000686324	0,013840867	qUC_CD44+_vs_HC_CD44+
hsa-miR-8085	6,309285548	23,26658809	5,201975056	4,472645069	7,7258E-06	0,000429444	qUC_CD44+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	2,851462254	0,922449444	3,0911854	0,001993561	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-1-3p	97,88744964	-7,210116801	1,306348696	-5,519289624	3,40373E-08	2,45068E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-106b-3p	39,94118164	3,138811072	0,762645653	4,11568736	3,86027E-05	0,000641698	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-10b-5p	600,0771585	-1,030952681	0,352346448	-2,925963028	0,003433917	0,02852793	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-125a-5p	67,32621226	3,479387203	1,124211211	3,094598643	0,001968403	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-1290	75,77449812	-3,38507008	1,15061645	-2,941962181	0,003261398	0,028178475	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-135b-5p	47,88245892	4,465925971	0,783650736	5,69887294	1,20602E-08	1,3025E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-146a-5p	222,0888016	2,269032213	0,49955107	4,542142637	5,56853E-06	0,00015035	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-17-5p	16,53349485	-2,041993446	0,620922216	-3,288646137	0,001006705	0,012791076	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-181b-5p	36,39010465	2,337190965	0,735889625	3,176007496	0,001493171	0,017918051	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-182-5p	229,8722431	2,201183566	0,448370406	4,909297167	9,14034E-07	2,82045E-05	aUC_CD66a+_vs_HC_CD66a+

miRNA							Comparison
hsa-miR-183-5p	155,9953185	1,747524702	0,569474099	3,068664064	0,002150182	0,019351641	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-191-3p	12,67245807	6,517847383	1,981499888	3,289350366	0,000688903	0,012791076	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-194-3p	154,7450325	-2,380388528	0,533157242	-4,464702604	8,018E-06	0,000192432	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-196b-5p	187,6678013	-1,581410765	0,46594887	-3,393957722	0,000688903	0,009920207	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-21-5p	6540,11313	1,081145567	0,208603756	5,182771322	2,18613E-07	9,44408E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-221-3p	160,4347215	1,508351149	0,530575322	2,842859599	0,004471076	0,034491159	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-222-3p	143,1615888	1,762577499	0,428269545	4,11557982	3,86207E-05	0,000641698	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-224-5p	55,54461285	1,100861581	0,401592768	2,741238559	0,006120805	0,044069796	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-24-3p	709,3028711	1,482452508	0,349153563	4,245846712	2,17769E-05	0,000461033	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-27a-3p	129,8078549	2,270844167	0,424721051	5,346672033	8,95861E-08	4,83765E-06	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-31-5p	83,18260453	8,334965649	1,225322242	6,802264223	1,02987E-11	2,22453E-09	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-335-5p	73,13769403	-2,738168492	0,555527927	-4,928948411	8,26734E-07	2,82045E-05	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-3960	68,24363582	2,167064445	0,693264828	3,125882574	0,001772723	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-421	6,110488268	3,532279775	1,143356355	3,089395322	0,002005644	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-425-5p	72,57277562	1,284781685	0,410240546	3,131776462	0,001737521	0,01883561	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-5100	92,15853454	-3,57941531	0,846407689	-4,228949425	2,34785E-05	0,000461033	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-552-3p	13,25665175	-4,670823342	1,678529083	-2,782688361	0,005391056	0,040154073	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-574-5p	55,87952961	2,486891752	0,643829669	3,862654788	0,000112161	0,001730491	aUC_CD66a+_vs_HC_CD66a+
hsa-miR-135b-5p	47,88245892	3,241157847	0,830346227	3,903381194	9,48581E-05	0,00355718	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-181b-5p	36,39010465	2,397593296	0,788757839	3,039707723	0,002368078	0,04440147	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-182-5p	229,8722431	1,937837861	0,478406407	4,050610174	5,10843E-05	0,002298791	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-27a-3p	129,8078549	2,455975298	0,455113825	5,396397916	6,79921E-08	7,64911E-06	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-31-5p	83,18260453	4,748693143	1,286768898	3,690400933	0,000223901	0,006297212	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-3195	75,3779283	-3,828012441	1,255626035	-3,048688331	0,002298428	0,04440147	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-4516	5,55272639	3,433220019	1,051241844	3,265870778	0,00109128	0,024553808	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-574-5p	55,87952961	2,475548954	0,688769126	3,594163648	0,000325435	0,008135881	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-7977	21,05479651	-3,706488913	0,911829648	-4,064891857	4,80547E-05	0,002298791	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-8085	6,309285548	-29,33874058	5,425260499	-5,407803106	6,38025E-08	7,64911E-06	aUC_CD66a+_vs_qUC_CD66a+
hsa-miR-99a-5p	59,5387003	-6,960153323	1,865965193	-3,730055281	0,000191448	0,006153357	aUC_CD66a+_vs_qUC_CD66a+
hsa-let-7c-5p	41,3470138	3,263230589	0,913201684	3,573395281	0,000352382	0,011729293	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-1-3p	97,88744964	-4,03851897	1,270340267	-3,179084435	0,00147741	0,034423664	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-106b-3p	39,94118164	2,605461932	0,756698757	3,443195736	0,000574883	0,014883084	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-125b-5p	67,32621226	5,240344711	1,11357634	4,705869299	2,52786E-06	0,000196331	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-1290	75,77449812	-5,682797943	1,151204215	-4,936394316	7,95801E-07	9,27109E-05	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-193a-5p	31,10438134	3,603673501	0,981363401	3,672109128	0,000240557	0,011209952	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-194-3p	154,7450325	-1,550488398	0,525091165	-2,952798488	0,003149075	0,049661554	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-199a-5p	14,52804232	4,026389014	1,316639275	3,058080592	0,002227597	0,039925385	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-335-5p	73,13769403	-1,966378477	0,5432463	-3,619681306	0,000294966	0,011454516	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-4497	12,00241834	3,388216988	1,094002603	3,097083114	0,001954351	0,037946976	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-552-3p	13,25665175	-4,887777941	1,657948633	-2,948123244	0,003197096	0,049661554	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-7704	24,39357806	3,181614078	0,911602334	3,490133756	0,000482779	0,014060934	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-7977	21,05479651	2,585580872	0,833281619	3,102889603	0,001916411	0,037946976	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-8085	6,309285548	28,36852471	5,046058072	5,621918001	1,88849E-08	4,40018E-06	qUC_CD66a+_vs_HC_CD66a+
hsa-miR-99a-5p	59,5387003	7,969518409	1,73359674	4,597100483	4,28411E-06	0,000249549	qUC_CD66a+_vs_HC_CD66a+
hsa-let-7c-5p	41,3470138	3,69754313	0,941151697	3,928742987	8,5391E-05	0,002487014	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1-3p	97,88744964	-6,038168401	1,286026468	-4,695213165	2,66329E-06	0,000155137	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-106b-3p	39,94118164	3,317500761	0,767622964	4,321784154	1,54773E-05	0,000515172	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-122-5p	37,12961791	6,00845394	1,865337519	3,22110818	0,001276959	0,017697243	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-125b-5p	67,32621226	3,801345078	1,13085706	3,36147265	0,00077528	0,013029354	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1261	44,62962729	-8,759489086	2,868067327	-3,054143466	0,002257041	0,02629453	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1275	51,24049769	-4,130337408	0,939134237	-4,398026658	1,0924E-05	0,000424214	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-1290	75,77449812	-3,647378398	1,133456573	-3,217925138	0,001291215	0,017697243	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-135b-5p	47,88245892	2,274617527	0,758445426	2,999052337	0,002708208	0,028682383	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-141-3p	120,4713798	-1,835404247	0,487623458	-3,763978574	0,000167231	0,003896487	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-181b-5p	36,39010465	2,893718185	0,746930011	3,87414904	0,000106998	0,002770057	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-191-3p	12,67245807	5,993391222	1,959306179	3,058935498	0,00222125	0,02629453	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-2110	20,2879364	-4,289528718	0,952842716	-4,501822436	6,73733E-06	0,000313959	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-27a-3p	129,8078549	1,208600419	0,416497269	2,901820751	0,003710008	0,03601799	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-296-5p	27,44112461	-25,11968628	4,992082738	-5,031905038	4,8563E-07	5,65759E-05	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-34a-5p	39,55171268	-4,718893432	1,293958122	-3,646867199	0,000265457	0,005622863	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-421	6,110488268	3,469143115	1,14609228	3,026931753	0,002470497	0,027410756	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-432-5p	34,80484808	-23,50354906	4,991512399	-4,708702931	2,49298E-06	0,000155137	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-484	22,9909067	-2,147360682	0,653085759	-3,288022517	0,001008948	0,015672166	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-501-3p	22,36904062	-4,858698036	0,891884941	-5,447673589	5,10329E-08	1,18907E-05	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-5100	92,15853454	-2,590546002	0,832885799	-3,110325573	0,001868812	0,024190737	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-574-5p	55,87952961	1,882269318	0,635669961	2,961079545	0,003065628	0,03105614	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-99a-5p	59,5387003	-5,787417056	1,723072275	-3,358777888	0,00078248	0,013029354	aUC_CD66a+_vs_aUC_CD44+
hsa-miR-106b-3p	39,94118164	2,922936233	0,788386106	3,707493336	0,000209321	0,007849535	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-1290	75,77449812	-4,899258004	1,174432917	-4,171594591	3,02475E-05	0,002268566	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-184	56,85736686	17,71235803	4,00115842	4,426807481	9,5638E-06	0,001075928	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-193a-5p	31,10438134	3,129197589	1,008236519	3,103634445	0,001911594	0,04778984	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-3168	59,22086756	26,58960094	3,674464708	7,236319587	4,61024E-13	1,0373E-10	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-3195	75,3779283	4,790946922	1,219259218	3,929391595	8,51611E-05	0,003832248	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-660-5p	14,96123124	2,979777877	0,82646905	3,605431901	0,000311634	0,010016814	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-7704	24,39357806	3,782260883	0,952822266	3,969534528	7,20132E-05	0,003832248	qUC_CD66a+_vs_qUC_CD44+
hsa-miR-99a-5p	59,5387003	6,346678222	1,782114779	3,561318437	0,000368997	0,010378047	qUC_CD66a+_vs_qUC_CD44+
hsa-let-7b-5p	4102,03731	-1,0523972	0,38038324	-2,7666762	0,0056631	0,04478995	HC_CD66a+_vs_HC_CD44+
hsa-let-7c-5p	41,3470138	-3,2460219	0,90950246	-3,5690083	0,00035834	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-let-7d-5p	49,3501572	-1,6833739	0,46724982	-3,6027277	0,0003149	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-let-7e-5p	114,882055	-2,2046774	0,55821794	-3,9494922	0,000078317	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-125a-5p	236,488155	-1,8479176	0,52325593	-3,5315752	0,00041309	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-143-3p	1460,47348	-2,9316605	0,62926979	-4,6588293	3,1801E-06	0,00055334	HC_CD66a+_vs_HC_CD44+
hsa-miR-17-5p	16,5334949	1,83351823	0,63709418	2,87793908	0,00400282	0,03665744	HC_CD66a+_vs_HC_CD44+
hsa-miR-196a-1-3p	21,3047645	-5,4353632	1,50768711	-3,6051003	0,00031203	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-200a-5p	13,1831738	1,49684288	0,53423353	2,80185127	0,00508103	0,04209996	HC_CD66a+_vs_HC_CD44+
hsa-miR-223-3p	171,311187	3,93347572	1,00768132	3,90349174	0,000094815	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-23b-3p	294,871966	-1,0154978	0,31104235	-3,2648216	0,00109533	0,01121043	HC_CD66a+_vs_HC_CD44+
hsa-miR-24-3p	709,302871	-1,4516046	0,34426665	-4,2165123	0,000024811	0,00215856	HC_CD66a+_vs_HC_CD44+
hsa-miR-296-5p	27,4411246	-17,671842	5,00751503	-3,5290643	0,00041703	0,00725635	HC_CD66a+_vs_HC_CD44+
hsa-miR-30e-5p	266,951533	-1,3528379	0,39898552	-3,3906943	0,00069716	0,0093312	HC_CD66a+_vs_HC_CD44+
hsa-miR-335-5p	73,137694	1,65482237	0,54757795	3,02207636	0,00251047	0,0242679	HC_CD66a+_vs_HC_CD44+
hsa-miR-340-3p	16,0090932	-4,1957066	1,07027906	-3,9201987	0,000088476	0,00329955	HC_CD66a+_vs_HC_CD44+
hsa-miR-432-5p	34,8048481	-16,987359	5,00751337	-3,3923742	0,0006929	0,0093312	HC_CD66a+_vs_HC_CD44+

hsa-miR-5100	92,1585345	2,93924392	0,85018883	3,45716599	0,00054589	0,00863496	HC_CD66a+_vs_HC_CD44+
hsa-miR-574-3p	67,2736589	-1,6642796	0,49874908	-3,3369075	0,00084716	0,01020122	HC_CD66a+_vs_HC_CD44+
hsa-miR-574-5p	55,8795296	-1,7528987	0,64210026	-2,7299454	0,00633448	0,04792173	HC_CD66a+_vs_HC_CD44+
hsa-miR-598-3p	24,1094631	-5,5456155	1,66709834	-3,3265077	0,00087942	0,01020122	HC_CD66a+_vs_HC_CD44+
hsa-miR-9-5p	25,9280149	-6,8856256	2,08458986	-3,3031081	0,0009562	0,01039862	HC_CD66a+_vs_HC_CD44+

Supplementary Table S5. The list of Reactome pathways significantly enriched with differentially expressed miRNAs in colonic epithelial cell populations of active (aUC) and quiescent (qUC) UC patients, healthy controls (HC)

comparison	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue

aUC_CD44+_vs_qUC_CD44+	R-HSA-437239	Recycling pathway of L1	7/343	39/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-109582	Hemostasis	34/343	470/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	35/343	490/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1226099	Signaling by FGFR in disease	8/343	51/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1266695	Interleukin-7 signaling	5/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	5/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	5/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1502540	Signaling by Activin	4/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-418885	DCC mediated attractive signaling	4/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654706	FRS-mediated FGFR3 signaling	5/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	4/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	7/343	40/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-69620	Cell Cycle Checkpoints	21/343	244/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-400253	Circadian Clock	9/343	64/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	6/343	30/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	6/343	30/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	5/343	21/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	5/343	21/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	5/343	21/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	5/343	21/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-114604	GPVI-mediated activation cascade	6/343	31/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-448424	Interleukin-17 signaling	9/343	66/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-373752	Netrin-1 signaling	7/343	42/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-171007	p38MAPK events	4/343	13/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654693	FRS-mediated FGFR1 signaling	4/343	13/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	10/343	80/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	10/343	80/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	10/343	80/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5689880	Ub-specific processing proteases	15/343	154/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654736	Negative regulation of FGFR1 signaling	5/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	5/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-69242	S Phase	15/343	156/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-4086398	Ca2+ pathway	8/343	56/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-75153	Apoptotic execution phase	7/343	44/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization	4/343	14/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	4/343	14/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	5/343	23/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	5/343	23/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654733	Negative regulation of FGFR4 signaling	4/343	23/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	8/343	57/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	8/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	8/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	8/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	8/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	8/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1980143	Signaling by NOTCH1	8/343	72/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	4/343	15/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/343	15/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	4/343	15/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-168638	NOD1/2 Signaling Pathway	6/343	35/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5673000	RAF activation	6/343	35/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6783783	Interleukin-10 signaling	6/343	35/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	6/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	6/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6807070	PTEN Regulation	13/343	132/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-111465	Apoptotic cleavage of cellular proteins	6/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5689896	Ovarian tumor domain proteases	6/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8853659	RET signaling	6/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-177929	Signaling by EGFR	7/343	48/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	8/343	61/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-194315	Signaling by Rho GTPases	27/343	375/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-156711	Polo-like kinase mediated events	4/343	16/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	4/343	16/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	4/343	16/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1181150	Signaling by NODAL	4/343	17/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2424491	DAP12 signaling	5/343	27/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-397795	G-protein beta:gamma signalling	5/343	27/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	10/343	93/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	7/343	52/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	7/343	52/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	5/343	28/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-167044	Signaling to RAS	4/343	18/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	4/343	18/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654696	Downstream signaling of activated FGFR2	4/343	18/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	4/343	18/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5687128	MAPK6/MAPK4 signaling	9/343	80/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	12/343	126/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-69481	G2/M Checkpoints	12/343	126/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	9/343	81/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	5/343	29/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2172127	DAP12 interactions	5/343	29/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-3214858	RMTs methylate histone arginines	5/343	29/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/343	29/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1059683	Interleukin-6 signaling	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-170968	Frs2-mediated activation	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-430116	GP1b-IX-V activation signalling	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5625970	RHO GTPases activate KTN1	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654710	PI-3K cascade:FGFR3	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8851805	MET activates RAS signaling	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8875555	MET activates RAP1 and RAC1	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9026731	Activated NTRK2 signals through FRS2 and FRS3	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	3/343	10/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	4/343	19/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2028269	Signaling by Hippo	4/343	19/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5621575	CD209 (DC-SIGN) signaling	4/343	19/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8876384	Listeria monocytogenes entry into host cells	4/343	19/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6675221	Negative regulation of MAPK pathway	8/343	42/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9664407	Parasite infection	7/343	56/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9664417	Leishmania phagocytosis	7/343	56/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9664422	FCGR3A-mediated phagocytosis	7/343	56/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-449836	Other interleukin signaling	4/343	20/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9679191	Potential therapeutics for SARS	8/343	71/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-111458	Formation of apoptosome	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-389359	CD28 dependent Vav1 pathway	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654689	PI-3K cascade:FGFR1	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9627069	Regulation of the apoptosome activity	3/343	11/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8943724	Regulation of PTEN gene transcription	7/343	58/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-112409	RAF-independent MAPK1/3 activation	4/343	21/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	6/343	43/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	11/343	119/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9679506	SARS-CoV Infections	12/343	136/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-198753	ERK/MAPK targets	4/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654727	Negative regulation of FGFR2 signaling	4/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-912446	Meiotic recombination	4/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	4/343	22/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-162594	Early Phase of HIV Life Cycle	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-169893	Prolonged ERK activation events	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-264642	Acetylcholine Neurotransmitter Release Cycle	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654720	PI-3K cascade:FGFR4	3/343	12/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5625740	RHO GTPases activate PKNs	5/343	34/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/343	34/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654738	Signaling by FGFR2	7/343	61/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	6/343	48/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	4/343	23/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	4/343	23/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5693532	DNA Double-Strand Break Repair	11/343	125/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/343	13/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/343	13/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-451927	Interleukin-2 family signaling	3/343	13/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-8875878	MET promotes cell motility	5/343	36/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-203927	MicroRNA (miRNA) biogenesis	4/343	24/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-3928663	EPHA-mediated growth cone collapse	4/343	24/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signalling pathway	4/343	24/8290	
aUC_CD44+_vs_qUC_CD44+	R-HSA-5627123	RHO GTPases activate PAKs	4/343	24/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	79/475	356/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	86/475	439/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	36/475	87/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-449147	Signaling by Interleukins	72/475	376/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	33/475	83/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	15/475	17/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	15/475	17/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-125760+	PIP3 activates AKT signaling	50/475	237/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-2559583	Cellular Senescence	34/475	123/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9006925	Intracellular signaling by second messengers	52/475	273/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-8939211	ESR-mediated signaling	38/475	154/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	29/475	91/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	16/475	27/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-8848021	Signaling by PTK6	21/475	56/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	21/475	56/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	44/475	219/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signaling	24/475	78/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9614085	FOXO-mediated transcription	21/475	55/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-69231	Cyclin D associated events in G1	19/475	47/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-69236	G1 Phase	19/475	47/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-5683057	MAPK family signaling cascades	48/475	278/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-8878166	Transcriptional regulation by RUNX2	28/475	105/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-194138	Signaling by VEGF	27/475	99/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-453279	Mitotic G1 phase and G1/S transition	33/475	146/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	26/475	94/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-166520	Signaling by NTRKs	20/475	125/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-109606	Intrinsic Pathway for Apoptosis	19/475	51/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	24/475	84/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-1433557	Signaling by SCF-KIT	17/475	41/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	16/475	36/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9675126	Diseases of mitotic cell cycle	16/475	36/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	16/475	36/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9669938	Signaling by KIT in disease	12/475	20/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	12/475	20/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-8878159	Transcriptional regulation by RUNX3	24/475	90/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	19/475	57/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	13/475	25/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-3700989	Transcriptional Regulation by TP53	51/475	343/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-6804757	Regulation of TP53 Degradation	15/475	35/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	13/475	23/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-2559585	Oncogene Induced Senescence	14/475	33/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-5684996	MAPK1/MAPK3 signaling	40/475	244/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-187037	Signaling by NTRK1 (TRKA)	25/475	108/8290	
aUC_CD44+_vs_HC_CD44+	R-HSA-74751	Insulin receptor signalling cascade	15/475	39/8290	

Comparison	Reactome ID	Description	Ratio	BgRatio	pvalue	p.adjust	qvalue
aUC_CD44+_vs_HC_CD44+	R-HSA-9607240	FLT3 Signaling	40/475	252/8290	2.8351955821953407e-9	7.195096344149064e-8	4.3638799838234727e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	9/475	13/8290	3.5983557192515748e-9	8.933309198663692e-8	5.418119137911982e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-157118	Signaling by NOTCH	31/475	188/8290	4.8449282158185686e-9	1.1772147286465262e-7	7.1398942127852666e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-5673001	RAF/MAP kinase cascade	38/475	239/8290	6.8622616243216116e-9	1.6326464114531834e-7	9.902123132341272e-8
aUC_CD44+_vs_HC_CD44+	R-HSA-389356	CD28 co-stimulation	13/475	32/8290	7.7679416662315616e-9	1.8104059694972333e-7	1.0980248370312283e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2990846	SUMOylation	30/475	166/8290	1.4284173076227967e-8	3.2625051306104686e-7	1.9787338703490534e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-422475	Axon guidance	59/475	483/8290	1.5802001498491978e-8	3.5384089565019290e-7	2.1460716134005619e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-186763	Downstream signal transduction	12/475	29/8290	2.3162030697999365e-8	5.0390115674643547e-7	3.0601983697958634e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	29/475	160/8290	2.3385955610823967e-8	5.0390115674643347e-7	3.0561983697958634e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-1227986	Signaling by ERBB2	15/475	47/8290	2.5951101077758006e-8	5.4881773019999934e-7	3.3286207620204236e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-109581	Apoptosis	29/475	161/8290	2.7027907823972448e-8	5.6119764983070966e-7	3.4037059043864464e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5357801	Programmed Cell Death	30/475	173/8290	3.8146171351989644e-8	7.7790942292807454e-7	4.7180790882724046e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-3928662	EPHB-mediated forward signaling	14/475	42/8290	4.0731439537467248e-8	8.1605796406664496e-7	4.9494528560763522e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	13/475	36/8290	4.1800288864467476e-8	8.2303327384865276e-7	4.9917586339055546e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5688426	Deubiquitination	35/475	224/8290	4.3613301467494e-8	8.2895871481287856e-7	5.0276936033447696e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	8/475	12/8290	4.4278851719426954e-8	8.2895871481287856e-7	5.0276936033447696e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	8/475	12/8290	4.4278851719426954e-8	8.2895871481287856e-7	5.0276936033447696e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	15/475	49/8290	4.8899688569793996e-8	9.0070071526943126e-7	5.4628175006629e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9006936	Signaling by TGFB family members	21/475	94/8290	5.1174004491838224e-8	9.2763036713776586e-7	5.6261478622605786e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2428924	IGF1R signaling cascade	13/475	37/8290	6.1116682777935536e-8	1.0905508083187873e-6	6.6142725769540286e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-186797	Signaling by PDGF	15/475	50/8290	6.6231779466459244e-8	1.1636414177030225e-6	7.0575726135919334e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	11/475	26/8290	6.8679351103360626e-8	1.1883608933390666e-6	7.2074980902729344e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	18/475	72/8290	7.4365421005194184e-8	1.2675419520568827e-6	7.6877371596885726e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	13/475	38/8290	8.8104584991694036e-8	1.4581947255147041e-6	8.8440605529419 86e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5654736	Signaling by FGFR1	13/475	38/8290	8.8104584991694036e-8	1.4581947255147041e-6	8.8440605529419 86e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	9/475	17/8290	9.9430633062195576e-8	1.5992927177046103e-6	9.6998304751556256e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	9/475	17/8290	9.9430633062195576e-8	1.5992927177046103e-6	9.6998304751556256e-7
aUC_CD44+_vs_HC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	27/475	152/8290	1.1152600222833376e-7	1.7630037424232737e-6	1.0692750138395375e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	14/475	46/8290	1.4944540908138748e-7	2.3378994133006094e-6	1.4179535696543586e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-12399	IRS-mediated signalling	12/475	33/8290	1.8798470455974088e-7	2.9010612514489746e-6	1.7595154429416086e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	8/475	14/8290	2.4243649502846766e-7	3.6429273331909216e-6	2.2094627940267545e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8849471	PI3K regulates RHO GTPases, RAS GTPase and MAP kinases	8/475	14/8290	2.4243649502846766e-7	3.6429273331909216e-6	2.2094627940267545e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2559580	Oxidative Stress Induced Senescence	16/475	62/8290	2.4739057932865247e-7	3.6690914492639116e-6	2.2253315297553496e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-114452	Activation of BH3-only proteins	11/475	29/8290	2.6233815363722 66e-7	3.8466925275017504e-6	2.3330479151056612e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-1236394	Signaling by ERBB4	14/475	48/8290	2.7021013337831005e-7	3.9060755989624064e-6	2.3690641940430176e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	15/475	56/8290	3.4745067658346916e-7	4.9598584082290216e-6	3.0081913841042466e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	11/475	30/8290	3.9364286330251706e-7	5.5498783937219074e-6	3.3660429376615495e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-9661928	FOXO-mediated transcription of cell cycle genes	8/475	15/8290	4.9355651614391326e-7	6.8736773345896206e-6	4.1689369399575736e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644602	Signaling by NOTCH1 PEST Domain Mutants in Cancer	15/475	58/8290	5.7181087344586565e-7	7.5058393469533e-6	4.5523479493919186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644603	Signaling by NOTCH1 in Cancer	15/475	58/8290	5.7181087344586565e-7	7.5058393469533e-6	4.5523479493919186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2644606	Constitutive Signaling by NOTCH1 PEST Domain Mutants	15/475	58/8290	5.7181087344586565e-7	7.5058393469533e-6	4.5523479493919186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2894858	Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	15/475	58/8290	5.7181087344586565e-7	7.5058393469533e-6	4.5523479493919186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2894862	Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	15/475	58/8290	5.7181087344586565e-7	7.5058393469533e-6	4.5523479493919186e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	18/475	82/8290	6.1485141517416956e-7	7.9790945014647954e-6	4.8393807557966956e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	18/475	83/8290	7.4420826654926246e-7	9.4431886799175246e-6	5.7273648736157544e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	18/475	83/8290	7.4420926549026246e-7	9.4431886799175246e-6	5.7273648736157544e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-69206	G1/S Transition	23/475	128/8290	7.9538157247777e-7	9.9610102932352226e-6	6.0414275720776134e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-1538133	G0 and Early G1	10/475	26/8290	8.0246317598720856e-7	9.9610102932352226e-6	6.0414275720776134e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-195721	Signaling by WNT	34/475	241/8290	8.2578525592162726e-7	1.0142087766263422e-5	6.1501607062414134e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-5654741	Signaling by FGFR3	11/475	32/8290	8.3719220490425236e-7	1.0170996659581494e-5	6.1687846673153446e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-74752	Signaling by Insulin receptor	15/475	60/8290	9.1913809953340086e-7	1.1049007470179738e-5	6.7013060331627516e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	9/475	21/8290	9.7743473003088786e-7	1.1507530532940969e-5	6.9794037152503995e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-982772	Growth hormone receptor signaling	9/475	21/8290	9.7743473003088786e-7	1.1507530532940969e-5	6.9794037152503995e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-373760	L1CAM interactions	19/475	94/8290	1.5476602653506686e-6	1.3465593071739942e-5	8.1610424749159e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-5654743	Signaling by FGFR4	11/475	33/8290	1.1916761574465485e-6	1.3744057757975599e-5	8.3372985895086876e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	18/475	86/8290	1.2943749511533624e-6	1.4635407863536037e-5	8.8764848135373 39e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-2682334	EPH-Ephrin signaling	18/475	86/8290	1.2943749511533624e-6	1.4635407863536037e-5	8.8764848135373 39e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-69615	G1/S DNA Damage Checkpoints	15/475	62/8290	1.4458174502123547e-6	1.6135646433832 2e-5	9.8164735090260026e-6
aUC_CD44+_vs_HC_CD44+	R-HSA-186712	Regulation of beta-cell development	11/475	34/8290	1.6717025044793744e-6	1.8132823055280707e-5	1.0997693400658779e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	8/475	17/8290	1.6830816496144966e-6	1.8132823055280707e-5	1.0997693400658779e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-445144	Signal transduction by L1	8/475	17/8290	1.6830816496144966e-6	1.8132823055280707e-5	1.0997693400658779e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	8/475	17/8290	1.6830816496144966e-6	1.8132823055280707e-5	1.0997693400658779e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8941326	RUNX2 regulates bone development	10/475	28/8290	1.7864530037524685e-6	1.9066629255005296e-5	1.1564053837574291e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-381340	Transcriptional regulation of white adipocyte differentiation	17/475	80/8290	2.0440367958156184e-6	2.1415504778178313e-5	1.2988664525800838e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	17/475	80/8290	2.0440367958156184e-6	2.1415504778178313e-5	1.2988664525800838e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8878171	Transcriptional regulation by RUNX1	25/475	155/8290	2.1367588036868938e-6	2.1944606929560505e-5	1.3309568955342257e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1980143	Signaling by NOTCH1	16/475	72/8290	2.1858589098668938e-6	2.1944606929560505e-5	1.3309568955342257e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6806834	Signaling by MET	16/475	72/8290	2.1858589098668938e-6	2.1944606929560505e-5	1.3309568955342257e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	18/475	89/8290	2.1906175045919244e-6	2.1944606929560505e-5	1.3309568955342257e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	18/475	89/8290	2.1906175045919244e-6	2.1944606929560505e-5	1.3309568955342257e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-73887	Death Receptor Signalling	23/475	136/8290	2.3792873992869413e-6	2.3627358347701626e-5	1.4330170331632106e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9006115	Signaling by NTRK2 (TRKB)	9/475	23/8290	2.4506864020602244e-6	2.4126585096144622e-5	1.4632955104860504e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	18/475	90/8290	2.5957053089446634e-6	2.5121147989955657e-5	1.5236164971325306e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	18/475	90/8290	2.5957053089446634e-6	2.5121147989955657e-5	1.5236164971325306e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	8/475	18/8290	2.8784864445094285e-6	2.7623794282603086e-5	1.6754038748228255e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	17/475	82/8290	2.9331248549424574e-6	2.7913571536202383e-5	1.6929790829447046e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	14/475	58/8290	3.2734347718424624e-6	3.0894731483000300e-5	1.8737886732251766e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-166166	MyD88-independent TLR4 cascade	18/475	92/8290	3.5148983684194086e-6	3.3562714932804586e-5	2.0356038737013014e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	18/475	92/8290	3.5148983684194086e-6	3.3562714932804586e-5	2.0356038737013014e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	9/475	24/8290	3.7237900641596566e-6	3.4294905630309026e-5	2.0800117675866336e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-373755	Semaphorin interactions	14/475	59/8290	4.1572666001493386e-6	3.7901122034705936e-5	2.2987315235354786e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69278	Cell Cycle, Mitotic	52/475	477/8290	4.1817350055805144e-6	3.7901122034705936e-5	2.2987315235354786e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5655332	Signaling by FGFR3 in disease	7/475	14/8290	4.6831828513349426e-6	4.1500014680672096e-5	2.5170070660781866e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	7/475	14/8290	4.6831828513349426e-6	4.1500014680672096e-5	2.5170070660781866e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-562575	CD209 (DC-SIGN) signaling	8/475	19/8290	4.7241697972744086e-6	4.1500014680672096e-5	2.5170070660781866e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9671555	Signaling by PDGFR in disease	8/475	19/8290	4.7241697972744086e-6	4.1500014680672096e-5	2.5170070660781866e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	10/475	31/8290	5.1652316243985244e-6	4.5028202405061946e-5	2.7309964300271226e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-400685	Sema4D in semaphorin signaling	9/475	25/8290	5.5257877470248064e-6	4.7806436417441896e-5	2.8994962819316768e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5653354	Signaling by FGFR3 fusions in cancer	5/475	6/8290	5.9126958253966846e-6	5.0769162651155359e-5	3.0791878536991799e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-450294	MAP kinase activation	14/475	61/8290	6.3041889514336072e-6	5.3952086433607296e-5	3.2721254008203e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6802957	Oncogenic MAPK signaling	16/475	78/8290	6.6351093544479466e-6	5.6128110242811516e-5	3.4042120508590636e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-388841	Costimulation by the CD28 family	11/475	62/8290	7.7551526524691166e-6	6.5120473023347966e-5	3.9496056087531564e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	7/475	15/8290	8.3491058964627095e-6	6.9368914901490009e-5	4.2210616048133092e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-69620	Cell Cycle Checkpoints	32/475	244/8290	8.5019274196802864e-6	7.0356529806339366e-5	4.2811786079035e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	16/475	80/8290	9.3502283888045256e-6	7.5730218581665026e-5	4.5930946471320486e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	16/475	80/8290	9.3502283888045256e-6	7.5730218581665026e-5	4.5930946471320486e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	16/475	80/8290	9.3502283888045256e-6	7.5730218581665026e-5	4.5930946471320486e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	17/475	89/8290	8.4441657258908356e-6	7.5952375063115024e-5	4.6065686046228094e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	10/475	33/8290	9.7154988401347438e-6	7.7588109618418876e-5	4.7057771341985025e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-400253	Circadian Clock	14/475	64/8290	1.1406893511706566e-5	8.9826918601887e-5	5.4480700809609627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	8/475	21/8290	1.1484001827211051e-5	8.9826918601887e-5	5.4480700809609627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	8/475	21/8290	1.1484001827211051e-5	8.9826918601887e-5	5.4480700809609627e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	6/475	11/8290	1.2379149790579528e-5	9.6169936111688519e-5	5.8323782357466044e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-190236	Signaling by FGFR	15/475	73/8290	1.2995647436050359e-5	9.7190739180761636e-5	5.8946913430676706e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	10/475	34/8290	1.3067069464657836e-5	1.0015171878178677e-4	6.0742798021961e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	7/475	16/8290	1.4113428391904336e-5	1.0745023482369845e-4	6.5169374609635535e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-1912422	Pre-NOTCH Expression and Processing	12/475	49/8290	1.4365598504227416e-5	1.0864578471409075e-4	6.5894484599038402e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	7/475	16/8290	1.6004849134845466e-5	1.1946103079733498e-4	7.2454012595310484e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	9/475	28/8290	1.6004849134845466e-5	1.1946103079733498e-4	7.2454012595310484e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-448424	Interleukin-17 signaling	14/475	66/8290	1.6707523011699157e-5	1.2389604726857428e-4	7.5143883401900515e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	8/475	22/8290	1.7148686552757366e-5	1.2634770975032187e-4	7.6630463509095e-5
aUC_CD44+_vs_HC_CD44+	R-HSA-5654708	Downstream signaling of activated FGFR3	7/475	17/8290	2.2814671116073146e-5	1.6608234367228e-4	1.0073031038469929e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-8853659	RET signaling	10/475	36/8290	2.2832713972458816e-5	1.6608234367228e-4	1.0073031038469929e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1227990	Signaling by ERBB2 in Cancer	8/475	23/8290	2.4987619966462604e-5	1.7834913751062684e-4	1.0817009169692366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	8/475	23/8290	2.4987619966462604e-5	1.7834913751062684e-4	1.0817009169692366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9006335	Signaling by Erythropoietin	8/475	23/8290	2.4987619966462604e-5	1.7834913751062684e-4	1.0817009169692366e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	13/475	60/8290	2.6299137784792043e-5	1.8539268734711427e-4	1.1244205758540069e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	13/475	60/8290	2.6299137784792043e-5	1.8539268734711427e-4	1.1244205758540069e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-109582	Hemostasis	49/475	470/8290	2.7012012185853372e-5	1.8924980316714694e-4	1.1478142730572651e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	12/475	52/8290	2.7453365267171899e-5	1.9001056445900051e-4	1.1524283744423668e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	12/475	52/8290	2.7453365267171899e-5	1.9001056445900051e-4	1.1524283744423668e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	19/475	116/8290	2.8639826297703195e-5	1.9702820260022713e-4	1.1949070299496194e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-109704	PI3K Cascade	9/475	30/8290	2.9909297501183107e-5	2.2108980174639e-4	1.2258061510917774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	9/475	30/8290	2.9909297501183107e-5	2.2108980174639e-4	1.2258061510917774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5655302	Signaling by FGFR1 in disease	9/475	30/8290	2.9909297501183107e-5	2.2108980174639e-4	1.2258061510917774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2029480	Fcgamma receptor (FCGR) dependent phagocytosis	15/475	79/8290	3.3972090457177167e-5	2.2821253772527025e-4	1.3841261851159492e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9018519	Estrogen-dependent gene expression	16/475	89/8290	3.7939459424204575e-5	2.5337346586223174e-4	1.5367291044091486e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5673135	MAP2K and MAPK activation	10/475	38/8290	3.8281045103180886e-5	2.5416830347863674e-4	1.5415000414867202e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-114604	GPVI-mediated activation cascade	9/475	31/8290	4.0031869905323144e-5	2.6426609935151e-4	1.6027362578441884e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6/475	13/8290	4.1566333947487556e-5	2.7334736195724213e-4	1.6578722877013726e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-383280	Nuclear Receptor transcription pathway	11/475	47/8290	5.1566333994748755e-5	3.3670293533160456e-4	2.0421058517110866e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	9/475	32/8290	5.2905527675813326e-5	4.3284730715423267e-4	2.0917739742838753e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5654716	Downstream signaling of activated FGFR4	9/475	32/8290	5.3454679913830546e-5	3.4488386788869e-4	2.0917739742838753e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5689880	Ub-specific processing proteases	22/475	154/8290	6.0902280603763676e-5	3.9073260926684333e-4	2.3698226278696924e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	9/475	32/8290	6.1886175834056086e-5	3.9482688716472662e-4	2.3946543736913234e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-177929	Signaling by EGFR	11/475	48/8290	6.3537005574109556e-5	4.0087989152283436e-4	2.4313666570337482e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2122947	NOTCH1 Intracellular Domain Regulates Transcription	11/475	48/8290	6.3537005574109556e-5	4.0087989152283436e-4	2.4313666570337482e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	9/475	33/8290	6.6192612922982256e-5	4.1534046130794366e-4	2.5190710990932524e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/475	25/8290	6.8339043602476766e-5	4.2646550707119376e-4	2.5865453373845e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69473	G2/M DNA damage checkpoint	12/475	57/8290	7.2399778177127775e-5	4.4935080302443476e-4	2.7253463765433226e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-69242	S Phase	22/475	156/8290	7.4231105297949986e-5	4.5826060675815614e-4	2.7791878792947431e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	10/475	39/8290	7.7720217377582076e-5	4.7008007191299796e-4	2.8510709456911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1250196	SHC1 events in ERBB2 signaling	7/475	20/8290	7.8209469057328926e-5	4.7008007191299796e-4	2.8510709456911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1266695	Interleukin-7 signaling	7/475	20/8290	7.8209469057328926e-5	4.7008007191299796e-4	2.8510709456911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	7/475	20/8290	7.8209469057328926e-5	4.7008007191299796e-4	2.8510709456911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	7/475	20/8290	7.8209469057328926e-5	4.7008007191299796e-4	2.8510709456911e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2262752	Cellular responses to stress	47/475	479/8290	8.9188863684427e-5	5.3327145113935146e-4	3.2343314116461966e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2454202	F-epsilon receptor (FCERI) signaling	19/475	126/8290	9.2059818121748816e-5	4.7564097903325e-4	3.3210173845538254e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-168898	Toll-like Receptor Cascades	20/475	137/8290	9.6294071673184196e-5	5.6978150181749e-4	3.4557676711737384e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-210993	Tie2 Signaling	6/475	14/8290	1.1005436957260078e-4	6.4123515336026072e-4	3.8891393758738626e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/475	15/8290	1.1005436957260078e-4	6.4123515332607264e-4	3.8891393758738626e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	6/475	15/8290	1.1005436957260078e-4	6.4123515332607264e-4	3.8891393758738626e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	7/475	21/8290	1.1157220267238762e-4	6.4677896168460274e-4	3.9227629800314084e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5673000	RAF activation	9/475	35/8290	1.1416474516264039e-4	6.5515647726500176e-4	3.9735732513623639e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6783783	Interleukin-10 signaling	9/475	35/8290	1.1416474516264039e-4	6.5515647726500176e-4	3.9735732513623639e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5664704	SHC-mediated cascade:FGFR3	5/475	10/8290	1.1983235291415019e-4	6.8083854242765926e-4	4.1293360568699774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	5/475	10/8290	1.1983235291415019e-4	6.8083854242765926e-4	4.1293360568699774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	12/475	60/8290	1.2243184268232943e-4	6.9216417991693174e-4	4.1980271480444386e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	14/475	76/8290	1.2415755995125134e-4	6.9942726422938067e-4	4.2362288903620774e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	10/475	44/8290	1.4729270846499822e-4	8.1260035298073384e-4	4.9284821850983124e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6802949	Signaling by RAS mutants	10/475	44/8290	1.4729270846499822e-4	8.1260035298073384e-4	4.9284821850983124e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	10/475	44/8290	1.4729270846499822e-4	8.1260035298073384e-4	4.9284821850983124e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9649948	Signaling downstream of RAS mutants	10/475	44/8290	1.4729270846499822e-4	8.1260035298073384e-4	4.9284821850983124e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	48/475	490/8290	1.5514847608078584e-4	8.5182519917653924e-4	5.1663825876936956e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-156711	Polo-like kinase mediated events	6/475	16/8290	1.6761892810186224e-4	9.1152772832826106e-4	5.5284841482160536e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9614657	FOXO-mediated transcription of cell death genes	6/475	16/8290	1.6761892810186224e-4	9.1152772832826106e-4	5.5284841482160536e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	26/475	211/8290	1.6909879903416164e-4	9.1700032391686174e-4	5.5616137588700693e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6802952	Signaling by BRAF and RAF fusions	12/475	62/8290	1.7023123351771164e-4	9.1790663269587174e-4	5.5671567174209e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2871796	FCERI mediated MAPK activation	8/475	30/8290	2.0895094216540137e-4	1.0010982308445588e-3	6.7139308607993344e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-6785552	Signaling by Leptin	5/475	11/8290	2.0937668885054944e-4	1.0010982308645588e-3	6.7139308607993344e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5654688	SHC-mediated cascade:FGFR1	5/475	11/8290	2.0937668885054944e-4	1.0010982308645588e-3	6.7139308607993344e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	5/475	11/8290	2.0937668885054944e-4	1.0011982308645588e-3	6.7139308607993344e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	7/475	23/8290	2.1279539996981558e-4	1.0119872565235796e-3	6.7911228498024e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	9/475	38/8290	2.2600122008833866e-4	1.0618076764357933e-3	7.1579820417642164e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-195258	RHO GTPase Effectors	29/475	251/8290	2.2632494888384084e-4	1.0618076764357933e-3	7.1579820417642164e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-111471	Apoptotic factor-mediated response	8/475	31/8290	2.4660730782802485e-4	1.1280094155849e-3	7.5684968433e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-187687	Signaling to ERKs	8/475	31/8290	2.6770540208194974e-4	1.0013771151764756153	8.3523069971513966e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-9022692	Regulation of MECP2 expression and activity	8/475	31/8290	2.6770540208194974e-4	1.0013771151764756153	8.3523069971513966e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-5621481	C-type lectin receptors (CLRs)	13/475	72/8290	2.8089662627145145e-4	1.0014384030180898338	8.7245682173973884e-4
aUC_CD44+_vs_HC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	5/475	12/8290	3.4210094665580086e-4	1.0017210541016780814	1.0010438524159029375
aUC_CD44+_vs_HC_CD44+	R-HSA-1502540	Signaling by Activin	5/475	12/8290	3.4210094665580086e-4	1.0017210541016780814	1.0010438524159029375
aUC_CD44+_vs_HC_CD44+	R-HSA-5654706	FRS-mediated FGFR3 signaling	5/475	12/8290	3.4210094665580086e-4	1.0017210541016780814	1.0010438524159029375
aUC_CD44+_vs_HC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	5/475	12/8290	3.4210094665580086e-4	1.0017210541016780814	1.0010438524159029375
aUC_CD44+_vs_HC_CD44+	R-HSA-5654696	Signaling downstream	5/475	12/8290	3.4210094665580086e-4	1.0017210541016780814	1.0010438524159029375
aUC_CD44+_vs_HC_CD44+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	6/475	18/8290	3.5215394970133290e-4	1.0017409515608611157	1.0010599002000614013
aUC_CD44+_vs_HC_CD44+	R-HSA-6804114	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	6/475	18/8290	3.5215394970133290e-4	1.0017409515608611157	1.0010599002000614013
aUC_CD44+_vs_HC_CD44+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	6/475	18/8290	3.5215394970133290e-4	1.0017409515608611157	1.0010599002000614013
aUC_CD44+_vs_HC_CD44+	R-HSA-201681	TCF dependent signaling in response to WNT	20/475	154/8290	4.7712878592703826e-4	1.0023486253169339552	1.0014244588898094334

aUC_CD44+_vs_HC_CD44+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/475	19/8290	4.900151511417123e-4	0.002367954246769404	0.001436182039242573e5
aUC_CD44+_vs_HC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	6/475	19/8290	4.900151511417123e-4	0.002367954246769404	0.001436182039242573e6
aUC_CD44+_vs_HC_CD44+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/475	19/8290	4.900151511417123e-4	0.002367954246769404	0.001436182039242573e6
aUC_CD44+_vs_HC_CD44+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	6/475	19/8290	4.900151511417123e-4	0.002367954246769404	0.001436182039242573e6
aUC_CD44+_vs_HC_CD44+	R-HSA-1251985	Nuclear signaling by ERBB4	7/475	26/8290	4.914230792332301e-4	0.002367954246769404	0.001436182039242573e6
aUC_CD44+_vs_HC_CD44+	R-HSA-1226099	Signaling by FGFR in disease	10/475	51/8290	5.286104626149848e-4	0.002521363775598557	0.001529226070922528
aUC_CD44+_vs_HC_CD44+	R-HSA-171007	p38MAPK events	5/475	13/8290	5.298838052799944e-4	0.002521363775598557	0.001529226070922528
aUC_CD44+_vs_HC_CD44+	R-HSA-5654693	FRS-mediated FGFR1 signaling	5/475	13/8290	5.298838052799944e-4	0.002521363775598557	0.001529226070922528
aUC_CD44+_vs_HC_CD44+	R-HSA-202733	Cell surface interactions at the vascular wall	15/475	101/8290	5.860616131950133e-4	0.002777105237629482-3	0.001684335188286847e5
aUC_CD44+_vs_HC_CD44+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	11/475	61/8290	5.983294636031534e-4	0.002823521683614880-3	0.001712487112009025e5
aUC_CD44+_vs_HC_CD44+	R-HSA-2424491	DAP12 signaling	7/475	27/8290	6.311165811236065e-4	0.002961888212523287	0.001798894132030899e3
aUC_CD44+_vs_HC_CD44+	R-HSA-168638	NOD1/2 Signaling Pathway	8/475	35/8290	6.523131516401202e-4	0.003004057803744088-7	0.001844133421178084e3
aUC_CD44+_vs_HC_CD44+	R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	8/475	35/8290	6.523131516401202e-4	0.003004057803744088-7	0.001844133421178084e3
aUC_CD44+_vs_HC_CD44+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/475	20/8290	6.665033006064498e-4	0.003094092558098607	0.001876590379970235e4
aUC_CD44+_vs_HC_CD44+	R-HSA-5693532	DNA Double-Strand Break Repair	17/475	125/8290	7.348471186027633e-4	0.003397552264669057	0.002060640971833020e6
aUC_CD44+_vs_HC_CD44+	R-HSA-194315	Signaling by Rho GTPases	37/475	375/8290	7.804899712178414e-4	0.003574885638774708-3	0.002168194995219613
aUC_CD44+_vs_HC_CD44+	R-HSA-1963640	GRB2 events in ERBB2 signaling	5/475	14/8290	7.857235510792046e-4	0.003574885638774708-3	0.002168194995219613
aUC_CD44+_vs_HC_CD44+	R-HSA-1963642	PI3K events in ERBB2 signaling	5/475	14/8290	7.857235510792046e-4	0.003574885638774708-3	0.002168194995219613
aUC_CD44+_vs_HC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	5/475	14/8290	7.857235510792046e-4	0.003574885638774708-3	0.002168194995219613
aUC_CD44+_vs_HC_CD44+	R-HSA-5688896	Ovarian tumor domain proteases	8/475	36/8290	7.973715505203353e-4	0.003585032719268594	0.002174349275766186
aUC_CD44+_vs_HC_CD44+	R-HSA-8875878	MET promotes cell motility	8/475	36/8290	7.973715505203353e-4	0.003585032719268594	0.002174349275766186
aUC_CD44+_vs_HC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	6/475	21/8290	8.884757397800711e-4	0.003978977626779794	0.002413279821568817
aUC_CD44+_vs_HC_CD44+	R-HSA-5693606	DNA Double Strand Break Response	8/475	37/8290	9.672557908672869e-4	0.004298078261363586e5	0.002606816753596866e4
aUC_CD44+_vs_HC_CD44+	R-HSA-8853884	Transcriptional Regulation by VENTX	8/475	37/8290	9.672557908672869e-4	0.004298078261363586e5	0.002606816753596866e4
aUC_CD44+_vs_HC_CD44+	R-HSA-2172127	DAP12 interactions	7/475	29/8290	0.001003977458899445	0.004376115488790711	0.002654146918263699e5
aUC_CD44+_vs_HC_CD44+	R-HSA-3214858	RMTs methylate histone arginines	7/475	29/8290	0.001003977458899445	0.004376115488790711	0.002654146918263699e5
aUC_CD44+_vs_HC_CD44+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	7/475	29/8290	0.001003977458899445	0.004376115488790711	0.002654146918263699e5
aUC_CD44+_vs_HC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	7/475	29/8290	0.001003977458899445	0.004376115488790711	0.002654146918263699e5
aUC_CD44+_vs_HC_CD44+	R-HSA-9645723	Diseases of programmed cell death	7/475	29/8290	0.001003977458899445	0.004376115488790711	0.002654146918263699e5
aUC_CD44+_vs_HC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	5/475	15/8290	0.001235581418325119	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-2691230	Signaling by NOTCH1 HD Domain Mutants in Cancer	5/475	15/8290	0.001235581418325119	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-2691232	Constitutive Signaling by NOTCH1 HD Domain Mutants	5/475	15/8290	0.001235581418325119	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-9664407	Parasite infection	10/475	56/8290	0.001390689117453	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-9664417	Leishmania phagocytosis	10/475	56/8290	0.001390689117453	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-9664422	FCGR3A-mediated phagocytosis	10/475	56/8290	0.001390689117453	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-198753	ERK/MAPK targets	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-3000170	Syndecan interactions	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-8863678	Neurodegenerative Diseases	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-912446	Meiotic recombination	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-933542	TRAF6 mediated NF-kB activation	6/475	22/8290	0.001163290450874522	0.004830827981449832	0.002929933460958605
aUC_CD44+_vs_HC_CD44+	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	10/475	57/8290	0.001312308116012398	0.005429912567346435	0.003293282762557927
aUC_CD44+_vs_HC_CD44+	R-HSA-6807070	PTEN Regulation	17/475	132/8290	0.001364757568009059	0.005626545641774455	0.003412542199527988
aUC_CD44+_vs_HC_CD44+	R-HSA-437239	Recycling pathway of L1	8/475	39/8290	0.00139351377562360e88	0.005724342688911425	0.0034712191239818377e4
aUC_CD44+_vs_HC_CD44+	R-HSA-1839134	FGFR1 mutant receptor activation	6/475	23/8290	0.001498759292476178e8	0.006078817946125635	0.003686848749701049
aUC_CD44+_vs_HC_CD44+	R-HSA-5654733	Negative regulation of FGFR4 signaling	6/475	23/8290	0.001498759292476178e8	0.006078817946125635	0.003686848749701049
aUC_CD44+_vs_HC_CD44+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	10/475	58/8290	0.001506397091728156e4	0.006078817946125635	0.003686848749701049
aUC_CD44+_vs_HC_CD44+	R-HSA-5619507	Activation of HOX genes during differentiation	10/475	58/8290	0.001506397091728156e4	0.006078817946125635	0.003686848749701049
aUC_CD44+_vs_HC_CD44+	R-HSA-8943724	Regulation of PTEN gene transcription	10/475	58/8290	0.001506397091728156e4	0.006078817946125635	0.003686848749701049
aUC_CD44+_vs_HC_CD44+	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/475	16/8290	0.001558075963446825e3	0.006199730837129876	0.003760183326418526
aUC_CD44+_vs_HC_CD44+	R-HSA-180292	GAB1 signalosome	5/475	16/8290	0.001558075963446825e3	0.006199730837129876	0.003760183326418526
aUC_CD44+_vs_HC_CD44+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/475	16/8290	0.001558075963446825e3	0.006199730837129876	0.003760183326418526
aUC_CD44+_vs_HC_CD44+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	5/475	16/8290	0.001558075963446825e3	0.006199730837129876	0.003760183326418526
aUC_CD44+_vs_HC_CD44+	R-HSA-1059683	Interleukin-6 signaling	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-430116	GP1b-IX-V activation signaling	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-5654710	PI-3K cascade:FGFR3	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-8851805	MET activates RAS signaling	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	4/475	10/8290	0.001693987557909132e8	0.006535871322037478	0.003963882692404728
aUC_CD44+_vs_HC_CD44+	R-HSA-1643713	Signaling by EGFR in Cancer	6/475	24/8290	0.001903095667465259e5	0.007293071316269485	0.004423025404717311
aUC_CD44+_vs_HC_CD44+	R-HSA-3928665	EPHA-mediated growth cone collapse	6/475	24/8290	0.001903095667465259e5	0.007293071316269485	0.004423025404717311
aUC_CD44+_vs_HC_CD44+	R-HSA-1181150	Signaling by NODAL	5/475	17/8290	0.002104522999121322	0.008038010919720902	0.004875114006061714
aUC_CD44+_vs_HC_CD44+	R-HSA-69481	G2/M Checkpoints	16/475	126/8290	0.002167100986102475	0.008246961417536342	0.005003501490826467
aUC_CD44+_vs_HC_CD44+	R-HSA-5654738	Signaling by FGFR2	10/475	61/8290	0.002232356580434265	0.008496166662777	0.005136886193111469
aUC_CD44+_vs_HC_CD44+	R-HSA-5675271	Negative regulation of MAPK pathway	8/475	42/8290	0.002298785809912085	0.008692759558264495	0.005272229906066267
aUC_CD44+_vs_HC_CD44+	R-HSA-8874081	MET activates PTK2 signaling	6/475	25/8290	0.002369545877186002245	0.008988473645681451	0.005451576789435335
aUC_CD44+_vs_HC_CD44+	R-HSA-9558195	Leishmania infection	20/475	176/8290	0.002528410410562955	0.009457160999434492	0.005735839190366608
aUC_CD44+_vs_HC_CD44+	R-HSA-4641265	Repression of WNT target genes	4/475	11/8290	0.002542336625942655	0.009457160999434892	0.005735839190366608
aUC_CD44+_vs_HC_CD44+	R-HSA-5654689	PI-3K cascade:FGFR1	4/475	11/8290	0.002542336625942655	0.009457160999434892	0.005735839190366608
aUC_CD44+_vs_HC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	4/475	11/8290	0.002542336625942655	0.009457160999434892	0.005735839190366608
aUC_CD44+_vs_HC_CD44+	R-HSA-75893	TNF signaling	8/475	43/8290	0.002685388673708233	0.009958531723050026	0.006039924300642522
aUC_CD44+_vs_HC_CD44+	R-HSA-5625740	RHO GTPases activate PKNs	7/475	34/8290	0.002699248353887115	0.009973862781643393	0.006050435717873863
aUC_CD44+_vs_HC_CD44+	R-HSA-1368082	RORA activates gene expression	5/475	18/8290	0.002778511095052099	0.010170063046663297	0.006168219637463817
aUC_CD44+_vs_HC_CD44+	R-HSA-167044	Signaling to RAS	5/475	18/8290	0.002778511095052099	0.010170063046663297	0.006168219637463817
aUC_CD44+_vs_HC_CD44+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	9/475	53/8290	0.002860083681379204	0.010431930466422236	0.006329022974018581
aUC_CD44+_vs_HC_CD44+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	7/475	35/8290	0.002952881104103673	0.010739484783272178	0.006513578198625610e5
aUC_CD44+_vs_HC_CD44+	R-HSA-8863795	Downregulation of ERBB2 signaling	6/475	26/8290	0.002952881104103673	0.010739484783272178	0.006513578198625610e5
aUC_CD44+_vs_HC_CD44+	R-HSA-6783589	Interleukin-6 family signaling	5/475	19/8290	0.003059583107502078	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-9013695	NOTCH4 Intracellular Domain Regulates Transcription	5/475	19/8290	0.003059583107502078	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	6/475	45/8290	0.003061124557050849	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-397795	G-protein beta:gamma signaling	6/475	27/8290	0.003061625140449228 78	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-179812	GRB2 events in EGFR signaling	4/475	12/8290	0.003642454465586097 3	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-2299718	Condensation of Prophase Chromosomes	4/475	12/8290	0.003642454465586097 3	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-418885	DCC mediated attractive signaling	4/475	12/8290	0.003642454465586097 3	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-5654720	PI-3K cascade:FGFR4	4/475	12/8290	0.003642454465586097 3	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/475	12/8290	0.003642454465586097 3	0.012878275540864778	0.007810770859884806
aUC_CD44+_vs_HC_CD44+	R-HSA-451927	Interleukin-2 family signaling	7/475	36/8290	0.003793577789459942	0.013330048724681400	0.008084774689764023
aUC_CD44+_vs_HC_CD44+	R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	7/475	36/8290	0.003793577789459942	0.013330048724810013	0.008084774689764023
aUC_CD44+_vs_HC_CD44+	R-HSA-176187	Activation of ATR in response to replication stress	7/475	37/8290	0.004453052923464895	0.015599344900168453	0.009461119867553539
aUC_CD44+_vs_HC_CD44+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	5/475	20/8290	0.004572273666491298	0.015919318680283727	0.009655186368900653
aUC_CD44+_vs_HC_CD44+	R-HSA-5625900	RHO GTPases activate CIT	5/475	20/8290	0.004572273666491298	0.015919318680283727	0.009655186368900653
aUC_CD44+_vs_HC_CD44+	R-HSA-3858494	Beta-catenin independent WNT signaling	16/475	137/8290	0.004691383101776685	0.016284375143875137	0.009876200560124267e4
aUC_CD44+_vs_HC_CD44+	R-HSA-187577	SCF(Skp2)-mediated degradation of p27/p21	9/475	57/8290	0.004741352185492617	0.016407952108583547	0.009951456213888812
aUC_CD44+_vs_HC_CD44+	R-HSA-9012852	Signaling by NOTCH3	8/475	47/8290	0.004765999925915781	0.016443419683975929	0.009973057564803893
aUC_CD44+_vs_HC_CD44+	R-HSA-180336	SHC1 events in EGFR signaling	4/475	13/8290	0.005025819032039991	0.017081802173120525	0.010360241340135 78
aUC_CD44+_vs_HC_CD44+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	4/475	13/8290	0.005025819032039991	0.017081802173120525	0.010360241340135 78
aUC_CD44+_vs_HC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	4/475	13/8290	0.005025819032039991	0.017081802173120525	0.010360241340135 78
aUC_CD44+_vs_HC_CD44+	R-HSA-6785631	ERBB2 Regulates Cell Motility	4/475	13/8290	0.005025819032039991	0.017081802173120525	0.010360241340135 78
aUC_CD44+_vs_HC_CD44+	R-HSA-9027284	Erythropoietin activates RAS	4/475	13/8290	0.005025819032039991	0.017081802173120525	0.010360241340135 78
aUC_CD44+_vs_HC_CD44+	R-HSA-5693616	Presynaptic phase of homologous DNA pairing and strand exchange	7/475	38/8290	0.005195553372001033	0.017606229994813452	0.010678310753605489
aUC_CD44+_vs_HC_CD44+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	6/475	29/8290	0.005265995324402333	0.017635558793515972	0.010696098890172729
aUC_CD44+_vs_HC_CD44+	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	6/475	29/8290	0.005265995324402333	0.017635558793515972	0.010696098890172729
aUC_CD44+_vs_HC_CD44+	R-HSA-4090294	SUMOylation of intracellular receptors	6/475	29/8290	0.005265995324402333	0.017635558793515972	0.010696098890172729
aUC_CD44+_vs_HC_CD44+	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	6/475	29/8290	0.005265995324402333	0.017635558793515972	0.010696098890172729
aUC_CD44+_vs_HC_CD44+	R-HSA-5693607	Processing of DNA double-strand break ends	9/475	59/8290	0.005985754162154547	0.019987518284153488	0.012125799896350926
aUC_CD44+_vs_HC_CD44+	R-HSA-1500620	Meiosis	8/475	49/8290	0.006184604314529281	0.020542419813514412	0.012459131935707284
aUC_CD44+_vs_HC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	11/475	81/8290	0.006187909526572817 64	0.020542419813514412	0.012459131935707284
aUC_CD44+_vs_HC_CD44+	R-HSA-162658	Golgi Cisternae Pericentriolar Stack Reorganization	4/475	14/8290	0.006721857464188206 5	0.022058500264663597	0.013378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-877312	Regulation of IFNG signaling	4/475	14/8290	0.006721857464188206 5	0.022058500264663597	0.013378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-8941856	RUNX3 regulates NOTCH signaling	4/475	14/8290	0.006721857464188206 5	0.022058500264663597	0.013378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-975163	IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	4/475	14/8290	0.006721857464188206 5	0.022058500264663597	0.013378651577240898
aUC_CD44+_vs_HC_CD44+	R-HSA-388396	GPCR downstream signalling	41/475	483/8290	0.006982609079848479	0.022500372499681078 3	0.013646462812225455
aUC_CD44+_vs_HC_CD44+	R-HSA-201451	Signaling by BMP	5/475	22/8290	0.007064687009092668 5	0.022920092512454054	0.013901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-5654727	Negative regulation of FGFR2 signaling	5/475	22/8290	0.007064687009092668 5	0.022920092512454054	0.013901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-937041	IKK complex recruitment mediated by RIP1	5/475	22/8290	0.007064687009092668 5	0.022920092512454054	0.013901208289422779
aUC_CD44+_vs_HC_CD44+	R-HSA-198615	Signaling by NOTCH2	6/475	31/8290	0.007408492259380993	0.023899712316986142	0.014495355059984224
aUC_CD44+_vs_HC_CD44+	R-HSA-5655253	Signaling by FGFR2 in disease	6/475	31/8290	0.007408492259380993	0.023899712316986142	0.014495355059984224
aUC_CD44+_vs_HC_CD44+	R-HSA-1592230	Mitochondrial biogenesis	10/475	72/8290	0.007572046900068313	0.024358528337684548	0.014773630423261153
aUC_CD44+_vs_HC_CD44+	R-HSA-5693579	Homologous DNA Pairing and Strand Exchange	7/475	41/8290	0.007983280217004307	0.025609286538958335	0.015532232836193449
aUC_CD44+_vs_HC_CD44+	R-HSA-5260271	Diseases of Immune System	5/475	23/8290	0.008610778414616	0.027467900990328825	0.016659488242556952
aUC_CD44+_vs_HC_CD44+	R-HSA-5602358	Diseases associated with the TLR signaling cascade	5/475	23/8290	0.008610778414616	0.027467900990328825	0.016659488242556952
aUC_CD44+_vs_HC_CD44+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/475	15/8290	0.008757602672317552	0.027781061810518454	0.016849422683533611
aUC_CD44+_vs_HC_CD44+	R-HSA-937072	TRAF6-mediated induction of TAK1 complex within TLR4 complex	4/475	15/8290	0.008757602672317552	0.027781061810518454	0.016849422683533611
aUC_CD44+_vs_HC_CD44+	R-HSA-373752	Netrin-1 signaling	7/475	42/8290	0.009120179098475553	0.028851092882158123	0.017498404568583701
aUC_CD44+_vs_HC_CD44+	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	10/475	74/8290	0.009149945442485501	0.028911084797656885	0.017534790116009058
aUC_CD44+_vs_HC_CD44+	R-HSA-416476	G alpha (q) signaling events	16/475	146/8290	0.009226822790854641	0.029027635336817907	0.017606478893380765
aUC_CD44+_vs_HC_CD44+	R-HSA-8941858	Regulation of RUNX3 expression and activity	6/475	32/8290	0.009565279415757656	0.030123723876762865	0.018945619690803640e4
aUC_CD44+_vs_HC_CD44+	R-HSA-4791275	Signaling by WNT in cancer	6/475	33/8290	0.010151586664607	0.031656289705521198	0.019199577751525188e41
aUC_CD44+_vs_HC_CD44+	R-HSA-212165	Epigenetic regulation of gene expression	11/475	87/8290	0.010513440477028292	0.032804232308104676	0.019896013327249402
aUC_CD44+_vs_HC_CD44+	R-HSA-1500931	Cell-Cell communication	12/475	99/8290	0.010693184306466	0.033318374084726276	0.020126188267344185
aUC_CD44+_vs_HC_CD44+	R-HSA-5693538	Homology Directed Repair	12/475	99/8290	0.010693184306466	0.033318374084726276	0.020126188267344185
aUC_CD44+_vs_HC_CD44+	R-HSA-9679506	SARS-CoV Infections	15/475	136/8290	0.010873105155335791	0.033650625443734492	0.020357897123300822
aUC_CD44+_vs_HC_CD44+	R-HSA-447115	Interleukin-12 family signaling	8/475	54/8290	0.011120720748328271	0.034160327307319306	0.020718495131547707
aUC_CD44+_vs_HC_CD44+	R-HSA-1295596	Spry regulation of FGF signaling	4/475	16/8290	0.011157444908607796	0.034160327307319306	0.020718495131547707
aUC_CD44+_vs_HC_CD44+	R-HSA-1433559	Regulation of KIT signaling	4/475	16/8290	0.011157444908607796	0.034160327307319306	0.020718495131547707
aUC_CD44+_vs_HC_CD44+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/475	16/8290	0.011157444908607796	0.034160327307319306	0.020718495131547707
aUC_CD44+_vs_HC_CD44+	R-HSA-5357905	Regulation of TNFR1 signaling	6/475	34/8290	0.011707508933249997	0.035653267204722399	0.021623973494606314
aUC_CD44+_vs_HC_CD44+	R-HSA-8953750	Transcriptional Regulation by E2F6	6/475	34/8290	0.011707508933249997	0.035653267204722399	0.021623973494606314
aUC_CD44+_vs_HC_CD44+	R-HSA-75153	Apoptotic execution phase	7/475	44/8290	0.011742795383611086	0.035665678938406054	0.021631685180336214
aUC_CD44+_vs_HC_CD44+	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	6/475	35/8290	0.013465411030083424	0.040789123067255536	0.024738909556875313
aUC_CD44+_vs_HC_CD44+	R-HSA-4086398	Ca2+ pathway	8/475	56/8290	0.013746215913756804	0.041529572945794537	0.025187997976826503
aUC_CD44+_vs_HC_CD44+	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	4/475	17/8290	0.013942959342295917	0.041792282332075956	0.025347333187516994
aUC_CD44+_vs_HC_CD44+	R-HSA-5689901	Metalloprotease DUBs	4/475	17/8290	0.013942959342295917	0.041792282332075956	0.025347333187516994
aUC_CD44+_vs_HC_CD44+	R-HSA-8854691	Interleukin-20 family signaling	4/475	17/8290	0.013942959342295917	0.041792282332075956	0.025347333187516994
aUC_CD44+_vs_HC_CD44+	R-HSA-1168372	Downstream signaling events of B Cell Receptor (BCR)	10/475	79/8290	0.014263195203409882	0.042528900558040231	0.025794097868171838
aUC_CD44+_vs_HC_CD44+	R-HSA-9013694	Signaling by NOTCH4	9/475	68/8290	0.014338050284541	0.042528900558040231	0.025794097868171838
aUC_CD44+_vs_HC_CD44+	R-HSA-5663205	RHO GTPases Activate Formins	14/475	128/8290	0.014392619005983345	0.043244490549720694	0.026228111109518126
aUC_CD44+_vs_HC_CD44+	R-HSA-392518	Signal amplification	5/475	26/8290	0.014616790796014027	0.043244490549720694	0.026228111109518126
aUC_CD44+_vs_HC_CD44+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	5/475	26/8290	0.014616790796014027	0.043244490549720694	0.026228111109518126
aUC_CD44+_vs_HC_CD44+	R-HSA-5687128	MAPK6/MAPK4 signaling	10/475	80/8290	0.014966487647619	0.045472917177770162	0.027735059159884857
aUC_CD44+_vs_HC_CD44+	R-HSA-1234158	Regulation of gene expression by Hypoxia-inducible Factor	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-170968	Frs2-mediated activation	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-8875555	MET activates RAP1 and RAC1	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-968136	Maturation of nucleoprotein	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-9694631	Maturation of nucleoprotein	3/475	10/8290	0.015657604324204105	0.048167533526706816	0.029213972020439006
aUC_CD44+_vs_HC_CD44+	R-HSA-216083	Integrin cell surface interactions	8/475	58/8290	0.016797336696713227	0.048686697508300078	0.029528784758784067
aUC_CD44+_vs_HC_CD44+	R-HSA-5693567	HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	11/475	93/8290	0.016852626030022158	0.048732580633032137	0.029553633409222272
aUC_CD44+_vs_HC_CD44+	R-HSA-69205	G1/S-Specific Transcription	5/475	27/8290	0.017116913385151119	0.049036740701402924	0.029741151609847114
aUC_CD44+_vs_HC_CD44+	R-HSA-1912420	Pre-NOTCH Processing in Golgi	4/475	18/8290	0.017132801698665286	0.049036740701402924	0.029741151609847114
aUC_CD44+_vs_HC_CD44+	R-HSA-446353	Cell-extracellular matrix interactions	4/475	18/8290	0.017132801698665286	0.049036740701402924	0.029741151609847114
aUC_CD44+_vs_HC_CD44+	R-HSA-622312	Inflammasomes	4/475	18/8290	0.017132801698665286	0.049036740701402924	0.029741151609847114
qUC_CD44+_vs_HC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	33/137	437/8290	0.037084011485434e-12	3.221577240765374e6e-9	0.434987150717020266e-9
qUC_CD44+_vs_HC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	27/137	356/8290	1.790555295222822204e-11	7.144315627930053e-9	5.399937811382506e-9
qUC_CD44+_vs_HC_CD44+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	9/137	23/8290	1.723003502333838e-11	4.742032791620788e-8	2.229085832957291566e-8
qUC_CD44+_vs_HC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	14/137	874/8290	1.123348788257109568e-10	2.339085383257156e-8	1.694383830713996e-8
qUC_CD44+_vs_HC_CD44+	R-HSA-8939211	ESR-mediated signaling	15/137	154/8290	4.792942025491139e-10	7.649535469584426e-8	5.781801641039278e-8
qUC_CD44+_vs_HC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signaling	12/137	68/8290	8.4480223237929e-10	1.123586654906437e-7	8.492485507286489e-8
qUC_CD44+_vs_HC_CD44+	R-HSA-9614085	FOXO-mediated transcription	11/137	55/8290	1.079271644996803e-9	1.230369675296456e-7	9.298588760846989e-8
qUC_CD44+_vs_HC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	27/137	439/8290	2.0512080094771743e-9	2.041645056443e-7	1.547054362408588e-7
qUC_CD44+_vs_HC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	19/137	219/8290	2.664401025807956e-9	2.36243557621683e-7	1.785616121606786e-7
qUC_CD44+_vs_HC_CD44+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	7/137	20/8290	4.891761605806913e-9	3.548750692121265e-7	2.682276937920923e-7
qUC_CD44+_vs_HC_CD44+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	7/137	20/8290	4.891761605806913e-9	3.548750692121265e-7	2.682276937920923e-7
qUC_CD44+_vs_HC_CD44+	R-HSA-125769x	PIP3 activates AKT signaling	19/137	237/8290	9.013990853619032e-9	6.592803906818e5e-7	4.980084944773607e-7
qUC_CD44+_vs_HC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	12/137	91/8290	2.649046654091285e8e-8	1.626107203583433e-6	1.229071802019619e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-449147	Signaling by Interleukins	23/137	376/8290	4.241460336139017e-8	2.417632391592396e-6	1.827335919253871e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-9675126	Diseases of mitotic cell cycle	8/137	36/8290	9.268573320701199e-8	4.581157535636715e-6	3.462621658354793e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-69871	Aberrant regulation of mitotic cell cycle due to RB1 defects	8/137	36/8290	9.268573320701199e-8	4.581157535636715e-6	3.462621658354793e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-9006925	Intracellular signaling by second messengers	19/137	273/8290	9.759396122586686e-8	4.581157535636715e-6	3.462621658354793e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	7/137	25/8290	1.082674100742004e-7	4.799851517995639e-6	3.627907951609307e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	7/137	27/8290	1.945480407436054e-7	8.171017711231762e-6	6.175067193068003e-6
qUC_CD44+_vs_HC_CD44+	R-HSA-114452	Activation of BH3-only proteins	7/137	29/8290	3.326590247257644e-7	1.327315003763539e-5	1.003054583184052e-5
qUC_CD44+_vs_HC_CD44+	R-HSA-195721	Signaling by WNT	17/137	241/8290	4.044458915276243e-7	1.536894387804972 4e-5	1.161641583184052e-5

	Comparison	Pathway ID	Description		
1	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5654738	Signaling by FGFR2	8/368	61/8290
2	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	6/368	37/8290
3	aUC_CD66a+_vs_aUC_CD44+	R-HSA-196299	Beta-catenin phosphorylation cascade	4/368	17/8290
4	aUC_CD66a+_vs_aUC_CD44+	R-HSA-450604	KSRP (KHSRP) binds and destabilizes mRNA	4/368	17/8290
5	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9031628	NGF-stimulated transcription	6/368	38/8290
6	aUC_CD66a+_vs_aUC_CD44+	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	9/368	77/8290
7	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8941326	RUNX2 regulates bone development	5/368	28/8290
8	aUC_CD66a+_vs_aUC_CD44+	R-HSA-69278	Cell Cycle, Mitotic	33/368	477/8290
9	aUC_CD66a+_vs_aUC_CD44+	R-HSA-3858494	Beta-catenin independent WNT signaling	13/368	136/8290
10	aUC_CD66a+_vs_aUC_CD44+	R-HSA-375165	NCAM signaling for neurite out-growth	7/368	52/8290
11	aUC_CD66a+_vs_aUC_CD44+	R-HSA-165159	MTOR signaling	6/368	40/8290
12	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9656223	Signaling by RAF1 mutants	6/368	40/8290
13	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2032785	YAP1- and WWTR1 (TAZ)-stimulated gene expression	3/368	10/8290
14	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	3/368	10/8290
15	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5625970	RHO GTPases activate KTN1	3/368	10/8290
16	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5654704	SHC-mediated cascade:FGFR3	3/368	10/8290
17	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8851805	MET activates RAS signaling	3/368	10/8290
18	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9634285	Constitutive Signaling by Overexpressed ERBB2	3/368	10/8290
19	aUC_CD66a+_vs_aUC_CD44+	R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex	5/368	29/8290
20	aUC_CD66a+_vs_aUC_CD44+	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	5/368	29/8290
21	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5357990	TNFR1-induced NFkappaB signaling pathway	5/368	29/8290
22	aUC_CD66a+_vs_aUC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/368	29/8290
23	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8979227	Triglyceride metabolism	5/368	29/8290
24	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	7/368	53/8290
25	aUC_CD66a+_vs_aUC_CD44+	R-HSA-422475	Axon guidance	33/368	483/8290
26	aUC_CD66a+_vs_aUC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	9/368	80/8290
27	aUC_CD66a+_vs_aUC_CD44+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	4/368	19/8290
28	aUC_CD66a+_vs_aUC_CD44+	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	4/368	19/8290
29	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2028269	Signaling by Hippo	4/368	19/8290
30	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	4/368	19/8290
31	aUC_CD66a+_vs_aUC_CD44+	R-HSA-6807004	Negative regulation of MET activity	4/368	19/8290
32	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	6/368	41/8290
33	aUC_CD66a+_vs_aUC_CD44+	R-HSA-447115	Interleukin-12 family signaling	7/368	54/8290
34	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2871796	FCERI mediated MAPK activation	5/368	30/8290
35	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5675221	Negative regulation of MAPK pathway	6/368	42/8290
36	aUC_CD66a+_vs_aUC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	9/368	82/8290
37	aUC_CD66a+_vs_aUC_CD44+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	4/368	20/8290
38	aUC_CD66a+_vs_aUC_CD44+	R-HSA-449836	Other interleukin signaling	4/368	20/8290
39	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/368	11/8290
40	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/368	11/8290
41	aUC_CD66a+_vs_aUC_CD44+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/368	11/8290
42	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	3/368	11/8290
43	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9013700	NOTCH4 Activation and Transmission of Signal to the Nucleus	3/368	11/8290
44	aUC_CD66a+_vs_aUC_CD44+	R-HSA-1980145	Signaling by NOTCH2	5/368	31/8290
45	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5655253	Signaling by FGFR2 in disease	5/368	31/8290
46	aUC_CD66a+_vs_aUC_CD44+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	6/368	43/8290
47	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9024446	NR1H2 and NR1H3-mediated signaling	6/368	43/8290
48	aUC_CD66a+_vs_aUC_CD44+	R-HSA-114608	Platelet degranulation	10/368	98/8290
49	aUC_CD66a+_vs_aUC_CD44+	R-HSA-450531	Regulation of mRNA stability by proteins that bind AU-rich elements	9/368	84/8290
50	aUC_CD66a+_vs_aUC_CD44+	R-HSA-112409	RAF-independent MAPK1/3 activation	4/368	21/8290
51	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2979096	NOTCH2 Activation and Transmission of Signal to the Nucleus	4/368	21/8290
52	aUC_CD66a+_vs_aUC_CD44+	R-HSA-982772	Growth hormone receptor signaling	4/368	21/8290
53	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	5/368	32/8290
54	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8943724	Regulation of PTEN gene transcription	6/368	45/8290
55	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9020591	Interleukin-12 signaling	6/368	45/8290
56	aUC_CD66a+_vs_aUC_CD44+	R-HSA-179812	GRB2 events in EGFR signaling	3/368	12/8290
57	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/368	12/8290
58	aUC_CD66a+_vs_aUC_CD44+	R-HSA-264642	Acetylcholine Neurotransmitter Release Cycle	3/368	12/8290
59	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/368	12/8290
60	aUC_CD66a+_vs_aUC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/368	12/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5668599	RHO GTPases Activate NADPH Oxidases	4/368	22/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	4/368	22/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-8863678	Neurodegenerative Diseases	4/368	22/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-912526	Interleukin receptor SHC signaling	4/368	22/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	10/368	103/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5357905	Regulation of TNFR1 signaling	5/368	34/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-5625740	RHO GTPases activate PKNs	5/368	34/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	5/368	34/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/368	34/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-9664323	FCGR3A-mediated IL10 synthesis	5/368	34/8290
	aUC_CD66a+_vs_aUC_CD44+	R-HSA-2980736	Peptide hormone metabolism	7/368	60/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	8/34	83/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8939211	ESR-mediated signaling	7/34	64/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	7/34	91/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	4/34	12/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	9/34	219/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1257604	PIP3 activates AKT signaling	9/34	239/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	10/34	356/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9006925	Intracellular signaling by second messengers	9/34	273/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/34	21/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-111452	Activation of BH3-only proteins	4/34	22/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signaling	5/34	68/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-389356	CD28 co-stimulation	4/34	32/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/34	12/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5628897	TP53 Regulates Metabolic Genes	5/34	81/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5/34	84/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-111447	Activation of BAD and translocation to mitochondria	3/34	15/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5633007	Regulation of TP53 Activity	5/34	152/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	9/34	439/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-109606	Intrinsic Pathway for Apoptosis	4/34	51/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1660499	Synthesis of PIPs at the plasma membrane	4/34	52/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-3700989	Transcriptional Regulation by TP53	8/34	343/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	4/34	57/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	3/34	23/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-388841	Costimulation by the CD28 family	4/34	62/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	3/34	25/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8936795	Downregulation of ERBB2 signaling	4/34	65/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6807070	PTEN Regulation	5/34	132/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5218920	VEGFR2 mediated vascular permeability	3/34	28/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	3/34	29/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	3/34	30/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1483255	PI Metabolism	4/34	78/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6804757	Regulation of TP53 Degradation	3/34	35/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-195721	Signaling by WNT	6/34	241/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2428928	IRS-related events triggered by IGF1R	3/34	36/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	3/34	36/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2428924	IGF1R signaling cascade	3/34	37/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9018519	Estrogen-dependent gene expression	4/34	89/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	3/34	38/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	3/34	39/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	4/34	93/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-165159	MTOR signaling	3/34	40/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	2/34	9/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1227986	Signaling by ERBB2	3/34	47/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	3/34	48/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	3/34	56/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	5/34	211/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-210745	Regulation of gene expression in beta cells	2/34	17/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8948751	Regulation of PTEN stability and activity	3/34	64/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	2/34	19/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	2/34	20/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-201681	TCF dependent signaling in response to WNT	4/34	154/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-8878171	Transcriptional regulation by RUNX1	4/34	156/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-912526	Interleukin receptor SHC signaling	2/34	22/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-109581	Apoptosis	4/34	161/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-69202	Cyclin E associated events during G1/S transition	3/34	80/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	3/34	82/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1855204	Synthesis of IP3 and IP4 in the cytosol	2/34	26/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5683057	MAPK family signaling cascades	5/34	278/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-5357801	Programmed Cell Death	4/34	173/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	3/34	108/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-397795	G-protein beta:gamma signalling	2/34	37/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-1483257	Phospholipid metabolism	4/34	182/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-109704	PI3K Cascade	2/34	42/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	3/34	118/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	3/34	103/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-112399	IRS-mediated signalling	2/34	34/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-186712	Regulation of beta-cell development	2/34	34/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-451927	Interleukin-2 family signaling	2/34	36/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-74751	Insulin receptor signalling cascade	2/34	39/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-109582	Hemostasis	6/34	470/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	2/34	43/8290
	qUC_CD66a+_vs_qUC_CD44+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	2/34	43/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	33/337	87/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	57/337	356/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-449147	Signaling by Interleukins	56/337	376/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	59/337	439/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-2559583	Cellular Senescence	29/337	123/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	24/337	83/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-8939211	ESR-mediated signaling	29/337	134/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	11/337	17/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	11/337	17/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-1257604	PIP3 activates AKT signaling	35/337	237/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	12/337	25/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-8848021	Signaling by PTK6	16/337	50/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	16/337	50/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-166520	Signaling by NTRKs	24/337	125/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	12/337	27/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9006931	Signaling by Nuclear Receptors	32/337	219/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-69231	Cyclin D associated events in G1	15/337	47/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-69236	G1 Phase	15/337	47/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9614085	FOXO-mediated transcription	16/337	55/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9006925	Intracellular signaling by second messengers	36/337	273/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-8878159	Transcriptional regulation by RUNX3	20/337	90/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9675126	Diseases of mitotic cell cycle	13/337	36/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	13/337	36/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-157118	Signaling by NOTCH	27/337	188/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-8878166	Transcriptional regulation by RUNX2	21/337	105/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9009391	Extra-nuclear estrogen signaling	17/337	68/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-2559585	Oncogene Induced Senescence	12/337	33/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-186763	Downstream signal transduction	11/337	29/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	10/337	23/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-187037	Signaling by NTRK1 (TRKA)	20/337	108/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-194138	Signaling by VEGF	19/337	99/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-453279	Mitotic G1 phase and G1/S transition	18/337	94/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	18/337	94/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-9006936	Signaling by TGFB family members	23/337	140/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	13/337	49/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-186797	Signaling by PDGF	13/337	50/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-109606	Intrinsic Pathway for Apoptosis	13/337	51/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	13/337	51/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	11/337	36/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-199418	Negative regulation of the PI3K/AKT network	19/337	91/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	15/337	72/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-8854116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	7/337	13/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-1912422	Pre-NOTCH Expression and Processing	12/337	49/8290
	HC_CD66a+_vs_HC_CD44+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	10/337	33/8290

Comparison	Pathway ID	Pathway Name	Ratio1	Ratio2	p-value	FDR1	FDR2
HC_CD66a+_vs_HC_CD44+	R-HSA-1433557	Signaling by SCF-KIT	11/337	41/8290	4.496597654520252e-7	9.878833072656604e-6	5.995779559373609e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-8953897	Cellular responses to external stimuli	44/337	490/8290	4.505123197407164e-7	9.878833072656604e-6	5.995779559373609e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	9/337	26/8290	4.616967379951046e-7	9.878833072656604e-6	5.995779559373609e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-198323	AKT phosphorylates targets in the cytosol	7/337	14/8290	4.626185243780653e-7	9.878833072656604e-6	5.995779559373609e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-9669938	Signaling by KIT in disease	11/337	20/8290	5.636486288263594e-7	1.155479689090430868e-5	7.012975571292178e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	8/337	20/8290	5.636486288263594e-7	1.155479689090430868e-5	7.012975571292178e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-186712	Regulation of beta-cell development	10/337	34/8290	5.917235769384406e-7	1.189248654514933e-5	7.217928461472587e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-2262752	Cellular responses to stress	43/337	479/8290	6.226584980624139e-7	1.227355693296104.3e-5	7.449214015281106e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-6804757	Regulation of TP53 Degradation	10/337	35/8290	7.988288878748103e-7	1.544904924663548e-5	9.376521802065796e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	7/337	15/8290	8.372725696892566e-7	1.588256956361077.4e-5	9.639639139506e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-5683057	MAPK family signaling cascades	30/337	278/8290	8.522354399986274e-7	1.588256956361077.4e-5	9.639639139506e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-2559580	Oxidative Stress Induced Senescence	13/337	62/8290	8.989525830945083e-7	1.645404281556.9123e-5	9.986484522728256e-6
HC_CD66a+_vs_HC_CD44+	R-HSA-8941326	RUNX2 regulates bone development	9/337	28/8290	9.490683732373161e-7	1.706658039593419.3e-5	1.035825315943.2202e-5
HC_CD66a+_vs_HC_CD44+	R-HSA-69242	S Phase	21/337	156/8290	1.197764818513012.6e-6	2.116739549958341.3e-5	1.284716892452251.3e-5

	Comparison	Pathway ID	Pathway name					
1	HC_CD66a-_vs_HC_CD44+	R-HSA-9013508	NOTCH3 Intracellular Domain Regulates Transcription	5/337	23/290	0.001979439514306484	0.008705121397091994	0.005283416426887157
	HC_CD66a-_vs_HC_CD44+	R-HSA-174824	Plasma lipoprotein assembly, remodeling, and clearance	8/337	57/290	0.001987315518945897	0.008705121397091994	0.005283416426887157
2	HC_CD66a-_vs_HC_CD44+	R-HSA-3928665	EPH-ephrin mediated repulsion of cells	7/337	45/290	0.002062323379064365	0.008995240270387124	0.005459498844460609
	HC_CD66a-_vs_HC_CD44+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	8/337	58/290	0.002225587810846803	0.009625432515265571	0.005841982661383347
3	HC_CD66a-_vs_HC_CD44+	R-HSA-5619507	Activation of HOX genes during differentiation	8/337	58/290	0.002225587810846803	0.009625432515265571	0.005841982661383347
	HC_CD66a-_vs_HC_CD44+	R-HSA-210744	Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	4/337	15/290	0.002564005255245086	0.010905001604257817	0.006618594041711291
4	HC_CD66a-_vs_HC_CD44+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	4/337	15/290	0.002564005255245086	0.010905001604257817	0.006618594041711291
	HC_CD66a-_vs_HC_CD44+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	4/337	15/290	0.002564005255245086	0.010905001604257817	0.006618594041711291
5	HC_CD66a-_vs_HC_CD44+	R-HSA-937072	TRAF6-mediated induction of TAK1 complex within TLR4 complex	4/337	15/290	0.002564005255245086	0.010905001604257817	0.006618594041711291
	HC_CD66a-_vs_HC_CD44+	R-HSA-5673000	RAF activation	6/337	35/290	0.002579457574069553	0.010925388448521195	0.006630967491497685
6	HC_CD66a-_vs_HC_CD44+	R-HSA-6807070	PTEN Regulation	13/337	132/290	0.002686547446486629	0.011332144576801202	0.006877840769183836
	HC_CD66a-_vs_HC_CD44+	R-HSA-74752	Signaling by Insulin receptor	8/337	60/290	0.002769102480372037	0.011632500173693867	0.007060136177307395
7	HC_CD66a-_vs_HC_CD44+	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	5/337	25/290	0.002923724650799865	0.012231909253346374	0.007423936707294178
	HC_CD66a-_vs_HC_CD44+	R-HSA-111465	Apoptotic cleavage of cellular proteins	6/337	36/290	0.002991524941910109	0.012414222937076363	0.007534588709434794
8	HC_CD66a-_vs_HC_CD44+	R-HSA-8875878	MET promotes cell motility	6/337	36/290	0.002991524941910109	0.012414222937076363	0.007534588709434794
	HC_CD66a-_vs_HC_CD44+	R-HSA-177929	Signaling by EGFR	7/337	48/290	0.003015208254693941	0.012462050246214877	0.007563616632105768
9	HC_CD66a-_vs_HC_CD44+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	4/337	16/290	0.003310377879876640427	0.013572549712932574	0.008237614254524418
	HC_CD66a-_vs_HC_CD44+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/337	16/290	0.003310377879876640427	0.013572549712932574	0.008237614254524418
10	HC_CD66a-_vs_HC_CD44+	R-HSA-69615	G1/S DNA Damage Checkpoints	8/337	62/290	0.003411059993178197	0.013929611127502529	0.008454326240169907
	HC_CD66a-_vs_HC_CD44+	R-HSA-1251985	Nuclear signaling by ERBB4	5/337	26/290	0.003502180630256394	0.014129183645719007	0.008575453180611139
11	HC_CD66a-_vs_HC_CD44+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	5/337	26/290	0.003502180630256394	0.014129183645719007	0.008575453180611139
	HC_CD66a-_vs_HC_CD44+	R-HSA-8863795	Downregulation of ERBB2 signaling	5/337	26/290	0.003502180630256394	0.014129183645719007	0.008575453180611139
12	HC_CD66a-_vs_HC_CD44+	R-HSA-1632852	Macroautophagy	12/337	122/290	0.003907747554472248	0.015707612718957067	0.009533452238155207
	HC_CD66a-_vs_HC_CD44+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	6/337	38/290	0.003960675611904667	0.015858173836727657	0.009624832593074251
13	HC_CD66a-_vs_HC_CD44+	R-HSA-5626467	RHO GTPases activate IQGAPs	5/337	27/290	0.004156420150406269	0.016400076559219077	0.009953730676763516
	HC_CD66a-_vs_HC_CD44+	R-HSA-1474165	Reproduction	8/337	64/290	0.004162847184778876	0.016400076559219077	0.009953730676763516
14	HC_CD66a-_vs_HC_CD44+	R-HSA-1592389	Activation of Matrix Metalloproteinases	4/337	17/290	0.004192019569283315	0.016400076559219077	0.009953730676763516
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654708	Downstream signaling of activated FGFR3	4/337	17/290	0.004192019569283315	0.016400076559219077	0.009953730676763516
15	HC_CD66a-_vs_HC_CD44+	R-HSA-5689901	Metalloprotease DUBs	4/337	17/290	0.004192019569283315	0.016400076559219077	0.009953730676763516
	HC_CD66a-_vs_HC_CD44+	R-HSA-8854691	Interleukin-20 family signaling	4/337	17/290	0.004192019569283315	0.016400076559219077	0.009953730676763516
16	HC_CD66a-_vs_HC_CD44+	R-HSA-373760	L1CAM interactions	10/337	94/290	0.004691920817957	0.018286035887391895	0.011109837667594208
	HC_CD66a-_vs_HC_CD44+	R-HSA-350054	Notch-HLH transcription pathway	5/337	28/290	0.004894606903416929	0.019003682106069052	0.011533942104941805
17	HC_CD66a-_vs_HC_CD44+	R-HSA-1368082	RORA activates gene expression	4/337	18/290	0.005219492604529575	0.019888401188263026	0.012070906395135906
	HC_CD66a-_vs_HC_CD44+	R-HSA-1912420	Pre-NOTCH Processing in Golgi	4/337	18/290	0.005219492604529575	0.019888401188263026	0.012070906395135906
18	HC_CD66a-_vs_HC_CD44+	R-HSA-3232118	SUMOylation of transcription factors	4/337	18/290	0.005219492604529575	0.019888401188263026	0.012070906395135906
	HC_CD66a-_vs_HC_CD44+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	4/337	18/290	0.005219492604529575	0.019888401188263026	0.012070906395135906
19	HC_CD66a-_vs_HC_CD44+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	4/337	18/290	0.005219492604529575	0.019888401188263026	0.012070906395135906
	HC_CD66a-_vs_HC_CD44+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	7/337	53/290	0.005309021499920172	0.020154618657104356	0.012232482286366776
20	HC_CD66a-_vs_HC_CD44+	R-HSA-438064	Post NMDA receptor activation events	8/337	67/290	0.005522426559468864	0.020887414293194042	0.012677293818029708
	HC_CD66a-_vs_HC_CD44+	R-HSA-2122948	Activated NOTCH1 Transmits Signal to the Nucleus	5/337	29/290	0.005721211964873259	0.021402344029179163	0.012989766697042243
21	HC_CD66a-_vs_HC_CD44+	R-HSA-5357956	TNFR1-induced NFkappaB signaling pathway	5/337	29/290	0.005721211964873259	0.021402344029179163	0.012989766697042243
	HC_CD66a-_vs_HC_CD44+	R-HSA-6804758	Regulation of TP53 Activity through Acetylation	5/337	29/290	0.005721211964873259	0.021402344029179163	0.012989766697042243
22	HC_CD66a-_vs_HC_CD44+	R-HSA-1442490	Collagen degradation	6/337	41/8290	0.005825298057228287	0.021712332003169507	0.013177908306929829
	HC_CD66a-_vs_HC_CD44+	R-HSA-3000178	ECM proteoglycans	7/337	54/8290	0.005892586095622074	0.021883698362364583	0.013281961600788957
23	HC_CD66a-_vs_HC_CD44+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	4/337	19/8290	0.006402825548458973	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-389513	CTLA4 inhibitory signaling	4/337	19/8290	0.006402825548458973	0.022739328491637	0.013801225302783124
24	HC_CD66a-_vs_HC_CD44+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	4/337	19/8290	0.006402825548458973	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-6783589	Interleukin-6 family signaling	4/337	19/8290	0.006402825548458973	0.022739328491637	0.013801225302783124
25	HC_CD66a-_vs_HC_CD44+	R-HSA-1059683	Interleukin-6 signaling	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-170968	Frs2-mediated activation	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
26	HC_CD66a-_vs_HC_CD44+	R-HSA-351906	Apoptotic cleavage of cell adhesion proteins	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-430116	GP1b-IX-V activation signalling	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
27	HC_CD66a-_vs_HC_CD44+	R-HSA-6803207	TP53 Regulates Transcription of Caspase Activators and Caspases	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-75205	Dissolution of Fibrin Clot	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
28	HC_CD66a-_vs_HC_CD44+	R-HSA-8875555	MET activates RAP1 and RAC1	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-9020558	Interleukin-23 signaling	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
29	HC_CD66a-_vs_HC_CD44+	R-HSA-9020956	Interleukin-27 signaling	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
30	HC_CD66a-_vs_HC_CD44+	R-HSA-937042	IRAK2 mediated activation of TAK1 complex	3/337	10/8290	0.006455750820565812	0.022739328491637	0.013801225302783124
	HC_CD66a-_vs_HC_CD44+	R-HSA-5675221	Negative regulation of MAPK pathway	6/337	42/8290	0.006569319170140329	0.023060110100668375	0.013995917914754658
31	HC_CD66a-_vs_HC_CD44+	R-HSA-9663891	Selective autophagy	8/337	69/8290	0.006601245062553618	0.023093092795568572	0.014015660165553044
	HC_CD66a-_vs_HC_CD44+	R-HSA-1474228	Degradation of the extracellular matrix	10/337	99/8290	0.006765449560335075	0.023587026526799088	0.014315720337121479
32	HC_CD66a-_vs_HC_CD44+	R-HSA-8986944	Transcriptional Regulation by MECP2	7/337	56/8290	0.007201817856054676	0.025023651045041186	0.015187419635783456
	HC_CD66a-_vs_HC_CD44+	R-HSA-75893	TNF signaling	6/337	43/8290	0.007380032186557426	0.025469808051250466	0.015458440624687061
33	HC_CD66a-_vs_HC_CD44+	R-HSA-977225	Amyloid fiber formation	6/337	43/8290	0.007380032186557426	0.025469808051250466	0.015458440624687061
	HC_CD66a-_vs_HC_CD44+	R-HSA-1266695	Interleukin-7 signaling	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450
34	HC_CD66a-_vs_HC_CD44+	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450
	HC_CD66a-_vs_HC_CD44+	R-HSA-5625900	RHO GTPases activate CIT	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450
35	HC_CD66a-_vs_HC_CD44+	R-HSA-5627117	RHO GTPases Activate ROCKs	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654687	Downstream signaling of activated FGFR1	4/337	20/8290	0.007751458129686459	0.026308756897114635	0.015967625495450
36	HC_CD66a-_vs_HC_CD44+	R-HSA-1592230	Mitochondrial biogenesis	8/337	72/8290	0.008509380854046554	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-190873	Gap junction degradation	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
37	HC_CD66a-_vs_HC_CD44+	R-HSA-2868552	Signaling by Leptin	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
38	HC_CD66a-_vs_HC_CD44+	R-HSA-5655291	Signaling by FGFR4 in disease	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-68689	CDC6 association with the ORC:origin complex	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
39	HC_CD66a-_vs_HC_CD44+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-8934903	Receptor Mediated Mitophagy	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
40	HC_CD66a-_vs_HC_CD44+	R-HSA-9013700	NOTCH4 Activation and Transmission of Signal to the Nucleus	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-9014325	TICAM1,TRAF6-dependent induction of TAK1 complex	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
41	HC_CD66a-_vs_HC_CD44+	R-HSA-9645460	Alpha-protein kinase 1 signaling pathway	3/337	11/8290	0.008612142124902908	0.028202701846727008	0.017117112122353417
	HC_CD66a-_vs_HC_CD44+	R-HSA-9679506	SARS-CoV Infections	12/337	136/8290	0.009217628782779342	0.029799537601536515	0.018082918445745345
42	HC_CD66a-_vs_HC_CD44+	R-HSA-190236	Signaling by FGFR	8/337	73/8290	0.009229059914702614	0.029799537601536515	0.018082918445745345
	HC_CD66a-_vs_HC_CD44+	R-HSA-2979096	NOTCH2 Activation and Transmission of Signal to the Nucleus	4/337	21/8290	0.009274197555990276	0.029799537601536515	0.018082918445745345
43	HC_CD66a-_vs_HC_CD44+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	4/337	21/8290	0.009274197555990276	0.029799537601536515	0.018082918445745345
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654732	Negative regulation of FGFR3 signaling	4/337	21/8290	0.009274197555990276	0.029799537601536515	0.018082918445745345
44	HC_CD66a-_vs_HC_CD44+	R-HSA-9615017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/337	21/8290	0.009274197555990276	0.029799537601536515	0.018082918445745345
	HC_CD66a-_vs_HC_CD44+	R-HSA-9612973	Autophagy	12/337	137/8290	0.009745669967625532	0.031216599115050533	0.018946351812061477
45	HC_CD66a-_vs_HC_CD44+	R-HSA-201681	TCF dependent signaling in response to WNT	13/337	154/8290	0.009822253150566549	0.031306383610900044	0.019057147047872006
	HC_CD66a-_vs_HC_CD44+	R-HSA-204998	Cell death signalling via NRAGE, NRIF and NADE	8/337	74/8290	0.009989197226895796	0.031810643346648507	0.019306886244182 46
46	HC_CD66a-_vs_HC_CD44+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	7/337	60/8290	0.010449692334322516	0.033058440255518697	0.020064224072724516
	HC_CD66a-_vs_HC_CD44+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	7/337	60/8290	0.010449692334322516	0.033058440255518697	0.020064224072724516
47	HC_CD66a-_vs_HC_CD44+	R-HSA-198753	ERK/MAPK targets	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-201451	Signaling by BMP	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
48	HC_CD66a-_vs_HC_CD44+	R-HSA-3000171	Syndecan interactions	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
49	HC_CD66a-_vs_HC_CD44+	R-HSA-5654726	Negative regulation of FGFR1 signaling	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-933542	TRAF6 mediated NF-kB activation	4/337	22/8290	0.010979184467144949	0.033391634250987914	0.020266450159007812
50	HC_CD66a-_vs_HC_CD44+	R-HSA-1250347	SHC1 events in ERBB4 signaling	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-1474151	Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
51	HC_CD66a-_vs_HC_CD44+	R-HSA-1502540	Signaling by Activin	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-162594	Early Phase of HIV Life Cycle	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
52	HC_CD66a-_vs_HC_CD44+	R-HSA-169893	Prolonged ERK activation events	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-209560	NF-kB is activated and signals survival	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
53	HC_CD66a-_vs_HC_CD44+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-391160	Signal regulatory protein family interactions	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
54	HC_CD66a-_vs_HC_CD44+	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
55	HC_CD66a-_vs_HC_CD44+	R-HSA-68884	Mitotic Telophase/Cytokinesis	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
	HC_CD66a-_vs_HC_CD44+	R-HSA-8984722	Interleukin-35 Signalling	3/337	12/8290	0.011141403818378408	0.033391634250987914	0.020266450159007812
56	HC_CD66a-_vs_HC_CD44+	R-HSA-936440	Negative regulators of DDX58/IFIH1 signaling	5/337	34/8290	0.011361599023786565	0.033853601742387295	0.020546832995893084
	HC_CD66a-_vs_HC_CD44+	R-HSA-9664323	FCGR3A-mediated IL10 synthesis	5/337	34/8290	0.011361599023786565	0.033853601742387295	0.020546832995893084
57	HC_CD66a-_vs_HC_CD44+	R-HSA-76002	Platelet activation, signaling and aggregation	16/337	211/8290	0.012002026660081047	0.035656819516832 8	0.021642098418120 48
	HC_CD66a-_vs_HC_CD44+	R-HSA-388841	Costimulation by the CD28 family	7/337	62/8290	0.012286454707621	0.036801836614749546	0.022336212191339843
58	HC_CD66a-_vs_HC_CD44+	R-HSA-442755	Activation of NMDA receptors and postsynaptic events	8/337	77/8290	0.012568134235547888	0.037124892194341744	0.022532283734897015
	HC_CD66a-_vs_HC_CD44+	R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	5/337	35/8290	0.012825289265440603	0.037702040872824 86	0.022882537715881382
59	HC_CD66a-_vs_HC_CD44+	R-HSA-1839124	FGFR1 mutant receptor activation	4/337	23/8290	0.012873867615511093	0.037702040872824 86	0.022882537715881382
	HC_CD66a-_vs_HC_CD44+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	4/337	23/8290	0.012873867615511093	0.037702040872824 86	0.022882537715881382
60	HC_CD66a-_vs_HC_CD44+	R-HSA-193704	p75 NTR receptor-mediated signalling	9/337	93/8290	0.013013368874636378	0.038002003123938144	0.023064630394092366
	HC_CD66a-_vs_HC_CD44+	R-HSA-212300	PRC2 methylates histones and DNA	3/337	13/8290	0.014054057342365188	0.040464631393045 84	0.024559278260202916
	HC_CD66a-_vs_HC_CD44+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	3/337	13/8290	0.014054057342365188	0.040464631393045 84	0.024559278260202916
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/337	13/8290	0.014054057342365188	0.040464631393045 84	0.024559278260202916
	HC_CD66a-_vs_HC_CD44+	R-HSA-6785631	ERBB2 Regulates Cell Motility	3/337	13/8290	0.014054057342365188	0.040464631393045 84	0.024559278260202916
	HC_CD66a-_vs_HC_CD44+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	5/337	36/8290	0.014411380285324796	0.041373721330380369	0.025113710730637903
	HC_CD66a-_vs_HC_CD44+	R-HSA-451927	Interleukin-2 family signaling	4/337	24/8290	0.014964988631415125	0.042608641666529175	0.025860546572445433
	HC_CD66a-_vs_HC_CD44+	R-HSA-3928663	EPHA-mediated growth cone collapse	4/337	24/8290	0.014964988631415125	0.042608641666529175	0.025860546572445433
	HC_CD66a-_vs_HC_CD44+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signalling pathway	4/337	24/8290	0.014964988631415125	0.042608641666529175	0.025860546572445433
	HC_CD66a-_vs_HC_CD44+	R-HSA-5607764	CLEC7A (Dectin-1) signaling	9/337	96/8290	0.015780091147211427	0.044827705334880009	0.027207367242430404
	HC_CD66a-_vs_HC_CD44+	R-HSA-8939902	Regulation of RUNX2 expression and activity	7/337	65/8290	0.015866410744460317	0.044925610533347586	0.027266789037441255
	HC_CD66a-_vs_HC_CD44+	R-HSA-5205647	Mitophagy	4/337	25/8290	0.017258559996677038	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-8874081	MET activates PTK2 signaling	4/337	25/8290	0.017258559996677038	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-9648002	RAS processing	4/337	25/8290	0.017258559996677038	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-1963642	PI3K events in ERBB2 signaling	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-844456	The NLRP3 inflammasome	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-877312	Regulation of IFNG signaling	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-8963898	Plasma lipoprotein assembly	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-8983432	Interleukin-15 signaling	3/337	14/8290	0.017357380793256987	0.047950527798081966	0.029105439207873115
	HC_CD66a-_vs_HC_CD44+	R-HSA-194315	Signaling by Rho GTPases	24/337	375/8290	0.018103028080909093	0.049937802239984 06	0.030308803018054 51
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	31/157	356/8290	0.7356570576400664e-13	4.019267214697249 44e-10	2.375190282845213e-10
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9614085	FOXO-mediated transcription	13/157	58/8290	1.787850135449444e-11	7.135522004432815e-9	4.215562424638689e-9
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006925	Intracellular signaling by second messengers	25/157	273/8290	4.054016353106329e-11	7.832749992628553e-9	6.373572372602e3e-9
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	31/157	439/8290	1.201363532575628e-10	2.396720247488379e-8	1.416344375247057e-8
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	14/157	83/8290	3.655206364310517e-10	5.833709357439584e-8	3.447436739391814e-8
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1257604	PIP3 activates AKT signaling	22/157	237/8290	5.215997738755501e-10	6.937276992544164e-8	4.099591205196921e-8
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	7/157	15/8290	4.330023746283264e-9	4.534195455440286e-7	2.679609502754733e-7
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006931	Signaling by Nuclear Receptors	20/157	219/8290	4.545683754931537e-9	4.534195455440286e-7	2.679609502754733e-7
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	13/157	87/8290	7.480951234601875e-9	6.631110094680033e-7	3.920646030394080e-7
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8848021	Signaling by PTK6	10/157	50/8290	2.387361411827940 8e-8	1.731922187853360 7e-6	1.023481255597982 54e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	10/157	50/8290	2.387361411827940 8e-8	1.731922187853360 7e-6	1.023481255597982 54e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559585	Cellular Senescence	14/157	123/8290	6.946696369491732e-8	4.619535310262002e-6	2.729919096923067 3e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	7/157	23/8290	1.452748994558497 7e-7	8.976438281360 1e-6	5.269891089572526e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8939211	ESR-mediated signaling	15/157	154/8290	1.880611264494218e-7	1.071948420736170 5e-6	6.334690574987526 5e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	7/157	25/8290	2.759196068610123 4e-7	1.467892308443661 7e-5	8.647251837852586e-6
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9669787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	6/157	17/8290	4.368265958332704 7e-7	2.056015432020558 7e-5	1.211754272032849 02e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	6/157	17/8290	4.368265958332704 7e-7	2.056015432020558 7e-5	1.211754272032849 02e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9009391	Extra-nuclear estrogen signaling	10/157	68/8290	5.044265714494682e-7	2.236291133425976e-5	1.321538619937788e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-449147	Signaling by Interleukins	24/157	454/8290	5.475607581440836e-7	2.301393184082872e-5	1.360010745977216e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69473	G2/M DNA damage checkpoint	9/157	52/8290	1.003630181304960 3a-6	4.112166234607029e-5	2.427841906129591e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3700989	Transcriptional Regulation by TP53	21/157	343/8290	1.771050618230024e-6	6.729992349274161e-5	3.977096125148165e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-76002	Platelet activation, signaling and aggregation	16/157	211/8290	2.182883050523599 7e-6	7.733041927290092e-5	4.569849338381 e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69231	Cyclin D associated events in G1	8/157	47/8290	2.325726895425519e-6	7.733041927290092e-5	4.569849338381301e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69236	G1 Phase	8/157	47/8290	2.325726895425519e-6	7.733041927290092e-5	4.569849338381301 e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6804757	Regulation of TP53 Degradation	7/157	35/8290	3.291924563093005e-6	1.053572320539272e-4	6.226987618811185959e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	7/157	36/8290	4.022063280441036e-6	1.106760861307567 9e-4	6.540415062205388e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	7/157	36/8290	4.022063280441036e-6	1.106760861307567 9e-4	6.540415062205388e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69526	Diseases of mitotic cell cycle	7/157	36/8290	4.022063280441036e-6	1.106760861307567 9e-4	6.540415062205388e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	7/157	36/8290	4.022063280441036e-6	1.106760861307567 9e-4	6.540415062205388e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109606	Intrinsic Pathway for Apoptosis	8/157	54/8290	4.416643704052872e-6	1.174822055276061e-4	6.942632962862059e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5683057	MAPK family signaling cascades	18/157	278/8290	4.740390040404064e-6	1.217525348261109e-4	7.194978075928909e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654736	Signaling by FGFR1	7/157	38/8290	5.890388596236377e-6	1.424403605444332e-4	8.417525011527582e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8878159	Transcriptional regulation by RUNX3	10/157	90/8290	6.945166623262095e-6	0.000163007146040117881	9.634544907418065
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109582	Hemostasis	24/157	470/8290	7.420053024386324e-6	1.691772135160081e-4	9.997144597067883 5e-5
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-199418	Negative regulation of the PI3K/AKT network	7/157	39/8290	7.677087899502518e-6	1.701754484409675e-4	1.005483639169057 5 4e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	6/157	21/8290	8.930988429812636e-6	1.926179709974268e-4	1.138277944966 1618e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-114452	Activation of BH3-only proteins	6/157	21/8290	1.388972197677159e-5	2.842050804477879e-4	1.679512940701056e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-186763	Downstream signal transduction	6/157	27/8290	1.388972197677159e-5	2.842050804477879e-4	1.679512940701056e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802957	Oncogenic MAPK signaling	9/157	78/8290	1.482290114462043 42e-5	2.969138383525294 8e-4	1.754615749451493e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-453279	Mitotic G1 phase and G1/S transition	12/157	146/8290	1.931013690374236 23e-5	3.758412011997630 4e-4	2.221037569184080 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166520	Signaling by NTRKs	11/157	126/8290	2.291071062559388 6e-5	3.315333670361453 4e-4	2.550152806207085 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654704	SHC-mediated cascade:FGFR3	4/157	10/8290	2.379838645136641e-5	4.315336701861453 4e-4	2.550152806207085 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9617629	Regulation of FOXO transcriptional activity by acetylation	4/157	10/8290	2.379838645136641e-5	4.315336701861453 4e-4	2.550152806207085 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654741	Signaling by FGFR3	6/157	32/8290	2.528153801857925 7e-5	4.414088351338559 e-4	2.605510983902384 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1227986	Signaling by ERBB2	7/157	42/8290	2.544461956811951 95e-5	4.414088351338559 e-4	2.605510983902384 e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8878166	Transcriptional regulation by RUNX2	10/157	105/8290	2.746431964371680 3e-5	4.663090238954477e-4	2.758283144804338e-4
	aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8878171	Transcriptional regulation by RUNX1	12/157	155/8290	3.514564393582241e-5	5.842963304330476e-4	3.452903569133434e-4

Comparison	Pathway ID	Pathway Name	Ratio	Ratio	p1	p2	p3
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654732	Negative regulation of FGFR3 signaling	5/157	21/8290	3.63987914114247e-5	5.87962340199871e-4	3.47456969277855546e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	4/157	11/8290	3.68397456265583e-5	5.87962340199871e-4	3.47456969277855546e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-186797	Signaling by PDGF	7/157	50/8290	3.85330948909368e-5	6.29296024111e-4	3.56301888774817e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2428928	IRS-related events triggered by IGF1R	6/157	36/8290	5.10449308199511e-5	7.83343361429250e-4	4.62917591241867e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654706	FRS-mediated FGFR3 signaling	4/157	12/8290	5.44458365350161e-5	8.19777349089227e-4	4.84448295469164e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5684996	MAPK1/MAPK3 signaling	15/157	244/8290	5.61619588907982e-5	8.29948948052907e-4	4.90459212145762e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006115	Signaling by NTRK2 (TRKB)	5/157	23/8290	5.83730604157289e-4	8.37060141336078e-4	5.00500116100413e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2428924	IGF1R signaling cascade	6/157	37/8290	5.99796321731011e-5	8.54709758466692e-4	5.05091639352431e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-190236	Signaling by FGFR	8/157	73/8290	6.55370107528021e-5	9.17518150536229e-4	5.42208325341742e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9006936	Signaling by TGFB family members	9/157	94/8290	6.70704830174491e-5	9.22797335309042e-4	5.45328085187245e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	6/157	38/8290	7.01213653437634e-5	9.48421178717392e-4	5.60470502658486e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6804116	TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	4/157	13/8290	7.48796722731041e-5	1.00101369504067855855	5.99044164242192e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	4/157	13/8290	7.48796722731041e-5	1.00101369504066785855	5.99044164242192e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8986944	Transcriptional Regulation by MECP2	7/157	56/8290	8.13521910741155e-5	1.00104708142705073	6.18773881174936e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5688426	Deubiquitination	14/157	224/8290	8.39903560837637e-5	0.0010638778437278339	6.48911448714e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-198323	AKT phosphorylates targets in the cytosol	4/157	14/8290	1.06888349702234056e-4	0.0012730881050408698	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5655332	Signaling by FGFR3 in disease	4/157	14/8290	1.06888349702234056e-4	0.0012730881050408698	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	4/157	14/8290	1.06888349702234056e-4	0.0012730881050408698	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/157	14/8290	1.06888349702234056e-4	0.0012730881050408698	7.52332767739212e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69481	G2/M Checkpoints	10/157	126/8290	1.30552989055298863e-4	0.0015320777245018868	9.05382958154393e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5633007	Regulation of TP53 Activity	11/157	152/8290	1.37909508527528865e-4	0.0015949534464488096	9.42539432804674e-4
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559580	Oxidative Stress Induced Senescence	7/157	62/8290	1.56880507718396e-4	0.0017884377879897214	0.0010568792098923563
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5673001	RAF/MAP kinase cascade	14/157	239/8290	1.67300058415927266e-4	0.0018803584030409853	0.0011131199794964201
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	8/157	84/8290	1.78272144128425e-4	0.0019758495974233872	0.0011676304178832576
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-195721	Signaling by WNT	14/157	241/8290	1.82561979566436e-4	0.0019956775300055022	0.0011793477555265134
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9614657	FOXO-mediated transcription of cell death genes	4/157	16/8290	1.88675056141263e-4	0.0020346310108206	0.0012023673563483128
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-400253	Circadian Clock	7/157	64/8290	1.91993672811148632e-4	0.0020428106787142115	0.0012072023216778337
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-187037	Signaling by NTRK1 (TRKA)	9/157	108/8290	1.96871128382292e-4	0.0020671468480140693	0.0012215826248651934
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69620	Cell Cycle Checkpoints	14/157	244/8290	2.07708642936997583e-4	0.0021483445613417413	0.0012695664997772063
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6791312	TP53 Regulates Transcription of Cell Cycle Genes	6/157	46/8290	2.09988566114618525e-4	0.0021483445613417413	0.0012695664997772063
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1181150	Signaling by NODAL	4/157	17/8290	2.43107761788929e-4	0.0023658553842386017	0.0013981036878233666
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	4/157	17/8290	2.43107761788929e-4	0.0023658553842386017	0.0013981036878233666
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654708	Downstream signaling of activated FGFR3	4/157	17/8290	2.43107761788929e-4	0.0023658553842386017	0.0013981036878233666
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	4/157	17/8290	2.43107761788929e-4	0.0023658553842386017	0.0013981036878233666
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1236394	Signaling by ERBB4	6/157	48/8290	2.66662865448871154e-4	0.0025332972217642787	0.0014970546832217344
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-177929	Signaling by EGFR	6/157	48/8290	2.66662865448871154e-4	0.0025332972217642787	0.0014970546832217344
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9607240	FLT3 Signaling	14/157	252/8290	2.89885987002797e-4	0.0027215178544979	0.0016082838659721751
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-157118	Signaling by NOTCH	11/157	168/8290	3.31603744808284e-4	0.0030769742832571054	0.0018341420000013613
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	5/157	33/8290	3.53375745893366843e-4	0.0031684701710043896	0.0018724108120665682
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559585	Oncogene Induced Senescence	5/157	33/8290	3.53375745893366843e-4	0.0031684701710043896	0.0018724108120665682
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654743	Signaling by FGFR4	5/157	33/8290	3.53375745893366843e-4	0.0031684701710043896	0.0018724108120665682
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5673000	RAF activation	5/157	35/8290	4.68836921689087e-4	0.0040625015641149854	0.0024007396131633493
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/157	20/8290	4.73449430408441e-4	0.0040625015641149854	0.0024007396131633493
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9669938	Signaling by KIT in disease	4/157	20/8290	4.73449430408441e-4	0.0040625015641149854	0.0024007396131633493
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	4/157	20/8290	4.73449430408441e-4	0.0040625015641149854	0.0024007396131633493
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5685896	Ovarian tumor domain proteases	5/157	36/8290	5.36222726667579e-4	0.0044501886796856612	0.0026067173346804
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9611017	FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	4/157	21/8290	5.76284487497832736e-4	0.0048407929248977949	0.0028607173346804
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5693532	DNA Double-Strand Break Repair	9/157	125/8290	5.856388669342704e-4	0.0048681230813911123	0.0028768225042385822
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2262752	Cellular responses to stress	20/157	479/8290	6.821585882977317e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	6/157	57/8290	6.85487029304873e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	5/157	38/8290	6.92531823037203044e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654726	Negative regulation of FGFR1 signaling	4/157	22/8290	6.9403968745589e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654727	Negative regulation of FGFR2 signaling	4/157	22/8290	6.9403968745589e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6654710	PI-3K cascade:FGFR3	3/157	10/8290	7.25223238857785e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8851805	MET activates RAS signaling	3/157	10/8290	7.25223238857785e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8853334	Signaling by FGFR3 fusions in cancer	3/157	10/8290	7.25223238857785e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8875555	MET activates RAP1 and RAC1	3/157	10/8290	7.25223238857785e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9028731	Activated NTRK2 signals through FRS2 and FRS3	3/157	10/8290	7.25223238857785e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69242	S Phase	10/157	156/8290	7.31301241718383e-4	0.0054540036531893438	0.0032230492502689206
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5617472	Activation of anterior HOX genes in hindbrain development during early embryogenesis	6/157	58/8290	7.52792086875117e-4	0.005511266837856362	0.0032568889900536214
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5619507	Activation of HOX genes during differentiation	6/157	58/8290	7.52792086875117e-4	0.005511266837856362	0.0032568889900536214
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5628897	TP53 Regulates Metabolic Genes	7/157	81/8290	8.21711561014663e-4	0.0058985327136834	0.0034857441705977797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	4/157	23/8290	8.27864240516976e-4	0.0058985327136834	0.0034857441705977797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654733	Negative regulation of FGFR4 signaling	4/157	23/8290	8.27864240516976e-4	0.0058985327136834	0.0034857441705977797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6807070	PTEN Regulation	9/157	130/8290	8.68495624052919e-4	0.0061332699882077	0.0036214627487163977
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8953897	Cellular responses to external stimuli	20/157	490/8290	9.05637287621095e-4	0.0063394610133476	0.003746311217490715
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-109581	Apoptosis	10/157	161/8290	9.33549631702876e-4	0.0064780226617295236	0.0038281943707358214
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654688	SHC-mediated cascade:FGFR1	3/157	11/8290	9.83367048194972e-4	0.0067070567563743238	0.0039635486887956634
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654699	SHC-mediated cascade:FGFR2	3/157	11/8290	9.83367048194972e-4	0.0067070567563743238	0.0039635486887956634
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802952	Signaling by BRAF and RAF fusions	6/157	62/8290	0.0010744003766866605	0.0072964888186094714	0.0042941274645675621
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3928662	EPHB-mediated forward signaling	5/157	42/8290	0.0011043951357662285	0.0074059438516608827	0.0043765503832222065
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-354192	Integrin signaling	4/157	25/8290	0.0011483475173732277	0.0076365109905531965	0.0045128042788000053
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1502540	Signaling by Activin	3/157	12/8290	0.0012930072766426115	0.008254558454086432	0.0048780400836706052
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-179812	GRB2 events in EGFR signaling	3/157	12/8290	0.0012930072766426115	0.008254558454086432	0.0048780400836706052
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654719	SHC-mediated cascade:FGFR4	3/157	12/8290	0.0012930072766426115	0.008254558454086432	0.0048780400836706052
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	3/157	12/8290	0.0012930072766426115	0.008254558454086432	0.0048780400836706052
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	3/157	12/8290	0.0012930072766426115	0.008254558454086432	0.0048780400836706052
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	4/157	26/8290	0.0013373211195854121	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	7/157	88/8290	0.0013436285068941208	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	5/157	44/8290	0.0013677372610729666	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802949	Signaling by RAS mutants	5/157	44/8290	0.0013677372610729666	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	5/157	44/8290	0.0013677372610729666	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9649948	Signaling downstream of RAS mutants	5/157	44/8290	0.0013677372610729666	0.0083317124758490963	0.0049236343437458449
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9018519	Estrogen-dependent gene expression	7/157	89/8290	0.0014355662280316847	0.0086786503802279138	0.0051286576577826864
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5357801	Programmed Cell Death	10/157	173/8290	0.0016110336989052435	0.0096556484886385599	0.0057059781415390443
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-180336	SHC1 events in EGFR signaling	3/157	13/8290	0.0016576630694672017	0.0096556484886385599	0.0057059781415390443
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	3/157	13/8290	0.0016576630694672017	0.0096556484886385599	0.0057059781415390443
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654693	FRS-mediated FGFR1 signaling	3/157	13/8290	0.0016576630694672017	0.0096556484886385599	0.0057059781415390443
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/157	13/8290	0.0016576630694672017	0.0096556484886385599	0.0057059781415390443
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8941326	RUNX2 regulates bone development	4/157	27/8290	0.0017784966365846726	0.0102843801159020707	0.0060754782169586067
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-383280	Nuclear Receptor transcription pathway	5/157	47/8290	0.0018458912915478888	0.0105972751845698904	0.0062624710231991199
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	7/157	94/8290	0.0019714006883509105	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-182971	EGFR downregulation	4/157	29/8290	0.0020329841464056794	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3214858	RMTs methylate histone arginines	4/157	29/8290	0.0020329841464056794	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4090294	SUMOylation of intracellular receptors	4/157	29/8290	0.0020329841464056794	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1963640	GRB2 events in ERBB2 signaling	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654712	FRS-mediated FGFR4 signaling	3/157	14/8290	0.0020806016294030996	0.0109954973527956	0.0064978008363373195
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1912422	Pre-NOTCH Expression and Processing	5/157	49/8290	0.0022261530447255243	0.0116109158803331227	0.0068614833087310251
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	5/157	49/8290	0.0022261530447255243	0.0116109158803331227	0.0068614833087310251
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2871796	FCERI mediated MAPK activation	4/157	30/8290	0.0023115784926747832	0.011887768458882	0.0070250809409943165
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5655302	Signaling by FGFR1 in disease	4/157	30/8290	0.0023115784926747832	0.011887768458882	0.0070250809409943165
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	6/157	72/8290	0.0023388216194404693	0.011887768458882	0.0070250809409943165
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6806834	Signaling by MET	6/157	72/8290	0.0023388216194404693	0.011887768458882	0.0070250809409943165
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-114608	Platelet degranulation	7/157	98/8290	0.0025022489282809917	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-111447	Activation of BAD and translocation to mitochondria	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5339716	Misspliced GSK3beta mutants stabilize beta-catenin	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/157	15/8290	0.0025644842237038035	0.0121830290625930638	0.007199573961273836
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-187687	Signaling to ERKs	4/157	31/8290	0.0026153939647325826	0.0122051718354187	0.0072126592563877935
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	4/157	31/8290	0.0026153939647325826	0.0122051718354187	0.0072126592563877935
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5693571	Nonhomologous End-Joining (NHEJ)	4/157	31/8290	0.0026153939647325826	0.0122051718354187	0.0072126592563877935
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-194138	Signaling by VEGF	7/157	99/8290	0.0026507079191376988	0.0122722869533369	0.0072523209995923335
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1226099	Signaling by FGFR in disease	5/157	51/8290	0.0026660533383224945	0.0122722869533369	0.0072523209995923335
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69206	G1/S Transition	8/157	128/8290	0.0029026464458298884	0.01331038612860474	0.0078657868165364657
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-389356	CD28 co-stimulation	4/157	32/8290	0.0029455298109958839	0.0133552999938324735	0.0078923286680811
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-76009	Platelet Aggregation (Plug Formation)	4/157	32/8290	0.0029455298109958839	0.0133552999938324735	0.0078923286680811
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1295596	Spry regulation of FGF signaling	3/157	16/8290	0.0031131959877567007	0.01387894028184272	0.0082017744971185
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-180292	GAB1 signalosome	3/157	16/8290	0.0031131959877567007	0.01387894028184272	0.0082017744971185
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	3/157	16/8290	0.0031131959877567007	0.01387894028184272	0.0082017744971185
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-3108232	SUMO E3 ligases SUMOylate target proteins	5/157	160/8290	0.0032931042498136633	0.0145277723356734	0.0085852024883031916
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-4791275	Signaling by WNT in cancer	4/157	33/8290	0.0030330068302692003	0.0145277723356734	0.0085852024883031916
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	7/157	103/8290	0.0031335158532902	0.0145277723356734	0.0085852024883031916
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-112399	IRS-mediated signalling	4/157	34/8290	0.0036890730417868545	0.0159952439692490083	0.0094524064084205013
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	4/157	34/8290	0.0036890730417868545	0.0159952439692490083	0.0094524064084205013
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-196299	Beta-catenin phosphorylation cascade	3/157	17/8290	0.0037282147597497866	0.0159952439692490083	0.0094524064084205013
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9034015	Signaling by NTRK3 (TRKC)	3/157	17/8290	0.0037282147597497866	0.0159952439692490083	0.0094524064084205013
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	6/157	80/8290	0.0039752556307206177	0.0166960736762659045	0.0098665624679687955
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	6/157	80/8290	0.0039752556307206177	0.0166960736762659045	0.0098665624679687955
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69202	Cyclin E associated events during G1/S transition	6/157	80/8290	0.0039752556307206177	0.0166960736762659045	0.0098665624679687955
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	6/157	80/8290	0.0039752556307206177	0.0166960736762659045	0.0098665624679687955
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-2990846	SUMOylation	6/157	166/8290	0.0040029065723838335	0.01755978557892031	0.0104704078111119673
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-167044	Signaling to RAS	3/157	18/8290	0.0044112261265647141	0.0180563307178790680	0.0106704078111119673
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654696	Downstream signaling of activated FGFR2	3/157	18/8290	0.0044112261265647141	0.0180563307178790680	0.0106704078111119673
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	3/157	18/8290	0.0044112261265647141	0.0180563307178790680	0.0106704078111119673
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	3/157	18/8290	0.0044112261265647141	0.0180563307178790680	0.0106704078111119673
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	6/157	82/8290	0.0044914743706723365	0.0181938911055662265	0.0107518992682929884
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	6/157	82/8290	0.0044914743706723365	0.0181938911055662265	0.0107518992682929884
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5362517	Signaling by Retinoic Acid	4/157	36/8290	0.0045506329615134899	0.01824826666069923	0.0107838326726159939
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8875878	MET promotes cell motility	4/157	36/8290	0.0045506329615134899	0.01824826666069923	0.0107838326726159939
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	6/157	83/8290	0.0047673774003838521	0.018839292683237297	0.0111331000159481712
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	6/157	83/8290	0.0047673774003838521	0.018839292683237297	0.0111331000159481712
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1989781	PPARA activates gene expression	7/157	110/8290	0.0047688435112956557	0.018839292683237297	0.0111331000159481712
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-389513	CTLA4 inhibitory signaling	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654716	Downstream signaling of activated FGFR4	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8876384	Listeria monocytogenes entry into host cells	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9671555	Signaling by PDGFR in disease	3/157	19/8290	0.0051674688128282893	0.019730404194643773	0.0116597033098540124
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-400206	Regulation of lipid metabolism by PPARalpha	7/157	112/8290	0.0052618912237336	0.019995186663879967	0.0118161767912123864
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69563	p53-Dependent G1 DNA Damage Response	5/157	60/8290	0.0053991505211973	0.0203237152779030042	0.0120100269786315153
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69580	p53-Dependent G1/S DNA damage checkpoint	5/157	60/8290	0.0053991505211973	0.0203237152779030042	0.0120100269786315153
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5674135	MAP2K and MAPK activation	4/157	38/8290	0.0055382879815501147	0.0207090479167693506	0.0122616902196303736
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	6/157	86/8290	0.0056700595469272688	0.0211439307685082626	0.0124976693040334
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-450294	MAP kinase activation	5/157	61/8290	0.0057932099547944805	0.0214024660982990197	0.0126474268727006009
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654738	Signaling by FGFR2	5/157	61/8290	0.0057932099547944805	0.0214026092592790197	0.0126474268727006009
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-392451	G beta:gamma signalling through PI3Kgamma	4/157	20/8290	0.0059995846350966614	0.0218478784834441	0.0129110269698982477
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5613921	VEGFR2 mediated cell proliferation	3/157	20/8290	0.0059954516509669614	0.0218478784834441	0.0129110269698982477
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5654687	Downstream signaling of activated FGFR1	3/157	20/8290	0.0059954516509669614	0.0218478784834441	0.0129110269698982477
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-74751	Insulin receptor signalling cascade	4/157	39/8290	0.0060818206888311368	0.0220600423166888951	0.0130366299932041594
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-388841	Costimulation by the CD28 family	5/157	62/8290	0.0062071322822657	0.0223121214149765897	0.0131853537458272088
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-69615	G1/S DNA Damage Checkpoints	4/157	40/8290	0.0066597204546146802	0.0236287324238263625	0.0139634246344824439
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-9656223	Signaling by RAF1 mutants	4/157	40/8290	0.0066597204546146802	0.0236287324236263625	0.0139634246344824439
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	6/157	89/8290	0.0066918456382641472	0.0236287326236325	0.0139634246344824439
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	6/157	89/8290	0.0066918456382641472	0.0236287326236325	0.0139634246344824439
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168188	Toll Like Receptor TLR1:TLR2 Cascade	6/157	89/8290	0.0066918456382641472	0.0236287326236325	0.0139634246344824439
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	3/157	21/8290	0.0069609065908133	0.0242524607969643	0.0143320491916043305
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	6/157	90/8290	0.0070603822738665	0.0246034281857881214	0.0145394220119154415
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	6/157	90/8290	0.0070603822738665	0.0246034281857881214	0.0145394220119154415
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-1433557	Signaling by SCF-KIT	4/157	41/8290	0.0072729082711807	0.0251245922933366	0.0148474044145153733
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	4/157	41/8290	0.0072729082711807	0.0251245922933366	0.0148474044145153733
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-166166	MyD88-independent TLR4 cascade	6/157	92/8290	0.0078412442764827186	0.0265287995569025352	0.0156772222268173797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	6/157	92/8290	0.0078412442764827186	0.0265287995569025352	0.0156772222268173797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-201451	Signaling by BMP	3/157	22/8290	0.0078788540034748506	0.0265287995569025352	0.0156772222268173797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	3/157	22/8290	0.0078788540034748506	0.0265287995569025352	0.0156772222268173797
aUC_CD66a+_vs_qUC_CD66a+	R-HSA-8863678	Neurodegenerative Diseases	3/157	22/8290	0.0078788540034748506	0.0265287995569025352	0.0156772222268173797

Comparison	Reactome ID	Pathway	Ratio1	Ratio2	p1	p2	p3
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5688426	Deubiquitination	29/508	224/8290	9.740456838358562e-5	6.491727998741324e-4	3.956495161587131e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1963640	GRB2 events in ERBB2 signaling	6/508	14/8290	1.010911608642021e-4	6.690863522764e-4	4.058494585490612e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8983432	Interleukin-15 signaling	6/508	14/8290	1.010911608642021e-4	6.690863522764e-4	4.058494585490612e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173788	Downregulation of TGF-beta receptor signaling	8/508	26/8290	1.098662187485619e-4	7.153932519662106e-4	4.360087084032463e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	8/508	26/8290	1.098662187485619e-4	7.153932519662106e-4	4.360087084032463e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4791275	Signaling by WNT in cancer	9/508	33/8290	1.162168094473894...e-4	7.524208291650985e-4	4.585758014864647e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1266695	Interleukin-7 signaling	7/508	20/8290	1.197258515784675...e-4	7.707351695363685e-4	4.697377908820258e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-422475	Axon guidance	50/508	483/8290	5.115587089406411...e-4	9.701469809985672e-4	5.912727500072886e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-140534	Caspase activation via Death Receptors in the presence of ligand	6/508	15/8290	1.598094456539891...e-4	0.001000354154287...	6.096830261648607e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	6/508	15/8290	1.598094456539891...e-4	0.001000354154287...	6.096830261648607e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637810	Constitutive Signaling by EGFRvIII	6/508	15/8290	1.598094456539891...e-4	0.001000354154287...	6.096830261648607e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637812	Signaling by EGFRvIII in Cancer	6/508	15/8290	1.598094456539891...e-4	0.001000354154287...	6.096830261648607e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1059683	Interleukin-6 signaling	5/508	10/8290	1.650021675097696...e-4	0.001010526788046318...	6.158829125826964e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654704	SHC-mediated cascade:FGFR3	5/508	10/8290	1.650021675097696...e-4	0.001010526788046318...	6.158829125826964e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	5/508	10/8290	1.650021675097696...e-4	0.001010526788046318...	6.158829125826964e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9026731	Activated NTRK2 signals through FRS2 and FRS3	5/508	10/8290	1.650021675097696...e-4	0.001010526788046318...	6.158829125826964e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-112409	RAF-independent MAPK1/3 activation	7/508	21/8290	1.701874127764367...e-4	0.001025650737636717	6.251004635013573e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8940973	RUNX2 regulates osteoblast differentiation	7/508	21/8290	1.701874127764367...e-4	0.001025650737636717	6.251004635013573e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8878171	Transcriptional regulation by RUNX1	22/508	155/8290	1.793503791917517...e-4	0.001075153331345263...	6.552706697287006e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5673000	RAF activation	9/508	35/8290	1.906011754141788...e-4	0.001136584903917182	6.927111970731374e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912631	Regulation of signaling by CBL	7/508	22/8290	2.365533059122637...e-4	0.001403219346837423	8.552161404157895e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	9/508	36/8290	2.405463634966843...e-4	0.001419471137589860	8.651228862599458e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1433559	Regulation of KIT signaling	6/508	16/8290	2.425436863194287...e-4	0.001423844541968459	8.677865188194458e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	11/508	52/8290	2.490489687680295...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	10/508	44/8290	2.552946316801059...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802949	Signaling by RAS mutants	10/508	44/8290	2.552946316801059...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	10/508	44/8290	2.552946316801059...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9649948	Signaling downstream of RAS mutants	10/508	44/8290	2.552946316801059...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114452	Activation of BH3-only proteins	8/508	29/8290	2.563605269586908...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4090294	SUMOylation of intracellular receptors	8/508	29/8290	2.563605269586908...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9645723	Diseases of programmed cell death	8/508	29/8290	2.563605269586908...e-4	0.001445057099723714	8.807148765902128e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation	15/508	88/8290	2.598791673140996...e-4	0.001457630091916968	8.883831879012266e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654689	SHC-mediated cascade:FGFR1	5/508	11/8290	2.873105304916013...e-4	0.001587916249010004...	9.677828395508552e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803211	TP53 Regulates Transcription of Death Receptors and Ligands	5/508	11/8290	2.873105304916013...e-4	0.001587916249010004...	9.677828395508552e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2151201	Transcriptional activation of mitochondrial biogenesis	11/508	53/8290	2.972427699705025...e-4	0.001634835234837751...	9.963784215669298e-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9020591	Interleukin-12 signaling	10/508	45/8290	3.105620329840049...e-4	0.001699839533102886...	0.001035596480022050...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654733	Negative regulation of FGFR1 signaling	7/508	23/8290	3.222769212340703...e-4	0.001755479575605852	0.001069907187602581...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	8/508	30/8290	3.310877087998168...e-4	0.001794843895072691...	0.001093898448615864...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	6/508	17/8290	3.555830900949880...e-4	0.001918455433702593	0.001169235624572993...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1592230	Mitochondrial biogenesis	13/508	72/8290	3.706413302086794...e-4	0.001990220981641324	0.001212974370749953
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9031628	NGF-stimulated transcription	9/508	38/8290	3.732018897039731...e-4	0.001994517646389063	0.001215593046900726...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114604	GPVI-mediated activation cascade	8/508	31/8290	4.226578105611282...e-4	0.002237716352176406	0.001363814674786035
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5655253	Signaling by FGFR2 in disease	8/508	31/8290	4.226578105611282...e-4	0.002237716352176406	0.001363814674786035
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357769	Caspase activation via extrinsic apoptotic signaling pathway	7/508	24/8290	4.312273244783702...e-4	0.002266080270580516	0.001381101538633515
aUC_CD66a+_vs_HC_CD66a+	R-HSA-400253	Circadian Clock	12/508	64/8290	4.320153031292068...e-4	0.002266080270580516	0.001381101538633515
aUC_CD66a+_vs_HC_CD66a+	R-HSA-383280	Nuclear Receptor transcription pathway	10/508	47/8290	4.512994784858286...e-4	0.002356324005181769	0.001436102148371106...
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654720	PI-3K cascade:FGFR4	5/508	12/8290	4.678321279243886...e-4	0.002431439453845561	0.001482549098980
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3232118	SUMOylation of transcription factors	6/508	18/8290	5.060051106697276...e-4	0.002617825526889504	0.001595478743568091
aUC_CD66a+_vs_HC_CD66a+	R-HSA-177929	Signaling by EGFR	10/508	48/8290	5.394181526410563...e-4	0.002778003486101044	0.001693101952787239
aUC_CD66a+_vs_HC_CD66a+	R-HSA-400685	Sema4D in semaphorin signaling	7/508	25/8290	5.676899232673013...e-4	0.002910374131501594	0.001773777516853297
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69473	G2/M DNA damage checkpoint	11/508	57/8290	5.759313788981559...e-4	0.002939325460773021	0.001791422401883311
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	18/508	126/8290	6.294527637497668...e-4	0.003198071685150160...	0.001949119721590147197
aUC_CD66a+_vs_HC_CD66a+	R-HSA-195258	RHO GTPase Effectors	29/508	251/8290	6.863012287504706...e-4	0.003471336125778049...	0.002115665442012729
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1236382	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	6/508	19/8290	7.016421141966997...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5637815	Signaling by Ligand-Responsive EGFR Variants in Cancer	6/508	19/8290	7.016421141966997...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-111461	Cytochrome c-mediated apoptotic response	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-354194	GRB2:SOS provides linkage to MAPK signaling for Integrins	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5210891	Uptake and function of anthrax toxins	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357786	TNFR1-induced proapoptotic signaling	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6785631	ERBB2 Regulates Cell Motility	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9027284	Erythropoietin activates RAS	5/508	13/8290	7.221608462209835...e-4	0.003511623342353536	0.002140219178319246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1538133	G0 and Early G1	7/508	26/8290	7.363618144057961...e-4	0.003565337593682716...	0.002172978532802994
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5675221	Negative regulation of MAPK pathway	9/508	42/8290	8.199324335295455...e-4	0.003953121051867979	0.002409297542644488
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1566948	Elastic fibre formation	7/508	27/8290	9.423419521333329...e-4	0.004504951188890574	0.002745619900508400-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2424491	VEGFR2 mediated cell proliferation	7/508	27/8290	9.423419521333329...e-4	0.004504951188890574	0.002745619900508400-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218921	VEGFR2 mediated cell proliferation	6/508	20/8290	9.103483784779264...e-4	0.004527405341792644	0.002759304960607040-7
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	9/508	43/8290	9.817865429742817...e-4	0.004645514880011975	0.002836591221524405
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168928	DDX58/IFIH1-mediated induction of interferon-alpha/beta	11/508	61/8290	0.001045087490716271	0.004835575955135	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654712	Regulation of IFNG signaling	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8849471	PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	5/508	14/8290	0.001067199560308085...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9658195	Leishmania infection	19/508	136/8290	0.001068746159653957...	0.004843557595551735	0.002951989392559836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-201681	TCF dependent signaling in response to WNT	20/508	154/8290	0.001107138454304238	0.004997561229986	0.003049504530343744
aUC_CD66a+_vs_HC_CD66a+	R-HSA-75153	Apoptotic execution phase	9/508	44/8290	0.001168591207135642	0.005254023165415403	0.003202154688621963-54
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5689896	Ovarian tumor domain proteases	8/508	36/8290	0.001236524764130201...	0.005515679361299799...	0.003367656255022549967
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693565	Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	5/508	15/8290	0.001236524764130201...	0.005515679361299799...	0.003360745267235042
aUC_CD66a+_vs_HC_CD66a+	R-HSA-525793	Myogenesis	6/508	21/8290	0.001263373807876372	0.005591416110640195	0.003407784613350646-4
aUC_CD66a+_vs_HC_CD66a+	R-HSA-982772	Growth hormone receptor signaling	6/508	21/8290	0.001263373807876372	0.005591416110640195	0.003407784613350464
aUC_CD66a+_vs_HC_CD66a+	R-HSA-193704	p75 NTR receptor-mediated signaling	14/508	93/8290	0.001477095745287482	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2172127	DAP12 interactions	7/508	29/8290	0.001488538669035744	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-445989	TAK1 activates NFkB by phosphorylation and activation of IKKs complex	7/508	29/8290	0.001488538669035744	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693606	DNA Double Strand Break Response	8/508	37/8290	0.001494633819501886	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8853884	Transcriptional Regulation by VENTX	8/508	37/8290	0.001494633819501886	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8950505	Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	8/508	37/8290	0.001494633819501886	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5339710	Misspliced GSK3beta mutants stabilize beta-catenin	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	5/508	15/8290	0.001508964176351323	0.006429752245450175	0.003918722973953836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-373760	L1CAM interactions	14/508	94/8290	0.001640741964236124	0.006891781863822407	0.004200314862886142
aUC_CD66a+_vs_HC_CD66a+	R-HSA-201451	Signaling by BMP	6/508	22/8290	0.001648431496112618	0.006891781863822407	0.004200314862886142
aUC_CD66a+_vs_HC_CD66a+	R-HSA-933542	TRAF6 mediated NF-kB activation	6/508	22/8290	0.001648431496112618	0.006891781863822407	0.004200314862886142
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	8/508	38/8290	0.001797068233411460	0.007471478252029083	0.004553620786960608
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69620	Cell Cycle Checkpoints	27/508	244/8290	0.001971082787092657	0.008192917344024088	0.004993314235910368
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2682334	EPH-Ephrin signaling	13/508	86/8290	0.002007520996619983	0.008566634285640954	0.005220108244658379355
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1295596	Spry regulation of FGF signaling	5/508	16/8290	0.002101963227786277	0.008566634285640954	0.005221082446583793355
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1362300	Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	5/508	16/8290	0.002101963227786277	0.008566634285640954	0.005221082446583793355
aUC_CD66a+_vs_HC_CD66a+	R-HSA-180292	GAB1 signalosome	5/508	16/8290	0.002101963227786277	0.008566634285640954	0.005221082446583793355
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173791	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	5/508	16/8290	0.002101963227786277	0.008566634285640954	0.005221082446583793355
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2129379	Molecules associated with elastic fibres	6/508	23/8290	0.002116486051952439	0.008594905723520122	0.005238312960123751
aUC_CD66a+_vs_HC_CD66a+	R-HSA-170968	Frs2-mediated activation	4/508	10/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/508	10/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-430116	GP1b-IX-V activation signaling	4/508	10/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5625970	RHO GTPases activate KTN1	4/508	10/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8851805	MET activates RAS signaling	4/508	10/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6804285	Constitutive Signaling by Overexpressed ERBB2	5/508	17/8290	0.002174353845069394	0.008644010198117	0.005268240525819106
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	7/508	31/8290	0.002254433010708386	0.008931022806087531	0.005443164548100765
aUC_CD66a+_vs_HC_CD66a+	R-HSA-194315	Signaling by Rho GTPases	37/508	375/8290	0.002590127965856295	0.010225139321565614	0.006231886835143531
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1643713	Signaling by EGFR in Cancer	6/508	24/8290	0.002678238961110464	0.010498087993039966	0.006399288867195283
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69273	Cyclin A/B1/B2 associated events during G2/M transition	5/508	18/8290	0.002678238961110464	0.010498087993039966	0.006399288867195283
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1181150	Signaling by NODAL	5/508	18/8290	0.002829629611396186	0.010979319471618478	0.006691534884918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1810476	RIP-mediated NFkB activation via ZBP1	5/508	18/8290	0.002829629611396186	0.010979319471618478	0.006691534884918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-196299	Beta-catenin phosphorylation cascade	5/508	18/8290	0.002829629611396186	0.010979319471618478	0.006691534884918216
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69242	S Phase	19/508	156/8290	0.003083607324333264	0.011921865148382907	0.007266003082525100
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3371578	Regulation by c-FLIP	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389359	CD28 dependent Vav1 pathway	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-428540	Activation of RAC1	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5218900	CASP8 activity is inhibited	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69416	Dimerization of procaspase-8	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8847993	ERBB2 Activates PTK6 Signaling	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9614399	Regulation of localization of FOXO transcription factors	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-975110	TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling	4/508	11/8290	0.003252664310542384	0.012243417487855568	0.007461961139065954
aUC_CD66a+_vs_HC_CD66a+	R-HSA-416476	G alpha (q) signalling events	18/508	146/8290	0.003435411004318379	0.012884790327527062	0.007855104980246974
aUC_CD66a+_vs_HC_CD66a+	R-HSA-373752	Netrin-1 signaling	8/508	42/8290	0.003489778863425939	0.013049239116374881	0.007953082975186437
aUC_CD66a+_vs_HC_CD66a+	R-HSA-167044	Signaling to RAS	5/508	19/8290	0.003733202655226096	0.013747111553215363	0.008374737376740431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1913420	Pre-NOTCH Processing in Golgi	5/508	19/8290	0.003733202655226096	0.013747111553215363	0.008374737376740431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	5/508	19/8290	0.003733202655226096	0.013747111553215363	0.008374737376740431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6804760	Regulation of TP53 Activity through Methylation	5/508	19/8290	0.003733202655226096	0.013747111553215363	0.008374737376740431
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69278	Cell Cycle, Mitotic	44/508	477/8290	0.003878140014694365	0.014266015153210427	0.008694466850590646
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802948	Signaling by high-kinase activity BRAF mutants	7/508	34/8290	0.003932668556131278	0.014373269271279802	0.008760035890002401
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9664323	FCGR3A-mediated IL10 synthesis	7/508	34/8290	0.003932668556131278	0.014373269271279802	0.008760035890002401
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6802952	Signaling by BRAF and RAF fusions	10/508	62/8290	0.004105428892037054	0.014956433873562642	0.009115455586990378
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1251940	SHC1 events in ERBB4 signaling	4/508	12/8290	0.004127338529293307	0.014987694497974621	0.009145070191619223
aUC_CD66a+_vs_HC_CD66a+	R-HSA-162594	Early Phase of HIV Life Cycle	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-169893	Prolonged ERK activation events	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-170670	Adenylate cyclase inhibitory pathway	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-179812	GRB2 events in EGFR signaling	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2299718	Condensation of Prophase Chromosomes	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-264870	Caspase-mediated cleavage of cytoskeletal proteins	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-418885	DCC mediated attractive signaling	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5654719	SHC-mediated cascade:FGFR4	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8984722	Interleukin-35 Signalling	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912694	Regulation of IFNA signaling	4/508	12/8290	0.004645080401851393	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-168638	NOD1/2 Signaling Pathway	7/508	35/8290	0.004662036637500082	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8936459	RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	7/508	35/8290	0.004662036637500082	0.016252576954731052	0.009905412256518392
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1362277	Transcription of E2F targets under negative control by DREAM complex	5/508	19/8290	0.004802491023935414	0.016589092469874212	0.010110507418811246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389513	CTLA4 inhibitory signaling	5/508	19/8290	0.004802491023935414	0.016589092469874212	0.010110507418811246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6783589	Interleukin-6 family signaling	5/508	19/8290	0.004802491023935414	0.016589092469874212	0.010110507418811246
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69206	G1/S Transition	16/508	128/8290	0.004930170209323753	0.016987836137660792	0.010347757601786473
aUC_CD66a+_vs_HC_CD66a+	R-HSA-111465	Apoptotic cleavage of cellular proteins	7/508	36/8290	0.005488884331072128	0.018461169536680972	0.011485123482472114
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5689880	Ub-specific processing proteases	18/508	154/8290	0.006051494363289656	0.020584444626063008	0.012545543433546134
aUC_CD66a+_vs_HC_CD66a+	R-HSA-350054	Notch-HLH transcription pathway	6/508	28/8290	0.006060037396358	0.020584444626063008	0.012545543433546134
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1606322	ZBP1(DAI) mediated induction of type I IFNs	5/508	20/8290	0.006066309752631185	0.020584444626063008	0.012545543433546134
aUC_CD66a+_vs_HC_CD66a+	R-HSA-450321	JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	5/508	20/8290	0.006066309752631185	0.020584444626063008	0.012545543433546134
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5627117	RHO GTPases Activate ROCKs	5/508	20/8290	0.006066309752631185	0.020584444626063008	0.012545543433546134
aUC_CD66a+_vs_HC_CD66a+	R-HSA-180336	SHC1 events in EGFR signaling	4/508	13/8290	0.006388602043537899	0.021450154151341075	0.013051764976817455
aUC_CD66a+_vs_HC_CD66a+	R-HSA-202670	ERKs are inactivated	4/508	13/8290	0.006388602043537899	0.021450154151341075	0.013051764976817455
aUC_CD66a+_vs_HC_CD66a+	R-HSA-75035	Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	4/508	13/8290	0.006388602043537899	0.021450154151341075	0.013051764976817455
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9664407	Parasite infection	9/508	56/8290	0.006501785822045976	0.021602707731314405	0.013166147377564935
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9664417	Leishmania phagocytosis	9/508	56/8290	0.006501785822045976	0.021602707731314405	0.013166147377564935
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9664422	FCGR3A-mediated phagocytosis	9/508	56/8290	0.006501785822045976	0.021602707731314405	0.013166147377564935
aUC_CD66a+_vs_HC_CD66a+	R-HSA-114608	Platelet degranulation	13/508	98/8290	0.006501785822058452	0.021749954699920527	0.013250398367768718
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9012852	Signaling by NOTCH3	6/508	29/8290	0.007109601267886812	0.023121336300250157	0.014099253045090811
aUC_CD66a+_vs_HC_CD66a+	R-HSA-438064	Post NMDA receptor activation events	10/508	67/8290	0.007204762993769569	0.023729661666603236	0.014442498989965582
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3214858	RMTs methylate histone arginines	7/508	38/8290	0.007272991052090457	0.023795856889035413	0.014492463200700
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	6/508	29/8290	0.007285517421746649	0.023856911094910272	0.014540004364412541
aUC_CD66a+_vs_HC_CD66a+	R-HSA-2029482	Regulation of actin dynamics for phagocytic cup formation	15/508	121/8290	0.007331491501144261	0.024018761830938	0.014633584934687768718
aUC_CD66a+_vs_HC_CD66a+	R-HSA-446652	Interleukin-1 family signaling	15/508	122/8290	0.007451665560029343	0.024156423458274	0.014722540789746424
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5674135	MAP2K and MAPK activation	7/508	38/8290	0.007465726320167555	0.024208670852572607	0.014771573348713365
aUC_CD66a+_vs_HC_CD66a+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	5/508	21/8290	0.007593477235367106	0.024554245583227944	0.014938734642077737
aUC_CD66a+_vs_HC_CD66a+	R-HSA-416572	Sema4D induced cell migration and growth-cone collapse	5/508	21/8290	0.007593477235367106	0.024554245583227944	0.014938734642077737
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8943724	Regulation of PTEN gene transcription	9/508	58/8290	0.008201888232104175	0.026292892774080314	0.016024958589395273
aUC_CD66a+_vs_HC_CD66a+	R-HSA-198323	AKT phosphorylates targets in the cytosol	4/508	14/8290	0.008517160461972908	0.027182937474406667	0.016567108267023525
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358565	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	4/508	14/8290	0.008517160461972908	0.027182937474406667	0.016567108267023525
aUC_CD66a+_vs_HC_CD66a+	R-HSA-71336	Pentose phosphate pathway	4/508	14/8290	0.008517160461972908	0.027182937474406667	0.016567108267023525
aUC_CD66a+_vs_HC_CD66a+	R-HSA-437239	Recycling pathway of L1	7/508	39/8290	0.008601560024307344	0.027409382482207702	0.016705028357768718
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69202	Cyclin E associated events during G1/S transition	11/508	80/8290	0.009179306820813709	0.029132085792666473	0.017755005019741646

Comparison	Reactome ID	Pathway	Count	BgRatio	pvalue	p.adjust	qvalue
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693532	DNA Double-Strand Break Repair	15/508	125/8290	0.00923497843639423	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3000170	Syndecan interactions	5/508	22/8290	0.00934202009985362	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-450302	activated TAK1 mediates p38 MAPK activation	5/508	22/8290	0.00934202009985362	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8862803	Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models	5/508	22/8290	0.00934202009985362	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8863678	Neurodegenerative Diseases	5/508	22/8290	0.00934202009985362	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-912446	Meiotic recombination	5/508	22/8290	0.00934202009985362	0.02915842637227039	0.017771103916206975
aUC_CD66a+_vs_HC_CD66a+	R-HSA-76005	Response to elevated platelet cytosolic Ca2+	13/508	102/8290	0.00990280094461786	0.03008782646325568	0.018776359139588117
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9656223	Signaling by RAF1 mutants	7/508	40/8290	0.00992485142020152	0.03008782646325568	0.018776359139588117
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5693571	Nonhomologous End-Joining (NHEJ)	6/508	31/8290	0.01018083811182945	0.03151609175055244	0.019200823587454963
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	11/508	82/8290	0.0109932954798926	0.0337800655829681	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-193639	p75NTR signals via NF-kB	4/508	15/8290	0.0110612571326004	0.0337800655829681	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-399954	Sema3A PAK dependent Axon repulsion	4/508	15/8290	0.0110612571326004	0.0337800655829681	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-432142	Platelet sensitization by LDL	4/508	15/8290	0.0110612571326004	0.0337800655829681	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5358508	Mismatch Repair	4/508	15/8290	0.0110612571326004	0.0337800655829681	0.020587841336393433
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian gene expression	5/508	23/8290	0.0113491128909373305	0.0343811361110780655	0.02095417409641112
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5260271	Diseases of Immune System	5/508	23/8290	0.0113491128909373305	0.0343811361110780655	0.02095417409641112
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5602358	Diseases associated with the TLR signaling cascade	5/508	23/8290	0.0113491128909373305	0.0343811361110780655	0.02095417409641112
aUC_CD66a+_vs_HC_CD66a+	R-HSA-1980143	Signaling by NOTCH1	10/508	72/8290	0.0118640695619117	0.0358460260836478	0.0218469764582836
aUC_CD66a+_vs_HC_CD66a+	R-HSA-76009	Platelet Aggregation (Plug Formation)	6/508	31/8290	0.0118988275602463	0.0358547117706353796	0.0221438082623e-8
aUC_CD66a+_vs_HC_CD66a+	R-HSA-112314	Neurotransmitter receptors and postsynaptic signal transmission	17/508	153/8290	0.0122211427813955	0.036728261990	0.0223846702906
aUC_CD66a+_vs_HC_CD66a+	R-HSA-69615	G1/S DNA Damage Checkpoints	9/508	62/8290	0.0125917899228370	0.0377420581549586	0.0230025457799
aUC_CD66a+_vs_HC_CD66a+	R-HSA-388396	GPCR downstream signaling	42/508	483/8290	0.0127717236745583	0.0381803771062650	0.0232696867949
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5627123	RHO GTPases activate PAKs	5/508	24/8290	0.0136309218198390	0.0406416695312570	0.0247697637501
aUC_CD66a+_vs_HC_CD66a+	R-HSA-983231	Factors involved in megakaryocyte development and platelet production	14/508	119/8290	0.0137629613780570	0.0409276508376	0.024944059970
aUC_CD66a+_vs_HC_CD66a+	R-HSA-4655427	SUMOylation of DNA methylation proteins	4/508	16/8290	0.0140476884359271	0.0416650026123	0.025393451678
aUC_CD66a+_vs_HC_CD66a+	R-HSA-3899300	SUMOylation of transcription cofactors	7/508	43/8290	0.0145506336253799	0.0432279726295	0.026346003060
aUC_CD66a+_vs_HC_CD66a+	R-HSA-75893	TNF signaling	7/508	43/8290	0.0146506336253799	0.0432279726295	0.026346003060
aUC_CD66a+_vs_HC_CD66a+	R-HSA-6807070	PTEN Regulation	15/508	132/8290	0.0148422565868	0.0436786407597	0.0266080
aUC_CD66a+_vs_HC_CD66a+	R-HSA-186712	Regulation of beta-cell development	6/508	34/8290	0.0159280129384	0.0466316244417	0.028420444
aUC_CD66a+_vs_HC_CD66a+	R-HSA-5357905	Regulation of TNFR1 signaling	6/508	34/8290	0.0159280129384	0.0466316244417	0.028420444
aUC_CD66a+_vs_HC_CD66a+	R-HSA-354192	Integrin signaling	5/508	25/8290	0.0162024702420	0.0470702532929	0.028877745
aUC_CD66a+_vs_HC_CD66a+	R-HSA-8874081	MET activates PTK2 signaling	5/508	25/8290	0.0162024702420	0.0470702532929	0.028877745
aUC_CD66a+_vs_HC_CD66a+	R-HSA-9013507	NOTCH3 Activation and Transmission of Signal to the Nucleus	5/508	25/8290	0.0162024702420	0.0470702532929	0.028877745
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers	38/213	356/8290	3.16101475881473e-14	1.52123137704957e-11	1.02206626054681e-11
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling	20/213	87/8290	3.36555614391499e-14	1.52123137704957e-11	1.02206626054681e-11
qUC_CD66a+_vs_HC_CD66a+	R-HSA-449147	Signaling by Interleukins	37/213	376/8290	9.11335293565840e-13	2.64039152208940e-10	1.77399383819933e-10
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	40/213	439/8290	1.16831483278292e-12	2.64039152208940e-10	1.77399383819933e-10
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559583	Cellular Senescence	19/213	123/8290	2.52545505187792e-10	4.22912480825390e-8	2.97161213487826e-8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559585	Oncogene Induced Senescence	11/213	33/8290	2.93556138107557e-10	4.22912480820539e-8	2.97161213487826e-8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006925	Intracellular signaling by second messengers	27/213	273/8290	1.34633866119003e-9	1.70955713163542e-7	1.14859625635030e-7
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1257604	PIP3 activates AKT signaling	25/213	237/8290	1.51288241737648e-9	1.70955713163542e-7	1.14859625635030e-7
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2219528	PI3K/AKT Signaling in Cancer	15/213	83/8290	2.23099030116092e-9	2.24090581361006e-7	1.50559228511098e-7
qUC_CD66a+_vs_HC_CD66a+	R-HSA-109606	Intrinsic Pathway for Apoptosis	12/213	51/8290	3.99300620604022e-9	3.60967610260364e-7	2.42252874516010e-7
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8939211	ESR-mediated signaling	19/213	154/8290	1.21786333910665e-8	1.00086223504765e-6	6.72447030300997e-7
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006931	Signaling by Nuclear Receptors	22/213	219/8290	3.81326487470631e-8	2.87265953894547e-6	1.93004722167153e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2262752	Cellular responses to stress	34/213	479/8290	4.89969534386304e-8	3.40717276219390e-6	2.28916940357002e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-199418	Negative regulation of the PI3K/AKT network	14/213	91/8290	6.64150466319e-8	4.28851443960862e-6	2.88134229068143e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8953897	Cellular responses to external stimuli	34/213	490/8290	8.53592534201428e-8	5.14431767278727e-6	3.45630099813490e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9009391	Extra-nuclear estrogen signaling	12/213	68/8290	1.24666673239045e-7	7.04366698630060e-6	4.73241249545343e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	13/213	84/8290	1.84787159123610e-7	9.82526540280847e-6	6.60127868819033e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2428928	IRS-related events triggered by IGF1R	9/213	36/8290	2.12441052878247e-7	1.06692617667730e-5	7.16833260266998e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2428924	IGF1R signaling cascade	9/213	37/8290	2.74523728394935e-7	1.30615500246853e-5	8.77563386614281e-6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	9/213	38/8290	3.51774750358353e-7	1.59002187161975e-5	1.06828437345668e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5683057	MAPK family signaling cascades	23/213	278/8290	6.45335170041097e-7	2.78014255797308e-5	1.86645811084658e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4420097	VEGFA-VEGFR2 Pathway	13/213	94/8290	7.09029054325686e-7	2.91346841411002e-5	1.95746298730105e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-194138	Signaling by VEGF	13/213	99/8290	1.30021747045240e-6	5.11041997082160e-5	3.43352622632052e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	10/213	57/8290	1.52635018169440e-6	5.74925235104894e-5	3.86273708262179e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9659787	Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	6/213	17/8290	2.61951531121081e-6	9.10785325902233e-5	6.11927260958846e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9661069	Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	6/213	17/8290	2.61951531121081e-6	9.10785325902233e-5	6.11927260958846e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559580	Oxidative Stress Induced Senescence	10/213	62/8290	3.39716491259562e-6	1.02945809842556e-4	6.91660213063757e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-109581	Apoptosis	16/213	161/8290	3.44375669187629e-6	1.02945809842556e-4	6.91660213063757e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-195721	Signaling by WNT	20/213	241/8290	3.45594194034082e-6	1.02945809842556e-4	6.91660213063757e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-166520	Signaling by NTRKs	14/213	125/8290	3.52163982122314e-6	1.02945809842556e-4	6.91660213063757e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-187037	Signaling by NTRK1 (TRKA)	13/213	108/8290	3.53022413773443e-6	1.02945809842556e-4	6.91660213063757e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9616222	Transcriptional regulation of granulopoiesis	7/213	27/8290	3.84067874158191e-6	1.07887451152097e-4	7.24860960814261e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8848021	Signaling by PTK6	9/213	50/8290	4.13650808693101e-6	1.07887451152097e-4	7.24860960814261e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases	9/213	50/8290	4.13650808693101e-6	1.07887451152097e-4	7.24860960814261e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5684996	MAPK1/MAPK3 signaling	20/213	244/8290	4.17705839637544e-6	1.07887451152097e-4	7.24860960814261e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-74751	Insulin receptor signalling cascade	8/213	38/8290	5.16000017213727e-6	1.29573337655802e-4	8.70561432550074e-5
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9607240	FLT3 Signaling	20/213	292/8290	6.81506365906457e-6	1.66508582373202e-4	1.11871741999438e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5357801	Programmed Cell Death	16/213	173/8290	8.75207239034048e-6	2.08207195859055e-4	1.39887694487852e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-389357	CD28 dependent PI3K/Akt signaling	6/213	21/8290	1.05369140018609680e-5	2.44240263017495e-4	1.64097149232760e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8866944	Transcriptional Regulation by MECP2	9/213	58/8290	1.09427006105952125e-5	2.45459653178070e-4	1.64916418122667e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2173793	Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	8/213	43/8290	1.11325727658196040e-5	2.45459653178071260e-4	1.64916418122667e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5673001	RAF/MAP kinase cascade	19/213	239/8290	1.14180003115290099e-5	2.45758863648150013e-4	1.65117448111409e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-170834	Signaling by TGF-beta Receptor Complex	10/213	72/8290	1.35406188175539e-5	2.84667893280069e-4	1.91259160999884e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8878159	Transcriptional regulation by RUNX3	11/213	90/8290	1.74567486560737e-5	3.58658806024743e-4	2.40969951544596e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-74752	Signaling by Insulin receptor	9/213	60/8290	1.95333006527644e-5	3.92034274283538e-4	2.63602425030326374e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-112399	IRS-mediated signalling	7/213	34/8290	1.99643431088677e-5	3.92342742835338766e-4	2.63602425030326374e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69231	Cyclin D associated events in G1	8/213	47/8290	2.10002155744383e-5	4.16217072665192e-4	2.79642816636538e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69236	G1 Phase	8/213	47/8290	2.10002155744383e-5	4.16217072665192e-4	2.79642816636538e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-157118	Signaling by NOTCH	15/213	168/8290	2.58289372602775e-5	4.72827740475324066e-4	3.1767697082279e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006936	Signaling by TGFB family members	11/213	94/8290	2.64774498125554266e-5	4.78712292661100206e-4	3.21631337723041e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559582	Senescence-Associated Secretory Phenotype (SASP)	8/213	49/8290	3.03258775020096e-5	5.37541045203715e-4	3.61156477939338e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-201681	TCF dependent signaling in response to WNT	14/213	154/8290	3.92251566819578e-5	6.81914262317115e-4	4.58156182293736e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1226099	Signaling by FGFR in disease	8/213	51/8290	4.09705445018493e-5	6.98818343490301e-4	4.69513489124488e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1433557	Signaling by SCF-KIT	7/213	41/8290	7.16138963386737e-5	0.0011988696720400587	8.05481836011983e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8878166	Transcriptional regulation by RUNX2	11/213	105/8290	7.46249463568077e-5	0.00120734977178240	8.11179341311655e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-114452	Activation of BH3-only proteins	7/213	29/8290	7.66234779819647e-5	0.00120734977178240	8.11179341311655e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-186763	Downstream signal transduction	6/213	29/8290	7.66234779819647e-5	0.00120734977178240	8.11179341311655e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559584	Formation of Senescence-Associated Heterochromatin Foci (SAHF)	4/213	10/8290	7.87982705034979e-5	0.00120734977178240	8.11179341311655e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8853334	FGFR3 fusions in cancer	4/213	10/8290	7.87982705034979e-5	0.00120734977178240	8.11179341311655e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-109704	PI3K Cascade	9/213	67/8290	9.50165969883436e-5	0.00140811481438470	9.46068893220718e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5655302	Signaling by FGFR1 in disease	6/213	30/8290	9.50165969883436e-5	0.00140811481438470	9.46068893220718e-4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2173796	SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	6/213	31/8290	1.15319807952172e-4	0.00168106425786630	0.00112945281414654
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5218921	VEGFR2 mediated cell proliferation	5/213	20/8290	1.20427006105952124e-4	0.00168106425786630	0.00112945281414654
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9669938	Signaling by KIT in disease	5/213	20/8290	1.20872983143065986e-4	0.00168106425786630	0.00112945281414654
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9670439	Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	5/213	20/8290	1.20872983143065986e-4	0.00168106425786630	0.00112945281414654
qUC_CD66a+_vs_HC_CD66a+	R-HSA-389356	CD28 co-stimulation	6/213	32/8290	1.38920751887934680e-4	0.00190097330075085	0.00127702601925064
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6807070	PTEN Regulation	12/213	132/8290	1.40890722099012670e-4	0.00190097330075085	0.00127702601925064
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1912408	Pre-NOTCH Transcription and Translation	6/213	33/8290	1.66919090809082594e-4	0.00216052079003129043	0.00145158418240341 97
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4791275	Signaling by WNT in cancer	6/213	33/8290	1.66919090809082594e-4	0.00216052079003129043	0.00145158418240341 97
qUC_CD66a+_vs_HC_CD66a+	R-HSA-109582	Hemostasis	26/213	470/8290	1.67296963829856854e-4	0.00216052079003129043	0.00145158418240341 97
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9673767	Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	4/213	12/8290	1.78355252485347760e-4	0.00223934928120492160	0.00150454650122873576
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9673770	Signaling by PDGFRA extracellular domain mutants	4/213	12/8290	1.78355252485347760e-4	0.00223934928120492160	0.00150454650122873576
qUC_CD66a+_vs_HC_CD66a+	R-HSA-198753	ERK/MAPK targets	5/213	22/8290	1.96874580995425266e-4	0.00237299494959819924	0.00159433871206119821
qUC_CD66a+_vs_HC_CD66a+	R-HSA-912526	Interleukin receptor SHC signaling	5/213	22/8290	1.96874580995425266e-4	0.00237299494959819924	0.00159433871206119821
qUC_CD66a+_vs_HC_CD66a+	R-HSA-912631	Regulation of signaling by CBL	5/213	22/8290	1.96874580995425266e-4	0.00237299494959819924	0.00159433871206119821
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3371453	Regulation of HSF1-mediated heat shock response	8/213	65/8290	2.38596795126193280e-4	0.00283804608939577 3	0.00190679156210580217
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9006335	Signaling by Erythropoietin	5/213	23/8290	2.46346480016371e-4	0.00289217166149090 8	0.00194315678700541 9
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3371556	Cellular response to heat stress	9/213	83/8290	2.60580718537233e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-451927	Interleukin-2 family signaling	6/213	36/8290	2.74078246439679 7e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6806003	Regulation of TP53 Expression and Degradation	6/213	36/8290	2.74078246439679 7e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8853659	RET signaling	6/213	36/8290	2.74078246439679 7e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9675126	Diseases of mitotic cell cycle	6/213	36/8290	2.74078246439679 7e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9687139	Aberrant regulation of mitotic cell cycle due to RB1 defects	6/213	36/8290	2.74078246439679 7e-4	0.00298514138290928 3	0.00200562021419872 57
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8853884	Transcriptional Regulation by VENTX	6/213	37/8290	3.20199513035131e-4	0.00344459566640923623	0.00231322770554043 933
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5655332	Signaling by FGFR3 in disease	4/213	14/8290	3.46358834586964 7e-4	0.00359869469709090 12	0.00241801630439508 62
qUC_CD66a+_vs_HC_CD66a+	R-HSA-71336	Pentose phosphate pathway	4/213	14/8290	3.46358834586964 7e-4	0.00359869469709090 12	0.00241801630439508 62
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	4/213	14/8290	3.46358834586964 7e-4	0.00359869469709090 12	0.00241801630439508 62
qUC_CD66a+_vs_HC_CD66a+	R-HSA-453279	Mitotic G1 phase and G1/S transition	12/213	146/8290	3.62637506464503 17e-4	0.00372627620277177 144	0.00250280883676796 453
qUC_CD66a+_vs_HC_CD66a+	R-HSA-210993	Tie2 Signaling	4/213	15/8290	4.62851044148905 2e-4	0.00470131847090573 4	0.00315866413334025 23
qUC_CD66a+_vs_HC_CD66a+	R-HSA-190236	Signaling by FGFR	8/213	73/8290	5.33044514606876 3e-4	0.00535413601338462 4	0.00359727116875049 9
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5689880	Ub-specific processing proteases	12/213	154/8290	5.89050735256599 e-4	0.00585166884254907 5	0.00393154741750113
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5218921	VEGFR2 mediated vascular permeability	5/213	28/8290	6.48073963054721 e-4	0.00629955766229147 16	0.00423246945871236 6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8941284	RUNX2 regulates bone development	5/213	28/8290	6.48073963054721 e-4	0.00629955766229147 16	0.00423246945871236 6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-512988	Interleukin-3, Interleukin-5 and GM-CSF signaling	6/213	43/8290	7.38646066346349 2e-4	0.00710356531980516	0.00477265625175636 6
qUC_CD66a+_vs_HC_CD66a+	R-HSA-111471	Apoptotic factor-mediated response	4/213	17/8290	7.75068121190271 8e-4	0.00714960797506128 2	0.00480365908262812 77
qUC_CD66a+_vs_HC_CD66a+	R-HSA-452723	Transcriptional regulation of pluripotent stem cells	4/213	17/8290	7.75068121190271 8e-4	0.00714960797506128 2	0.00480365908262812 77
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654708	Downstream signaling of activated FGFR3	4/213	17/8290	7.75068121190271 8e-4	0.00714960797506128 2	0.00480365908262812 77
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8934593	Regulation of RUNX1 Expression and Activity	4/213	17/8290	7.75068121190271 8e-4	0.00714960797506128 2	0.00480365908262812 77
qUC_CD66a+_vs_HC_CD66a+	R-HSA-450294	MAP kinase activation	7/213	61/8290	8.99869343168964 1e-4	0.00806697682598 179	0.00541994134675301 8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-450282	MAPK targets/ Nuclear events mediated by MAP kinases	5/213	30/8290	9.01288340070974 2e-4	0.00806697682598 179	0.00541994134675301 8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	5/213	30/8290	9.01288340070974 2e-4	0.00806697682598 179	0.00541994134675301 8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654696	Downstream signaling of activated FGFR2	4/213	18/8290	9.76612633290905e-4	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6803204	TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	4/213	18/8290	9.76612633290905e-4	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade	8/213	80/8290	9.85992443344003e-4	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade	8/213	80/8290	9.85992443344003e-4	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-975871	MyD88 cascade initiated on plasma membrane	8/213	80/8290	9.85992443344003e-4	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-388841	Costimulation by the CD28 family	7/213	62/8290	0.00099086889317469755	0.00863660055549 1974	0.00580343726525939 995
qUC_CD66a+_vs_HC_CD66a+	R-HSA-76002	Platelet activation, signaling and aggregation	14/213	211/8290	0.00105026782397009834	0.00904261254895	0.00586437131556 0396
qUC_CD66a+_vs_HC_CD66a+	R-HSA-187687	Signalling to ERKs	5/213	31/8290	0.00105243613470 92044	0.00872846113391854	0.00586437131556 0396
qUC_CD66a+_vs_HC_CD66a+	R-HSA-202733	Cell surface interactions at the vascular wall	8/213	81/8290	0.00111179027419879 4	0.00912689872614218 4	0.00613430670407380
qUC_CD66a+_vs_HC_CD66a+	R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	8/213	82/8290	0.00116038783799 4753	0.00945036581675363 47	0.00634939675644 97289
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1227986	Signaling by ERBB2	6/213	47/8290	0.00119461126759 724	0.00964221957134 92	0.00647829605623416
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9673155	Signaling by PDGFR in disease	4/213	19/8290	0.00121235538599 7238	0.00968711484800678 5	0.00650842235343000 2
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654741	Signaling by FGFR3	5/213	32/8290	0.00122160565009 4767	0.00968711484808 785	0.00650842235343000 2
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade	8/213	83/8290	0.00125667264069 581	0.00979100005792 1563	0.00657829065966863
qUC_CD66a+_vs_HC_CD66a+	R-HSA-975155	MyD88 dependent cascade initiated on endosome	8/213	83/8290	0.00125667264069 581	0.00979100005792 1563	0.00657829065966863
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3700989	Transcriptional Regulation by TP53	19/213	343/8290	0.00128836017840 075	0.00995432237361 3862	0.00668798814479 2833
qUC_CD66a+_vs_HC_CD66a+	R-HSA-448424	Interleukin-17 signaling	6/213	48/8290	0.00144163752469 7501	0.01101044409511 14873	0.00740320524260 2931
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1250196	SHC1 events in ERBB2 signaling	4/213	20/8290	0.00148442599121 38874	0.01123154255921 1754	0.00754611091839 3934
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1912422	Pre-NOTCH Expression and Processing	6/213	49/8290	0.00149012729098 9054	0.01123154255921 1754	0.00754611091839 3934
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade	8/213	86/8290	0.00158277893134 99862	0.01182505912347 4277	0.00794487554057 3366
qUC_CD66a+_vs_HC_CD66a+	R-HSA-186797	Signaling by PDGF	6/213	50/8290	0.00165855138400 4025	0.01228969349072 7926	0.00825698159027 7304
qUC_CD66a+_vs_HC_CD66a+	R-HSA-170968	Frs2-mediated activation	3/213	10/8290	0.00175610825560 0362	0.01259937986744 0261	0.00846511665521 31754
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654710	PI-3K cascade:FGFR3	3/213	10/8290	0.00175610825560 0362	0.01259937986744 0261	0.00846511665521 31754
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9027276	Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	3/213	10/8290	0.00175610825560 0362	0.01259937986744 0261	0.00846511665521 31754
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9026731	Activated NTRK2 signals through FRS2 and FRS3	3/213	10/8290	0.00175610825560 0362	0.01259937986744 0261	0.00846511665521 31754
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5633007	Regulation of TP53 Activity	11/213	152/8290	0.00181013862473 4932	0.01288476627469 0061	0.00865668585706 75554
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6783783	Interleukin-10 signaling	5/213	35/8290	0.00185009760659 5979	0.01291561764430 7294	0.00867586610113308
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6804757	Regulation of TP53 Degradation	5/213	35/8290	0.00185009760659 5979	0.01291561764430 7294	0.00867586610113308
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5688426	Deubiquitination	14/213	224/8290	0.00185733439657 52155	0.01291561764430 7294	0.00867586610113308
qUC_CD66a+_vs_HC_CD66a+	R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane	8/213	89/8290	0.00197306058097 19984	0.01330102796755 214079	0.00894304694699 29062
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade	8/213	89/8290	0.00197306058097 19984	0.01330102796755 214079	0.00894304694699 29062
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade	8/213	89/8290	0.00197306058097 19984	0.01330102796755 214079	0.00894304694699 29062
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9018519	Estrogen-dependent gene expression	8/213	89/8290	0.00197306058097 19984	0.01330102796755 214079	0.00894304694699 29062
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1660499	Synthesis of PIPs at the plasma membrane	6/213	52/8290	0.00200854025668 841507	0.01353608764913 5825	0.00909446037907705
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168643	Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	6/213	52/8290	0.00200854025668 841507	0.01353608764913 5825	0.00909446037907705
qUC_CD66a+_vs_HC_CD66a+	R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade	8/213	90/8290	0.00213876064438896	0.01387950664389 696	0.00932518245848 594
qUC_CD66a+_vs_HC_CD66a+	R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade	8/213	90/8290	0.00213876064438896	0.01387950664389 696	0.00932518245848 594
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9664565	Signaling by ERBB2 KD Mutants	4/213	22/8290	0.00215397343795 80205	0.01408574526916 07	0.00941190964346 6703
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654695	PI-3K cascade:FGFR4	3/213	11/8290	0.00236914983873 5763	0.01518942360848 00663	0.01020528344439 9863
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5655291	Signaling by FGFR4 in disease	3/213	11/8290	0.00236914983873 5763	0.01518942360848 00663	0.01020528344439 9863
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6806834	Signaling by MET	7/213	72/8290	0.00239551467751 7424	0.01519255513106 1025	0.01024601541803 7846
qUC_CD66a+_vs_HC_CD66a+	R-HSA-166166	MyD88-independent TLR4 signaling	8/213	92/8290	0.00245596363625 255	0.01528980774314 776	0.01027279830437 7846
qUC_CD66a+_vs_HC_CD66a+	R-HSA-937061	TRIF(TICAM1)-mediated TLR4 signaling	8/213	92/8290	0.00245596363625 255	0.01528980774314 776	0.01027279830437 7846
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1227990	Signaling by ERBB2 in Cancer	4/213	23/8290	0.00255557911331 4154	0.01548040905046 2419	0.01041730235526 5189
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1839124	FGFR1 mutant receptor activation	4/213	23/8290	0.00255557911331 4154	0.01548040905046 2419	0.01041730235526 5189
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2173795	Downregulation of SMAD2/3:SMAD4 transcriptional activity	4/213	23/8290	0.00255557911331 4154	0.01548040905046 2419	0.01041730235526 5189
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4500115	Signaling by NTRK2 (TRKB)	4/213	23/8290	0.00255557911331 4154	0.01548040905046 2419	0.01041730235526 5189
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9634638	Estrogen-dependent nuclear events downstream of ESR-membrane signaling	5/213	38/8290	0.00264876931601 9919	0.01559402779668 78444	0.01041730235526 5189
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3769402	Deactivation of the beta-catenin transactivating complex	5/213	38/8290	0.00268773626814 0490	0.01573452746662 76065	0.01058187545582 92
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654736	Signaling by FGFR1	5/213	38/8290	0.00268773626814 0490	0.01573452746662 76065	0.01058187545582 92
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9614085	FOXO-mediated transcription	6/213	55/8290	0.00272076147051 2698	0.01618137085094 7394	0.01087174077898 7723
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4086398	Ca2+ pathway	6/213	56/8290	0.00298327839519 7181	0.01751670347697 003	0.01176552607198 5525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-422475	Axon guidance	23/213	483/8290	0.00300130152921 51574	0.01751670347697 003	0.01176552607198 5525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1358803	Downregulation of ERBB2:ERBB3 signaling	3/213	12/8290	0.00309941068100 83187	0.01751670347697 003	0.01176552607198 5525

Manuscripts submitted to Journal of Crohn's and Colitis

Comparison	Reactome ID	Pathway	Ratio	Background	p-value	value	value
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1502540	Signaling by Activin	3/213	12/8290	0.00309941068100831187	0.0175116703476997003	0.0117655260719855525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-169893	Prolonged ERK activation events	3/213	12/8290	0.00309941068100831187	0.0175116703476997003	0.0117655260719855525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2299718	Condensation of Prophase Chromosomes	3/213	12/8290	0.00309941068100831187	0.0175116703476997003	0.0117655260719855525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654706	FRS-mediated FGFR3 signaling	3/213	12/8290	0.00309941068100831187	0.0175116703476997003	0.0117655260719855525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6804759	Regulation of TP53 Activity through Association with Co-factors	3/213	12/8290	0.00309941068100831187	0.0175116703476997003	0.0117655260719855525
qUC_CD66a+_vs_HC_CD66a+	R-HSA-400685	Sema4D in semaphorin signaling	4/213	25/8290	0.00350722185098337215	0.0195711163909193112	0.0131492333204529
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5674400	Constitutive Signaling by AKT1 E17K in Cancer	4/213	25/8290	0.00350722185098337215	0.0195711163909193112	0.0131492333204529
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5633008	TP53 Regulates Transcription of Cell Death Genes	5/213	41/8290	0.00377073548944438235	0.0208091229646655093	0.0139809780514811196
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802957	Oncogenic MAPK signaling	7/213	78/8290	0.00377510637845528	0.0208091229646665593	0.0139809780514811196
qUC_CD66a+_vs_HC_CD66a+	R-HSA-373755	Semaphorin interactions	6/213	59/8290	0.00388491615289566683	0.0211476973510657	0.0142084552533566685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-203615	eNOS activation	3/213	13/8290	0.00395349651807004	0.0211476973510657	0.0142084552533566685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654700	FRS-mediated FGFR2 signaling	3/213	13/8290	0.00395349651807004	0.0211476973510657	0.0142084552533566685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6803205	TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	3/213	13/8290	0.00395349651807004	0.0211476973510657	0.0142084552533566685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9027284	Erythropoietin activates RAS	3/213	13/8290	0.00395349651807004	0.0211476973510657	0.0142084552533566685
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2559586	DNA Damage/Telomere Stress Induced Senescence	4/213	26/8290	0.004062666573106123	0.02147748878413997	0.0144300314723436695
qUC_CD66a+_vs_HC_CD66a+	R-HSA-442742	CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	4/213	26/8290	0.004062666573106123	0.02147748878413997	0.0144300314723436695
qUC_CD66a+_vs_HC_CD66a+	R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	6/213	60/8290	0.004226123586840815	0.02221171931688428	0.014923337268097617
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69202	Cyclin E associated events during G1/S transition	7/213	80/8290	0.004348133297168723	0.0227208815065926 34	0.01526542690883087
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654738	Signaling by FGFR2	6/213	61/8290	0.004588987686150484	0.023841637174023204	0.01601842646647 8098
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5628897	TP53 Regulates Metabolic Genes	7/213	81/8290	0.00468193585805014	0.024062897151815612	0.0161670839038165
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1963642	PI3K events in ERBB2 signaling	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839735	AXIN mutants destabilize the destruction complex, activating WNT signaling	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839744	truncated APC mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839748	AMER1 mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467337	APC truncation mutants have impaired AXIN binding	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467340	AXIN missense mutants destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5467348	Truncations of AMER1 destabilize the destruction complex	3/213	14/8290	0.004937261340837412	0.024523539846796817	0.0164765748621352 63
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69656	Cyclin A:Cdk2-associated events at S phase entry	7/213	82/8290	0.00498465545560069 1	0.024623653179579937	0.0165438377790140 88
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2454202	Fc epsilon receptor (FCERI) signaling	9/213	126/8290	0.0050561792522416365	0.024693861765358913	0.0169100866163495
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802946	Signaling by moderate kinase activity BRAF mutants	5/213	44/8290	0.00513544912819411	0.024693861765358913	0.0169100866163495
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802949	Signaling by RAS mutants	5/213	44/8290	0.00513544912819411	0.024693861765358913	0.0169100866163495
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6802955	Paradoxical activation of RAF signaling by kinase inactive BRAF	5/213	44/8290	0.00513544912819411	0.024693861765358913	0.0169100866163495
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9649948	Signaling downstream of RAS mutants	5/213	44/8290	0.00513544912819411	0.024693861765358913	0.0169100866163495
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2730905	Role of LAT2/NTAL/LAB on calcium mobilization	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4839743	phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5339716	Misspliced GSK3beta mutants stabilize beta-catenin	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358747	S33 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358749	S37 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358751	S45 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5358752	T41 mutants of beta-catenin aren't phosphorylated	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9617828	FOXO-mediated transcription of cell cycle genes	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9665348	Signaling by ERBB2 ECD mutants	3/213	15/8290	0.00605586391500954	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-4641262	Disassembly of the destruction complex and recruitment of AXIN to the membrane	4/213	29/8290	0.006078401637759409	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8979227	Triglyceride metabolism	4/213	29/8290	0.006078401637759409	0.02761243759062566	0.01855190555401 8405
qUC_CD66a+_vs_HC_CD66a+	R-HSA-881907	Gastrin-CREB signalling pathway via PKC and MAPK	3/213	16/8290	0.007313804388265156	0.032893926203938814	0.02210036727944363
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9022699	MECP2 regulates neuronal receptors and channels	3/213	16/8290	0.007313804388265156	0.032893926203938814	0.02210036727944363
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5655253	Signaling by FGFR2 in disease	4/213	31/8290	0.007737464972845706	0.03428758987966921	0.02300367249191 53626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8964043	Plasma lipoprotein clearance	4/213	31/8290	0.007737464972845706	0.03428758987966921	0.02300367249191 53626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9022692	Regulation of MECP2 expression and activity	4/213	31/8290	0.007737464972845706	0.03428758987966921	0.02300367249191 53626
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3858494	Beta-catenin independent WNT signaling	9/213	136/8290	0.00825463953357542	0.036400947016352096	0.024456621363201627
qUC_CD66a+_vs_HC_CD66a+	R-HSA-2173789	TGF-beta receptor signaling activates SMADs	4/213	32/8290	0.008668302018959895	0.03751583710686766	0.02505068003104639
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1181150	Signaling by NODAL	3/213	17/8290	0.008714962159781204	0.03751583710686766	0.02505068003104639
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1810470	RIP-mediated NFkB activation via ZBP1	3/213	17/8290	0.008714962159781204	0.03751583710686766	0.02505068003104639
qUC_CD66a+_vs_HC_CD66a+	R-HSA-196299	Beta-catenin phosphorylation cascade	3/213	17/8290	0.008714962159781204	0.03751583710686766	0.02505068003104639
qUC_CD66a+_vs_HC_CD66a+	R-HSA-202131	Metabolism of nitric oxide: NOS3 activation and regulation	3/213	17/8290	0.008714962159781204	0.03751583710686766	0.02505068003104639
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654743	Signaling by FGFR4	4/213	33/8290	0.009669437120109599	0.04142735145298141	0.0278337002659178 8
qUC_CD66a+_vs_HC_CD66a+	R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade	8/213	116/8290	0.009851240299550 19	0.04206637793905348	0.0282630415356705 4
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1980143	Signaling by NOTCH1	6/213	72/8290	0.010237686153991734	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-163560	Triglyceride catabolism	3/213	18/8290	0.010262632065091464	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-1839117	Signaling by cytosolic FGFR1 fusion mutants	3/213	18/8290	0.010262632065091464	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-3232118	SUMOylation of transcription factors	3/213	18/8290	0.010262632065091464	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-622312	Inflammasomes	3/213	18/8290	0.010262632065091464	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-8964038	LDL clearance	3/213	18/8290	0.010262632065091464	0.04255696966441598	0.028592654280819776
qUC_CD66a+_vs_HC_CD66a+	R-HSA-69278	Cell Cycle, Mitotic	21/213	477/8290	0.010827533076241886	0.04469447443343683	0.030028774741608116
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6673000	RAF activation	4/213	35/8290	0.011890257984804638	0.048050850148171266	0.033238381524859667
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9029569	NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	4/213	35/8290	0.011890257984804638	0.048050850148171266	0.033238381524859667
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5621575	CD209 (DC-SIGN) signaling	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.033238381524859667
qUC_CD66a+_vs_HC_CD66a+	R-HSA-5654716	Downstream signaling of activated FGFR4	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.033238381524859667
qUC_CD66a+_vs_HC_CD66a+	R-HSA-6783589	Interleukin-6 family signaling	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.033238381524859667
qUC_CD66a+_vs_HC_CD66a+	R-HSA-9665686	Signaling by ERBB2 TMD/JMD mutants	3/213	19/8290	0.011959558941746166	0.048050850148171266	0.033238381524859667

Supplementary Table S6. The list of correlations between endoscopic Mayo score and normalized expression of miRNAs expressed in crypt-bottom (CD44+) colonic epithelial cell population

mir	cell_type	estimate	statistic	p.value	method	alternative	padj
hsa-let-7a-3p	CD44+	0,381959736	10021,52289	0,008807758	Spearman's rank correlation rho	two.sided	0,008807758
hsa-let-7a-5p	CD44+	-0,343472059	21784,39943	0,019437858	Spearman's rank correlation rho	two.sided	0,019437858
hsa-let-7b-3p	CD44+	0,309654918	11193,9455	0,036245582	Spearman's rank correlation rho	two.sided	0,036245582
hsa-let-7b-5p	CD44+	-0,514746255	24561,61052	0,000252206	Spearman's rank correlation rho	two.sided	0,000252206
hsa-let-7c-5p	CD44+	-0,290238221	20921,21276	0,050387026	Spearman's rank correlation rho	two.sided	0,050387026
hsa-let-7d-3p	CD44+	-0,154318315	18717,27147	0,305842948	Spearman's rank correlation rho	two.sided	0,305842948
hsa-let-7d-5p	CD44+	-0,322887487	21450,6206	0,028621868	Spearman's rank correlation rho	two.sided	0,028621868
hsa-let-7e-5p	CD44+	-0,420004442	23025,37203	0,003661731	Spearman's rank correlation rho	two.sided	0,003661731
hsa-let-7f-1-3p	CD44+	0,205256926	12886,75895	0,171177725	Spearman's rank correlation rho	two.sided	0,171177725
hsa-let-7f-2-3p	CD44+	0,441014098	9063,956399	0,00215697	Spearman's rank correlation rho	two.sided	0,00215697
hsa-let-7f-5p	CD44+	-0,241868722	20136,90133	0,105353872	Spearman's rank correlation rho	two.sided	0,105353872
hsa-let-7g-5p	CD44+	-0,235337079	20030,99074	0,115392622	Spearman's rank correlation rho	two.sided	0,115392622
hsa-let-7i-3p	CD44+	0,119376703	14279,30677	0,429409878	Spearman's rank correlation rho	two.sided	0,429409878
hsa-let-7i-5p	CD44+	0,098304527	14620,99209	0,515716749	Spearman's rank correlation rho	two.sided	0,515716749
hsa-miR-1-3p	CD44+	0,015174524	15968,94509	0,920271335	Spearman's rank correlation rho	two.sided	0,920271335
hsa-miR-100-5p	CD44+	-0,133086292	18372,99423	0,377925261	Spearman's rank correlation rho	two.sided	0,377925261
hsa-miR-101-3p	CD44+	0,159134577	13634,63284	0,290808367	Spearman's rank correlation rho	two.sided	0,290808367
hsa-miR-103a-3p	CD44+	0,281916271	11643,72767	0,057679166	Spearman's rank correlation rho	two.sided	0,057679166
hsa-miR-106b-3p	CD44+	0,059840407	15244,68781	0,692811658	Spearman's rank correlation rho	two.sided	0,692811658
hsa-miR-106b-5p	CD44+	-0,088935908	17657,09574	0,556693985	Spearman's rank correlation rho	two.sided	0,556693985
hsa-miR-10a-3p	CD44+	0,091508979	14731,1819	0,545288742	Spearman's rank correlation rho	two.sided	0,545288742
hsa-miR-10a-5p	CD44+	-0,284159462	20822,64567	0,055634958	Spearman's rank correlation rho	two.sided	0,055634958
hsa-miR-10b-3p	CD44+	0,161006736	13604,27578	0,28509604	Spearman's rank correlation rho	two.sided	0,28509604
hsa-miR-10b-5p	CD44+	-0,541994422	25003,43956	0,000100079	Spearman's rank correlation rho	two.sided	0,000100079
hsa-miR-1180-3p	CD44+	0,570929431	6957,37928	3,42351E-05	Spearman's rank correlation rho	two.sided	3,42351E-05
hsa-miR-122-5p	CD44+	0,048302021	15431,78273	0,749900445	Spearman's rank correlation rho	two.sided	0,749900445
hsa-miR-1224-5p	CD44+	0,184179313	13228,53244	0,220461425	Spearman's rank correlation rho	two.sided	0,220461425
hsa-miR-1246	CD44+	0,139341719	13955,57403	0,355710544	Spearman's rank correlation rho	two.sided	0,355710544
hsa-miR-1247-3p	CD44+	-0,370338339	22220,03617	0,01129546	Spearman's rank correlation rho	two.sided	0,01129546
hsa-miR-1247-5p	CD44+	0,128929408	14124,40965	0,393133324	Spearman's rank correlation rho	two.sided	0,393133324
hsa-miR-1248	CD44+	0,114911714	14351,70656	0,446988781	Spearman's rank correlation rho	two.sided	0,446988781
hsa-miR-1249-3p	CD44+	0,21836236	12674,25434	0,144866176	Spearman's rank correlation rho	two.sided	0,144866176
hsa-miR-125a-3p	CD44+	0,391410209	9868,283454	0,007148081	Spearman's rank correlation rho	two.sided	0,007148081
hsa-miR-125a-5p	CD44+	-0,134393504	18394,19067	0,373216125	Spearman's rank correlation rho	two.sided	0,373216125
hsa-miR-125b-5p	CD44+	-0,135185219	18407,02832	0,370381167	Spearman's rank correlation rho	two.sided	0,370381167
hsa-miR-126-3p	CD44+	0,285544962	11584,88845	0,054401745	Spearman's rank correlation rho	two.sided	0,054401745
hsa-miR-126-5p	CD44+	0,502305726	8070,112657	0,000375009	Spearman's rank correlation rho	two.sided	0,000375009
hsa-miR-1261	CD44+	0,271797846	11807,79793	0,06766082	Spearman's rank correlation rho	two.sided	0,06766082
hsa-miR-1262	CD44+	0,206708671	12863,2189	0,168103879	Spearman's rank correlation rho	two.sided	0,168103879
hsa-miR-1266-5p	CD44+	0,406369118	9625,72475	0,005073567	Spearman's rank correlation rho	two.sided	0,005073567
hsa-miR-1269a	CD44+	0,318205893	11055,29145	0,031150236	Spearman's rank correlation rho	two.sided	0,031150236
hsa-miR-127-3p	CD44+	0,260184245	11996,11246	0,080757563	Spearman's rank correlation rho	two.sided	0,080757563
hsa-miR-1271-5p	CD44+	0,231296486	12464,52748	0,121956551	Spearman's rank correlation rho	two.sided	0,121956551
hsa-miR-1275	CD44+	0,226477249	12542,67141	0,130149305	Spearman's rank correlation rho	two.sided	0,130149305
hsa-miR-128-3p	CD44+	0,069011097	15095,98505	0,648592153	Spearman's rank correlation rho	two.sided	0,648592153
hsa-miR-1287-5p	CD44+	0,252941349	12113,55602	0,089881601	Spearman's rank correlation rho	two.sided	0,089881601
hsa-miR-1290	CD44+	-0,235846446	20039,25012	0,114584573	Spearman's rank correlation rho	two.sided	0,114584573
hsa-miR-1291	CD44+	0,119838636	14271,81652	0,427613646	Spearman's rank correlation rho	two.sided	0,427613646
hsa-miR-1294	CD44+	0,45487209	8839,249058	0,001493243	Spearman's rank correlation rho	two.sided	0,001493243
hsa-miR-1296-5p	CD44+	0,286752603	11565,30654	0,053344885	Spearman's rank correlation rho	two.sided	0,053344885
hsa-miR-1299	CD44+	0,324804937	10948,28795	0,027636773	Spearman's rank correlation rho	two.sided	0,027636773
hsa-miR-1301-3p	CD44+	-0,009996318	16377,0903	0,947430314	Spearman's rank correlation rho	two.sided	0,947430314
hsa-miR-1303	CD44+	0,063051919	15192,61314	0,67720168	Spearman's rank correlation rho	two.sided	0,67720168
hsa-miR-1304-3p	CD44+	-0,265685912	20523,09706	0,074325295	Spearman's rank correlation rho	two.sided	0,074325295
hsa-miR-1304-5p	CD44+	-0,308439308	21216,34338	0,03702268	Spearman's rank correlation rho	two.sided	0,03702268
hsa-miR-1306-3p	CD44+	0,196585515	13027,36587	0,190387217	Spearman's rank correlation rho	two.sided	0,190387217
hsa-miR-1306-5p	CD44+	-0,070407454	17356,65686	0,641958274	Spearman's rank correlation rho	two.sided	0,641958274
hsa-miR-1307-3p	CD44+	0,039491623	15574,64334	0,794419825	Spearman's rank correlation rho	two.sided	0,794419825
hsa-miR-1307-5p	CD44+	-0,06753913	17310,14699	0,655614509	Spearman's rank correlation rho	two.sided	0,655614509
hsa-miR-130a-3p	CD44+	0,25712381	12045,73741	0,084520004	Spearman's rank correlation rho	two.sided	0,084520004
hsa-miR-130b-3p	CD44+	0,14820538	13811,84976	0,325628651	Spearman's rank correlation rho	two.sided	0,325628651
hsa-miR-130b-5p	CD44+	0,02305939	15841,09199	0,879098277	Spearman's rank correlation rho	two.sided	0,879098277
hsa-miR-132-3p	CD44+	-0,1729396	19019,21561	0,250416194	Spearman's rank correlation rho	two.sided	0,250416194
hsa-miR-132-5p	CD44+	0,270610091	11827,05737	0,068917355	Spearman's rank correlation rho	two.sided	0,068917355
hsa-miR-133a-3p	CD44+	0,132566611	14065,4324	0,379807147	Spearman's rank correlation rho	two.sided	0,379807147
hsa-miR-135a-3p	CD44+	0,325464841	10937,5876	0,027304344	Spearman's rank correlation rho	two.sided	0,027304344
hsa-miR-135a-5p	CD44+	0,30133604	11328,83611	0,041841922	Spearman's rank correlation rho	two.sided	0,041841922
hsa-miR-135b-5p	CD44+	0,298278367	11378,41628	0,044068517	Spearman's rank correlation rho	two.sided	0,044068517
hsa-miR-136-3p	CD44+	0,13257479	14065,29978	0,379777487	Spearman's rank correlation rho	two.sided	0,379777487
hsa-miR-139-3p	CD44+	0,172922609	13411,0599	0,250463456	Spearman's rank correlation rho	two.sided	0,250463456
hsa-miR-139-5p	CD44+	0,358525867	10401,50307	0,014418357	Spearman's rank correlation rho	two.sided	0,014418357
hsa-miR-140-3p	CD44+	0,314207697	11120,12219	0,033453462	Spearman's rank correlation rho	two.sided	0,033453462
hsa-miR-140-5p	CD44+	0,12985316	14109,43101	0,389723197	Spearman's rank correlation rho	two.sided	0,389723197
hsa-miR-141-3p	CD44+	0,258692651	12020,29866	0,082574556	Spearman's rank correlation rho	two.sided	0,082574556
hsa-miR-141-5p	CD44+	0,236179778	12385,3449	0,114058114	Spearman's rank correlation rho	two.sided	0,114058114
hsa-miR-142-3p	CD44+	0,338588156	10724,79306	0,021354053	Spearman's rank correlation rho	two.sided	0,021354053
hsa-miR-142-5p	CD44+	0,407468966	9607,890724	0,004944271	Spearman's rank correlation rho	two.sided	0,004944271
hsa-miR-143-3p	CD44+	-0,303490486	21136,09823	0,040328939	Spearman's rank correlation rho	two.sided	0,040328939
hsa-miR-143-5p	CD44+	0,350211255	10536,3245	0,017033396	Spearman's rank correlation rho	two.sided	0,017033396
hsa-miR-144-3p	CD44+	0,383050861	10003,83029	0,008600563	Spearman's rank correlation rho	two.sided	0,008600563
hsa-miR-144-5p	CD44+	0,267970569	11869,85722	0,07177599	Spearman's rank correlation rho	two.sided	0,07177599
hsa-miR-145-3p	CD44+	-0,385159178	22460,36581	0,008211992	Spearman's rank correlation rho	two.sided	0,008211992
hsa-miR-145-5p	CD44+	0,246238337	12222,24536	0,099021037	Spearman's rank correlation rho	two.sided	0,099021037
hsa-miR-1468-5p	CD44+	0,136290637	14005,04732	0,366444571	Spearman's rank correlation rho	two.sided	0,366444571
hsa-miR-146a-3p	CD44+	0,208793746	12829,4094	0,163759337	Spearman's rank correlation rho	two.sided	0,163759337
hsa-miR-146a-5p	CD44+	0,473115277	8543,435781	0,000898407	Spearman's rank correlation rho	two.sided	0,000898407
hsa-miR-146b-3p	CD44+	0,365938686	10281,3042	0,012383132	Spearman's rank correlation rho	two.sided	0,012383132
hsa-miR-146b-5p	CD44+	0,118889099	14287,21326	0,431310514	Spearman's rank correlation rho	two.sided	0,431310514
hsa-miR-147b-3p	CD44+	-0,232231856	19980,63954	0,120412548	Spearman's rank correlation rho	two.sided	0,120412548
hsa-miR-147b-5p	CD44+	0,108445249	14456,56028	0,473133683	Spearman's rank correlation rho	two.sided	0,473133683
hsa-miR-148a-3p	CD44+	0,121660099	14242,28149	0,420572174	Spearman's rank correlation rho	two.sided	0,420572174
hsa-miR-148a-5p	CD44+	0,214739385	12733,00088	0,151820215	Spearman's rank correlation rho	two.sided	0,151820215
hsa-miR-148b-3p	CD44+	0,478063492	8463,200483	0,000778931	Spearman's rank correlation rho	two.sided	0,000778931
hsa-miR-148b-5p	CD44+	0,441534156	9055,523658	0,00212799	Spearman's rank correlation rho	two.sided	0,00212799
hsa-miR-149-5p	CD44+	0,167209454	13503,6987	0,266696951	Spearman's rank correlation rho	two.sided	0,266696951
hsa-miR-150-3p	CD44+	0,386967929	9940,315026	0,007891006	Spearman's rank correlation rho	two.sided	0,007891006
hsa-miR-150-5p	CD44+	0,041367073	15544,23292	0,784883465	Spearman's rank correlation rho	two.sided	0,784883465

miRNA	Cell	rho	value	p	Test	Alt	p
hsa-miR-151a-3p	CD44+	0,085109288	14834,95289	0,573860301	Spearman's rank correlation rho	two.sided	0,573860301
hsa-miR-151a-5p	CD44+	-0,03846412	16838,69571	0,799657209	Spearman's rank correlation rho	two.sided	0,799657209
hsa-miR-152-3p	CD44+	0,238518646	12347,42015	0,110415701	Spearman's rank correlation rho	two.sided	0,110415701
hsa-miR-153-3p	CD44+	-0,060777194	17200,50219	0,688244907	Spearman's rank correlation rho	two.sided	0,688244907
hsa-miR-155-5p	CD44+	0,182424173	13256,99204	0,224967637	Spearman's rank correlation rho	two.sided	0,224967637
hsa-miR-15a-5p	CD44+	0,022136378	15856,05863	0,883903875	Spearman's rank correlation rho	two.sided	0,883903875
hsa-miR-15b-3p	CD44+	0,180797069	13283,37552	0,2292015	Spearman's rank correlation rho	two.sided	0,2292015
hsa-miR-15b-5p	CD44+	0,527941493	7654,428687	0,000162791	Spearman's rank correlation rho	two.sided	0,000162791
hsa-miR-16-2-3p	CD44+	0,214950436	12729,57869	0,151408508	Spearman's rank correlation rho	two.sided	0,151408508
hsa-miR-16-5p	CD44+	0,300785462	11337,76373	0,042235921	Spearman's rank correlation rho	two.sided	0,042235921
hsa-miR-17-3p	CD44+	0,265306372	11913,05717	0,074755632	Spearman's rank correlation rho	two.sided	0,074755632
hsa-miR-17-5p	CD44+	-0,003595924	16273,30791	0,98107786	Spearman's rank correlation rho	two.sided	0,98107786
hsa-miR-181a-2-3p	CD44+	0,165412516	13532,83605	0,271944056	Spearman's rank correlation rho	two.sided	0,271944056
hsa-miR-181a-5p	CD44+	-0,026126572	16638,64237	0,863161008	Spearman's rank correlation rho	two.sided	0,863161008
hsa-miR-181b-5p	CD44+	-0,12805979	18291,48949	0,396359501	Spearman's rank correlation rho	two.sided	0,396359501
hsa-miR-181c-3p	CD44+	0,341764479	10673,28897	0,020090635	Spearman's rank correlation rho	two.sided	0,020090635
hsa-miR-181c-5p	CD44+	0,259772302	12002,79212	0,081256211	Spearman's rank correlation rho	two.sided	0,081256211
hsa-miR-181d-5p	CD44+	0,286842738	11563,84501	0,053266673	Spearman's rank correlation rho	two.sided	0,053266673
hsa-miR-182-5p	CD44+	0,536254494	7519,633388	0,000122397	Spearman's rank correlation rho	two.sided	0,000122397
hsa-miR-183-3p	CD44+	0,091360943	14733,5823	0,545941869	Spearman's rank correlation rho	two.sided	0,545941869
hsa-miR-183-5p	CD44+	0,358580607	10400,61546	0,014402344	Spearman's rank correlation rho	two.sided	0,014402344
hsa-miR-184	CD44+	0,050844064	15390,5635	0,73719654	Spearman's rank correlation rho	two.sided	0,73719654
hsa-miR-185-3p	CD44+	0,370272348	10211,03387	0,011311148	Spearman's rank correlation rho	two.sided	0,011311148
hsa-miR-185-5p	CD44+	0,15630242	13680,55626	0,299590123	Spearman's rank correlation rho	two.sided	0,299590123
hsa-miR-186-5p	CD44+	-0,247014865	20220,34604	0,097926987	Spearman's rank correlation rho	two.sided	0,097926987
hsa-miR-18a-3p	CD44+	0,312949999	11140,51577	0,034206406	Spearman's rank correlation rho	two.sided	0,034206406
hsa-miR-18a-5p	CD44+	0,156773937	13672,91061	0,298116352	Spearman's rank correlation rho	two.sided	0,298116352
hsa-miR-190a-5p	CD44+	0,279270071	11686,6358	0,060167658	Spearman's rank correlation rho	two.sided	0,060167658
hsa-miR-190b-5p	CD44+	0,022073121	15857,08435	0,884233372	Spearman's rank correlation rho	two.sided	0,884233372
hsa-miR-191-3p	CD44+	0,185251011	13211,15485	0,217740845	Spearman's rank correlation rho	two.sided	0,217740845
hsa-miR-191-5p	CD44+	0,258692651	12020,29866	0,082574556	Spearman's rank correlation rho	two.sided	0,082574556
hsa-miR-192-3p	CD44+	0,224459551	12575,38838	0,13369928	Spearman's rank correlation rho	two.sided	0,13369928
hsa-miR-192-5p	CD44+	0,133865695	14044,36776	0,375113282	Spearman's rank correlation rho	two.sided	0,375113282
hsa-miR-193a-5p	CD44+	0,118265972	14297,31726	0,433746248	Spearman's rank correlation rho	two.sided	0,433746248
hsa-miR-193b-3p	CD44+	0,272936452	11789,33543	0,066473427	Spearman's rank correlation rho	two.sided	0,066473427
hsa-miR-193b-5p	CD44+	0,292517565	11471,82768	0,048525584	Spearman's rank correlation rho	two.sided	0,048525584
hsa-miR-194-3p	CD44+	-0,076466407	17454,90279	0,613496852	Spearman's rank correlation rho	two.sided	0,613496852
hsa-miR-194-5p	CD44+	0,113413075	14376,00699	0,452976342	Spearman's rank correlation rho	two.sided	0,452976342
hsa-miR-195-5p	CD44+	0,026160367	15790,80965	0,862985696	Spearman's rank correlation rho	two.sided	0,862985696
hsa-miR-196a-1-3p	CD44+	-0,367664697	22176,68306	0,011946208	Spearman's rank correlation rho	two.sided	0,011946208
hsa-miR-196a-5p	CD44+	-0,039981573	16863,3012	0,791925582	Spearman's rank correlation rho	two.sided	0,791925582
hsa-miR-196b-5p	CD44+	-0,272085818	20626,87154	0,06735893	Spearman's rank correlation rho	two.sided	0,06735893
hsa-miR-197-3p	CD44+	0,04921824	15416,92624	0,745313873	Spearman's rank correlation rho	two.sided	0,745313873
hsa-miR-199a-5p	CD44+	-0,04275521	16908,27572	0,777844954	Spearman's rank correlation rho	two.sided	0,777844954
hsa-miR-199b-5p	CD44+	0,319067236	11041,32476	0,030671649	Spearman's rank correlation rho	two.sided	0,030671649
hsa-miR-19a-3p	CD44+	-0,018540454	16515,63345	0,902663603	Spearman's rank correlation rho	two.sided	0,902663603
hsa-miR-19b-3p	CD44+	0,243591615	12265,16197	0,102820855	Spearman's rank correlation rho	two.sided	0,102820855
hsa-miR-200a-3p	CD44+	0,267929318	11870,52611	0,071821399	Spearman's rank correlation rho	two.sided	0,071821399
hsa-miR-200a-5p	CD44+	0,315564129	11098,12764	0,032656803	Spearman's rank correlation rho	two.sided	0,032656803
hsa-miR-200b-3p	CD44+	0,1410571	13927,75913	0,349760657	Spearman's rank correlation rho	two.sided	0,349760657
hsa-miR-200b-5p	CD44+	0,162631315	13577,93323	0,280198906	Spearman's rank correlation rho	two.sided	0,280198906
hsa-miR-200c-3p	CD44+	0,223923198	12584,08535	0,134655004	Spearman's rank correlation rho	two.sided	0,134655004
hsa-miR-200c-5p	CD44+	-0,27243312	20632,50304	0,066996267	Spearman's rank correlation rho	two.sided	0,066996267
hsa-miR-203a-3p	CD44+	0,138352076	13971,62109	0,359171032	Spearman's rank correlation rho	two.sided	0,359171032
hsa-miR-203b-3p	CD44+	0,243581161	12265,33148	0,102836082	Spearman's rank correlation rho	two.sided	0,102836082
hsa-miR-204-5p	CD44+	0,120593806	14259,57144	0,424686277	Spearman's rank correlation rho	two.sided	0,424686277
hsa-miR-205-5p	CD44+	-0,088056091	17642,82951	0,560619392	Spearman's rank correlation rho	two.sided	0,560619392
hsa-miR-206	CD44+	0,004190264	16147,05488	0,977951097	Spearman's rank correlation rho	two.sided	0,977951097
hsa-miR-20a-3p	CD44+	-0,073610063	17408,58717	0,626847621	Spearman's rank correlation rho	two.sided	0,626847621
hsa-miR-20a-5p	CD44+	0,095863408	14660,57484	0,526246474	Spearman's rank correlation rho	two.sided	0,526246474
hsa-miR-21-3p	CD44+	-0,032263353	16738,15027	0,831440867	Spearman's rank correlation rho	two.sided	0,831440867
hsa-miR-21-5p	CD44+	0,357063154	10425,22095	0,014851904	Spearman's rank correlation rho	two.sided	0,014851904
hsa-miR-210-3p	CD44+	0,311894184	11157,6358	0,034849233	Spearman's rank correlation rho	two.sided	0,034849233
hsa-miR-210-5p	CD44+	-0,2153268	19706,52406	0,150676355	Spearman's rank correlation rho	two.sided	0,150676355
hsa-miR-2110	CD44+	0,149949394	13783,57058	0,319903659	Spearman's rank correlation rho	two.sided	0,319903659
hsa-miR-2116-3p	CD44+	-0,194857742	19374,61828	0,19439084	Spearman's rank correlation rho	two.sided	0,19439084
hsa-miR-215-3p	CD44+	0,27615187	11737,19743	0,063209512	Spearman's rank correlation rho	two.sided	0,063209512
hsa-miR-215-5p	CD44+	0,2931982	11460,79119	0,047980678	Spearman's rank correlation rho	two.sided	0,047980678
hsa-miR-218-5p	CD44+	0,179944823	13297,1947	0,231440825	Spearman's rank correlation rho	two.sided	0,231440825
hsa-miR-219a-1-3p	CD44+	-0,049654741	17020,15163	0,743131807	Spearman's rank correlation rho	two.sided	0,743131807
hsa-miR-22-3p	CD44+	0,213762864	12748,83516	0,153735878	Spearman's rank correlation rho	two.sided	0,153735878
hsa-miR-22-5p	CD44+	0,252291093	12124,09993	0,090738403	Spearman's rank correlation rho	two.sided	0,090738403
hsa-miR-221-3p	CD44+	0,392360417	9852,875831	0,006997285	Spearman's rank correlation rho	two.sided	0,006997285
hsa-miR-221-5p	CD44+	0,105350485	14506,74189	0,485927641	Spearman's rank correlation rho	two.sided	0,485927641
hsa-miR-222-3p	CD44+	0,344461702	10629,55351	0,01906779	Spearman's rank correlation rho	two.sided	0,01906779
hsa-miR-223-3p	CD44+	0,412285228	9529,795035	0,004411357	Spearman's rank correlation rho	two.sided	0,004411357
hsa-miR-223-5p	CD44+	0,414922276	9487,035294	0,004141422	Spearman's rank correlation rho	two.sided	0,004141422
hsa-miR-224-3p	CD44+	-0,059589366	17181,24156	0,694037301	Spearman's rank correlation rho	two.sided	0,694037301
hsa-miR-224-5p	CD44+	0,133469838	14050,78658	0,376539918	Spearman's rank correlation rho	two.sided	0,376539918
hsa-miR-23a-3p	CD44+	0,080490955	14909,83917	0,594894718	Spearman's rank correlation rho	two.sided	0,594894718
hsa-miR-23a-5p	CD44+	-0,239838252	20103,97725	0,108400145	Spearman's rank correlation rho	two.sided	0,108400145
hsa-miR-23b-3p	CD44+	-0,202019102	19490,73974	0,178179257	Spearman's rank correlation rho	two.sided	0,178179257
hsa-miR-23b-5p	CD44+	0,429993695	9242,652236	0,002858943	Spearman's rank correlation rho	two.sided	0,002858943
hsa-miR-24-2-5p	CD44+	-0,025206015	16623,71553	0,867938934	Spearman's rank correlation rho	two.sided	0,867938934
hsa-miR-24-3p	CD44+	0,064920574	15162,3129	0,668179551	Spearman's rank correlation rho	two.sided	0,668179551
hsa-miR-25-3p	CD44+	0,31642182	11084,22019	0,032161206	Spearman's rank correlation rho	two.sided	0,032161206
hsa-miR-25-5p	CD44+	0,373395376	10160,39398	0,010588847	Spearman's rank correlation rho	two.sided	0,010588847
hsa-miR-26a-2-3p	CD44+	0,250301732	12156,35742	0,093399069	Spearman's rank correlation rho	two.sided	0,093399069
hsa-miR-26a-5p	CD44+	-0,357195107	22006,91866	0,014812344	Spearman's rank correlation rho	two.sided	0,014812344
hsa-miR-26b-3p	CD44+	0,138476663	13969,60091	0,358734269	Spearman's rank correlation rho	two.sided	0,358734269
hsa-miR-26b-5p	CD44+	0,074025288	15014,67995	0,624899346	Spearman's rank correlation rho	two.sided	0,624899346
hsa-miR-27a-3p	CD44+	0,171472125	13434,5795	0,254520324	Spearman's rank correlation rho	two.sided	0,254520324
hsa-miR-27a-5p	CD44+	0,208458209	12834,85015	0,164452904	Spearman's rank correlation rho	two.sided	0,164452904
hsa-miR-27b-3p	CD44+	0,148248505	13811,15049	0,325486318	Spearman's rank correlation rho	two.sided	0,325486318
hsa-miR-27b-5p	CD44+	0,173978423	13393,93987	0,247538002	Spearman's rank correlation rho	two.sided	0,247538002
hsa-miR-28-3p	CD44+	-0,204724126	19534,6017	0,172315977	Spearman's rank correlation rho	two.sided	0,172315977
hsa-miR-28-5p	CD44+	-0,009434596	16367,98197	0,950380569	Spearman's rank correlation rho	two.sided	0,950380569
hsa-miR-296-5p	CD44+	0,161209667	13600,98524	0,284481288	Spearman's rank correlation rho	two.sided	0,284481288
hsa-miR-29a-3p	CD44+	0,470608182	8584,088331	0,000964986	Spearman's rank correlation rho	two.sided	0,000964986

hsa-miR-29a-5p	CD44+	-0,225185424	19866,38164	0,132413932	Spearman's rank correlation rho	two.sided	0,132413932
hsa-miR-29b-1-5p	CD44+	0,165219671	13535,96304	0,272511196	Spearman's rank correlation rho	two.sided	0,272511196
hsa-miR-29b-2-5p	CD44+	0,023194923	15838,89432	0,878392991	Spearman's rank correlation rho	two.sided	0,878392991
hsa-miR-29b-3p	CD44+	-0,005311411	16301,12453	0,972053773	Spearman's rank correlation rho	two.sided	0,972053773
hsa-miR-29c-3p	CD44+	0,103222936	14541,24009	0,494826712	Spearman's rank correlation rho	two.sided	0,494826712
hsa-miR-29c-5p	CD44+	-0,093904393	17737,65974	0,534772651	Spearman's rank correlation rho	two.sided	0,534772651
hsa-miR-30a-3p	CD44+	0,248281364	12189,11768	0,096162649	Spearman's rank correlation rho	two.sided	0,096162649
hsa-miR-30a-5p	CD44+	-0,102662121	17879,6663	0,4971864	Spearman's rank correlation rho	two.sided	0,4971864
hsa-miR-30b-3p	CD44+	0,232403985	12446,56939	0,120130034	Spearman's rank correlation rho	two.sided	0,120130034
hsa-miR-30b-5p	CD44+	0,182160268	13261,27126	0,225650649	Spearman's rank correlation rho	two.sided	0,225650649
hsa-miR-30c-1-3p	CD44+	-0,375287622	22300,28879	0,01017076	Spearman's rank correlation rho	two.sided	0,01017076
hsa-miR-30c-5p	CD44+	-0,126344409	18263,67459	0,402768408	Spearman's rank correlation rho	two.sided	0,402768408
hsa-miR-30d-3p	CD44+	0,0662544	15140,68491	0,661767749	Spearman's rank correlation rho	two.sided	0,661767749
hsa-miR-30d-5p	CD44+	0,068021455	15112,03211	0,653310193	Spearman's rank correlation rho	two.sided	0,653310193
hsa-miR-30e-3p	CD44+	0,077192145	14963,32936	0,610124095	Spearman's rank correlation rho	two.sided	0,610124095
hsa-miR-30e-5p	CD44+	0,035891049	15633,02664	0,812810419	Spearman's rank correlation rho	two.sided	0,812810419
hsa-miR-31-5p	CD44+	0,468610358	8616,483043	0,001021162	Spearman's rank correlation rho	two.sided	0,001021162
hsa-miR-3127-5p	CD44+	0,027450329	15769,89292	0,856298883	Spearman's rank correlation rho	two.sided	0,856298883
hsa-miR-3145-5p	CD44+	0,102813103	14547,88554	0,496550562	Spearman's rank correlation rho	two.sided	0,496550562
hsa-miR-3150b-5p	CD44+	-0,159960822	18808,76473	0,288278232	Spearman's rank correlation rho	two.sided	0,288278232
hsa-miR-3168	CD44+	0,230794438	12472,66819	0,122791412	Spearman's rank correlation rho	two.sided	0,122791412
hsa-miR-3173-5p	CD44+	0,307190057	11233,91323	0,037835498	Spearman's rank correlation rho	two.sided	0,037835498
hsa-miR-3177-3p	CD44+	-0,051934475	17057,11751	0,731768146	Spearman's rank correlation rho	two.sided	0,731768146
hsa-miR-3182	CD44+	0,073904731	15016,63479	0,625464751	Spearman's rank correlation rho	two.sided	0,625464751
hsa-miR-3187-3p	CD44+	-0,242118918	20140,95825	0,104983094	Spearman's rank correlation rho	two.sided	0,104983094
hsa-miR-3188	CD44+	0,024778645	15813,21427	0,870158684	Spearman's rank correlation rho	two.sided	0,870158684
hsa-miR-3195	CD44+	0,028900246	15746,38251	0,848794797	Spearman's rank correlation rho	two.sided	0,848794797
hsa-miR-32-3p	CD44+	0,343437854	10646,15519	0,019450756	Spearman's rank correlation rho	two.sided	0,019450756
hsa-miR-32-5p	CD44+	0,314863663	11109,48571	0,03306622	Spearman's rank correlation rho	two.sided	0,03306622
hsa-miR-320a-3p	CD44+	0,030481001	15720,75057	0,840628626	Spearman's rank correlation rho	two.sided	0,840628626
hsa-miR-324-3p	CD44+	0,467202061	8639,318577	0,001062499	Spearman's rank correlation rho	two.sided	0,001062499
hsa-miR-324-5p	CD44+	0,294275281	11443,32632	0,047128533	Spearman's rank correlation rho	two.sided	0,047128533
hsa-miR-326	CD44+	0,205256926	12886,75895	0,171177725	Spearman's rank correlation rho	two.sided	0,171177725
hsa-miR-328-3p	CD44+	-0,386395091	22480,3964	0,007991503	Spearman's rank correlation rho	two.sided	0,007991503
hsa-miR-328-5p	CD44+	-0,366642874	22160,11421	0,012203251	Spearman's rank correlation rho	two.sided	0,012203251
hsa-miR-329-3p	CD44+	0,254179486	12093,47964	0,088267584	Spearman's rank correlation rho	two.sided	0,088267584
hsa-miR-330-3p	CD44+	0,087431936	14797,29115	0,563411954	Spearman's rank correlation rho	two.sided	0,563411954
hsa-miR-331-3p	CD44+	0,063311966	15188,39647	0,675943416	Spearman's rank correlation rho	two.sided	0,675943416
hsa-miR-335-3p	CD44+	0,225704555	12555,20064	0,131500357	Spearman's rank correlation rho	two.sided	0,131500357
hsa-miR-335-5p	CD44+	-0,029491358	16693,20237	0,845739234	Spearman's rank correlation rho	two.sided	0,845739234
hsa-miR-338-3p	CD44+	0,116634501	14323,77156	0,440159712	Spearman's rank correlation rho	two.sided	0,440159712
hsa-miR-338-5p	CD44+	-0,180472714	19141,36506	0,230052	Spearman's rank correlation rho	two.sided	0,230052
hsa-miR-339-3p	CD44+	0,066708102	15133,32813	0,659592188	Spearman's rank correlation rho	two.sided	0,659592188
hsa-miR-339-5p	CD44+	0,192932236	13086,6038	0,198922511	Spearman's rank correlation rho	two.sided	0,198922511
hsa-miR-33b-3p	CD44+	-0,264951609	20511,19034	0,075159652	Spearman's rank correlation rho	two.sided	0,075159652
hsa-miR-340-3p	CD44+	-0,123819599	18222,73479	0,41230972	Spearman's rank correlation rho	two.sided	0,41230972
hsa-miR-340-5p	CD44+	0,420228288	9400,998318	0,003641773	Spearman's rank correlation rho	two.sided	0,003641773
hsa-miR-342-3p	CD44+	0,151613291	13756,59049	0,314501289	Spearman's rank correlation rho	two.sided	0,314501289
hsa-miR-342-5p	CD44+	0,427037424	9290,588165	0,00307857	Spearman's rank correlation rho	two.sided	0,00307857
hsa-miR-345-5p	CD44+	0,078714452	14938,64516	0,603075378	Spearman's rank correlation rho	two.sided	0,603075378
hsa-miR-34a-5p	CD44+	0,183991634	13231,57565	0,220940271	Spearman's rank correlation rho	two.sided	0,220940271
hsa-miR-3605-5p	CD44+	-0,04672123	16972,58475	0,757833872	Spearman's rank correlation rho	two.sided	0,757833872
hsa-miR-3609	CD44+	0,552222873	7260,706119	6,92726E-05	Spearman's rank correlation rho	two.sided	6,92726E-05
hsa-miR-361-3p	CD44+	0,341426797	10678,76449	0,020221888	Spearman's rank correlation rho	two.sided	0,020221888
hsa-miR-361-5p	CD44+	0,102790908	14548,24543	0,496644005	Spearman's rank correlation rho	two.sided	0,496644005
hsa-miR-3613-3p	CD44+	-0,113595531	18056,95153	0,452245042	Spearman's rank correlation rho	two.sided	0,452245042
hsa-miR-3613-5p	CD44+	0,160496987	13612,54136	0,286644074	Spearman's rank correlation rho	two.sided	0,286644074
hsa-miR-3615	CD44+	0,323376166	10971,45546	0,028368077	Spearman's rank correlation rho	two.sided	0,028368077
hsa-miR-362-3p	CD44+	0,335231426	10779,22243	0,022761151	Spearman's rank correlation rho	two.sided	0,022761151
hsa-miR-362-5p	CD44+	0,129548249	14114,37514	0,390846882	Spearman's rank correlation rho	two.sided	0,390846882
hsa-miR-363-3p	CD44+	0,369853587	10217,82408	0,011411138	Spearman's rank correlation rho	two.sided	0,011411138
hsa-miR-3651	CD44+	0,325464841	10937,5876	0,027304344	Spearman's rank correlation rho	two.sided	0,027304344
hsa-miR-3652	CD44+	-0,214099372	19686,62132	0,15307375	Spearman's rank correlation rho	two.sided	0,15307375
hsa-miR-3654	CD44+	0,245682401	12231,25986	0,099810062	Spearman's rank correlation rho	two.sided	0,099810062
hsa-miR-3659	CD44+	0,232609119	12443,24314	0,119794003	Spearman's rank correlation rho	two.sided	0,119794003
hsa-miR-3660	CD44+	-0,05127457	17046,41716	0,73505182	Spearman's rank correlation rho	two.sided	0,73505182
hsa-miR-369-3p	CD44+	-0,018113258	16508,70647	0,904895952	Spearman's rank correlation rho	two.sided	0,904895952
hsa-miR-369-5p	CD44+	-0,259474403	20422,37744	0,081618313	Spearman's rank correlation rho	two.sided	0,081618313
hsa-miR-370-3p	CD44+	0,250905422	12146,56859	0,092585358	Spearman's rank correlation rho	two.sided	0,092585358
hsa-miR-374a-3p	CD44+	0,347935382	10573,22779	0,017815542	Spearman's rank correlation rho	two.sided	0,017815542
hsa-miR-374a-5p	CD44+	0,382871652	10006,73616	0,008634302	Spearman's rank correlation rho	two.sided	0,008634302
hsa-miR-374b-3p	CD44+	-0,153220344	18699,46788	0,309338794	Spearman's rank correlation rho	two.sided	0,309338794
hsa-miR-374b-5p	CD44+	0,132942028	14059,34501	0,378447119	Spearman's rank correlation rho	two.sided	0,378447119
hsa-miR-375-3p	CD44+	0,013920977	15989,27136	0,926838959	Spearman's rank correlation rho	two.sided	0,926838959
hsa-miR-376a-3p	CD44+	0,388440731	9916,433541	0,007637624	Spearman's rank correlation rho	two.sided	0,007637624
hsa-miR-376c-3p	CD44+	0,360637744	10367,25897	0,013811431	Spearman's rank correlation rho	two.sided	0,013811431
hsa-miR-377-3p	CD44+	0,408612793	9589,343561	0,004812865	Spearman's rank correlation rho	two.sided	0,004812865
hsa-miR-378a-3p	CD44+	0,086956622	14804,99838	0,565542916	Spearman's rank correlation rho	two.sided	0,565542916
hsa-miR-378a-5p	CD44+	0,207105655	12856,78181	0,167270336	Spearman's rank correlation rho	two.sided	0,167270336
hsa-miR-378c	CD44+	0,069452794	15088,82295	0,646490777	Spearman's rank correlation rho	two.sided	0,646490777
hsa-miR-378d	CD44+	-0,032135361	16736,07487	0,832099923	Spearman's rank correlation rho	two.sided	0,832099923
hsa-miR-379-3p	CD44+	0,427288087	9286,523669	0,003059388	Spearman's rank correlation rho	two.sided	0,003059388
hsa-miR-379-5p	CD44+	0,246814393	12212,90462	0,098208535	Spearman's rank correlation rho	two.sided	0,098208535
hsa-miR-381-3p	CD44+	0,124883052	14190,02132	0,408275239	Spearman's rank correlation rho	two.sided	0,408275239
hsa-miR-382-3p	CD44+	-0,260002326	20430,93772	0,080977475	Spearman's rank correlation rho	two.sided	0,080977475
hsa-miR-382-5p	CD44+	0,414097446	9500,409906	0,004224255	Spearman's rank correlation rho	two.sided	0,004224255
hsa-miR-3909	CD44+	0,087767283	14791,85351	0,561910758	Spearman's rank correlation rho	two.sided	0,561910758
hsa-miR-3912-3p	CD44+	0,373230405	10163,06899	0,010625986	Spearman's rank correlation rho	two.sided	0,010625986
hsa-miR-3940-3p	CD44+	0,346911733	10589,82624	0,018177118	Spearman's rank correlation rho	two.sided	0,018177118
hsa-miR-3960	CD44+	0,220624388	12637,57555	0,140645538	Spearman's rank correlation rho	two.sided	0,140645538
hsa-miR-409-3p	CD44+	-0,191690396	19323,25978	0,201884422	Spearman's rank correlation rho	two.sided	0,201884422
hsa-miR-411-5p	CD44+	0,251565265	12135,86923	0,091702254	Spearman's rank correlation rho	two.sided	0,091702254
hsa-miR-421	CD44+	0,145594428	13854,18635	0,334318916	Spearman's rank correlation rho	two.sided	0,334318916
hsa-miR-423-3p	CD44+	0,290823057	11499,30413	0,049903995	Spearman's rank correlation rho	two.sided	0,049903995
hsa-miR-423-5p	CD44+	-0,358382678	22026,17513	0,014460317	Spearman's rank correlation rho	two.sided	0,014460317
hsa-miR-424-3p	CD44+	-0,199687066	19452,92577	0,183347987	Spearman's rank correlation rho	two.sided	0,183347987
hsa-miR-424-5p	CD44+	0,35852605	10401,50009	0,014418303	Spearman's rank correlation rho	two.sided	0,014418303
hsa-miR-425-3p	CD44+	0,456399546	8814,481356	0,001432572	Spearman's rank correlation rho	two.sided	0,001432572
hsa-miR-425-5p	CD44+	0,203866435	12909,30575	0,174159775	Spearman's rank correlation rho	two.sided	0,174159775

hsa-miR-4284	CD44+	0,418993362	9421,02264	0,003753077	Spearman's rank correlation rho	two.sided	0,003753077
hsa-miR-4286	CD44+	0,179955614	13297,01971	0,231412376	Spearman's rank correlation rho	two.sided	0,231412376
hsa-miR-429	CD44+	-0,052780954	17070,84317	0,727563019	Spearman's rank correlation rho	two.sided	0,727563019
hsa-miR-432-5p	CD44+	0,167082635	13505,75507	0,267065045	Spearman's rank correlation rho	two.sided	0,267065045
hsa-miR-4326	CD44+	-0,206708671	19566,7811	0,168103879	Spearman's rank correlation rho	two.sided	0,168103879
hsa-miR-4443	CD44+	0,203377885	12917,22759	0,17521636	Spearman's rank correlation rho	two.sided	0,17521636
hsa-miR-4444	CD44+	0,094726352	14679,01221	0,531187084	Spearman's rank correlation rho	two.sided	0,531187084
hsa-miR-4446-3p	CD44+	0,321505415	11001,7897	0,029349869	Spearman's rank correlation rho	two.sided	0,029349869
hsa-miR-4448	CD44+	0,103202678	14541,56858	0,49491185	Spearman's rank correlation rho	two.sided	0,49491185
hsa-miR-4455	CD44+	-0,205124949	19541,10105	0,171459167	Spearman's rank correlation rho	two.sided	0,171459167
hsa-miR-4468	CD44+	0,315962218	11091,67264	0,032425997	Spearman's rank correlation rho	two.sided	0,032425997
hsa-miR-4484	CD44+	-0,096670028	17782,5045	0,522755439	Spearman's rank correlation rho	two.sided	0,522755439
hsa-miR-4488	CD44+	0,12251779	14228,37404	0,41727939	Spearman's rank correlation rho	two.sided	0,41727939
hsa-miR-4492	CD44+	0,304630869	11275,41046	0,039546401	Spearman's rank correlation rho	two.sided	0,039546401
hsa-miR-4497	CD44+	0,421283972	9383,880399	0,003548932	Spearman's rank correlation rho	two.sided	0,003548932
hsa-miR-450a-5p	CD44+	0,045731374	15473,46578	0,762814237	Spearman's rank correlation rho	two.sided	0,762814237
hsa-miR-450b-5p	CD44+	0,417673594	9442,422679	0,003875316	Spearman's rank correlation rho	two.sided	0,003875316
hsa-miR-4516	CD44+	0,183749363	13235,50409	0,221559471	Spearman's rank correlation rho	two.sided	0,221559471
hsa-miR-451a	CD44+	0,26304708	11949,6916	0,077358112	Spearman's rank correlation rho	two.sided	0,077358112
hsa-miR-452-3p	CD44+	0,361517463	10352,99434	0,013565112	Spearman's rank correlation rho	two.sided	0,013565112
hsa-miR-452-5p	CD44+	0,093076642	14705,76225	0,538395362	Spearman's rank correlation rho	two.sided	0,538395362
hsa-miR-4525	CD44+	-0,2470682	20221,21087	0,097852187	Spearman's rank correlation rho	two.sided	0,097852187
hsa-miR-454-3p	CD44+	0,104674457	14517,70367	0,488746222	Spearman's rank correlation rho	two.sided	0,488746222
hsa-miR-454-5p	CD44+	0,16867156	13479,99066	0,262477508	Spearman's rank correlation rho	two.sided	0,262477508
hsa-miR-455-3p	CD44+	0,186498962	13190,91934	0,21460231	Spearman's rank correlation rho	two.sided	0,21460231
hsa-miR-4636	CD44+	-0,295741775	21010,45288	0,045988098	Spearman's rank correlation rho	two.sided	0,045988098
hsa-miR-4662a-5p	CD44+	0,303513657	11293,52605	0,040312914	Spearman's rank correlation rho	two.sided	0,040312914
hsa-miR-4681	CD44+	-0,042067607	16897,12624	0,781329265	Spearman's rank correlation rho	two.sided	0,781329265
hsa-miR-4685-3p	CD44+	0,112051764	14398,08065	0,458452906	Spearman's rank correlation rho	two.sided	0,458452906
hsa-miR-4708-3p	CD44+	-0,253403282	20323,93423	0,089276771	Spearman's rank correlation rho	two.sided	0,089276771
hsa-miR-4758-5p	CD44+	-0,401023893	22717,60242	0,005744831	Spearman's rank correlation rho	two.sided	0,005744831
hsa-miR-4791	CD44+	-0,079219077	17499,53734	0,600746653	Spearman's rank correlation rho	two.sided	0,600746653
hsa-miR-4804-5p	CD44+	-0,218282902	19754,45726	0,145016117	Spearman's rank correlation rho	two.sided	0,145016117
hsa-miR-484	CD44+	0,227262003	12529,94662	0,128787836	Spearman's rank correlation rho	two.sided	0,128787836
hsa-miR-485-3p	CD44+	0,116502525	14325,91156	0,440680811	Spearman's rank correlation rho	two.sided	0,440680811
hsa-miR-485-5p	CD44+	0,383404446	9998,096914	0,008534328	Spearman's rank correlation rho	two.sided	0,008534328
hsa-miR-486-3p	CD44+	0,080899286	14903,21808	0,593021324	Spearman's rank correlation rho	two.sided	0,593021324
hsa-miR-486-5p	CD44+	0,129577242	14113,90502	0,390739952	Spearman's rank correlation rho	two.sided	0,390739952
hsa-miR-487b-3p	CD44+	0,487177348	8315,419303	0,000595512	Spearman's rank correlation rho	two.sided	0,000595512
hsa-miR-493-5p	CD44+	0,002969387	16166,8514	0,984374319	Spearman's rank correlation rho	two.sided	0,984374319
hsa-miR-494-3p	CD44+	0,189050942	13149,53898	0,208282558	Spearman's rank correlation rho	two.sided	0,208282558
hsa-miR-495-3p	CD44+	0,440063082	9079,377128	0,002210871	Spearman's rank correlation rho	two.sided	0,002210871
hsa-miR-497-5p	CD44+	0,309301555	11199,67528	0,036470079	Spearman's rank correlation rho	two.sided	0,036470079
hsa-miR-499a-5p	CD44+	-0,253849554	20331,17052	0,088695457	Spearman's rank correlation rho	two.sided	0,088695457
hsa-miR-500a-3p	CD44+	0,226531198	12541,79662	0,130055365	Spearman's rank correlation rho	two.sided	0,130055365
hsa-miR-501-3p	CD44+	0,136154469	14007,25528	0,366928125	Spearman's rank correlation rho	two.sided	0,366928125
hsa-miR-501-5p	CD44+	-0,021147326	16557,90389	0,889057878	Spearman's rank correlation rho	two.sided	0,889057878
hsa-miR-502-3p	CD44+	0,225685486	12555,50985	0,131533832	Spearman's rank correlation rho	two.sided	0,131533832
hsa-miR-505-3p	CD44+	0,031901457	15697,71788	0,833304633	Spearman's rank correlation rho	two.sided	0,833304633
hsa-miR-505-5p	CD44+	-0,33430756	21635,79708	0,023161795	Spearman's rank correlation rho	two.sided	0,023161795
hsa-miR-5100	CD44+	0,165996101	13523,37323	0,270232548	Spearman's rank correlation rho	two.sided	0,270232548
hsa-miR-511-5p	CD44+	0,022106797	15856,53829	0,884057956	Spearman's rank correlation rho	two.sided	0,884057956
hsa-miR-5191	CD44+	-0,20932167	19609,15088	0,162672414	Spearman's rank correlation rho	two.sided	0,162672414
hsa-miR-532-3p	CD44+	0,058397935	15268,07749	0,69986465	Spearman's rank correlation rho	two.sided	0,69986465
hsa-miR-532-5p	CD44+	0,18004903	13295,50498	0,231166214	Spearman's rank correlation rho	two.sided	0,231166214
hsa-miR-539-5p	CD44+	-0,060447241	17195,15202	0,689852153	Spearman's rank correlation rho	two.sided	0,689852153
hsa-miR-543	CD44+	0,421104991	9386,782578	0,003564524	Spearman's rank correlation rho	two.sided	0,003564524
hsa-miR-548e-3p	CD44+	0,481286414	8410,940802	0,000708975	Spearman's rank correlation rho	two.sided	0,000708975
hsa-miR-548i	CD44+	0,43021139	9239,122309	0,00284333	Spearman's rank correlation rho	two.sided	0,00284333
hsa-miR-548k	CD44+	0,219352216	12658,20381	0,143007857	Spearman's rank correlation rho	two.sided	0,143007857
hsa-miR-548l	CD44+	-0,276260447	20694,56315	0,06310157	Spearman's rank correlation rho	two.sided	0,06310157
hsa-miR-550a-5p	CD44+	0,354500634	10466,77222	0,015638174	Spearman's rank correlation rho	two.sided	0,015638174
hsa-miR-552-3p	CD44+	0,149628703	13788,77059	0,320951579	Spearman's rank correlation rho	two.sided	0,320951579
hsa-miR-552-5p	CD44+	0,293747374	11451,88633	0,047544645	Spearman's rank correlation rho	two.sided	0,047544645
hsa-miR-556-5p	CD44+	0,002507637	16174,33867	0,986803933	Spearman's rank correlation rho	two.sided	0,986803933
hsa-miR-5571-3p	CD44+	0,376079507	10116,87079	0,010000052	Spearman's rank correlation rho	two.sided	0,010000052
hsa-miR-5697	CD44+	-0,171311177	18992,81074	0,254973182	Spearman's rank correlation rho	two.sided	0,254973182
hsa-miR-574-3p	CD44+	0,076930613	14967,57011	0,611338612	Spearman's rank correlation rho	two.sided	0,611338612
hsa-miR-574-5p	CD44+	0,114270766	14362,09954	0,449544247	Spearman's rank correlation rho	two.sided	0,449544247
hsa-miR-576-3p	CD44+	0,369414473	10224,94432	0,011516801	Spearman's rank correlation rho	two.sided	0,011516801
hsa-miR-576-5p	CD44+	0,381874885	10022,89873	0,00882405	Spearman's rank correlation rho	two.sided	0,00882405
hsa-miR-577	CD44+	0,010360499	16047,00451	0,945517947	Spearman's rank correlation rho	two.sided	0,945517947
hsa-miR-582-3p	CD44+	0,298738713	11370,95176	0,043727249	Spearman's rank correlation rho	two.sided	0,043727249
hsa-miR-582-5p	CD44+	0,254616251	12086,39749	0,087703636	Spearman's rank correlation rho	two.sided	0,087703636
hsa-miR-584-5p	CD44+	0,412546767	9525,554176	0,004383915	Spearman's rank correlation rho	two.sided	0,004383915
hsa-miR-589-5p	CD44+	0,427288087	9286,523669	0,003059388	Spearman's rank correlation rho	two.sided	0,003059388
hsa-miR-590-3p	CD44+	0,103304844	14539,91195	0,49448256	Spearman's rank correlation rho	two.sided	0,49448256
hsa-miR-592	CD44+	0,365366514	10290,58197	0,012530955	Spearman's rank correlation rho	two.sided	0,012530955
hsa-miR-598-3p	CD44+	-0,127320695	18279,50507	0,399113543	Spearman's rank correlation rho	two.sided	0,399113543
hsa-miR-6126	CD44+	-0,068957881	17333,15203	0,648845516	Spearman's rank correlation rho	two.sided	0,648845516
hsa-miR-622	CD44+	-0,211301383	19641,25192	0,158643238	Spearman's rank correlation rho	two.sided	0,158643238
hsa-miR-624-5p	CD44+	-0,071863587	17380,26807	0,635069669	Spearman's rank correlation rho	two.sided	0,635069669
hsa-miR-625-3p	CD44+	-0,014846017	16455,72816	0,921991971	Spearman's rank correlation rho	two.sided	0,921991971
hsa-miR-625-5p	CD44+	0,211393847	12787,24876	0,15845685	Spearman's rank correlation rho	two.sided	0,15845685
hsa-miR-628-3p	CD44+	-0,062756907	17232,60324	0,678630175	Spearman's rank correlation rho	two.sided	0,678630175
hsa-miR-628-5p	CD44+	0,31629217	11086,32246	0,032235719	Spearman's rank correlation rho	two.sided	0,032235719
hsa-miR-629-5p	CD44+	0,151688622	13755,369	0,31425808	Spearman's rank correlation rho	two.sided	0,31425808
hsa-miR-642a-3p	CD44+	0,214653652	12734,39103	0,151987692	Spearman's rank correlation rho	two.sided	0,151987692
hsa-miR-642a-5p	CD44+	-0,253337292	20322,86419	0,089362981	Spearman's rank correlation rho	two.sided	0,089362981
hsa-miR-651-5p	CD44+	0,033523143	15671,42224	0,824960154	Spearman's rank correlation rho	two.sided	0,824960154
hsa-miR-6511b-3p	CD44+	-0,046916307	16975,74792	0,7568535	Spearman's rank correlation rho	two.sided	0,7568535
hsa-miR-6513-3p	CD44+	-0,309452614	21232,77413	0,03637397	Spearman's rank correlation rho	two.sided	0,03637397
hsa-miR-652-3p	CD44+	0,197928578	13005,58811	0,187315804	Spearman's rank correlation rho	two.sided	0,187315804
hsa-miR-654-3p	CD44+	0,343546221	10644,39803	0,019409918	Spearman's rank correlation rho	two.sided	0,019409918
hsa-miR-660-5p	CD44+	0,341051973	10684,84225	0,020368422	Spearman's rank correlation rho	two.sided	0,020368422
hsa-miR-663a	CD44+	0,179746864	13300,4046	0,231963114	Spearman's rank correlation rho	two.sided	0,231963114
hsa-miR-664a-3p	CD44+	0,018047828	15922,35447	0,905237925	Spearman's rank correlation rho	two.sided	0,905237925
hsa-miR-664a-5p	CD44+	0,253339028	12107,10766	0,089360712	Spearman's rank correlation rho	two.sided	0,089360712
hsa-miR-671-3p	CD44+	0,2554741	12072,48746	0,086604159	Spearman's rank correlation rho	two.sided	0,086604159

hsa-miR-671-5p	CD44+	0,118650808	14291,07715	0,432241062	Spearman's rank correlation rho	two.sided	0,432241062
hsa-miR-6729-5p	CD44+	0,154153664	13715,39835	0,306365565	Spearman's rank correlation rho	two.sided	0,306365565
hsa-miR-6734-5p	CD44+	-0,431907418	23218,37878	0,002724241	Spearman's rank correlation rho	two.sided	0,002724241
hsa-miR-6787-5p	CD44+	0,277679198	11712,43181	0,0617046	Spearman's rank correlation rho	two.sided	0,0617046
hsa-miR-6803-3p	CD44+	0,071960353	15048,16288	0,634612965	Spearman's rank correlation rho	two.sided	0,634612965
hsa-miR-6803-5p	CD44+	-0,087767283	17638,14649	0,561910758	Spearman's rank correlation rho	two.sided	0,561910758
hsa-miR-6821-5p	CD44+	0,217636465	12686,02472	0,146240251	Spearman's rank correlation rho	two.sided	0,146240251
hsa-miR-6859-5p	CD44+	-0,315962218	21338,32736	0,032425997	Spearman's rank correlation rho	two.sided	0,032425997
hsa-miR-6866-5p	CD44+	0,362705254	10333,7343	0,013238485	Spearman's rank correlation rho	two.sided	0,013238485
hsa-miR-6869-5p	CD44+	-0,416901867	22975,06377	0,0039484	Spearman's rank correlation rho	two.sided	0,0039484
hsa-miR-6887-5p	CD44+	-0,366642874	22160,11421	0,012203251	Spearman's rank correlation rho	two.sided	0,012203251
hsa-miR-7-1-3p	CD44+	0,280417716	11668,02673	0,05907806	Spearman's rank correlation rho	two.sided	0,05907806
hsa-miR-7-5p	CD44+	0,379297131	10064,69702	0,009331518	Spearman's rank correlation rho	two.sided	0,009331518
hsa-miR-744-5p	CD44+	0,293579175	11454,61368	0,047677848	Spearman's rank correlation rho	two.sided	0,047677848
hsa-miR-769-5p	CD44+	0,152664169	13739,5505	0,311119297	Spearman's rank correlation rho	two.sided	0,311119297
hsa-miR-7704	CD44+	0,355545702	10449,82644	0,015313345	Spearman's rank correlation rho	two.sided	0,015313345
hsa-miR-7706	CD44+	0,136657766	13999,09432	0,365142752	Spearman's rank correlation rho	two.sided	0,365142752
hsa-miR-7854-3p	CD44+	-0,142143404	18519,85529	0,346024487	Spearman's rank correlation rho	two.sided	0,346024487
hsa-miR-7975	CD44+	-0,169623189	18965,44	0,259755276	Spearman's rank correlation rho	two.sided	0,259755276
hsa-miR-7976	CD44+	0,219286226	12659,27385	0,143131193	Spearman's rank correlation rho	two.sided	0,143131193
hsa-miR-7977	CD44+	-0,067627683	17311,58288	0,655191208	Spearman's rank correlation rho	two.sided	0,655191208
hsa-miR-8085	CD44+	-0,150722161	18658,95984	0,317387381	Spearman's rank correlation rho	two.sided	0,317387381
hsa-miR-874-3p	CD44+	0,234765012	12408,28534	0,116305287	Spearman's rank correlation rho	two.sided	0,116305287
hsa-miR-877-3p	CD44+	0,161676573	13593,41436	0,283070153	Spearman's rank correlation rho	two.sided	0,283070153
hsa-miR-877-5p	CD44+	-0,197371312	19415,37582	0,188585885	Spearman's rank correlation rho	two.sided	0,188585885
hsa-miR-9-3p	CD44+	0,225449377	12559,33835	0,131948831	Spearman's rank correlation rho	two.sided	0,131948831
hsa-miR-9-5p	CD44+	-0,247778808	20232,73338	0,096859789	Spearman's rank correlation rho	two.sided	0,096859789
hsa-miR-92a-1-5p	CD44+	0,122925019	14221,77082	0,415721136	Spearman's rank correlation rho	two.sided	0,415721136
hsa-miR-92a-3p	CD44+	-0,131952385	18354,60793	0,38203856	Spearman's rank correlation rho	two.sided	0,38203856
hsa-miR-92b-3p	CD44+	0,246172357	12223,31523	0,099114429	Spearman's rank correlation rho	two.sided	0,099114429
hsa-miR-92b-5p	CD44+	0,361385486	10355,13434	0,013601825	Spearman's rank correlation rho	two.sided	0,013601825
hsa-miR-93-3p	CD44+	0,340819586	10688,61042	0,02045972	Spearman's rank correlation rho	two.sided	0,02045972
hsa-miR-93-5p	CD44+	0,331398415	10841,37469	0,024462182	Spearman's rank correlation rho	two.sided	0,024462182
hsa-miR-940	CD44+	-0,272342538	20631,03426	0,067090705	Spearman's rank correlation rho	two.sided	0,067090705
hsa-miR-941	CD44+	0,089711233	14760,33235	0,553245537	Spearman's rank correlation rho	two.sided	0,553245537
hsa-miR-942-5p	CD44+	0,170888878	13444,03684	0,256163979	Spearman's rank correlation rho	two.sided	0,256163979
hsa-miR-95-3p	CD44+	0,252622841	12118,72063	0,09030049	Spearman's rank correlation rho	two.sided	0,09030049
hsa-miR-96-5p	CD44+	-0,021741837	16567,54389	0,885959291	Spearman's rank correlation rho	two.sided	0,885959291
hsa-miR-98-5p	CD44+	0,111103908	14413,45013	0,4622872	Spearman's rank correlation rho	two.sided	0,4622872
hsa-miR-99a-5p	CD44+	0,159583106	13627,35993	0,289433092	Spearman's rank correlation rho	two.sided	0,289433092
hsa-miR-99b-3p	CD44+	-0,171470864	18995,40006	0,254523869	Spearman's rank correlation rho	two.sided	0,254523869
hsa-miR-99b-5p	CD44+	0,220070377	12646,55884	0,141670706	Spearman's rank correlation rho	two.sided	0,141670706

Supplementary Table S7. The list of correlations between endoscopic Mayo score and normalized expression of miRNAs expressed in crypt-top (CD66a+) colonic epithelial cell population

mir	cell_type	estimate	statistic	p.value	method	alternative	padj
hsa-let-7a-3p	CD66a+	0,07775984	16991,3528	0,59935271	Spearman's rank correlation rho	two.sided	0,59935271
hsa-let-7a-5p	CD66a+	-0,07901	19879,6793	0,59347752	Spearman's rank correlation rho	two.sided	0,59347752
hsa-let-7b-3p	CD66a+	-0,1934417	21987,9691	0,18771848	Spearman's rank correlation rho	two.sided	0,18771848
hsa-let-7b-5p	CD66a+	0,07941903	16960,7839	0,59156053	Spearman's rank correlation rho	two.sided	0,59156053
hsa-let-7c-5p	CD66a+	0,02320041	17996,5557	0,87562227	Spearman's rank correlation rho	two.sided	0,87562227
hsa-let-7d-3p	CD66a+	0,18875898	14946,3046	0,19883605	Spearman's rank correlation rho	two.sided	0,19883605
hsa-let-7d-5p	CD66a+	-0,1087556	20427,7124	0,4618489	Spearman's rank correlation rho	two.sided	0,4618489
hsa-let-7e-5p	CD66a+	0,10203504	16544,1064	0,49013779	Spearman's rank correlation rho	two.sided	0,49013779
hsa-let-7f-1-3p	CD66a+	0,04787089	17542,0267	0,74661789	Spearman's rank correlation rho	two.sided	0,74661789
hsa-let-7f-2-3p	CD66a+	0,41418417	10793,0709	0,00342695	Spearman's rank correlation rho	two.sided	0,00342695
hsa-let-7f-5p	CD66a+	0,00619457	18309,8713	0,96666905	Spearman's rank correlation rho	two.sided	0,96666905
hsa-let-7g-5p	CD66a+	-0,2583018	23182,9516	0,07629298	Spearman's rank correlation rho	two.sided	0,07629298
hsa-let-7i-3p	CD66a+	-0,1207326	20648,3777	0,41369557	Spearman's rank correlation rho	two.sided	0,41369557
hsa-let-7i-5p	CD66a+	0,37103119	11588,1213	0,00942563	Spearman's rank correlation rho	two.sided	0,00942563
hsa-miR-1-3p	CD66a+	-0,3086556	24110,6708	0,03280345	Spearman's rank correlation rho	two.sided	0,03280345
hsa-miR-100-5p	CD66a+	-0,0754785	19814,6153	0,6101396	Spearman's rank correlation rho	two.sided	0,6101396
hsa-miR-101-3p	CD66a+	-0,0562771	19460,8485	0,70400286	Spearman's rank correlation rho	two.sided	0,70400286
hsa-miR-103a-3p	CD66a+	-0,1039635	20339,4242	0,48192913	Spearman's rank correlation rho	two.sided	0,48192913
hsa-miR-106b-3p	CD66a+	0,09055417	16755,6299	0,5404717	Spearman's rank correlation rho	two.sided	0,5404717
hsa-miR-106b-5p	CD66a+	-0,0258302	18899,8952	0,86165449	Spearman's rank correlation rho	two.sided	0,86165449
hsa-miR-10a-3p	CD66a+	0,1468912	15717,6766	0,31911241	Spearman's rank correlation rho	two.sided	0,31911241
hsa-miR-10a-5p	CD66a+	-0,1226641	20683,9637	0,40620891	Spearman's rank correlation rho	two.sided	0,40620891
hsa-miR-10b-3p	CD66a+	-0,0756912	19818,5353	0,60913006	Spearman's rank correlation rho	two.sided	0,60913006
hsa-miR-10b-5p	CD66a+	-0,4077895	25937,1141	0,00401488	Spearman's rank correlation rho	two.sided	0,00401488
hsa-miR-1180-3p	CD66a+	0,13500214	15936,7206	0,36026239	Spearman's rank correlation rho	two.sided	0,36026239
hsa-miR-122-5p	CD66a+	-0,1124324	20495,4551	0,44675331	Spearman's rank correlation rho	two.sided	0,44675331
hsa-miR-1224-5p	CD66a+	0,15622146	15545,7758	0,28899397	Spearman's rank correlation rho	two.sided	0,28899397
hsa-miR-1246	CD66a+	0,15369539	15592,3161	0,29695891	Spearman's rank correlation rho	two.sided	0,29695891
hsa-miR-1247-3p	CD66a+	-0,4458134	26637,6667	0,00149512	Spearman's rank correlation rho	two.sided	0,00149512
hsa-miR-1247-5p	CD66a+	-0,0159836	18718,4816	0,91413425	Spearman's rank correlation rho	two.sided	0,91413425
hsa-miR-1248	CD66a+	0,02878292	17893,7034	0,84602116	Spearman's rank correlation rho	two.sided	0,84602116
hsa-miR-1249-3p	CD66a+	0,08098525	16931,9277	0,58424652	Spearman's rank correlation rho	two.sided	0,58424652
hsa-miR-125a-3p	CD66a+	0,19542366	14823,5144	0,18314903	Spearman's rank correlation rho	two.sided	0,18314903
hsa-miR-125a-5p	CD66a+	-0,0152527	18705,015	0,91804716	Spearman's rank correlation rho	two.sided	0,91804716
hsa-miR-125b-5p	CD66a+	0,00759711	18284,0308	0,95912822	Spearman's rank correlation rho	two.sided	0,95912822
hsa-miR-126-3p	CD66a+	0,17981776	15111,0375	0,22133993	Spearman's rank correlation rho	two.sided	0,22133993
hsa-miR-126-5p	CD66a+	0,3695628	11615,1751	0,00973376	Spearman's rank correlation rho	two.sided	0,00973376
hsa-miR-1261	CD66a+	0,12575949	16107,0072	0,39437556	Spearman's rank correlation rho	two.sided	0,39437556
hsa-miR-1262	CD66a+	0,13336549	15966,8742	0,36616868	Spearman's rank correlation rho	two.sided	0,36616868
hsa-miR-1266-5p	CD66a+	0,50264629	9163,24466	0,00027184	Spearman's rank correlation rho	two.sided	0,00027184
hsa-miR-1269a	CD66a+	0,1399379	15845,7842	0,34280334	Spearman's rank correlation rho	two.sided	0,34280334
hsa-miR-127-3p	CD66a+	0,48328415	9519,97277	0,00050237	Spearman's rank correlation rho	two.sided	0,00050237
hsa-miR-1271-5p	CD66a+	0,32717621	12396,1055	0,02321592	Spearman's rank correlation rho	two.sided	0,02321592
hsa-miR-1275	CD66a+	0,17444135	15210,0926	0,23569107	Spearman's rank correlation rho	two.sided	0,23569107
hsa-miR-128-3p	CD66a+	0,08520452	16854,192	0,56474873	Spearman's rank correlation rho	two.sided	0,56474873
hsa-miR-1287-5p	CD66a+	0,28523204	13168,8849	0,04940396	Spearman's rank correlation rho	two.sided	0,04940396
hsa-miR-1290	CD66a+	0,01621735	18125,2116	0,91288324	Spearman's rank correlation rho	two.sided	0,91288324
hsa-miR-1291	CD66a+	0,01844261	18084,2134	0,90098547	Spearman's rank correlation rho	two.sided	0,90098547
hsa-miR-1294	CD66a+	0,27280291	13397,8792	0,06065949	Spearman's rank correlation rho	two.sided	0,06065949
hsa-miR-1296-5p	CD66a+	0,29766683	12939,7863	0,03990123	Spearman's rank correlation rho	two.sided	0,03990123
hsa-miR-1299	CD66a+	0,32975698	12348,5574	0,02208889	Spearman's rank correlation rho	two.sided	0,02208889
hsa-miR-1301-3p	CD66a+	-0,0734642	19777,5044	0,61973223	Spearman's rank correlation rho	two.sided	0,61973223
hsa-miR-1303	CD66a+	-0,1626719	21421,0676	0,26929216	Spearman's rank correlation rho	two.sided	0,26929216
hsa-miR-1304-3p	CD66a+	-0,1706553	21568,1525	0,24617122	Spearman's rank correlation rho	two.sided	0,24617122
hsa-miR-1304-5p	CD66a+	-0,0896361	20075,4564	0,54460161	Spearman's rank correlation rho	two.sided	0,54460161
hsa-miR-1306-3p	CD66a+	0,18892201	14943,301	0,19844134	Spearman's rank correlation rho	two.sided	0,19844134
mir							
hsa-miR-1306-5p	CD66a+	-0,171732	21587,9901	0,24315916	Spearman's rank correlation rho	two.sided	0,24315916
hsa-miR-1307-3p	CD66a+	0,15004701	15659,534	0,30871074	Spearman's rank correlation rho	two.sided	0,30871074
hsa-miR-1307-5p	CD66a+	0,01294782	18185,4493	0,93039797	Spearman's rank correlation rho	two.sided	0,93039797
hsa-miR-130a-3p	CD66a+	-0,1007713	20280,6096	0,49555628	Spearman's rank correlation rho	two.sided	0,49555628
hsa-miR-130b-3p	CD66a+	-0,0763864	19831,343	0,60583667	Spearman's rank correlation rho	two.sided	0,60583667
hsa-miR-130b-5p	CD66a+	-0,0352973	19074,3183	0,81174526	Spearman's rank correlation rho	two.sided	0,81174526
hsa-miR-132-3p	CD66a+	-0,1039248	20338,7113	0,48209312	Spearman's rank correlation rho	two.sided	0,48209312
hsa-miR-132-5p	CD66a+	0,17152741	15263,7791	0,24372952	Spearman's rank correlation rho	two.sided	0,24372952
hsa-miR-133a-3p	CD66a+	0,1672221	15343,1	0,2559436	Spearman's rank correlation rho	two.sided	0,2559436
hsa-miR-135a-3p	CD66a+	0,41535327	10771,5314	0,00332807	Spearman's rank correlation rho	two.sided	0,00332807
hsa-miR-135a-5p	CD66a+	0,22639076	14252,9767	0,12179027	Spearman's rank correlation rho	two.sided	0,12179027
hsa-miR-135b-5p	CD66a+	0,43633159	10385,0268	0,00193322	Spearman's rank correlation rho	two.sided	0,00193322
hsa-miR-136-3p	CD66a+	0,08176991	16917,4711	0,58059766	Spearman's rank correlation rho	two.sided	0,58059766
hsa-miR-139-3p	CD66a+	0,12248617	16167,3147	0,40689534	Spearman's rank correlation rho	two.sided	0,40689534
hsa-miR-139-5p	CD66a+	0,1951979	14827,6739	0,18366547	Spearman's rank correlation rho	two.sided	0,18366547
hsa-miR-140-3p	CD66a+	0,23729927	14051,9983	0,10437335	Spearman's rank correlation rho	two.sided	0,10437335
hsa-miR-140-5p	CD66a+	0,18196561	15071,4655	0,21577967	Spearman's rank correlation rho	two.sided	0,21577967
hsa-miR-141-3p	CD66a+	0,05201099	17465,7496	0,72552688	Spearman's rank correlation rho	two.sided	0,72552688
hsa-miR-141-5p	CD66a+	0,41229121	10827,9467	0,00359254	Spearman's rank correlation rho	two.sided	0,00359254
hsa-miR-142-3p	CD66a+	0,06966344	17140,5208	0,63800322	Spearman's rank correlation rho	two.sided	0,63800322
hsa-miR-142-5p	CD66a+	0,251815	13784,5605	0,08424269	Spearman's rank correlation rho	two.sided	0,08424269
hsa-miR-143-3p	CD66a+	0,17818146	15141,1847	0,225642	Spearman's rank correlation rho	two.sided	0,225642
hsa-miR-143-5p	CD66a+	0,38509226	11329,0602	0,00687628	Spearman's rank correlation rho	two.sided	0,00687628
hsa-miR-144-3p	CD66a+	-0,0518719	19379,6884	0,72623213	Spearman's rank correlation rho	two.sided	0,72623213
hsa-miR-144-5p	CD66a+	-0,0107534	18622,121	0,94217213	Spearman's rank correlation rho	two.sided	0,94217213
hsa-miR-145-3p	CD66a+	0,01551901	18138,0778	0,91662108	Spearman's rank correlation rho	two.sided	0,91662108
hsa-miR-145-5p	CD66a+	0,05750897	17364,4548	0,69782896	Spearman's rank correlation rho	two.sided	0,69782896
hsa-miR-1468-5p	CD66a+	0,14537013	15745,7007	0,32420417	Spearman's rank correlation rho	two.sided	0,32420417
hsa-miR-146a-3p	CD66a+	0,22703375	14241,1302	0,12070633	Spearman's rank correlation rho	two.sided	0,12070633
hsa-miR-146a-5p	CD66a+	0,54962173	8297,76922	5,2083E-05	Spearman's rank correlation rho	two.sided	5,2083E-05
hsa-miR-146b-3p	CD66a+	0,14755808	15705,39	0,31689607	Spearman's rank correlation rho	two.sided	0,31689607
hsa-miR-146b-5p	CD66a+	0,09122377	16743,2933	0,53746898	Spearman's rank correlation rho	two.sided	0,53746898
hsa-miR-147b-3p	CD66a+	-0,3023522	23994,5368	0,03673448	Spearman's rank correlation rho	two.sided	0,03673448
hsa-miR-147b-5p	CD66a+	0,0004968	18414,8469	0,99732613	Spearman's rank correlation rho	two.sided	0,99732613
hsa-miR-148a-3p	CD66a+	0,41006865	10868,8951	0,00379591	Spearman's rank correlation rho	two.sided	0,00379591
hsa-miR-148a-5p	CD66a+	0,3607266	11777,9732	0,01177734	Spearman's rank correlation rho	two.sided	0,01177734
hsa-miR-148b-3p	CD66a+	0,29348223	13016,8835	0,04291564	Spearman's rank correlation rho	two.sided	0,04291564
hsa-miR-148b-5p	CD66a+	0,17453768	15208,3177	0,23542845	Spearman's rank correlation rho	two.sided	0,23542845
hsa-miR-149-5p	CD66a+	0,06353905	17253,3565	0,66789294	Spearman's rank correlation rho	two.sided	0,66789294

hsa-miR-150-3p	CD66a+	0,42448998	10603,1966	0,00263797	Spearman's rank correlation rho	two.sided	0,00263797
hsa-miR-150-5p	CD66a+	-0,0975937	20222,0654	0,50931568	Spearman's rank correlation rho	two.sided	0,50931568
hsa-miR-151a-3p	CD66a+	-0,0622379	19570,6705	0,67431145	Spearman's rank correlation rho	two.sided	0,67431145
hsa-miR-151a-5p	CD66a+	0,18875898	14946,3046	0,19883605	Spearman's rank correlation rho	two.sided	0,19883605
hsa-miR-152-3p	CD66a+	0,24615974	13888,7529	0,09168959	Spearman's rank correlation rho	two.sided	0,09168959
hsa-miR-153-3p	CD66a+	-0,004267	18502,6151	0,97703729	Spearman's rank correlation rho	two.sided	0,97703729
hsa-miR-155-5p	CD66a+	0,15696799	15532,0217	0,286667	Spearman's rank correlation rho	two.sided	0,286667
hsa-miR-15a-5p	CD66a+	0,06136128	17293,4798	0,6786485	Spearman's rank correlation rho	two.sided	0,6786485
hsa-miR-15b-3p	CD66a+	-0,2175932	22432,9368	0,13736971	Spearman's rank correlation rho	two.sided	0,13736971
hsa-miR-15b-5p	CD66a+	0,02822619	17903,9607	0,84896451	Spearman's rank correlation rho	two.sided	0,84896451
hsa-miR-16-2-3p	CD66a+	0,04412168	17611,1022	0,76587775	Spearman's rank correlation rho	two.sided	0,76587775
hsa-miR-16-5p	CD66a+	0,04242694	17642,326	0,77463063	Spearman's rank correlation rho	two.sided	0,77463063
hsa-miR-17-3p	CD66a+	0,31621676	12598,0225	0,02855401	Spearman's rank correlation rho	two.sided	0,02855401
hsa-miR-17-5p	CD66a+	-0,226803	22602,6179	0,12109452	Spearman's rank correlation rho	two.sided	0,12109452
hsa-miR-181a-2-3p	CD66a+	0,1144366	16315,6201	0,43864085	Spearman's rank correlation rho	two.sided	0,43864085
hsa-miR-181a-5p	CD66a+	0,14481262	15755,9724	0,3260832	Spearman's rank correlation rho	two.sided	0,3260832
hsa-miR-181b-5p	CD66a+	0,10715139	16449,8428	0,46852016	Spearman's rank correlation rho	two.sided	0,46852016
hsa-miR-181c-3p	CD66a+	0,37794195	11460,7974	0,00808583	Spearman's rank correlation rho	two.sided	0,00808583
hsa-miR-181c-5p	CD66a+	0,15530276	15562,702	0,29187447	Spearman's rank correlation rho	two.sided	0,29187447
hsa-miR-181d-5p	CD66a+	0,05573096	17397,2128	0,7067458	Spearman's rank correlation rho	two.sided	0,7067458
hsa-miR-182-5p	CD66a+	0,38879674	11260,8088	0,00631386	Spearman's rank correlation rho	two.sided	0,00631386
hsa-miR-183-3p	CD66a+	0,05664153	17380,4365	0,70217427	Spearman's rank correlation rho	two.sided	0,70217427
hsa-miR-183-5p	CD66a+	0,24673078	13878,2322	0,09091521	Spearman's rank correlation rho	two.sided	0,09091521
hsa-miR-184	CD66a+	0,06368692	17250,6322	0,66716503	Spearman's rank correlation rho	two.sided	0,66716503
hsa-miR-185-3p	CD66a+	0,33573732	12238,3757	0,01965299	Spearman's rank correlation rho	two.sided	0,01965299
hsa-miR-185-5p	CD66a+	0,00295127	18369,6259	0,98411675	Spearman's rank correlation rho	two.sided	0,98411675
hsa-miR-186-5p	CD66a+	0,02641457	17937,338	0,85855606	Spearman's rank correlation rho	two.sided	0,85855606
hsa-miR-18a-3p	CD66a+	0,39198978	11201,9803	0,00586164	Spearman's rank correlation rho	two.sided	0,00586164
hsa-miR-18a-5p	CD66a+	-0,2835568	23648,2505	0,05081399	Spearman's rank correlation rho	two.sided	0,05081399
hsa-miR-190a-5p	CD66a+	0,19038156	14916,4101	0,19493226	Spearman's rank correlation rho	two.sided	0,19493226
hsa-miR-190b-5p	CD66a+	-0,0113985	18634,005	0,9387098	Spearman's rank correlation rho	two.sided	0,9387098
hsa-miR-191-3p	CD66a+	0,1587384	15499,4036	0,28119757	Spearman's rank correlation rho	two.sided	0,28119757
hsa-miR-191-5p	CD66a+	0,37255062	11560,1275	0,00911569	Spearman's rank correlation rho	two.sided	0,00911569
hsa-miR-192-3p	CD66a+	-0,0070435	18553,7688	0,96210453	Spearman's rank correlation rho	two.sided	0,96210453
hsa-miR-192-5p	CD66a+	-0,2492437	23016,0653	0,08756772	Spearman's rank correlation rho	two.sided	0,08756772
hsa-miR-193a-5p	CD66a+	-0,016363	18725,472	0,91210385	Spearman's rank correlation rho	two.sided	0,91210385
hsa-miR-193b-3p	CD66a+	0,38688331	11296,0619	0,00659915	Spearman's rank correlation rho	two.sided	0,00659915
hsa-miR-193b-5p	CD66a+	0,41772725	10727,7932	0,00313499	Spearman's rank correlation rho	two.sided	0,00313499
hsa-miR-194-3p	CD66a+	-0,6300342	30031,7506	1,6005E-06	Spearman's rank correlation rho	two.sided	1,6005E-06
hsa-miR-194-5p	CD66a+	0,12161221	16183,4167	0,41027645	Spearman's rank correlation rho	two.sided	0,41027645
hsa-miR-195-5p	CD66a+	-0,1818051	21773,5769	0,21619184	Spearman's rank correlation rho	two.sided	0,21619184
hsa-miR-196a-1-3p	CD66a+	-0,2731968	23457,378	0,06027372	Spearman's rank correlation rho	two.sided	0,06027372
hsa-miR-196a-5p	CD66a+	-0,1581368	21337,512	0,28304847	Spearman's rank correlation rho	two.sided	0,28304847
hsa-miR-196b-5p	CD66a+	-0,5273564	28140,0135	0,00011748	Spearman's rank correlation rho	two.sided	0,00011748
hsa-miR-197-3p	CD66a+	0,06165347	17288,0964	0,67720167	Spearman's rank correlation rho	two.sided	0,67720167
hsa-miR-199a-5p	CD66a+	-0,107128	20397,7259	0,46861787	Spearman's rank correlation rho	two.sided	0,46861787
hsa-miR-199b-5p	CD66a+	0,35228066	11933,5811	0,01406406	Spearman's rank correlation rho	two.sided	0,01406406
hsa-miR-19a-3p	CD66a+	0,05593553	17393,4438	0,70571785	Spearman's rank correlation rho	two.sided	0,70571785
hsa-miR-19b-3p	CD66a+	-0,0339834	19050,1098	0,81863287	Spearman's rank correlation rho	two.sided	0,81863287
hsa-miR-200a-3p	CD66a+	0,07895151	16969,3974	0,5937516	Spearman's rank correlation rho	two.sided	0,5937516
hsa-miR-200a-5p	CD66a+	0,11629423	16281,3951	0,43119521	Spearman's rank correlation rho	two.sided	0,43119521
hsa-miR-200b-3p	CD66a+	0,00210382	18385,2393	0,98867724	Spearman's rank correlation rho	two.sided	0,98867724
hsa-miR-200b-5p	CD66a+	-0,2636782	23282,0067	0,0701629	Spearman's rank correlation rho	two.sided	0,0701629
hsa-miR-200c-3p	CD66a+	-0,1122035	20491,2369	0,44768527	Spearman's rank correlation rho	two.sided	0,44768527
hsa-miR-200c-5p	CD66a+	-0,1835343	21805,4361	0,21178066	Spearman's rank correlation rho	two.sided	0,21178066
hsa-miR-203a-3p	CD66a+	-0,0246614	18878,3614	0,86785749	Spearman's rank correlation rho	two.sided	0,86785749
hsa-miR-203b-3p	CD66a+	-0,0684747	19685,5772	0,64376251	Spearman's rank correlation rho	two.sided	0,64376251
hsa-miR-204-5p	CD66a+	-0,1442635	21081,91	0,32794072	Spearman's rank correlation rho	two.sided	0,32794072
hsa-miR-205-5p	CD66a+	-0,1929688	21979,2574	0,18882052	Spearman's rank correlation rho	two.sided	0,18882052
hsa-miR-206	CD66a+	-0,0393068	19148,1892	0,79081703	Spearman's rank correlation rho	two.sided	0,79081703
hsa-miR-20a-3p	CD66a+	-0,2503343	23036,1592	0,08614512	Spearman's rank correlation rho	two.sided	0,08614512
hsa-miR-20a-5p	CD66a+	-0,1122619	20492,3136	0,44744729	Spearman's rank correlation rho	two.sided	0,44744729
hsa-miR-21-3p	CD66a+	0,2969251	12953,4519	0,04042249	Spearman's rank correlation rho	two.sided	0,04042249
hsa-miR-21-5p	CD66a+	0,53051208	8649,84551	0,00010505	Spearman's rank correlation rho	two.sided	0,00010505
hsa-miR-210-3p	CD66a+	0,09080272	16751,0506	0,53935615	Spearman's rank correlation rho	two.sided	0,53935615
hsa-miR-210-5p	CD66a+	-0,165318	21469,8194	0,26147434	Spearman's rank correlation rho	two.sided	0,26147434
hsa-miR-2110	CD66a+	0,0544991	17419,9087	0,71294667	Spearman's rank correlation rho	two.sided	0,71294667
hsa-miR-2116-3p	CD66a+	-0,1810794	21760,2067	0,21806198	Spearman's rank correlation rho	two.sided	0,21806198
hsa-miR-215-3p	CD66a+	0,19618077	14809,5655	0,18142476	Spearman's rank correlation rho	two.sided	0,18142476
hsa-miR-215-5p	CD66a+	-0,0174149	18744,8524	0,90647772	Spearman's rank correlation rho	two.sided	0,90647772
hsa-miR-218-5p	CD66a+	0,09131638	16741,587	0,53705429	Spearman's rank correlation rho	two.sided	0,53705429
hsa-miR-219a-1-3p	CD66a+	0,08773169	16807,6313	0,55321722	Spearman's rank correlation rho	two.sided	0,55321722
hsa-miR-22-3p	CD66a+	0,13154689	16000,3801	0,37279965	Spearman's rank correlation rho	two.sided	0,37279965
hsa-miR-22-5p	CD66a+	0,2537126	13749,5991	0,08185287	Spearman's rank correlation rho	two.sided	0,08185287
hsa-miR-221-3p	CD66a+	0,36489507	11701,1733	0,01077154	Spearman's rank correlation rho	two.sided	0,01077154
hsa-miR-221-5p	CD66a+	-0,2402928	22851,1545	0,09994571	Spearman's rank correlation rho	two.sided	0,09994571
hsa-miR-222-3p	CD66a+	0,4095427	10878,5853	0,00384549	Spearman's rank correlation rho	two.sided	0,00384549
hsa-miR-223-3p	CD66a+	0,56434844	8026,44438	2,9437E-05	Spearman's rank correlation rho	two.sided	2,9437E-05
hsa-miR-223-5p	CD66a+	0,34173964	12127,7888	0,0174402	Spearman's rank correlation rho	two.sided	0,0174402
hsa-miR-224-3p	CD66a+	-0,1947434	22011,9529	0,18470822	Spearman's rank correlation rho	two.sided	0,18470822
hsa-miR-224-5p	CD66a+	0,40352345	10989,4839	0,00445471	Spearman's rank correlation rho	two.sided	0,00445471
hsa-miR-23a-3p	CD66a+	0,45857328	9975,24584	0,00104561	Spearman's rank correlation rho	two.sided	0,00104561
hsa-miR-23a-5p	CD66a+	-0,145138	21098,022	0,32498581	Spearman's rank correlation rho	two.sided	0,32498581
hsa-miR-23b-3p	CD66a+	0,17923337	15121,8044	0,22286981	Spearman's rank correlation rho	two.sided	0,22286981
hsa-miR-23b-5p	CD66a+	0,28949927	13090,2654	0,04595523	Spearman's rank correlation rho	two.sided	0,04595523
hsa-miR-24-2-5p	CD66a+	0,13935989	15856,4335	0,34482043	Spearman's rank correlation rho	two.sided	0,34482043
hsa-miR-24-3p	CD66a+	0,53401843	8585,24436	9,2653E-05	Spearman's rank correlation rho	two.sided	9,2653E-05
hsa-miR-25-3p	CD66a+	0,12278099	16161,8829	0,40575841	Spearman's rank correlation rho	two.sided	0,40575841
hsa-miR-25-5p	CD66a+	0,21428519	14476,0098	0,14359685	Spearman's rank correlation rho	two.sided	0,14359685
hsa-miR-26a-2-3p	CD66a+	0,15423809	15582,3174	0,29523588	Spearman's rank correlation rho	two.sided	0,29523588
hsa-miR-26a-5p	CD66a+	-0,3181436	24285,478	0,02754766	Spearman's rank correlation rho	two.sided	0,02754766
hsa-miR-26b-3p	CD66a+	0,20786762	14594,2469	0,15627058	Spearman's rank correlation rho	two.sided	0,15627058
hsa-miR-26b-5p	CD66a+	0,12985215	16031,604	0,3790433	Spearman's rank correlation rho	two.sided	0,3790433
hsa-miR-27a-3p	CD66a+	0,55692665	8163,18349	3,9377E-05	Spearman's rank correlation rho	two.sided	3,9377E-05
hsa-miR-27a-5p	CD66a+	0,03114815	17850,1264	0,8335403	Spearman's rank correlation rho	two.sided	0,8335403
hsa-miR-27b-3p	CD66a+	0,27425569	13371,1131	0,05924643	Spearman's rank correlation rho	two.sided	0,05924643
hsa-miR-27b-5p	CD66a+	0,28224798	13223,8632	0,05193815	Spearman's rank correlation rho	two.sided	0,05193815

#	miRNA	Cell	rho	value	p	test	alt	p
1	hsa-miR-28-3p	CD66a+	-0,2347507	22749,0472	0,10826023	Spearman's rank correlation rho	two.sided	0,10826023
2	hsa-miR-28-5p	CD66a+	-0,0250705	18885,8982	0,86568553	Spearman's rank correlation rho	two.sided	0,86568553
3	hsa-miR-296-5p	CD66a+	0,14499807	15752,5556	0,3254574	Spearman's rank correlation rho	two.sided	0,3254574
4	hsa-miR-29a-3p	CD66a+	0,07690613	17007,0814	0,60337945	Spearman's rank correlation rho	two.sided	0,60337945
5	hsa-miR-29a-5p	CD66a+	-0,2846475	23668,3454	0,04989232	Spearman's rank correlation rho	two.sided	0,04989232
6	hsa-miR-29b-1-5p	CD66a+	0,08801916	16802,335	0,55191262	Spearman's rank correlation rho	two.sided	0,55191262
7	hsa-miR-29b-2-5p	CD66a+	0,0021335	18384,6924	0,9885175	Spearman's rank correlation rho	two.sided	0,9885175
8	hsa-miR-29b-3p	CD66a+	0,1273135	16078,3761	0,38851158	Spearman's rank correlation rho	two.sided	0,38851158
9	hsa-miR-29c-3p	CD66a+	0,12961839	16035,9107	0,37990934	Spearman's rank correlation rho	two.sided	0,37990934
10	hsa-miR-29c-5p	CD66a+	-0,0207505	18806,3065	0,88866881	Spearman's rank correlation rho	two.sided	0,88866881
11	hsa-miR-30a-3p	CD66a+	0,22956401	14194,5126	0,11651161	Spearman's rank correlation rho	two.sided	0,11651161
12	hsa-miR-30a-5p	CD66a+	0,13855961	15871,1778	0,34762521	Spearman's rank correlation rho	two.sided	0,34762521
13	hsa-miR-30b-3p	CD66a+	0,25564824	13713,9368	0,07947025	Spearman's rank correlation rho	two.sided	0,07947025
14	hsa-miR-30b-5p	CD66a+	0,05616018	17389,3049	0,70458961	Spearman's rank correlation rho	two.sided	0,70458961
15	hsa-miR-30c-1-3p	CD66a+	-0,3436872	24756,0933	0,01676922	Spearman's rank correlation rho	two.sided	0,01676922
16	hsa-miR-30c-5p	CD66a+	-0,418893	26141,6844	0,00304384	Spearman's rank correlation rho	two.sided	0,00304384
17	hsa-miR-30d-3p	CD66a+	0,06327773	17258,1711	0,66918013	Spearman's rank correlation rho	two.sided	0,66918013
18	hsa-miR-30d-5p	CD66a+	-0,101626	20296,3568	0,49188833	Spearman's rank correlation rho	two.sided	0,49188833
19	hsa-miR-30e-3p	CD66a+	0,07883463	16971,5507	0,59429993	Spearman's rank correlation rho	two.sided	0,59429993
20	hsa-miR-30e-5p	CD66a+	-0,1060674	20378,1849	0,47305736	Spearman's rank correlation rho	two.sided	0,47305736
21	hsa-miR-31-5p	CD66a+	0,39754421	11099,6455	0,00514198	Spearman's rank correlation rho	two.sided	0,00514198
22	hsa-miR-3127-5p	CD66a+	-0,183252	21800,235	0,21249647	Spearman's rank correlation rho	two.sided	0,21249647
23	hsa-miR-3145-5p	CD66a+	0,13950328	15853,7915	0,34431934	Spearman's rank correlation rho	two.sided	0,34431934
24	hsa-miR-3150b-5p	CD66a+	-0,0683049	19682,449	0,64458679	Spearman's rank correlation rho	two.sided	0,64458679
25	hsa-miR-3168	CD66a+	0,17212246	15252,8158	0,24207305	Spearman's rank correlation rho	two.sided	0,24207305
26	hsa-miR-3173-5p	CD66a+	0,05339446	17440,2605	0,71852279	Spearman's rank correlation rho	two.sided	0,71852279
27	hsa-miR-3177-3p	CD66a+	-0,2430274	22901,5369	0,09602892	Spearman's rank correlation rho	two.sided	0,09602892
28	hsa-miR-3182	CD66a+	-0,1280718	20783,5952	0,38566883	Spearman's rank correlation rho	two.sided	0,38566883
29	hsa-miR-3187-3p	CD66a+	-0,256962	23158,2676	0,07788444	Spearman's rank correlation rho	two.sided	0,07788444
30	hsa-miR-3188	CD66a+	0,05921027	17333,1099	0,68933436	Spearman's rank correlation rho	two.sided	0,68933436
31	hsa-miR-3195	CD66a+	-0,0570091	19474,3356	0,70033183	Spearman's rank correlation rho	two.sided	0,70033183
32	hsa-miR-32-3p	CD66a+	0,01049071	18230,7191	0,94358256	Spearman's rank correlation rho	two.sided	0,94358256
33	hsa-miR-32-5p	CD66a+	0,18469329	15021,2108	0,20885959	Spearman's rank correlation rho	two.sided	0,20885959
34	hsa-miR-320a-3p	CD66a+	-0,2485424	23003,1451	0,08849207	Spearman's rank correlation rho	two.sided	0,08849207
35	hsa-miR-324-3p	CD66a+	0,20692123	14611,6832	0,15820686	Spearman's rank correlation rho	two.sided	0,15820686
36	hsa-miR-324-5p	CD66a+	0,25234597	13774,7778	0,08356855	Spearman's rank correlation rho	two.sided	0,08356855
37	hsa-miR-326	CD66a+	0,13492546	15938,1333	0,3605378	Spearman's rank correlation rho	two.sided	0,3605378
38	hsa-miR-328-3p	CD66a+	-0,3621591	25096,4185	0,01142298	Spearman's rank correlation rho	two.sided	0,01142298
39	hsa-miR-328-5p	CD66a+	-0,3076788	24092,6748	0,03338874	Spearman's rank correlation rho	two.sided	0,03338874
40	hsa-miR-329-3p	CD66a+	0,26929569	13462,4961	0,06418221	Spearman's rank correlation rho	two.sided	0,06418221
41	hsa-miR-330-3p	CD66a+	0,17288225	15238,8174	0,23996915	Spearman's rank correlation rho	two.sided	0,23996915
42	hsa-miR-331-3p	CD66a+	0,2286226	14211,8572	0,11805917	Spearman's rank correlation rho	two.sided	0,11805917
43	hsa-miR-335-3p	CD66a+	-0,1376905	20960,8096	0,3506871	Spearman's rank correlation rho	two.sided	0,3506871
44	hsa-miR-335-5p	CD66a+	-0,320189	24323,162	0,02651194	Spearman's rank correlation rho	two.sided	0,02651194
45	hsa-miR-338-3p	CD66a+	0,20705498	14609,219	0,15793216	Spearman's rank correlation rho	two.sided	0,15793216
46	hsa-miR-338-5p	CD66a+	-0,0894511	20072,0467	0,54543602	Spearman's rank correlation rho	two.sided	0,54543602
47	hsa-miR-339-3p	CD66a+	-0,0854698	19998,6958	0,56353295	Spearman's rank correlation rho	two.sided	0,56353295
48	hsa-miR-339-5p	CD66a+	0,09011831	16763,6602	0,54243062	Spearman's rank correlation rho	two.sided	0,54243062
49	hsa-miR-33b-3p	CD66a+	-0,2780345	23546,5077	0,05569438	Spearman's rank correlation rho	two.sided	0,05569438
50	hsa-miR-340-3p	CD66a+	-0,0282277	18944,0675	0,84895641	Spearman's rank correlation rho	two.sided	0,84895641
51	hsa-miR-340-5p	CD66a+	0,18578866	15001,0298	0,2061249	Spearman's rank correlation rho	two.sided	0,2061249
52	hsa-miR-342-3p	CD66a+	-0,0624132	19573,9005	0,67344529	Spearman's rank correlation rho	two.sided	0,67344529
53	hsa-miR-342-5p	CD66a+	0,16568221	15371,4711	0,26041039	Spearman's rank correlation rho	two.sided	0,26041039
54	hsa-miR-345-5p	CD66a+	0,08921487	16780,3052	0,54650186	Spearman's rank correlation rho	two.sided	0,54650186
55	hsa-miR-34a-5p	CD66a+	0,30054863	12886,692	0,03792804	Spearman's rank correlation rho	two.sided	0,03792804
56	hsa-miR-3605-5p	CD66a+	-0,0462952	19276,9436	0,75469419	Spearman's rank correlation rho	two.sided	0,75469419
57	hsa-miR-3609	CD66a+	0,31243822	12667,6382	0,03061642	Spearman's rank correlation rho	two.sided	0,03061642
58	hsa-miR-361-3p	CD66a+	0,15322788	15600,9296	0,29844844	Spearman's rank correlation rho	two.sided	0,29844844
59	hsa-miR-361-5p	CD66a+	-0,2920797	23805,2761	0,04396668	Spearman's rank correlation rho	two.sided	0,04396668
60	hsa-miR-3613-3p	CD66a+	-0,3345007	24586,8404	0,02013718	Spearman's rank correlation rho	two.sided	0,02013718
	hsa-miR-3613-5p	CD66a+	-0,1721377	21595,4644	0,24203083	Spearman's rank correlation rho	two.sided	0,24203083
	hsa-miR-3615	CD66a+	0,24880095	13840,0912	0,08815038	Spearman's rank correlation rho	two.sided	0,08815038
	hsa-miR-362-3p	CD66a+	0,22626771	14255,2438	0,12199855	Spearman's rank correlation rho	two.sided	0,12199855
	hsa-miR-362-5p	CD66a+	0,01285804	18187,1034	0,9308794	Spearman's rank correlation rho	two.sided	0,9308794
	hsa-miR-363-3p	CD66a+	0,1568724	15533,7829	0,28696428	Spearman's rank correlation rho	two.sided	0,28696428
	hsa-miR-3651	CD66a+	0,17067522	15279,4798	0,24611516	Spearman's rank correlation rho	two.sided	0,24611516
	hsa-miR-3652	CD66a+	-0,0934991	20146,6266	0,52732664	Spearman's rank correlation rho	two.sided	0,52732664
	hsa-miR-3654	CD66a+	0,22300045	14315,4397	0,12762766	Spearman's rank correlation rho	two.sided	0,12762766
	hsa-miR-3659	CD66a+	0,19404196	14848,9709	0,18632599	Spearman's rank correlation rho	two.sided	0,18632599
	hsa-miR-3660	CD66a+	-0,1036703	20334,0208	0,48317278	Spearman's rank correlation rho	two.sided	0,48317278
	hsa-miR-369-3p	CD66a+	-0,0987281	20242,9668	0,50438122	Spearman's rank correlation rho	two.sided	0,50438122
	hsa-miR-369-5p	CD66a+	-0,2714951	23426,0253	0,06195453	Spearman's rank correlation rho	two.sided	0,06195453
	hsa-miR-370-3p	CD66a+	0,40058246	11043,6688	0,00478198	Spearman's rank correlation rho	two.sided	0,00478198
	hsa-miR-374a-3p	CD66a+	0,09090975	16749,0787	0,53887613	Spearman's rank correlation rho	two.sided	0,53887613
	hsa-miR-374a-5p	CD66a+	-0,1222617	20676,5491	0,40776232	Spearman's rank correlation rho	two.sided	0,40776232
	hsa-miR-374b-3p	CD66a+	-0,2275182	22615,7962	0,11989439	Spearman's rank correlation rho	two.sided	0,11989439
	hsa-miR-374b-5p	CD66a+	-0,0284315	18947,8219	0,84787884	Spearman's rank correlation rho	two.sided	0,84787884
	hsa-miR-375-3p	CD66a+	-0,1065933	20387,8751	0,47085308	Spearman's rank correlation rho	two.sided	0,47085308
	hsa-miR-376a-3p	CD66a+	0,36825762	11639,2215	0,01001487	Spearman's rank correlation rho	two.sided	0,01001487
	hsa-miR-376c-3p	CD66a+	0,35210477	11936,8218	0,01411545	Spearman's rank correlation rho	two.sided	0,01411545
	hsa-miR-377-3p	CD66a+	0,25185414	13783,8394	0,08419286	Spearman's rank correlation rho	two.sided	0,08419286
	hsa-miR-378a-3p	CD66a+	-0,3721415	25280,3357	0,00919826	Spearman's rank correlation rho	two.sided	0,00919826
	hsa-miR-378a-5p	CD66a+	-0,0522839	19387,2785	0,72414344	Spearman's rank correlation rho	two.sided	0,72414344
	hsa-miR-378c	CD66a+	0,08522071	16853,8937	0,5646745	Spearman's rank correlation rho	two.sided	0,5646745
	hsa-miR-378d	CD66a+	-0,0585429	19502,5937	0,69266229	Spearman's rank correlation rho	two.sided	0,69266229
	hsa-miR-379-3p	CD66a+	0,23485378	14097,054	0,10810094	Spearman's rank correlation rho	two.sided	0,10810094
	hsa-miR-379-5p	CD66a+	0,22717827	14238,4676	0,1204637	Spearman's rank correlation rho	two.sided	0,1204637
	hsa-miR-381-3p	CD66a+	0,09232995	16722,9129	0,53252622	Spearman's rank correlation rho	two.sided	0,53252622
	hsa-miR-382-3p	CD66a+	-0,3575996	25012,4142	0,01258375	Spearman's rank correlation rho	two.sided	0,01258375
	hsa-miR-382-5p	CD66a+	0,39654916	11117,9782	0,00526492	Spearman's rank correlation rho	two.sided	0,00526492
	hsa-miR-3909	CD66a+	0,09296286	16711,2522	0,52970825	Spearman's rank correlation rho	two.sided	0,52970825
	hsa-miR-3912-3p	CD66a+	0,2785097	13292,7373	0,05526011	Spearman's rank correlation rho	two.sided	0,05526011
	hsa-miR-3940-3p	CD66a+	0,09168695	16734,7597	0,53539665	Spearman's rank correlation rho	two.sided	0,53539665
	hsa-miR-3960	CD66a+	0,14890337	15680,6044	0,31245488	Spearman's rank correlation rho	two.sided	0,31245488
	hsa-miR-409-3p	CD66a+	-0,2041854	22185,9126	0,16390289	Spearman's rank correlation rho	two.sided	0,16390289
	hsa-miR-411-5p	CD66a+	0,36556876	11688,7612	0,01061613	Spearman's rank correlation rho	two.sided	0,01061613
	hsa-miR-421	CD66a+	0,12080062	16198,3695	0,41343066	Spearman's rank correlation rho	two.sided	0,41343066

hsa-miR-423-3p	CD66a+	-0,0416088	19190,6004	0,77886616	Spearman's rank correlation rho	two.sided	0,77886616
hsa-miR-423-5p	CD66a+	-0,0494397	19334,8763	0,73860351	Spearman's rank correlation rho	two.sided	0,73860351
hsa-miR-424-3p	CD66a+	-0,0570815	19475,6692	0,6999692	Spearman's rank correlation rho	two.sided	0,6999692
hsa-miR-424-5p	CD66a+	0,42057359	10675,3522	0,00291655	Spearman's rank correlation rho	two.sided	0,00291655
hsa-miR-425-3p	CD66a+	0,09685234	16639,5925	0,51255323	Spearman's rank correlation rho	two.sided	0,51255323
hsa-miR-425-5p	CD66a+	0,32264344	12479,6172	0,02531222	Spearman's rank correlation rho	two.sided	0,02531222
hsa-miR-4284	CD66a+	0,26321716	13574,487	0,07067272	Spearman's rank correlation rho	two.sided	0,07067272
hsa-miR-4286	CD66a+	-0,0341304	19052,8187	0,81786148	Spearman's rank correlation rho	two.sided	0,81786148
hsa-miR-429	CD66a+	-0,1113269	20475,0866	0,45126339	Spearman's rank correlation rho	two.sided	0,45126339
hsa-miR-432-5p	CD66a+	0,14499807	15752,5556	0,3254574	Spearman's rank correlation rho	two.sided	0,3254574
hsa-miR-4326	CD66a+	0,07823801	16982,543	0,59710243	Spearman's rank correlation rho	two.sided	0,59710243
hsa-miR-4443	CD66a+	0,04569954	17582,0316	0,7577544	Spearman's rank correlation rho	two.sided	0,7577544
hsa-miR-4444	CD66a+	-0,0677788	19672,7562	0,64714353	Spearman's rank correlation rho	two.sided	0,64714353
hsa-miR-4446-3p	CD66a+	0,35972333	11796,4574	0,01203109	Spearman's rank correlation rho	two.sided	0,01203109
hsa-miR-4448	CD66a+	0,13224048	15987,6014	0,37026226	Spearman's rank correlation rho	two.sided	0,37026226
hsa-miR-4455	CD66a+	-0,1786342	21715,156	0,22444602	Spearman's rank correlation rho	two.sided	0,22444602
hsa-miR-4468	CD66a+	0,2723719	13405,8201	0,06108386	Spearman's rank correlation rho	two.sided	0,06108386
hsa-miR-4484	CD66a+	0,17758713	15152,1347	0,22721878	Spearman's rank correlation rho	two.sided	0,22721878
hsa-miR-4488	CD66a+	0,14393603	15772,1227	0,32905143	Spearman's rank correlation rho	two.sided	0,32905143
hsa-miR-4492	CD66a+	-0,0762633	19829,0751	0,6064193	Spearman's rank correlation rho	two.sided	0,6064193
hsa-miR-4497	CD66a+	0,11428118	16318,4836	0,43926702	Spearman's rank correlation rho	two.sided	0,43926702
hsa-miR-450a-5p	CD66a+	0,09130451	16741,8057	0,53710744	Spearman's rank correlation rho	two.sided	0,53710744
hsa-miR-450b-5p	CD66a+	0,37314863	11549,1096	0,00899614	Spearman's rank correlation rho	two.sided	0,00899614
hsa-miR-4516	CD66a+	0,2904007	13073,6574	0,04525239	Spearman's rank correlation rho	two.sided	0,04525239
hsa-miR-451a	CD66a+	-0,0210966	18812,6836	0,88682373	Spearman's rank correlation rho	two.sided	0,88682373
hsa-miR-452-3p	CD66a+	0,27275147	13398,827	0,06071001	Spearman's rank correlation rho	two.sided	0,06071001
hsa-miR-452-5p	CD66a+	0,16123548	15453,3976	0,27360041	Spearman's rank correlation rho	two.sided	0,27360041
hsa-miR-4525	CD66a+	-0,2957299	23872,5274	0,04127419	Spearman's rank correlation rho	two.sided	0,04127419
hsa-miR-454-3p	CD66a+	0,38610854	11310,3363	0,00671782	Spearman's rank correlation rho	two.sided	0,00671782
hsa-miR-454-5p	CD66a+	-0,0952209	20178,3499	0,51971465	Spearman's rank correlation rho	two.sided	0,51971465
hsa-miR-455-3p	CD66a+	-0,1431295	21061,0184	0,33179722	Spearman's rank correlation rho	two.sided	0,33179722
hsa-miR-4636	CD66a+	-0,2814095	23608,6892	0,0526688	Spearman's rank correlation rho	two.sided	0,0526688
hsa-miR-4662a-5p	CD66a+	0,34425426	12081,4594	0,01657803	Spearman's rank correlation rho	two.sided	0,01657803
hsa-miR-4681	CD66a+	0,03451778	17788,0444	0,81582995	Spearman's rank correlation rho	two.sided	0,81582995
hsa-miR-4685-3p	CD66a+	0,25408396	13742,7571	0,08139146	Spearman's rank correlation rho	two.sided	0,08139146
hsa-miR-4708-3p	CD66a+	-0,2363279	22778,1046	0,10584203	Spearman's rank correlation rho	two.sided	0,10584203
hsa-miR-4758-5p	CD66a+	-0,2911945	23788,9669	0,04464078	Spearman's rank correlation rho	two.sided	0,04464078
hsa-miR-4791	CD66a+	-0,0730259	19769,4286	0,6218281	Spearman's rank correlation rho	two.sided	0,6218281
hsa-miR-4804-5p	CD66a+	-0,2327725	22712,5999	0,11135294	Spearman's rank correlation rho	two.sided	0,11135294
hsa-miR-484	CD66a+	-0,144462	21085,5675	0,32726847	Spearman's rank correlation rho	two.sided	0,32726847
hsa-miR-485-3p	CD66a+	-0,0724552	19758,9145	0,62456121	Spearman's rank correlation rho	two.sided	0,62456121
hsa-miR-485-5p	CD66a+	0,36948515	11616,6056	0,00975029	Spearman's rank correlation rho	two.sided	0,00975029
hsa-miR-486-3p	CD66a+	-0,0582198	19496,6412	0,69427537	Spearman's rank correlation rho	two.sided	0,69427537
hsa-miR-486-5p	CD66a+	0,0019285	18388,4694	0,98962075	Spearman's rank correlation rho	two.sided	0,98962075
hsa-miR-487b-3p	CD66a+	0,3637954	11721,4336	0,01102943	Spearman's rank correlation rho	two.sided	0,01102943
hsa-miR-493-5p	CD66a+	-0,0286407	18951,6763	0,84677285	Spearman's rank correlation rho	two.sided	0,84677285
hsa-miR-494-3p	CD66a+	0,07724852	17000,7733	0,60176308	Spearman's rank correlation rho	two.sided	0,60176308
hsa-miR-495-3p	CD66a+	0,25859869	13659,5778	0,07594377	Spearman's rank correlation rho	two.sided	0,07594377
hsa-miR-497-5p	CD66a+	0,21148509	14527,5987	0,14902947	Spearman's rank correlation rho	two.sided	0,14902947
hsa-miR-499a-5p	CD66a+	-0,4661674	27012,668	0,00083958	Spearman's rank correlation rho	two.sided	0,00083958
hsa-miR-500a-3p	CD66a+	-0,3474406	24825,2451	0,01553778	Spearman's rank correlation rho	two.sided	0,01553778
hsa-miR-501-3p	CD66a+	-0,3032206	24010,5363	0,03617091	Spearman's rank correlation rho	two.sided	0,03617091
hsa-miR-501-5p	CD66a+	-0,2010402	22127,9648	0,17063437	Spearman's rank correlation rho	two.sided	0,17063437
hsa-miR-502-3p	CD66a+	0,1718209	15258,3717	0,24291154	Spearman's rank correlation rho	two.sided	0,24291154
hsa-miR-505-3p	CD66a+	-0,1808795	21756,5237	0,2185791	Spearman's rank correlation rho	two.sided	0,2185791
hsa-miR-505-5p	CD66a+	-0,3624704	25102,155	0,01134718	Spearman's rank correlation rho	two.sided	0,01134718
hsa-miR-5100	CD66a+	-0,1852869	21837,7253	0,20737453	Spearman's rank correlation rho	two.sided	0,20737453
hsa-miR-511-5p	CD66a+	-0,1442927	21082,4485	0,32784169	Spearman's rank correlation rho	two.sided	0,32784169
hsa-miR-5191	CD66a+	-0,1524721	21233,1451	0,30086673	Spearman's rank correlation rho	two.sided	0,30086673
hsa-miR-532-3p	CD66a+	-0,0383424	19130,421	0,7958382	Spearman's rank correlation rho	two.sided	0,7958382
hsa-miR-532-5p	CD66a+	-0,0197525	18787,9198	0,89399183	Spearman's rank correlation rho	two.sided	0,89399183
hsa-miR-539-5p	CD66a+	-0,1188686	20614,0352	0,42099493	Spearman's rank correlation rho	two.sided	0,42099493
hsa-miR-543	CD66a+	0,26091469	13616,9078	0,07326304	Spearman's rank correlation rho	two.sided	0,07326304
hsa-miR-548e-3p	CD66a+	0,21887899	14391,3736	0,13500438	Spearman's rank correlation rho	two.sided	0,13500438
hsa-miR-548i	CD66a+	0,20400303	14665,4481	0,16428793	Spearman's rank correlation rho	two.sided	0,16428793
hsa-miR-548k	CD66a+	0,14279825	15793,0851	0,33292924	Spearman's rank correlation rho	two.sided	0,33292924
hsa-miR-548l	CD66a+	-0,4499587	26714,0397	0,00133313	Spearman's rank correlation rho	two.sided	0,00133313
hsa-miR-550a-5p	CD66a+	0,3825203	11376,446	0,0072919	Spearman's rank correlation rho	two.sided	0,0072919
hsa-miR-552-3p	CD66a+	0,07604193	17023,0035	0,60746767	Spearman's rank correlation rho	two.sided	0,60746767
hsa-miR-552-5p	CD66a+	0,17778204	15148,5437	0,22670085	Spearman's rank correlation rho	two.sided	0,22670085
hsa-miR-556-5p	CD66a+	0,12578188	16106,5946	0,39429068	Spearman's rank correlation rho	two.sided	0,39429068
hsa-miR-5571-3p	CD66a+	0,43021843	10497,6556	0,00227283	Spearman's rank correlation rho	two.sided	0,00227283
hsa-miR-5697	CD66a+	-0,1336578	20886,5107	0,36510966	Spearman's rank correlation rho	two.sided	0,36510966
hsa-miR-574-3p	CD66a+	-0,0584978	19501,7626	0,69288743	Spearman's rank correlation rho	two.sided	0,69288743
hsa-miR-574-5p	CD66a+	0,21166719	14524,2437	0,14867162	Spearman's rank correlation rho	two.sided	0,14867162
hsa-miR-576-3p	CD66a+	0,2038166	14668,8829	0,16468212	Spearman's rank correlation rho	two.sided	0,16468212
hsa-miR-576-5p	CD66a+	0,08949002	16775,2359	0,5452604	Spearman's rank correlation rho	two.sided	0,5452604
hsa-miR-577	CD66a+	0,00926389	18253,3221	0,95017137	Spearman's rank correlation rho	two.sided	0,95017137
hsa-miR-582-3p	CD66a+	0,41938174	10697,3108	0,00300632	Spearman's rank correlation rho	two.sided	0,00300632
hsa-miR-582-5p	CD66a+	0,52864045	8684,32844	0,00011227	Spearman's rank correlation rho	two.sided	0,00011227
hsa-miR-584-5p	CD66a+	0,30970354	12718,022	0,03218499	Spearman's rank correlation rho	two.sided	0,03218499
hsa-miR-589-5p	CD66a+	0,29352206	13016,1496	0,0428861	Spearman's rank correlation rho	two.sided	0,0428861
hsa-miR-590-3p	CD66a+	0,05339446	17440,2605	0,71852279	Spearman's rank correlation rho	two.sided	0,71852279
hsa-miR-592	CD66a+	-0,144694	21089,8424	0,32648384	Spearman's rank correlation rho	two.sided	0,32648384
hsa-miR-598-3p	CD66a+	-0,1856677	21844,7426	0,20642552	Spearman's rank correlation rho	two.sided	0,20642552
hsa-miR-6126	CD66a+	0,0050266	18331,3899	0,97295091	Spearman's rank correlation rho	two.sided	0,97295091
hsa-miR-622	CD66a+	-0,3000634	23952,3674	0,03825457	Spearman's rank correlation rho	two.sided	0,03825457
hsa-miR-624-5p	CD66a+	-0,0719544	19749,6882	0,62696369	Spearman's rank correlation rho	two.sided	0,62696369
hsa-miR-625-3p	CD66a+	0,05680609	17377,4045	0,70134917	Spearman's rank correlation rho	two.sided	0,70134917
hsa-miR-625-5p	CD66a+	0,42986771	10504,1173	0,00229382	Spearman's rank correlation rho	two.sided	0,00229382
hsa-miR-628-3p	CD66a+	-0,15552	21289,3005	0,29119165	Spearman's rank correlation rho	two.sided	0,29119165
hsa-miR-628-5p	CD66a+	0,05330823	17441,8492	0,71895868	Spearman's rank correlation rho	two.sided	0,71895868
hsa-miR-629-5p	CD66a+	0,274643	13363,9773	0,05887421	Spearman's rank correlation rho	two.sided	0,05887421
hsa-miR-642a-3p	CD66a+	0,04959653	17510,2336	0,73780362	Spearman's rank correlation rho	two.sided	0,73780362
hsa-miR-642a-5p	CD66a+	-0,2518765	23064,5731	0,08416436	Spearman's rank correlation rho	two.sided	0,08416436
hsa-miR-651-5p	CD66a+	-0,140694	21016,1458	0,34017589	Spearman's rank correlation rho	two.sided	0,34017589
hsa-miR-6511b-3p	CD66a+	-0,0671595	19661,3472	0,65015815	Spearman's rank correlation rho	two.sided	0,65015815

miRNA	Cell	rho	Value	p-value	Method	Test	p-value
hsa-miR-6513-3p	CD66a+	-0,2042716	22187,5003	0,16372122	Spearman's rank correlation rho	two.sided	0,16372122
hsa-miR-652-3p	CD66a+	-0,0112788	18631,8004	0,93935203	Spearman's rank correlation rho	two.sided	0,93935203
hsa-miR-654-3p	CD66a+	0,30208816	12858,3278	0,03690725	Spearman's rank correlation rho	two.sided	0,03690725
hsa-miR-660-5p	CD66a+	0,20474769	14651,7286	0,16272025	Spearman's rank correlation rho	two.sided	0,16272025
hsa-miR-663a	CD66a+	0,12564258	16109,1611	0,39481878	Spearman's rank correlation rho	two.sided	0,39481878
hsa-miR-664a-3p	CD66a+	0,02750167	17917,3093	0,85279794	Spearman's rank correlation rho	two.sided	0,85279794
hsa-miR-664a-5p	CD66a+	0,17964736	15114,1771	0,22178528	Spearman's rank correlation rho	two.sided	0,22178528
hsa-miR-671-3p	CD66a+	-0,014643	18693,783	0,92131226	Spearman's rank correlation rho	two.sided	0,92131226
hsa-miR-671-5p	CD66a+	0,01937684	18067,0011	0,89599668	Spearman's rank correlation rho	two.sided	0,89599668
hsa-miR-6729-5p	CD66a+	0,20696056	14610,9587	0,15812606	Spearman's rank correlation rho	two.sided	0,15812606
hsa-miR-6734-5p	CD66a+	-0,3076788	24092,6748	0,03338874	Spearman's rank correlation rho	two.sided	0,03338874
hsa-miR-6787-5p	CD66a+	0,12711079	16082,1109	0,38927357	Spearman's rank correlation rho	two.sided	0,38927357
hsa-miR-6803-3p	CD66a+	0,00268872	18374,463	0,98552957	Spearman's rank correlation rho	two.sided	0,98552957
hsa-miR-6803-5p	CD66a+	-0,1350607	20912,3581	0,36005217	Spearman's rank correlation rho	two.sided	0,36005217
hsa-miR-6821-5p	CD66a+	0,16638815	15358,4648	0,25835623	Spearman's rank correlation rho	two.sided	0,25835623
hsa-miR-6859-5p	CD66a+	-0,2524971	23076,0073	0,0833774	Spearman's rank correlation rho	two.sided	0,0833774
hsa-miR-6866-5p	CD66a+	0,35280623	11923,8981	0,01391147	Spearman's rank correlation rho	two.sided	0,01391147
hsa-miR-6869-5p	CD66a+	-0,2267645	22601,9101	0,12115925	Spearman's rank correlation rho	two.sided	0,12115925
hsa-miR-6887-5p	CD66a+	-0,3546768	24958,5652	0,01337976	Spearman's rank correlation rho	two.sided	0,01337976
hsa-miR-7-1-3p	CD66a+	-0,1306075	20830,3118	0,37625301	Spearman's rank correlation rho	two.sided	0,37625301
hsa-miR-7-5p	CD66a+	0,05762116	17362,3877	0,69726762	Spearman's rank correlation rho	two.sided	0,69726762
hsa-miR-744-5p	CD66a+	0,33510921	12249,948	0,01989767	Spearman's rank correlation rho	two.sided	0,01989767
hsa-miR-769-5p	CD66a+	-0,174762	21643,8151	0,23481772	Spearman's rank correlation rho	two.sided	0,23481772
hsa-miR-7704	CD66a+	0,01326644	18179,579	0,92868956	Spearman's rank correlation rho	two.sided	0,92868956
hsa-miR-7706	CD66a+	-0,0756369	19817,5341	0,60938784	Spearman's rank correlation rho	two.sided	0,60938784
hsa-miR-7854-3p	CD66a+	-0,0985528	20239,7359	0,50514237	Spearman's rank correlation rho	two.sided	0,50514237
hsa-miR-7975	CD66a+	-0,327837	24464,0682	0,02292287	Spearman's rank correlation rho	two.sided	0,02292287
hsa-miR-7976	CD66a+	0,26646069	13514,7282	0,06714749	Spearman's rank correlation rho	two.sided	0,06714749
hsa-miR-7977	CD66a+	-0,1385926	20977,4299	0,34750934	Spearman's rank correlation rho	two.sided	0,34750934
hsa-miR-8085	CD66a+	-0,1874607	21877,7753	0,20199923	Spearman's rank correlation rho	two.sided	0,20199923
hsa-miR-874-3p	CD66a+	-0,1578952	21333,0617	0,28379384	Spearman's rank correlation rho	two.sided	0,28379384
hsa-miR-877-3p	CD66a+	-0,0419416	19196,7319	0,77714249	Spearman's rank correlation rho	two.sided	0,77714249
hsa-miR-877-5p	CD66a+	-0,2056161	22212,2708	0,16090587	Spearman's rank correlation rho	two.sided	0,16090587
hsa-miR-9-3p	CD66a+	0,39172406	11206,8759	0,00589816	Spearman's rank correlation rho	two.sided	0,00589816
hsa-miR-9-5p	CD66a+	-0,2718089	23431,8073	0,06164177	Spearman's rank correlation rho	two.sided	0,06164177
hsa-miR-92a-1-5p	CD66a+	0,00268865	18374,4644	0,98552997	Spearman's rank correlation rho	two.sided	0,98552997
hsa-miR-92a-3p	CD66a+	-0,0966002	20203,7618	0,51365685	Spearman's rank correlation rho	two.sided	0,51365685
hsa-miR-92b-3p	CD66a+	-0,0367019	19100,1954	0,80439843	Spearman's rank correlation rho	two.sided	0,80439843
hsa-miR-92b-5p	CD66a+	0,25623132	13703,1942	0,07876332	Spearman's rank correlation rho	two.sided	0,07876332
hsa-miR-93-3p	CD66a+	0,18426915	15029,0251	0,20992528	Spearman's rank correlation rho	two.sided	0,20992528
hsa-miR-93-5p	CD66a+	0,0831007	16892,9527	0,57443289	Spearman's rank correlation rho	two.sided	0,57443289
hsa-miR-940	CD66a+	-0,3165056	24255,2985	0,02840125	Spearman's rank correlation rho	two.sided	0,02840125
hsa-miR-941	CD66a+	0,13060391	16017,7535	0,37626608	Spearman's rank correlation rho	two.sided	0,37626608
hsa-miR-942-5p	CD66a+	0,21551251	14453,3975	0,1412625	Spearman's rank correlation rho	two.sided	0,1412625
hsa-miR-95-3p	CD66a+	0,21873835	14393,9647	0,1352616	Spearman's rank correlation rho	two.sided	0,1352616
hsa-miR-96-5p	CD66a+	-0,0035065	18488,6047	0,9811288	Spearman's rank correlation rho	two.sided	0,9811288
hsa-miR-98-5p	CD66a+	-0,0658611	19637,425	0,65649707	Spearman's rank correlation rho	two.sided	0,65649707
hsa-miR-99a-5p	CD66a+	0,06262282	17270,2371	0,67241013	Spearman's rank correlation rho	two.sided	0,67241013
hsa-miR-99b-3p	CD66a+	-0,1382173	20970,515	0,34882931	Spearman's rank correlation rho	two.sided	0,34882931
hsa-miR-99b-5p	CD66a+	0,03608725	17759,1284	0,80761139	Spearman's rank correlation rho	two.sided	0,80761139